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Abstract 
 
Background and Objectives: Alterations in the habitual sleep/wake patterns of women 
with breast cancer and their informal caregivers may be concurrently exacerbated and co-
vary during the patient’s treatment. The current study set out to longitudinally explore sleep-
wake patterns of patient-caregiver dyads in the context of adjuvant chemotherapy (CTh) for 
breast cancer. Taking into consideration the complexity of mechanisms interfering with a 
care dyad’s sleep, diverse sleep-impairing factors were also investigated. 
Design and Methods: Descriptive, observational, repeated-measures dyadic study. Forty 
eight newly diagnosed women receiving outpatient adjuvant CTh for early stage breast can-
cer (stage I-IIIA) and their nominated primary informal caregiver completed self-reported 
sleep measures at pre-treatment (week prior to CTh), post-CTh cycle 1, post-CThC4, and 
approximately 30 days after the end of CTh (total of ≥6 cycles received). Additional data on 
the dyads’ sleep hygiene practices (SH), patient physical burden, caregiving burden 
(CRACB), psychological burden (PSYCH), nocturnal sleep disturbances (SDSTRB), and 
maladaptive coping strategies were collected at each assessment point. 
Results: Prior to CTh, 65% of dyads consisted of at least one poor sleeper, a rate further in-
creasing to approximately 88% at CThC4. Multivariate hierarchical linear modelling re-
vealed curvilinear trajectories for most dyads’ sleep/wake parameters that nevertheless 
reached significance (p<.05) for patients only. In both groups, sleep/wake impairment 
reached its peak at mid-treatment (CThC4); yet, patients consistently reported significantly 
more sleep problems than their carers. Partial convergence also emerged as suggested by 
positive correlations and no between-groups differences in daily disturbance, daytime nap-
ping duration, total sleep time, and overall sleep/wake impairment at pre-treatment. At 
CThC4, rates of change in sleep latency and daytime napping duration were also similar. In 
exploratory analyses, increased CRACB, poor SH, and SDSTRB consistently predicted 
poorer outcomes in the dyad members’ own sleep-wake patterns. Cross-partner effects most 
frequently emerged with regard to the dyads’ PSYCH, as well as for CRACB. Among the 
most interesting findings, increased patient PSYCH adversely affected caregiver perceived 
sleep quality and daytime napping. Reversely, increased CRACB was related to worse pa-
tient sleep quality, reduced sleep time, and difficulty to fall asleep. Some links might be 
suggested for own poor sleep hygiene and worse partner outcomes on daytime functioning, 
sleep efficiency, or wake after sleep onset. 
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Conclusions and Future Implications: This is one of the first studies to show that a dyadic 
approach in the assessment of sleep/wake patterns in patients with breast cancer and their 
informal carers is a promising method to enhance exploration of potentially concurrent 
sleep/wake-impairment and associations with sleep-impairing factors that may co-vary in 
dyad members. Replication of the current findings in future dyadic sleep research is war-
ranted. Meanwhile, clinicians will need to engage in concurrent systematic and ongoing 
sleep assessments that synthesise and contrast data to establish a care dyad’s level of sleep 
quality. 
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PART I 
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PREFACE. 
Rationale for Thesis and Overview of Chapters 
 
 
Background 
A diagnosis of cancer severely disturbs a person’s continuum of life. As far as women with 
breast cancer are concerned, sudden and abrupt changes may be posed post-diagnosis and 
during anti-cancer treatment, which, when combined with a permanent body disfigurement 
indicating that the threat may still be present, can be profoundly disrupting. Several sources 
of discomfort can be identified along the continuum of illness, and sleep/wake impairment is 
one of them [1]. Sleep is a vital human process known to be essential for health, well-being, 
and optimal physical and psychological functioning [2], thus making it reasonable to argue 
that any severe and/or long-term disruption may have serious consequences on the equilibri-
um of life [3, 4]. Admittedly, throughout the period of diagnosis and treatment, women with 
breast cancer are also in great need of support [5]. To a considerable extent, support is ex-
pected to be provided by their significant others, family members and/or friends, who are 
frequently recognised as patients’ informal caregivers. However, caregiving can be so de-
manding and stressful that the burden posed to these persons may lead to alterations in their 
own sleep, too [6]. 
At the early stages of breast cancer, women and their primary informal caregivers are faced 
with a host of challenges; not only do they have to go through intense curative treatment 
modalities, but also they must effectively cope with illness, both as individuals and as mem-
bers of a close relationship. With regard to adjuvant chemotherapy, patients and caregivers 
are most frequently required to deal with unknown procedures, toxic agents, and the experi-
ence of multiple symptoms, the intensity of which can disproportionately increase the physi-
cal and psychological burden posed [6]. As they share closely their everyday concerns, these 
care dyads may be faced with similar challenges and most of their needs may manifest at the 
same time. 
Sleep/wake problems may be prominent for both the patient and their caregiver, even at the 
same time, possibly for a considerable time period and, in other cases, long after treatment is 
completed, thus posing an additional short-, mid- or long-term burden on their lives. All 
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women with breast cancer and their informal caregivers need initial and ongoing screening 
for debilitating symptoms such as sleep/wake impairments throughout anti-cancer treatment. 
When nocturnal disturbance and/or daytime dysfunction are evident or suspected, further 
tailored assessment and treatment is required. The present study attempts to add to the body 
of knowledge in the emerging field of sleep research in cancer care by suggesting a more 
comprehensive approach to the assessment of sleep-related issues in people affected by can-
cer: this more detailed assessment recognises the dyadic nature of sleep, acknowledges the 
potential for interdependence in sleep/wake patterns, and includes additional sleep-impairing 
factors that arise at the dyadic level. 
 
 
Research interest 
The present study derives from the researcher’s interest in how the experience and challeng-
es of cancer affect quality-of-life issues in patients and their informal caregivers, who are 
seen as a unit instead of merely as individual parts when receiving care. Sleep is one such 
issue. It can be postulated that when altered sleep/wake patterns occur at the same time (or 
period) in two closely interacting individuals, as in the patient-caregiver relationship, the 
related adverse effects can be even more disturbing for both of them. By mapping changes in 
sleep/wake patterns over time, exploring inter-relationships between these changing patterns, 
as well as identifying influential and reciprocal sleep-impairing factors, care can become 
more responsive and tailored, not only to each individual’s but also to the care dyad’s com-
bined (sleep) needs. 
 
 
Importance for Cancer Care 
The current thesis proposes that sleep assessment protocols should aim to simultaneously 
address sleep/wake impairment in both patients and their caregivers. Neither the patient nor 
the caregiver goes through the experience of cancer independently, but rather as a pair. That 
being said, individualistic assessments may fall short when sleep/wake patterns of the care 
dyad are the focus. Instead, a dyadic approach to sleep assessment takes into consideration 
the concurrent situation of dyad members, acknowledges the potential for interdependence 
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that affects and is affected by close relationships, and examines the possibility for nocturnal 
and daytime interactions. It is evident that in order for the multidisciplinary team to com-
plete comprehensive sleep assessments, not only do they need to possess the knowledge re-
quired but they also need to know where to look to gather as much relevant information as 
possible. 
This study draws upon previous successful longitudinal sleep studies in women with early 
stage breast cancer receiving chemotherapy treatment [7-9]. However, it goes one step fur-
ther by also including informal caregivers and it does so by targeting care dyads (i.e. paired 
patients and carers) rather than two arbitrary groups. Given the scarcity of longitudinal re-
search data [10], information till now unknown will be also gathered regarding changes in 
informal caregivers’ sleep/wake patterns in order to promote targeted multidisciplinary sleep 
assessments. Most importantly, the advantages of repeated sleep measurements will be re-
flected in the analysis of dyadic sleep data, the results of which are expected to shed light on 
similarities, differences and interrelations in the dyads’ sleep/wake patterns, and will begin 
to clarify how changes in one member’s sleep/wake parameters may (or may not) be related 
to changes in the other’s. 
It is also anticipated that dyadic longitudinal sleep assessment will shed light on the impact 
that already known and still unexplored factors have on patients’ and caregivers’ sleep. Al-
though for now inferences will only refer to the fast-moving period of uncertainty and new 
challenges that are associated with adjuvant chemotherapy for breast cancer, this dyadic ap-
proach can be well applied to investigate relationships in other cancer contexts, too. With the 
dyadic methodology implemented here, not only own but also cross-partner effects of key 
sleep-impairing factors will be explored, thus promoting a more thorough investigation of 
the multiple individualistic and dyadic sources of sleep disturbance. What is more, being 
able to anticipate the time points where sleep/wake disruption/deprivation reaches a peak for 
both members of the care dyad and what the main causes for them may be, will allow for 
interventions to support the patient-caregiver dyad and enhance their well-being. 
It is hoped that the present study will stimulate further dyadic sleep research that will even-
tually inform the development of sleep intervention protocols for the comprehensive man-
agement of sleep disorders in people affected by cancer throughout their illness experience. 
These interventions will ensure that sleep/wake patterns are assessed in depth and are man-
aged in a concurrent manner to achieve concurrently increased levels of well-being for pa-
tients and their caregivers. 
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Thesis Content Guide 
The thesis is presented in two Parts. Part I will attempt to provide an overview of the state-
of-the-art literature pertinent to sleep-related issues in the context of cancer and health care. 
Part I comprises the following four chapters: 
 Chapter 1 introduces the basic knowledge about sleep physiology and sleep-related is-
sues in the context of cancer care. The concept of nine key parameters for the assess-
ment of sleep in cancer populations is introduced along with terminology for sleep-
wake disturbances. In addition, a general approach to sleep-impairing factors is pre-
sented, drawing upon the principles of three theoretical models. 
 Chapter 2 begins with providing facts and figures about breast cancer focusing mainly 
on the early stages of diagnosis. A brief discussion of the experience of living with 
early stage breast cancer follows, culminating with a discussion about the experience 
of impaired sleep/wake patterns. Findings from two systematic literature reviews con-
ducted for the purposes of this project are discussed in detail. The first section pro-
vides evidence with regard to the extent that habitual sleep/wake patterns are com-
promised in women receiving neo-/adjuvant chemotherapy for breast cancer. The se-
cond section brings together evidence with regard to six categories of sleep-impairing 
factors in this population. The Chapter concludes with a discussion pertinent to the 
limitations of the current body of evidence. 
 In Chapter 3, the role of supportive systems for patients with (breast) cancer is re-
viewed, in particular the role and competencies of significant others as informal care-
givers. The extent of burden placed on persons assuming caregiving roles is then ana-
lysed, which, when combined with physiologic and emotional effects, can lead to in-
terruptions in habitual sleep. As part of this Chapter, a systematic review of studies 
investigating caregiver sleep and correlates in the context of cancer and other major 
chronic illnesses was conducted, and its findings are presented here. Limitations and 
research gaps in the existing knowledge are thoroughly discussed in the last section. 
 Chapter 4 introduces the novel concept of exploring sleep/wake patterns in dyads of 
persons in close relationships, such as the patient-caregiver relationship. The Chapter 
starts off with a discussion of the added value of concurrent assessments of health 
outcomes in patient-caregiver dyads based on findings of a scoping review of dyadic 
studies irrespective of health care context. Next, the theoretical underpinnings of dy-
adic sleep assessment are taken into consideration, where it is recognised that, despite 
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its hypothesised advantages, to date, sleep assessment is viewed and conducted in a 
confined individualistic way. This observation is evident in the findings of a systemat-
ic review conducted for the purposes of this thesis, where sleep assessment in patient-
caregiver dyads is still an under-researched area. Current research gaps are addressed 
towards the end of this Chapter. 
 
Part II is dedicated to the research project conducted as part of the present thesis. It consists 
of the following five chapters: 
 Chapter 5 (Methodology) summarises the evidence analysed in the previous four 
chapters and introduces the specific research problem to be addressed. A detailed dis-
cussion follows with regard to the selection of research design and methods, and out-
come and predictor variables to be examined. Next, an account of the screening pro-
cedures to select the most appropriate outcome measures is provided. The final section 
refers to information pertinent to the analysis of dyadic data, according to basic dyadic 
principles and via the use of sophisticated statistical techniques. 
 Chapter 6 (Study Aims and Methods) explicitly details the aims, hypotheses and re-
search questions that have driven the current project, and then moves on to describe 
all of the procedural steps taken. This section includes an account of population and 
sample eligibility criteria, data collection schematics and procedures, ethical consider-
ations, instrumentation, and data analytic strategy. Preliminary findings of the pro-
ject’s feasibility phase are discussed prior to proceeding to the next Chapter. 
 Chapter 7 (Results) is divided into four sections to provide a clear account of results. 
The first section discusses accrual rates, attrition rates and patterns of missingness, 
and gives an overview of the dyads’ demographic and clinical characteristics. The se-
cond section attempts a descriptive analysis of dyadic outcome and predictor varia-
bles, followed by preliminary bivariate correlation analyses. The third and fourth sec-
tions are dedicated to the main data analysis, providing findings with regard to over-
time changes in the sleep/wake patterns of care dyads, and modelling the effects of 
sleep-impairing factors, respectively. 
 Finally, Chapter 8 (Discussion and Future Implications) attempts a critical discussion 
of important findings and implications of the current study. This Chapter is also divid-
ed into four sections. The first section concentrates on the essence of the previously 
stated results, provides an overall appraisal of findings, and links these with previous 
7 
 
 
research and/or past hypotheses. The strengths and limitations of the current project 
are explicitly analysed in the next section. The Chapter concludes with a detailed ac-
count of implications for future research and clinical practice, and a brief recapitula-
tion of all important concepts, findings and suggestions derived from the current 
study, whilst the requirement for replication in future research is re-stressed. 
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CHAPTER 1. 
Overview of Sleep-Related Research and Clinical Issues 
in the Context of Cancer 
 
 
1.1. Introduction 
Sleep difficulties have been reported as a frequent complication of, and are associated with, 
various clinical conditions [11]. Over the past fifteen years, the attention of the scientific 
community has shifted towards systematic investigation of sleep/wake impairments during 
the experience of cancer as an important aspect of care in this population. 
Changes in habitual sleep are among the most remarkable and important concerns of patients 
with cancer [12], and most prominent and debilitating symptoms of their caregivers [10]. 
Patients and caregivers identify sleep-related issues as vital aspects of the experience of can-
cer. If sleep/wake impairments persist, physical and psychosocial function, mood, symptom 
distress, quality of life, or even survival may well be affected [13]. Importantly, while for 
healthy people sleep provides a needed refuge from the demands of animate and inanimate 
environment, for those facing the threat of cancer it constitutes a form of respite from the 
jumble of physical discomfort and psychological distress, and may allow them to meet the 
next day with renewed energy and motivation [11]. 
The fact that disordered sleep constitutes a major problem during the cancer experience is 
evident by the extent of relevant literature, and verified by the importance attributed to quali-
ty of sleep by both patients and caregivers (through personal, subjective experiencing), and 
clinicians (through systematic, objective investigation) in several aspects of life during the 
experience of cancer [13-16]. The subjective importance patients with cancer and their care-
givers attribute to sleep/wake problems has potential consequences for behaviours associated 
with self-care and the identification of symptoms, help-seeking strategies and reporting of 
disturbances to the health care team, as well as acceptance and compliance with recom-
mended therapeutic interventions [17, 18]. Alternatively, objective significance of frag-
maneted/restricted sleep includes its potential to adversely affect clinical and care-related 
outcomes in patients with cancer [13], including fatigue [19-23], performance status [24, 
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25], mood [26-30], immune function [31], quality of life [30, 32, 33], and survival [34-36]. 
This reported significance dictates the need for continuing intervention and the provision of 
relief to patients and carers in times of distress. 
 
 
1.2. Overview of Sleep Physiology 
Sleep is a fundamental and omnipresent biological phenomenon, a homeostatically regulated 
process that is necessary for the body to restore energy and revitalise, in which there is min-
imal processing of sensory information and no interaction with the environment [2]. Howev-
er, human sleep also is a complex and dynamic physiologic process [11]. In order for clini-
cians and researchers to better interpret the varying aspects of impaired sleep, it is important 
to have a clear understanding of the basic physiologic mechanisms that rule its functions. 
One difficulty in understanding sleep is that it is not a unitary state, but a combination of two 
sub-states of distinct brain activity actively generated in specific brain regions [37]. There-
fore, sleep definition requires the combined input from an electroencephalogram (EEG), an 
electrooculogram (EOG), and an electromyogram (EMG). The resulting polysomnogram 
identifies the sleep state and stages [38]. Each stage of sleep has a characteristic EEG fre-
quency and waveform (Figure 1-A1, Appendix 1) [38]. One state is characterised by Rapid 
Eye Movements (REM) and is usually termed REM Sleep (REMS); the other, in which no 
rapid eye movements occur, is known as non-REM Sleep (NREMS). 
In humans, NREMS is usually subdivided into stages 1-4, which correspond roughly to in-
creasing depth of sleep, decreasing muscle tone and cognitive quiescence [11, 37]. Stages 3 
and 4 are often grouped together under the label ‘slow wave sleep’ (SWS) [38]. Interesting-
ly, in NREMS the metabolic rate is increased above resting waking levels [38]. REMS is a 
completely different sleep stage, characterised by a virtual absence of muscle tone in an-
tigravity muscles, a largely awake brain, and dreaming. In the normal sequence (called 
‘sleep architecture’), waking is followed by NREMS’s lighter stages (1 and 2) and then 
within 10 to 20 minutes by SWS. These stages of deeper sleep are maintained for nearly one 
hour in normal young individuals but are much shorter (5-10 min), if present at all, in older 
individuals. Lighter stages of NREMS then re-appear and the first REM period is initiated 
[37, 39]. This cycle is repeated three to four times during the night but with decreasing 
amounts of SWS and increasing amounts of REMS [38]. It can be said that the deepest stag-
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es of sleep occur predominantly during the first half of sleep, whereas the significantly long-
er and more intense REM periods occur during the second half of the night [11].  
The sleep/wake cycle is a component of the body’s overall circadian rhythm [11]. The tim-
ing, duration, and depth, or intensity, of sleep is regulated by two interacting processes, the 
relationship of which has been formalised in the Two-Process Model of Sleep Regulation 
[40-42]. This model provides an understanding of the physiological mechanisms that drive 
sleep and wakefulness [40, 41]. Visually, the model is a wave-like structure that shows the 
relationship between the two physiological processes of sleep regulation (Figure 2-A1). The 
homeostatic/somnostat component (Process S) increases during the awake state (i.e. drives 
the need for sleep) and decreases during sleep (i.e. decreases the need for sleep). Process S 
reflects the physiologic need for sleep, which builds across the day and dissipates through 
the night [42]. If there is a deficit in nocturnal sleep, a compensatory mechanism boosts the 
need for sleep, which can be translated into a sleepy feeling in the daytime and need for 
napping. The circadian process (process C) determines alterations of high and low sleep 
propensity that are independent of prior levels of sleep/wakefulness or the wake-like process 
S, which determines the onset and end of sleep [40, 41]. Conversely, process C is the mech-
anism that helps the body stay asleep. It is directed by a clocklike mechanism that resides in 
the hypothalamus; this ‘pacemaker’ works in conjunction with neurotransmitters that facili-
tate sleep (such as melatonin) and thermoregulatory processes (rhythm of core body temper-
ature) [43]. The coordination between the two dynamic processes modulates the onset and 
offset of sleep as well as the rhythms of sleep propensity, wake propensity and the degree of 
daytime alertness. Importantly, onset and maintenance of normal sleep patterns are depend-
ent on the satisfaction of a number of conditions, including: 
 Appropriate timing of sleep within the 24-hour circadian rhythm; 
 Adequate level of physical comfort; 
 Acceptable sleeping environment; 
 Intact central nervous system function; and 
 Relative absence of psychological distress and psycho-physiologic arousal [11]. 
That said, the restorative functions of sleep are dependent on a reasonably uninterrupted 
sleep architecture, which, in many medical conditions, is adversely affected. Hence, factors 
that oppose or enhance the aforementioned processes can have significant effects on the tim-
ing, duration and structure of sleep, and daytime wakefulness (see Section 1.5) [4, 43]. 
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1.3. Classification and Terminology of Sleep/Wake Disorders 
Alterations in normal or habitual sleep (the one a person is used to consider as normal and 
‘functions’ as normal for them) mark the onset of sleep/wake disorders, which may be short-
term or persist for long periods of time. Sleep/wake disorders include a wide array of prob-
lems characterised by the symptoms of insomnia, excessive daytime sleepiness, or abnormal 
movements, behaviours, or sensations during sleep [4, 43]. Traditionally, sleep/wake disor-
ders have been classified according to the American Academy of Sleep Medicine (AASM) 
in the International Classification of Sleep Disorders [44] into three primary groups: (i) dys-
somnias, (ii) parasomnias, and (iii) sleep disorders secondary to medical or psychiatric con-
ditions. Dyssomnias are those disorders that result in disturbance in quality, quantity, or tim-
ing of nocturnal sleep, or produce excessive daytime sleepiness. Dyssomnias may be related 
to intrinsic factors (e.g., idiopathic insomnia, obstructive sleep apnoea, periodic limb move-
ments), extrinsic factors (e.g., medications, environmental conditions), or circadian rhythm 
factors. (e.g., shift work, irregular sleep/wake pattern, advanced or delayed sleep phase). 
Parasomnias include abnormal behaviours or sensations during sleep, such as nightmares, 
sleep walking, and bruxism. The third category includes sleep disorders associated with 
medical or psychiatric disorders, such as Parkinson’s disease, sleep-related epilepsy, and 
mood disorders. However, a recent revision of sleep/wake disorders suggested their catego-
risation into the following eight groups [45]: 
 Insomnias: Primary disorders that lead to repeated difficulty with sleep initiation, 
duration, consolidation, or quality; this difficulty occurs despite adequate time and 
opportunity for sleep and results in daytime impairment; 
 Sleep-related breathing disorders: They are characterised by disordered respira-
tion during sleep; 
 Hypersomnias of central origin: Disorders characterised by the primary complaint 
of daytime sleepiness. This is unrelated to circadian rhythm sleep disorders, sleep-
related breathing disorders, or other disorders; 
 Circadian rhythm sleep disorders: Recurrent or chronic patterns of sleep impair-
ment resulting from alterations to the circadian system or misalignment between cir-
cadian rhythms and the 24-hour social and physical environments (e.g., shift work, 
irregular sleep/wake patterns, advanced or delayed sleep phase); 
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 Parasomnias: Undesirable physical events or experiences that occur at sleep onset, 
during sleep, or during arousal from sleep (e.g., nightmares, sleep terrors, sleep 
walking, or enuresis); 
 Sleep-related movement disorders: Conditions primarily characterised by relative-
ly simple, stereotyped movements that disturb sleep (e.g., periodic limb move-
ments); 
 Isolated symptoms and unresolved issues: Symptoms that either lie at the border-
line between normal and abnormal sleep or that exist on a continuum of normal to 
abnormal events in sleep (e.g., snoring); 
 Other sleep disorders: Disorders not otherwise classified (e.g., other physiolog-
ic/organic sleep disorders) [11, 43, 45]. 
 
Numerous additional sleep-related terms can help characterise sleep/wake disorders and are 
outlined in Table 1-A2 (Appendix 2). 
Two of the most common complaints or symptoms, also defined in the International Classi-
fication of Sleep Disorders, are insomnia and excessive daytime sleepiness. Insomnia may 
be a primary sleep disorder (see above) or a symptom of one of many other sleep/wake dis-
orders, such as sleep-related breathing disorders [43]. Sateia and Santulli [11] argue that in 
clinical practice, insomnia can be defined as a subjective complaint of poor sleep, and in that 
sense insomnia is a symptom rather than a diagnosis. This definition encompasses com-
plaints of insufficient sleep, difficulty initiating or maintaining sleep, interrupted sleep, poor 
quality or ‘non-restorative’ sleep, or sleep which occurs at the wrong time in the day-night 
cycle [11]. A comprehensive description should include clarification of the nature of the 
complaint and consideration of potential aetiologies, or contributing factors (see Section 
1.5). In most cases, sleep deprivation in the form of insomnia results in a broad spectrum of 
psycho-physiological changes, depending on the degree, type and duration of deprivation, 
and most frequently includes progressive fatigue, sleepiness, impairment of concentration, 
and irritability [11, 45]. 
Daytime sleepiness is defined as the inability to stay awake and alert during the major wak-
ing episodes of the day, resulting in unintended lapses into drowsiness or sleep; it also may 
be seen in a wide range of sleep/wake disorders as their most common consequence [4]. In-
terestingly, because of its often vague and non-specific presentation, the condition is fre-
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quently overlooked [11, 46]. The sleepy individual is inactive and poorly motivated [11], 
and may have little insight into the nature and severity of the problem or the negative effects 
that daytime sleepiness has on his/her life. In milder forms, daytime sleepiness may cause 
only minor decrements in social and occupational functioning [45]. When severe or exces-
sive, however, the condition can be debilitating, causing a broad range of neuropsychologi-
cal deficits that affect daytime functioning and quality of life [4]. Daytime sleepiness can be 
life-threatening because of associated alterations in alertness and reactivity [47]. What is 
more, while poor sleep can cause excessive daytime sleepiness, abnormal daytime sleep pat-
terns can also adversely affect nocturnal sleep. 
In contrast to the above-mentioned congruent terms, more general terms, such as sleep/wake 
disturbances, sleep problems, sleep disruption/fragmentation, sleep deprivation, alterations 
in sleep or impaired sleep, are also frequently reported in an attempt to describe complaints, 
symptoms, or groups of symptoms experienced by individuals. They are not diagnostic enti-
ties as defined by the AASM; yet, they are often implemented when a specific diagnosis has 
not or cannot be made [43]. The lack of standardisation in the definition of these terms has 
led to them being used interchangeably. In order to facilitate interpretation of findings in this 
study, use of such terms throughout the thesis will be employed to indicate the following 
concepts: 
 Sleep/wake alterations/impairments: Adverse changes in habitual sleep/wake pat-
terns that may lead to perceptions of ‘a problem’ with sleep. 
 Sleep deprivation/restriction: Diminished duration of nocturnal sleep that may 
lead to ‘sleep debt’. 
 Sleep disruption: Interruptions in nocturnal sleep that may lead to sleep fragmenta-
tion and perceptions of diminished sleep quality and restfulness. 
 Nocturnal sleep disturbances: Actual triggers occurring during the night such as 
feelings of hot/cold or nightmares that may lead to sleep impairments. 
 
 
1.4. Key Parameters for the Assessment of Sleep in Cancer Populations 
The empirical observation of impaired sleep in people affected by cancer has been supported 
and boosted by systematic research. Two major assessment methods have been used in sleep 
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research in the context of cancer; most frequently these employ subjective measures, but 
also, increasingly, objective. Subjective sleep measures range from single-item scales (e.g. 
visual analogue scales) to multi-item, multidimensional assessment tools (e.g. sleep-specific 
questionnaires, sleep diaries/logs, diagnostic interviews) [4, 43] that evaluate a variety of 
aspects of sleep [13]: sleep quality, number of awakenings, depth and length of sleep, feel-
ings on arising, satisfaction with sleep, and soundness of sleep [4, 48]. Such features reflect 
an individual’s perceptions; thus, measuring these perceptions has been argued to be utterly 
important in nursing research [49]. Conversely, the gold standard for the objective meas-
urement of sleep is laboratory or in-home ambulatory polysomnography. It entails the simul-
taneous recording via EEG, EOG and EMG [50] of multiple variables, which allows for de-
tecting specific sleep and wake states [43] through the provision of in-depth information 
about stages of sleep. An alternative method, (wrist) actigraphy can be used to record 
movement over time in the form of activity and rest counts, thereby providing an indirect 
objective measurement of sleep [43, 51]. Compared to subjective sleep measures, objective 
measures have the advantage of providing highly reliable data on several sleep and wake 
variables, as well as on circadian rhythms. 
Current evidence indicates that sleep/wake impairment in the cancer continuum is a multi-
faceted experience, including total sleep time of less than 50 hours per week [52]; fewer than 
usual hours of sleep [53]; multiple awakenings in the middle of the night; difficulty falling 
asleep [53, 54]; decreased sleep duration and efficiency [55]; early morning awakenings, leg 
restlessness or interruptions of breathing during sleep [54]; drowsiness [56], daytime sleepi-
ness [12] and the need to nap at unusual hours during the day [53]; frequent and/or unpleas-
ant dreams [12, 14]; feelings of inadequate restfulness the next day[55]; and the need for the 
use of hypnotics or sedatives [55, 57, 58]. Despite current advances, knowledge gained so 
far is still fragmentary, mainly because of methodological inconsistencies that limit compa-
rability of assessment evidence. First, whereas it has become evident that a thorough de-
scription of sleep/wake patterns requires comprehensive evaluation of several key features, 
sleep studies in the context of cancer have only rarely or sporadically included all or most of 
them. Second, whereas prevalence rates for sleep deficits have been consistently reported, 
data pertinent to severity are lacking. Third, inadequate research measures, inconsistencies in 
the phase of treatment or cancer experience, as well as a lack of consensus regarding which 
sleep parameters to measure and report, have all played an important role in contributing to 
these inconsistencies within the knowledge. Due mainly to these issues, assessment has been 
identified as one of the major challenges that researchers face when examining the 
sleep/wake patterns of patients with cancer and/or their caregivers [43]. 
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In light of an evident lack of standardisation of variables required for a comprehensive as-
sessment of sleep and wakefulness, in 2005, a panel of expert clinicians and researchers pro-
posed the use of a core of nine sleep/wake parameters to provide a common language for the 
quantification of the problem in patients with cancer and their caregivers [43, 49]. The sys-
tematic use of these variables was anticipated to increase consistency in terminology that 
could allow studies to be easily compared and contrasted [4, 43, 49]. These key sleep pa-
rameters include total sleep time; sleep latency; nocturnal awakenings; wake time after sleep 
onset; napping during the day; excessive daytime sleepiness; quality of perceived sleep; sta-
bility of circadian rhythms; and sleep efficiency. Definitions of these terms are outlined in 
Tables 2-A2 and 3-A2. Because of the complex nature of the problem, no single parameter 
is recommended to screen for sleep/wake impairment in patients with cancer and their care-
givers [49]. Instead, all nine parameters collectively describe the nature/characteristics of 
impaired sleep. 
 
 
1.5. Aetiology of Sleep/Wake Impairment: Theoretical Background 
The aetiology of sleep/wake impairments in patients with cancer and their caregivers is mul-
tidimensional, given that numerous factors are likely to alter the normal regulatory processes 
of sleep [4, 59]. As described earlier, onset and maintenance of normal or habitual sleep is 
dependent on a host of person- and environment-related prerequisites (see Section 1.2). Yet, 
additional sleep-impairing factors can exert adverse effects. Knowledge of the underlying 
reasons for sleep impairment is essential for a comprehensive assessment and targeted man-
agement of sleep/wake disorders [60]. Given that care is specifically rather than vaguely fo-
cused on the potential source of the problem, the latter can be resolved even if no actual 
hypnotic treatment is administered. 
One method of identification and classification of sleep-impairing factors is the use of cer-
tain theories, models or frameworks as a structured way to better understand pertinent defi-
nitions and assessment/measurement of specific sleep variables [61]; thus, familiarity with 
this body of knowledge is regarded to be paramount [49]. In spite of their importance, a re-
cent literature review revealed that only three out of ten identified sleep studies in patients 
with cancer included a description of a sleep-related theory, model or framework that pro-
vided conceptual guidance [61]. Three conceptual models were found to focus on 
sleep/wake disturbances as a primary variable of interest, whereas eight additional mod-
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el/theories tended to include sleep/wake disturbances as a secondary variable or as one vari-
able within a cluster of several symptoms [61]. Two of the most influential models related to 
sleep/wake disturbances are the Conceptual Framework for Understanding Impaired Sleep 
and Spielman’s Three-Factor Insomnia Model, which can be used in conjunction to offer 
various approaches to the examination of sleep-impairing factors in people with cancer and 
their caregivers. 
 
1.5.1. Conceptual Framework for Understanding Impaired Sleep 
According to the Conceptual Framework for Understanding Impaired Sleep [62], sleep loss 
can be conceptualised to result from sleep deprivation/restriction (i.e. inadequate amount of 
sleep) and/or sleep disruption (i.e. fragmentation of sleep). As outlined in Figure 1-1, sleep 
deprivation can be the consequence of self-imposed sleep restriction such as poor sleep hy-
giene or multiple responsibilities, and/or of noxious stimuli in the sleeping environment. The 
resulting ‘sleep debt’ can increase daytime sleepiness and dysfunction. Alternatively, sleep 
fragmentation can result from a host of sleep-impairing factors, including health conditions, 
physical and/or psychological distress, alcohol/caffeine intake, nicotine use, relationships 
and situations in the home, restless bed partners, or own disturbances such as disordered 
breathing or parasomnias. Sleep disruption may affect an individual’s perception of sleep 
quality and restfulness gained. Regardless of the underlying mechanism, sleep loss may 
place an individual at risk for adverse health outcomes and diminished well-being. 
 
1.5.2. Spielman’s Three-Factor Insomnia Model 
Spielman’s Three-Factor Insomnia Model (also known as the 3P model) proposes interac-
tions among predisposing, precipitating, and perpetuating factors of insomnia symptoms 
(Figure 1-2) [63, 64]. The model includes both stress and behavioural factors to explain the 
evolution of insomnia symptoms and describes how individual differences cause initiation of 
acute disturbances in sleep that become chronic. The model can be used for the classification 
of explanatory factors into three comprehensive groups: 
 Predisposing: Highly subjective traits that increase a person’s overall risk and vul-
nerability to develop sleep disorders. Factors that predispose the development of in-
somnia symptoms may include advancing age, female gender, arousability, past pa-
tient and family history of sleep disorders and medical illnesses, and disruptive sleep 
behaviours (in other words, sleep hygiene) [60, 63-65]. 
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Figure 1-1. Lee Conceptual Model of Impaired Sleep. Source: Lee et al. 2004 [62] 
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 Precipitating: Situations and conditions that, albeit temporary, are actual triggers of 
insomnia symptoms. Diseases such as cancer constitute possible contributors to 
sleep problems, since they are not single events but a succession of major stressful 
factors, each of which can act by itself and detrimentally on sleep [60]. Factors like-
ly to promote sleep problems in people with cancer and their caregivers include dis-
ease-related, treatment-related and psychosocial factors. 
 Perpetuating: Variables involved in the reinforcement of insomnia symptoms over 
longer periods of time. In many cases, sleep problems are simply opportunistic and 
normal rhythms can be restored after precipitating factors have abated or after an in-
dividual’s adjustment to their prolonged occurrence. However, insomnia symptoms 
can become chronic, especially among the more susceptible individuals. Perpetuat-
ing factors exert their negative effects by increasing alertness (physical, cognitive, 
behavioural) and causing anxiety (the inherent ‘pressure’ to sleep) [64]. Several of 
these variables (e.g., maladaptive sleep behaviours or faulty beliefs and attitudes 
about sleep) are difficult to change and require training and consultation [59]. 
 
 
Figure 1-2. Spielman’s Three-Factor Insomnia Model. Source: Glovinsky et al. 2008 [66] 
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Collectively seen, the models suggest that a host of internal (person-related) and external 
(environment-related or circumstantial) factors can interfere with habitual sleep/wake pro-
cesses at different levels and through different mechanisms. A group of factors can alter the 
homeostatic/somnostat process of sleep, heighten arousal and increase the likelihood for 
sleep deprivation. Another group can interfere with the circadian process of sleep and cause 
disruption/fragmentation. The ways that these factors act can be direct (precipitating and/or 
perpetuating effects) or indirect (predisposing effects). In addition, depending on their na-
ture, some of these factors contribute only in acute and transitory episodes of sleep/wake 
disruption (precipitating), whereas others potentially result in prolongation and chronicity of 
sleep deprivation (predisposing and/or perpetuating). In general, patients with cancer and 
their caregivers are considered to be at high risk for disruption in their sleep/wake patterns 
because of a number of such factors that may alter normal sleep regulatory processes. A de-
tailed description of sleep-impairing factors in women with early stage breast cancer and 
their caregivers is provided in Chapters 2 and 3, respectively. 
 
 
1.6. Summary 
Impaired sleep/wake patterns can be frequent complaints among people affected by cancer 
that pose significant consequences on their daytime functioning and general well-being. 
Eight groups of sleep/wake disorders have been suggested; however, symptoms of insomnia 
and excessive daytime sleepiness are those most commonly reported. Assessment of 
sleep/wake patterns is paramount to the effective management of these potentially debilitat-
ing problems. Nine parameters of sleep/wake disturbance have been proposed to provide a 
common language in studies assessing patients with cancer and/or informal caregivers. The-
se parameters can serve as key outcomes in both exploratory and experimental studies. Un-
derpinned by theoretical models, this research will be able to investigate how these variables 
are affected by a host of factors that may predispose individuals to alterations in sleep archi-
tecture, as well as precipitate and/or perpetuate sleep deprivation and disruption. 
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CHAPTER 2. 
Breast Cancer and the Experience of Impaired 
Sleep/Wake Patterns 
 
 
2.1. Breast Cancer Epidemiology, Clinical Evaluation and Management 
Worldwide, breast cancer is the most frequently diagnosed life-threatening cancer in women 
[67]. Current data reveal that 425,147 new cases of invasive breast cancer occurred in 
Europe in 2008 [68]. The lowest European rates are seen in eastern and southern Europe and 
the highest in northern and western Europe [69, 70]. In the UK, breast cancer is the most 
common cancer in women: 46,458 women were diagnosed in 2008 [68, 70] accounting for 
31% of all cancers [71], while around 126 new cases of breast cancer are diagnosed each day 
[72]. 
Over the past 35 years, breast cancer incidence rates have risen (and still rise) globally, with 
the highest rates occurring in the westernised countries. Reasons for this trend include 
changes in reproductive patterns, increased screening, dietary changes, and decreased activi-
ty. Although breast cancer incidence is on the rise, breast cancer mortality has been decreas-
ing, especially in industrialised countries [71, 73]. Increased public awareness and improved 
screening have led to earlier diagnosis at stages amenable to complete surgical resection and 
curative therapies [74]. Consequently, survival rates for breast cancer have improved signifi-
cantly, particularly in younger women [67]. Almost 2 out of 3 women with breast cancer 
now survive their disease beyond 20 years. The most recent estimate (2008) suggests that 
around 550,000 women are alive in the UK, who have had a diagnosis of breast cancer [75]. 
Nevertheless, supportive care needs of women living with and beyond breast cancer still ex-
ist, thus urging for comprehensive assessment and management services. 
Breast cancer is diagnosed by taking a biopsy, or sample of breast tissue, and examining it 
under the microscope [72]. Subsequent treatment decisions are based on the extent of the 
disease and characteristics of the cancer, menopausal status and general health of the patient. 
Breast cancers are derived from the epithelial cells that line the terminal duct lobular unit, 
and are usually subdivided into non-invasive (in situ) and invasive cancer [71, 76]. Cancer 
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cells that remain within the basement membrane of the elements of the terminal duct lobular 
unit and the draining duct are classified as in situ. Conversely, an invasive breast cancer is 
one in which there is dissemination of cancer cells outside the basement membrane of the 
ducts and lobules into the surrounding adjacent normal tissue [76]. 
When an invasive breast cancer is diagnosed the extent of the disease should be assessed and 
the tumour staged. Prognosis in breast cancer relates to the stage of the disease at presenta-
tion [76]. The American Joint Committee on Cancer staging system groups patients accord-
ing to extent of the primary tumour (T); absence or presence of lymph node metastasis (N); 
and absence or presence of distant metastasis (M). This classification system is widely 
known as the TNM system [76]. It is often used in combination with the International Union 
Against Cancer (Union Internacional Contra la Cancrum, UICC) staging system, which clas-
sifies breast tumours into five stages [71] (see Table 4-A2). The earlier the cancer is diag-
nosed, the more favourable survival rates are. Around 9 out of 10 women diagnosed with 
stage I breast cancer survive their disease beyond five years. However, this drops to around 
1 out of 10 if diagnosed with stage IV disease [72]. The term early stage breast cancer re-
fers to those patients whose cancer has not spread outside the breast and the axillary lymph 
glands under the arm on the same side as the tumour (stages I-IIIA). Selection of patients for 
the present study was based on the afore-mentioned definition. 
The treatment of early stage breast cancer is usually multimodality, requiring careful co-
ordination and planning among all members of the multidisciplinary team. Treatment at this 
stage of the disease is given with curative intent [72]. Surgery is considered to be the prima-
ry treatment for breast cancer, and many patients with an early-stage disease are managed 
with surgery alone [67]. This may consist of either breast conservation (e.g., wide local exci-
sion, central excision, quadrantectomy) or mastectomy, which may be followed by immedi-
ate or delayed breast reconstruction and adjuvant treatment [67, 72, 77]. 
Adjuvant therapy is given to reduce the risk of cancer recurrence from the microscopic 
spread of cancer cells to the axillary lymph nodes that is known or suspected, and cannot be 
detected at the time of diagnosis. Among the different modalities of adjuvant treatment in 
breast cancer, chemotherapy has become firmly established as one of the major therapeutic 
modalities as it reduces the risk of recurrence and death by about 30%-50% and 20%, re-
spectively [72, 78-80]; however, its benefits in women over 70 are not well established. Be-
cause of its side-effects, adjuvant chemotherapy is usually given to women at significant risk 
of recurrence (i.e., lymph node metastasis), or if their cancers are oestrogen-receptor nega-
tive [72]. Nevertheless, there has been an increasing trend to give chemotherapy to almost 
all young patients with operable breast cancers regardless of lymph node status as there is 
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evidence of real benefit in their disease-free survival [79]. Regimens based on anthracyclines 
such as doxorubicin and epirubicin are the current standards of care [81]. Other commonly 
used drugs in the treatment of early stage breast cancer include alkylating agents (e.g., cy-
clophosphamide) and anti-metabolites (e.g., methotrexate, 5-fluorouracil). Examples of 
some widely used combination regimens include the following: 
 CMF = cyclophosphamide, methotrexate, fluorouracil 
 AC = doxorubicin, cyclophosphamide 
 EC = epirubicin, cyclophosphamide 
 FEC = fluorouracil, epirubicin, cyclophosphamide 
 CAF = cyclophosphamide, doxorubicin, fluorouracil 
 E-CMF = combination of epirubicin with the CMF regimen [79]. 
The addition of a taxane (paclitaxel or docetaxel) is usually recommended in sub-groups of 
women with higher risk disease, including those with increasing size of the primary cancer, 
higher histological grade and presence of tumour in the axillary nodes [72, 82]. 
 
 
2.2. Experiencing Early Stage Breast Cancer 
The experience of living with breast cancer, even at an early stage, can have a multilevel 
impact on a woman (physical, psychological/emotional, social) and may affect her over a 
trajectory that is extended over (at least) three distinct, yet interrelated, phases: pre-
diagnosis/diagnosis phase; pre-/treatment phase; and recovery and follow-up phase. This 
‘treatment’ pathway is not always as straightforward as described; rather, it may represent a 
particularly demanding and difficult ‘roller-coaster’-like experience (Figure 3-A1), which 
deserves the attention of the multidisciplinary team throughout its trajectory [83]. 
A diagnosis of breast cancer can be numbing, not just for its immediate impact, but because 
it represents the loss of present familiarity and the loss of a sense of control and future [83-
85]. Women display numerous different reactions to their diagnosis of breast cancer. Shock, 
feelings of anger, anxiety, sadness and despondency are entirely appropriate responses to a 
life-threatening situation. However, when they become persistent and overwhelming, these 
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feelings can be profoundly damaging [84]. Among other related areas of functioning, sleep 
may also become affected. 
Obtaining a treatment plan and relevant information can afford some relief from anxiety. 
Yet, the emotional ‘roller-coaster’ keeps on going, and anxiety occurs as the woman waits 
for treatment to commence. Fears with regard to side effects and their impact, as well as the 
likelihood of treatment failure may be prominent [83]. During treatment, then, the woman 
has to deal not only with the ongoing emotional and psychosocial impact of the diagnosis, 
but also the burdens and costs of disfiguring, toxic and lengthy treatment [84]. In most cases, 
treatment begins with surgery. The physical removal of breast cancer can be reassuring but 
leads to some kind of disfigurement (partial or total removal of the breast), which induces a 
profound sense of loss and threatens a woman’s sexual identity and ability for social interac-
tions [77, 84]. However, it is chemotherapy that has been traditionally associated with the 
most debilitating side effects and the highest emotional burden [85, 86]. Although, nowa-
days, symptom management shows considerable progress, most women with breast cancer 
will experience at least some chemotherapy-related symptoms, such as nausea and vomiting, 
fatigue, and hot flashes and/or night sweats [84], in most cases accompanied by disturbed 
sleep and daytime sleepiness [87-93]. The daily disruption and cumulative effect of having 
chemotherapy may be significant [94]. Even the treatments used to counteract the side ef-
fects of chemotherapy can cause side effects of their own; for instance, steroids as part of the 
anti-emetic regime may increase appetite resulting in weight gain and feelings of an altered 
body image and decreased attractiveness [85]. Aside from its emotional and physical impact, 
chemotherapy can result in increased psychological manifestations. The incidence of anxiety 
and depression has been described as significantly higher in women receiving chemotherapy 
after mastectomy, directly related to the degree of toxicity experienced [95, 96]. 
The period following treatment can be particularly difficult. In addition to side effects con-
tinuing to be experienced, the loss of contact with the health care team can trigger consider-
able fear and uncertainty [83, 84]. Women struggle to re-enter their world and regain their 
life; some of them will seek to return to work or previous engagements. Having lived with 
cancer during the intensive period of treatment might be followed by changes, including 
physical discomfort, sleep disturbances, difficulty in emotional relationships, empowerment 
or regret, and fragility, which will influence the extent of and time for a woman’s adjustment 
[84, 97, 98] during rehabilitation and survivorship. 
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2.3. Sleep/Wake Patterns of Women Receiving Chemotherapy for Early 
Stage Breast Cancer 
Sleep has been suggested as an area of functioning that is frequently and largely impaired in 
women who go through the lived experience of breast cancer [99]. Of note, regardless of 
disease stage, post-diagnosis cases of insomnia reach 33% [100], while post-treatment inci-
dence of impaired sleep/wake patterns widely ranges between 57% and 99% [87, 101-103]. 
These facts have given rise to an impressive number of sleep studies, which have invariably 
explored sleep/wake disturbances as a result of both the disease itself and the treatment [33, 
88, 100, 102, 104-110]. A significant part of this research has specifically focused on wom-
en diagnosed with breast cancer at an early stage (I-IIIA), especially in the context of 
chemotherapy treatment. It can be argued that research in this area has been legitimised as 
highly significant due to the increased vulnerability of this specific population [99]. As de-
scribed earlier, the cumulative effect of toxic agents on bodily functions, the physical impact 
of concurrent, frequent, severe and/or distressing symptoms, the emotional burden of daily 
disruptions in life, together with a host of anxieties and depressed mood, may well be re-
sponsible for, or pave the way towards, alteration of habitual sleep/wake patterns. Such body 
and life changes become especially important for women already susceptible to sleep altera-
tions given the unseen or evidenced impact of breast cancer diagnosis and of primary breast 
surgery on their sleep. By interfering with the onset and maintenance of normal sleep, and 
depending on their very nature, these triggers can contribute to a spectrum of experienced 
sleep impairment even before, but mainly during and after chemotherapy for early-stage 
breast cancer. 
A systematic search for publications that evaluated the sleep/wake patterns of women with 
early-stage breast cancer across chemotherapy treatment was conducted. This systematic 
review aimed to answer two questions: 
a. What do research findings report about key sleep/wake parameters of women receiv-
ing neo-/adjuvant chemotherapy for breast cancer? 
b. What are the methodological and research gaps in this body of evidence? 
The systematic search aimed to identify original research studies conducted in the context of 
early-stage breast cancer, specifically focussing on examination of women’s sleep/wake pat-
terns during neo-/adjuvant chemotherapy. Studies were identified by systematically search-
ing three research and evidence electronic databases, namely Medline (1948-2011 May week 
02), CINAHL (Beginning-2011), and EMBASE (1980-2011 Week 18). An initial search 
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strategy was devised and subsequently revised through an iterative process (Appendix 3). 
Using a snowballing strategy, the reference lists of retrieved studies were also examined for 
any studies that may have been overlooked. Reference lists of key topical research reviews 
also were examined [12, 13, 43, 49, 59, 60, 99, 111-115]. Additional literature was sought 
through use of the search engine Google Scholar to locate relevant publications using the 
aforementioned key words. 
Studies were eligible in this review if they were written in the English language; were con-
ducted with adult (>18 years of age) women diagnosed with early-stage (I-IIIA) breast can-
cer [71]; examined sleep/wake patterns as a primary or secondary variable via use of sleep-
specific measures (objective and/or self-reported); examined sleep/wake patterns prior to, 
during and after adjuvant/neo-adjuvant chemotherapy treatment, in chemotherapy naïve pa-
tients; and were published as original articles in peer-reviewed journals from January 1980 
to July 2011 representing the period in which sleep-specific instruments were developed, 
and studies of sleep within different clinical populations emerged. Exploratory studies, both 
quantitative and qualitative, were included, although intervention studies were also consid-
ered if they provided baseline and/or control arm sleep data. 
Studies were excluded on the basis of the following criteria: (a) studies with mixed samples 
with regard to type of disease or treatment, except if data for patients with early-stage breast 
cancer were reported separately; (b) studies using generic quality of life measures or single 
item tools to elicit information about sleep patterns; (c) studies conducted with patients pre-
selected for insomnia or impaired sleep; (d) studies where the stage of disease or the type of 
chemotherapy were not explicitly described; and (e) unpublished studies, dissertation stud-
ies, or conference presentations. 
A shortlist of papers was initially compiled, where titles and abstracts were screened to as-
sess relevance to the review. Potentially eligible papers were retrieved in full and checked 
for adherence using the afore-mentioned inclusion and exclusion criteria. Study characteris-
tics of the finally selected studies were extracted using a systematic scheme. Due to hetero-
geneity of the studies retrieved, findings were only integrated in a narrative synthesis. In or-
der to summarise findings with regard to specific sleep/wake parameters, weighted grand 
means (X¯ ) and standard deviations were calculated based on information from different 
studies, and adjusting for different sample sizes. The weighted mean is similar to the com-
mon arithmetic mean, where instead of each of the data contributing equally to the final av-
erage, some data contribute more than others, namely those deriving from bigger sample 
sizes. The weighted mean’s mathematical definition is given in Figure 4-A1. 
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The evidence categories employed by the Department of Health in the National Service 
Frameworks (DOHNSF, 2001) [116] were used for levelling evidence, and aiding appraisal 
of quality of the papers reviewed. This framework was used because it has been piloted for 
use with both peer-reviewed and non-peer-reviewed research [117]. Table 5-A2 outlines the 
levels of evidence as established using the DOHNSF validated grading hierarchy. No studies 
were excluded on the grounds of quality, given the lack of agreement in the application and 
interpretation of quality criteria [118]. 
The selected studies were analysed, summarised and synthesised to provide evidence regard-
ing alteration in key sleep/wake parameters in this population. Additional sleep/wake pa-
rameters, including perceived sources of sleep disturbance, use of sleep aids, insomnia syn-
drome, feelings upon waking, and total rest time, also were appropriately summarised or 
clustered into respective categories. A brief description of the characteristics of the included 
studies can be found in Appendix 3. Findings presented below and in Appendix 3 were pub-
lished in a peer-reviewed journal and can be found in Kotronoulas et al. [119] (see Appendix 
7). 
 
2.3.1. Overall Incidence of Sleep/Wake Impairment 
Evidence suggests that sleep in women with early-stage breast cancer may already be dis-
turbed before chemotherapy commences [120, 121]. Data show deficits in almost all key 
sleep parameters before the first cycle of adjuvant/neo-adjuvant chemotherapy, mainly in the 
last 48-72 hours before treatment [9, 121-124], although wider assessment time frames rang-
ing from 1 week to 1 month have also been used [8, 120, 125]. However, impairment of 
sleep/wake patterns is maximised during adjuvant chemotherapy [90]. A focus on the first 
(CThC1) [7-9, 49, 104, 123, 126-128], third (CThC3) [122, 124, 129] and fourth (CThC4) 
[8, 9, 122, 123, 130] chemotherapy cycles was noted in the relevant studies. Purposeful as-
sessment of women’s sleep/wake patterns soon after (mainly within the following 30 to 60 
days) the last chemotherapy cycle was infrequently included as an important clinical end-
point within the studies reviewed [49, 104, 122, 123, 131]. Nevertheless, the on-going sleep 
problems evidenced suggest that sleep alterations initially occurring during treatment can 
become chronic in nature [111]. 
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2.3.2. Subjective Sleep Quality 
Subjective sleep quality – the perception of sleep as restorative and sufficient for function 
[113] – was reported to be generally and consistently poor throughout the course of chemo-
therapy [7, 8, 121-125, 129, 130, 132, 133]. Despite inconsistencies or limited available da-
ta, it can be inferred that initially poor perceived sleep quality might reach a peak during 
treatment, with a tendency for a slight improvement close to the end of treatment. However, 
only partial or no significant over-time relationships between distinct time-points exist [122, 
130, 131], which could suggest that fluctuations in poor sleep quality are subtle rather than 
marked, and ratings of greater sleep disruption may be associated with temporal adverse 
events during a period of consistently poor quality of sleep. Among women reporting lower 
pre-treatment sleep disruptions, adverse effects on their sleep patterns might be more evident 
during treatment [8]. Moreover, greater sleep disturbance at baseline might anticipate the 
maintenance of poor sleep quality during treatment [8], but more research is needed to im-
plicitly confirm this hypothesis. 
 
2.3.3. Sleep Efficiency 
Despite progressive decline, sleep efficiency remained within normal range for the majority 
of women and across all phases of chemotherapy. Predominantly within the first week prior 
to chemotherapy initiation, sleep efficiency was found to be at or above the normal cut-off 
value of 80%, with a weighted grand mean of 85.2% (range of means 75.9%-89.1%) based 
on actigraphic recordings [120-123, 125], and 89% based on daily sleep diaries [122]. Over 
the course of treatment, sleep efficiency presented with no major changes compared to base-
line as reported for the week following CThC1; however, during the first week after CThC4, 
objective sleep efficiency was found to average at 81.8% [122, 123, 125]. Kuo et al. [129] 
observed a similarly decreased sleep efficiency (79.9%-82.1%) during the active (week 1) 
and recovery (week 3) phases following administration of CThC3. Four weeks following 
four to eight cycles of adjuvant chemotherapy treatment, sleep efficiency was restored close 
to baseline based on actigraphic findings [104, 122, 123]. 
 
2.3.4. Nocturnal Total Sleep Time 
One to three days prior to chemotherapy treatment, total sleep time averaged at 392.4 
minutes (6.54 hours) based on actigraphic data [120-123, 125, 128, 134]. Similarly, a 
weighted grand mean of 0.89 (range 0.75-0.99) on the respective Pittsburgh Sleep Quality 
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Index (PSQI) component indicated duration of sleep of seven hours or less for the previous 
month [7, 120, 125, 130]. A trend towards somewhat longer sleep at night seemed to be 
maintained during chemotherapy treatment with actigraphic measures yielding weighted 
grand means of slightly more than seven hours of sleep in the first three days post-treatment 
initiation [7, 122, 128], and one week (7-10 days) after CThC3 [122, 129], whereas a drop to 
approximately 7 hours per night on average was evident following CThC4 [122, 123, 125, 
128]. Control data from a randomised clinical trial (RCT) suggested that at different time 
points following adjuvant treatment women’s nocturnal sleep time was slightly below 7 
hours per night [122, 123]. 
 
2.3.5. Sleep-Onset Latency 
Within the month prior to chemotherapy initiation, subjective sleep latency may well exceed 
the normal value of 20 minutes as evidenced by a weighted grand mean of 1.15 (range .92-
1.49) on the PSQI sleep latency component, implying that sleep latency may fluctuate be-
tween 16 to 30 minutes per night [7, 120, 121, 125, 130]. After initial chemotherapy admin-
istration [130] and over treatment continuation [130], a trend of consistent increases in sub-
jective sleep latency is evidenced, with perceived time to fall asleep possibly averaging 35 
minutes the week after CThC3 [129], and objective latency for all three weeks over-reaching 
20 minutes [104, 129]. Three weeks after CThC4, perceived sleep latency might approxi-
mate baseline levels [125], although actigraphic data may suggest that difficulty falling 
asleep still is prominent exceeding 25 minutes on average [104]. 
 
2.3.6. Nocturnal Awakenings 
Actigraphically-recorded episodes of awakening during the week prior to chemotherapy ini-
tiation may be particularly elevated ( =19.8/night) [120-123, 125]. During the first few 
nights (days 1-7) after CThC1, nocturnal awakenings may further increase in frequency [7, 
122, 126] with the first night’s sleep after treatment described as the most fragmented [7]. 
Over treatment continuation, awakenings seem to become stabilised at this high level. De-
spite a decline in their frequency, awakenings may still be prominent approximately 4, 8, 
and 12 weeks after the end of chemotherapy [104, 122, 123], although it is unclear to what 
extent this might be the result of other treatment modalities commencing at this particular 
period of time. Interestingly, self-reports may not corroborate objective findings, with per-
29 
 
 
ceived awakening episodes not exceeding an average of 3/night, irrespective of chemothera-
py phase [122, 129]. 
 
2.3.7. Wakefulness after Sleep Onset (WASO) 
The nights before chemotherapy initiation women may spend approximately 18% of their 
total rest time in wakefulness [120, 121]. During this period, WASO may be as high as 77.4 
minutes/night [120-122, 125], very similar to the week after initial treatment [7, 122]. Mani-
festation of multiple nocturnal awakenings during the course of chemotherapy may result in 
increased night-time restlessness and prolonged time in sleeplessness post-sleep onset, pos-
sibly exceeding one hour per night [104, 122, 123, 125, 129]. Using a 7-day sleep diary, 
Berger et al. [122] showed that WASO fluctuated during the course of treatment with greater 
increases occurring the week after CThC1 and CThC4, and a moderate decline 30 days or 
more after the end of treatment. Yet, self-reported WASO was considerably lower (approx-
imately 23-33 minutes lower) than the objectively recorded. 
 
2.3.8. Daytime Napping 
At pre-treatment, total daytime nap time may be increased, exceeding 1 hour per day 
( =64.8 minutes) [120, 121]. During treatment continuation, the overall need for rest may 
be further increased, and women who may be less active during the day may take more naps 
and spend more time resting [127, 129]. Disappointingly, evidence with regard to daytime 
napping during the course of chemotherapy is near to zero. In a small feasibility study, Ber-
ger et al. [124] described a trend towards increased objectively measured napping time in the 
first three days after CThC3 as compared to the days before chemotherapy administration, 
and days 5-7 post-treatment, which might have been related to concurrently increased levels 
of fatigue. 
 
2.3.9. Daytime Sleepiness/Dysfunction 
Daytime sleepiness per se has not been systematically examined in women receiving chemo-
therapy for early stage breast cancer. Instead, the broader term of daytime dysfunction as 
measured by the PSQI has received greater attention, but mainly during the pre-treatment 
period. Daytime dysfunction may be prevalent the week prior to chemotherapy initiation (  
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PSQI daytime dysfunction=.82) [7, 120, 121, 125, 130, 134], and further deteriorates during 
the first week post-initial treatment, and remain relatively increased over treatment continua-
tion (i.e., CThC3 and CThC4) [125, 129, 130]. In this period, daytime sleepiness might be 
more prominent immediately (first week) after chemotherapy rather than during the recovery 
phase, that is, the following two weeks in a three-weekly administered regimen [129]. Fol-
lowing treatment, levels of daytime dysfunction associated with sleepiness remain unknown. 
 
2.3.10. Circadian Rhythms 
Pre-treatment circadian rhythms in women with early stage breast cancer were described as 
robust and synchronised in the studies reviewed [9, 120, 121] with acrophases, mesors and 
amplitudes within normal limits. Nevertheless, progressively impaired circadian activity and 
rest cycles such as low activity, less consolidation of higher daytime, and lower night-time 
activity were recorded after initial chemotherapy administration [9, 49, 104, 126, 127, 134]. 
Similarly dampened circadian rhythms were prevalent over treatment continuation, especial-
ly after CThC3 and CThC4, where mesor, amplitude, up-mesor, down-mesor and rhythmici-
ty remained impaired [9, 49, 104, 126, 134]. After the end of treatment, sleep architecture 
was still altered with less SWS sleep and less REM sleep compared to normative data [135]. 
Yet, despite these deficits, circadian rhythms of women may be significantly closer to nor-
mal at this point compared to CThC1 and CThC3 [49]. 
 
2.3.11. Use of Sleep Aids 
Moore et al. [136] reported that 17%-20% of women were using a sleep aid two days prior 
to chemotherapy initiation, which slightly increased to 23% the first night post-treatment 
with a decline to 14% seven days later. This pattern was similar during cycles two through 
four, whereas an over-time decrease in sleep aid use was noted up to one year later. Prescrip-
tion sedative/hypnotics were the most frequent (46%) sleep aids in use, followed by over-
the- counter analgesics (24%), whereas use of alcohol or herbs was rather infrequent. Cos-
tantini et al. [137] concluded with similar findings; nearly 14% of the women were making 
use of a sleep aid prior to the treatment, whereas approximately 32% were prescribed a sleep 
aid during chemotherapy. Benzodiazepines (39.2%) and non-benzodiazepines (37.3%) were 
the most frequently prescribed sleep aids in this sample. 
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2.4. Sleep-Impairing Factors in Women Receiving Chemotherapy for Early 
Stage Breast Cancer  
Within the scope of a broader meta-analytic review of the literature looking at sleep-
impairing factors in women diagnosed with breast cancer, a systematic search was undertak-
en to locate studies where potential triggers for sleep/wake impairment had been examined 
in the context of neo-/adjuvant chemotherapy treatment. Studies were identified by system-
atically searching three research and evidence electronic databases, namely Ovid (Medline 
1988 – 2012), EMBASE (1980 – 2012), and CINAHL (Inception – 2012). The reference 
lists of included studies were searched by hand for any studies that may have been over-
looked. 
Studies were eligible to this review if they were published in English; employed any re-
search design (cross-sectional/longitudinal surveys, case-control studies, intervention con-
trolled/non-controlled trials etc.); studied adult (≥ 18 years of age) female patients with his-
tologically confirmed diagnosis of breast cancer, irrespective of tumour stage or type of 
treatment; examined sleep as a primary or secondary variable via use of sleep-specific 
measures, namely polysomnography or actigraphy (objective) and/or validated sleep 
scales/instruments (subjective); studied patients with no other medical co-morbidities; pro-
vided measures of statistical associations between sleep patterns and sleep-impairing factors 
in the target population; were published in the period between January 1990 and March 
2012. 
Studies were excluded if they utilised generic quality of life measures or symptom scales, or 
single item sleep scales to elicit information about sleep patterns; reported on mixed cancer 
samples, except if separate analyses and associations were reported for groups of patients 
with breast cancer; were unpublished studies, conference papers, or dissertation abstracts. 
Methodological quality of each study was evaluated through use of an adapted version of the 
14-item standardised checklist of pre-defined criteria introduced by Mols and colleagues 
[138]. Adaptation was based on information from previous similar reviews [139, 140]. Areas 
of concern included a study’s research design, sampling and bias, and data collection and 
measurement. Clarification of the different methodological components will be aided 
through use of the STROBE statement checklist for reports of observational studies (Table 
7-A2) [141, 142]. To promote an evidence-type approach, a validated grading hierarchy was 
also used to assess the level of evidence presented according to the type of research using 
the evidence categories employed by the DOHNSF (2001) [117] (Table 6-A2). 
32 
 
 
Twenty-six articles reporting on 16 studies were identified (Table 9-A2). Relevant findings 
were critically analysed and clustered into six broad categories. Figure 2-1 presents an 
overview of the identified factors, theoretical categorisation of which was performed accord-
ing to a combination of main points of the Conceptual Framework for Understanding Im-
paired Sleep [62] and Spielman’s Three-Factor Insomnia Model [63, 64]. Effect sizes r (rES) 
were calculated to estimate clinical significance of the identified relationships between 
sleep-impairing factors and different sleep/wake parameters (see Tables 11-A2, 12-A2 and 
13-A2). Research and clinical limitations of the current body of evidence also were dis-
cussed. A brief account of the characteristics of the included studies can be found in Appen-
dix 4. 
 
 
Figure 2-1. Classification of identified triggers of sleep/wake impairment in women receiving chemo-
therapy for early stage breast cancer according to two theoretical sleep models. 
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2.4.1. Demographic Factors 
In only six studies was age examined as a potential covariate of sleep/wake impairment [7, 
8, 121, 123, 125, 131, 132, 136, 143-148], hence evidence is inconclusive. At different 
points during chemotherapy treatment, Roscoe et al. [147] found no significant relationships 
between age and sleep/wake circadian parameters. Despite a similar overall absence of sig-
nificant associations, a few partial and/or weak correlations were reported in women after 
administration of CThC1. Specifically, actigraphic data showed that older women had great-
er ratios spent in WASO (rES=.17 to .28) [7], less total sleep time (rES=–.22 to –.35) [7, 8, 
121, 123, 125, 131, 132, 136, 143, 145, 146], and percentages spent asleep at night (rES=–.17 
to –.28) [7, 121, 123, 131, 136, 143]. Perceived sleep difficulty was also greater, yet of lim-
ited significance (rES=–.07), for older women 3 to 4 months post-surgery [144]. However, a 
secondary RCT data analysis showed that it was the younger rather than the older women 
who made greater use of sleep aids during CThC6 and 90 days after the end of adjuvant 
chemotherapy; clinical significance of this finding was nevertheless negligent (rES=–.05) 
[136]. 
Limited and inconsistent findings exist with regard to the role of race/ethnicity in increasing 
susceptibility of women with early stage breast cancer to sleep loss. Whereas Colagiuri et al. 
[144] concluded with no significant associations between subjective sleep difficulty and eth-
nicity, Liu et al. [146] reported a few associations of non-Caucasian race and greater overall 
sleep/wake impairment (rES=–.21), and more time in WASO (rES=–.22); yet, no differences 
were found for total sleep time, total wake time, or daytime napping duration [146, 148]. 
The sleep-impairing effects of educational attainment are also questionable as evidenced by 
the consistent absence of significant links to objective sleep data [7, 8, 121, 123, 125, 131, 
132, 136, 143, 145, 146]. In terms of subjective complaints, two studies provided only in-
consistent findings (rES=.04 [144] and rES=.22 [148]), yet women with a higher educational 
background seemed to be more susceptible to poorer sleep quality. In addition, education 
seems not to influence actual use of sleep aids during adjuvant chemotherapy [136]. The 
overall socio-economic status rather than education itself has been proposed as a more ro-
bust predictor of sleep quality among women [149]. In the context examined here, though, 
such a link is yet to be established. Similarly, the studies reviewed revealed no significant 
links between either employment status or personal income, and sleep [144, 146, 148]. The 
presence of a (sleep) partner/roommate and/or children at home could represent an additional 
source of sleep disturbance. Yet again, limited current evidence has failed to indicate sleep-
impairing effects for marital status [144, 146, 148] or presence of children at home [144]. 
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2.4.2. Medical and Cancer-Related Clinical Factors 
A host of medical and cancer-related clinical factors can, in theory at least, predispose wom-
en receiving adjuvant chemotherapy for breast cancer to sleep/wake impairments. Research 
evidence, however, only partially supports this hypothesis. For instance, only scarcely has 
sleep history of women been evaluated in the chemotherapy treatment context [7, 136, 137]. 
Yet, positive associations have been yielded, with past history of poor sleep quality (rES=.14) 
[136] or past sleep aid use (rES=.35) [137] associated with more frequent use of sleep aids 
during chemotherapy. Similarly under-researched, coexistence of medical illnesses or psy-
chiatric disorders can increase the risk for deregulation of sleep/wake patterns [60, 150], 
however the magnitude of these relationships might be small (rES=.06 and .08, respectively) 
[144]. A retrospective chart review also reported trends towards increased sleep aid use dur-
ing chemotherapy for women with a psychiatric disorder (rES=.16) or past use of psychiatric 
medications (rES=.18) [137]. 
Functional ability can be compromised as a result of primary treatment and can interfere 
with sleep architecture. At different points during chemotherapy, two research groups con-
cluded with predominantly weak associations (rES=.07 to .29) between poorer performance 
status and greater alteration in circadian parameters such as acrophase, peak activity, mesor 
and amplitude [7, 121, 123, 131, 136, 143, 147], but no link with daytime sleep [147]. Pre-
treatment menopausal status can also predispose women with breast cancer to sleep/wake 
deregulation, especially as natural menopause is frequently accompanied by complaints of 
poor sleep [151, 152]. Rissling et al. [125] found only a modest relationship between meno-
pausal status and actigraphically measured duration of nocturnal awakenings, so that prior to 
chemotherapy post-menopausal women had longer awakenings at night than the pre-/peri-
menopausal ones (rES=.33). A similar in direction, but not in magnitude, relationship was 
also reported for self-reported data (rES=.08) [144]. A notable absence of any other signifi-
cant findings became apparent when menopausal status was examined as a potential covari-
ate for objective [7, 8, 121, 123, 125, 131, 132, 136, 143, 145, 146] and/or subjective [7, 8, 
121, 123, 125, 131, 132, 136, 137, 143, 145, 146] sleep deficits. Yet, trends indicated that it 
was the pre-menopausal women who seemed to be more susceptible to manifesting poor 
sleep. 
Having been diagnosed with early stage breast cancer can represent an independent trigger 
to sleep/wake impairment; two studies compared women receiving chemotherapy with 
healthy controls [128] or men with prostate cancer [153] and concluded with particularly 
mixed findings with regard to all different sleep parameters. Primary breast cancer surgery 
can be seen as an additional trigger to increase the likelihood for sleep/wake impairment 
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during chemotherapy treatment [154, 155]. However, in the studies reviewed, neither time 
since surgery [126, 127] nor type of surgery (mastectomy v. lumpectomy) [144, 146] was 
associated with either recorded or self-reported sleep deficits. Extent of disease is of predic-
tive value to breast cancer prognosis, but can also trigger worrying thoughts about survival 
which can subsequently interfere with sleep [156]. Yet again, in all but one study [7, 121, 
123, 131, 136, 143], tests fell short of statistical significance. Specifically, during CThC1, 
only weak relationships between higher stage breast cancer and more dampened circadian 
rhythms were found (rES=–.04) [143]. 
 
2.4.3. Lifestyle and Behavioural Factors 
Long-term poor sleep/wake behaviours and lifestyle habits may trigger, preserve and perpet-
uate an individual’s trouble sleeping, especially in the wake of a life-threatening disease 
such as cancer [4]. The term ‘sleep hygiene’ characterises an array of sleep-related activities 
that expose persons to numerous, complex and interrelated cues that, when favourable, pre-
pare them for an appropriately timed and effective sleep [65, 157]. Conversely, when used 
inappropriately or abused, they can act more as stimuli to wakefulness and alertness than as 
sleep promoters, and hence disrupt sleep. Poor sleep hygiene can be seen as disruptive be-
haviour with regard to (a) scheduling (e.g., irregular sleep/wake schedule); (b) sleep practic-
es (e.g., inadequate bedtime routine; prolonged daytime napping); (c) environmental factors 
(e.g., inadequate room temperature; loud noises; intense light level); and (d) physiologic fac-
tors (e.g., excessive exercise close to bedtime; timing/consistency of meals; smoking, alco-
hol or caffeine consumption close to bedtime) [157]. Interestingly, while it has been tested 
as a potential intervention to improve sleep quality of women with breast cancer [122, 124, 
158-161], no study was found that specifically examined sleep hygiene as a long-term pre-
dictor of poor or good quality of sleep during active adjuvant chemotherapy. Yet, among 
women 3-4 months post-breast cancer surgery (44% during active chemotherapy), alcohol 
(rES=.02) and nicotine intake (rES=.08) were weak covariates of poor sleep quality [144]. 
Reduced daytime activity and a sedentary lifestyle have been suggested as possible anteced-
ents to sleep/wake deficits in patients with cancer [150, 162]. Moderate physical activity can 
positively influence depth of subsequent sleep through either altered plasma concentrations 
of biologic sleep mediators [163] or increases in body temperature. Whilst converging evi-
dence (a) describes daytime circadian activity as reduced and correlated with increased lev-
els of fatigue across adjuvant chemotherapy for breast cancer [9, 49, 126, 127], and (b) sup-
ports physical exercise of moderate intensity to improve sleep quality during treatment [163, 
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164], it is unclear whether reduced physical activity predisposes women with breast cancer 
to sleep/wake impairment during chemotherapy as only one of the studies reviewed found a 
weak to modest relationship in favour (rES=.12) [144]. In addition, three studies evaluated 
body mass index (BMI) as a proxy measure of physical activity. Findings suggest that 
throughout adjuvant chemotherapy women with higher BMI experienced greater objective 
sleep impairments (rES=.24 to .26) [8, 125, 132, 145, 146] and circadian rhythm alterations 
(rES=–.22) [7, 121, 123, 131, 136, 143], but not greater daytime dysfunction [146], than 
those with lower BMI. Interestingly, only a weak positive relationship of self-reported sleep 
problems with higher BMI was found [144]. 
 
2.4.4. Psychological, Emotional and Social Factors 
Multiple sources of anxiety and worry can be recognised for women with breast cancer 
throughout chemotherapy. These include intrusive thoughts; nocturnal anxiety attacks; fear 
of relapse; uncertainty regarding treatment effectiveness [100]; unfamiliarity with forthcom-
ing procedures; anticipatory worry about possibly debilitating symptoms; and concerns 
about family or daily living matters. Actigraphic data yielded only a few sporadic significant 
relationships between circadian activity rhythm parameters and perceived anxiety distress 
following CThC1 and CThC3, and 30 days after adjuvant chemotherapy [7, 121, 123, 131, 
136, 143]. Overall, magnitude of associations was rather weak, with rES ranging from .01 to 
.08. However, when the more qualitative aspects of sleep/wake impairment were taken into 
consideration, two studies concluded with modest effect sizes (rES=.28 to .44) for the rela-
tionship between anxiety and self-reported sleep quality [144, 165], thus supporting its sub-
jective nature. 
Compared to anxiety, depressed mood was identified as one of the most consistent correlates 
of sleep/wake impairment in the studies reviewed. Prior to chemotherapy initiation, at a pe-
riod where fatigue also was high, depressive symptoms were strongly correlated to poor sub-
jective sleep quality (rES=.52) [8, 132]. What is more, as part of a cluster of interrelated 
symptoms, pre-treatment higher depressive symptoms could contribute to worse sleep during 
chemotherapy treatment [8]. Between cycles one and four of adjuvant chemotherapy, a 
slight trend of increase in depression was also documented [128], which theoretically can be 
related to consolidation of altered sleep/wake patterns. Converging evidence gives partial 
support to this hypothesis. Despite some moderate associations between more depressive 
mood and poorer self-reported sleep at different points during treatment (rES=.36 to .38) 
[144, 165], evidence regarding further impact on circadian activity parameters (e.g., circadi-
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an consistency, strength of circadian rhythms, amplitude) over chemotherapy continuation 
was rather weak [132, 143, 147]. However, between CThC2 and CThC4, Roscoe et al. [147] 
reported a significant increase in daytime napping duration (possibly suggesting more day-
time dysfunction) as women’s depressive mood became worse (rES=.36). Even after the end 
of chemotherapy, depressive symptoms were found to perpetuate sleep loss further in the 
treatment continuum [166]. 
Additional psychosocial factors may play a role in determining who is at greatest risk for 
impaired sleep in response to cancer experience [110]. For instance, coping processes and 
social support can possibly orientate towards psychological adjustment to cancer diagnosis 
and treatment [110, 167]. Unfortunately, only one cross-sectional study was found that ex-
amined the effects of coping and perceived social support on sleep in the context of adjuvant 
chemotherapy. Hanprasitkam et al. [165] reported that among 159 women during active 
chemotherapy, perceived greater support from the family or friends was moderately correlat-
ed to more favourable outcomes in self-reported sleep/wake parameters. Albeit indirectly 
measured, positive coping (as perceived through the use of religious practices) also was re-
lated to better sleep outcomes (rES=–.16) [165]. 
 
2.4.5. Biological Factors 
Several hormones and neuropeptides such as cortisol, melatonin and serotonin have the ca-
pacity to affect sleep [2]. That said, alterations in circadian activity evidenced in women un-
dergoing treatment for non-metastatic breast cancer are considered to contribute to altered 
hormone secretion and cytokine production that could independently or collectively affect 
sleep and wakefulness [4]. In a small sample (n=11) of women during adjuvant chemothera-
py for breast cancer, mean serum serotonin levels were significantly lower the day before 
and after CThC4 compared to CThC1 [128]. Conversely, no significant between-treatments 
fluctuations in melatonin were recorded, whereas cortisol levels decreased significantly the 
day after chemotherapy in the breast cancer group, possibly due to the effects of pre-
chemotherapy corticosteroid administration [128]. Although no direct tests between seroto-
nin and sleep variables were performed, the significant positive associations between seroto-
nin levels and fatigue, and between serotonin levels and depression, as well as between 
night-time melatonin levels and depression, propose the potential for an indirect link to dis-
turbed sleep. 
Several cytokines including interleukin-1 (IL-1), interleukin-6 (IL-6), C-reactive protein 
(CRP), and tumour necrosis factor alpha (TNF-α) are also thought to play a key role in the 
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circadian process of thermoregulation that is related to sleep regulation [168]. Of note, can-
cer cells produce, or stimulate the production of such biomarkers [169]. In the studies re-
viewed, two research groups explored associations between these biomarkers and 
sleep/wake parameters in women during chemotherapy, providing, however, mixed findings 
[145, 166]. Throughout treatment (pre-treatment, post-CThC1, post-CThC4), Liu et al. [145] 
found only a few significant relationships, whereby changes in objective recordings of 
WASO were negatively associated with changes in CRP levels (rES=–.40), and increases in 
IL-1 (rES=.32) and IL-6 levels (rES=.35) predicted increases in negative sleep quality reports. 
Conversely, close to the end of chemotherapy, cross-sectional associations of self-reported 
sleep with either IL-1 or TNF or CRP fell short of significance [166]. What is more, whereas 
anaemia or a decreased haemoglobin level is a considered factor that contributes to fatigue 
(see below), the indirect relationship between reduced haemoglobin levels and more sleep 
disturbance remained too unverified [165]. 
 
2.4.6. Chemotherapy-Related Factors 
Cytotoxic systemic therapy can increase the risk for disordered sleep [60]. Indeed, converg-
ing evidence suggests that women who had received adjuvant chemotherapy rather than ra-
diotherapy or hormone therapy were more likely to report persistent sleep/wake impairment 
after treatment was over [100, 102, 166]. The reason for this is twofold. Chemotherapy ad-
ministration logistics, such as chemotherapy protocol/regimen, chemotherapy cycle length, 
or active versus recovery period in a chemotherapy cycle, can exert adverse effects on wom-
en’s sleep/wake patterns as their intensity increases. Three of the selected studies examined 
these potential triggers of sleep/wake impairment [126, 127, 129, 136]. Given doxorubicin’s 
known high toxicity profile [170], women receiving doxorubicin-based regimens (CAF, AC) 
were found to experience greater fatigue, more dampened circadian rhythms (e.g. mean 
mesor values of 65%-75% of norms), and greater sleep disturbance from CThC1 to CThC3 
than women on other chemotherapy protocols (CMF) [126, 127]. Yet, Berger [126] reported 
that nocturnal awakenings were similarly elevated irrespective of treatment group. Effect 
sizes for these relationships were small to large (rES=–.10 to –.45). 
In terms of cycle length, women on the more intense 21-day protocols had more disrupted 
mesor and amplitude values than those on 28-day protocols [126]. Within the same CThC, 
three studies examined differences in sleep/wake patterns of women between the active (i.e. 
the first two weeks post-chemotherapy administration) and recovery period (i.e. weeks 3/4 
before administration of the next CThC) [126, 127, 129, 146]. Although the magnitude of 
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associated effects could not be estimated based on the available data, there was a general 
clinical trend towards greater circadian rhythm alterations (dampened mesor and amplitude), 
more difficulty in sleep onset and maintenance (prolonged sleep latency, WASO, nocturnal 
awakenings; decreased total sleep time), poorer sleep quality and more daytime dysfunction 
(more daytime sleepiness, prolonged naptime) in the first two weeks of each CThC com-
pared to later time points [126, 127, 129, 146]. 
The toxic effects of chemotherapeutic agents are widely known. High chemotherapy toxicity 
means more frequent, severe and distressful physical symptomatology as well as sleep-
disruptive events (e.g. the need to use the bathroom at night due to nocturia, nightmares), 
which independently or collectively have the potential of interfering with habitual 
sleep/wake patterns [160]. In general, sleep disturbances including pain, hot flashes, cold, 
coughing and/or snoring, and difficulty breathing were described in the selected studies as 
highly prevalent irrespective of chemotherapy phase for early stage breast cancer [119]. The 
greatest part of available data relate to the pre-treatment period, where sleep disturbances 
may occur at least once or twice a week [7, 121, 125, 132]. Consistently high levels of sleep 
disturbances post-CThC1, and over chemotherapy continuation (CThC3 and CThC4) were 
also reported [125, 146], without, however, evidence of significant over time variations. 
Payne et al. [128] concluded with no significant within-cycles time effects, suggesting that 
sleep disturbances were equally prevalent both the night before and the night after CThC1 
and CThC4. 
In the studies reviewed, fatigue, hot flashes, and nausea/vomiting were specifically exam-
ined as potential covariates of sleep/wake impairment during chemotherapy for early stage 
breast cancer [7, 8, 104, 121, 123, 125-127, 131-133, 143, 145-147, 165, 166, 171]. Not sur-
prisingly, the studies mainly focused on chemotherapy-induced fatigue as a primary and 
consistent covariate of poor sleep in this context. Over the course of chemotherapy, women 
who self-reported greater overall sleep/wake impairment (rES=.12 to .56) [7, 8, 121, 123, 
131-133, 143, 145, 146, 165, 166, 171], prolonged sleep latency (rES=.25 to .30) [7, 104, 
121, 123, 131, 136, 143], more frequent use of sleep aids (rES=.21 to .25) [121, 123, 131, 
132, 136, 143], and poorer sleep quality (rES=.21 to .31) [121, 123, 132, 133, 143] were 
found to experience increased levels of fatigue. Conversely, daytime fatigue was not found 
to consistently increase time in rest and napping during the day [7, 121, 131, 132, 143, 146, 
147], but was related to greater daytime dysfunction (rES=.21 to .42) [120, 121] during this 
period. What is more, robustness of circadian activity rhythms (peak activity, mesor, 24h 
auto-correlation, amplitude) was adversely affected in fatigued women [7, 104, 121, 123, 
126, 127, 131, 143, 147]. Indeed, by prospectively assessing fatigue, circadian activity and 
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rest during chemotherapy, Berger and Farr [127] reported that increased fatigue during 
CThC3 was associated with severe reduction in daily activity. The relationship between fa-
tigue and subjective/objective measures of total sleep time, sleep efficiency, WASO, and 
nocturnal awakenings is nevertheless shrouded in ambiguity. 
Berger et al. [123] examined the perceived impact of hot flashes on sleep of women during 
chemotherapy, and concluded with significant over time increases from baseline to follow-
up for the pre- and peri-menopausal rather than the post-menopausal individuals [123]. De-
spite the absence of specific measures of frequency or severity of menopausal symptoms, 
control of menopausal status after treatment, and explicit inferential statistics to test associa-
tions, these results possibly suggest greater influence of climacteric symptoms on the sleep 
of women with regular or irregular menses during chemotherapy. This notion was partially 
supported by longitudinal data describing several objectively recorded sleep deficits follow-
ing treatment among women with regular menses both before and after treatment, possibly 
due to increases in depression related to climacteric symptoms [125]. Nevertheless, the sig-
nificant increase in vasomotor symptoms after treatment in the peri-menopausal group was 
not followed by similar disruption in objective and subjective sleep parameters. Two studies 
specifically explored the impact of hot flashes on overall sleep/wake impairment close to 
post-treatment and concluded with weak to modest effect sizes (rES=.17 to .19) [148, 172], 
suggesting a positive relationship where increase in hot flashes was accompanied by greater 
disruption in sleep/wake patterns. 
A significant positive, yet moderate, relationship between nausea/vomiting-related distress 
and sleep/wake impairment was also found over chemotherapy continuation (at least two 
CThC received), thus supporting hypotheses regarding the sleep-disruptive effects of nausea 
on nocturnal sleep [165]. Lastly, between CThC3 and CThC4, overall physical symptom 
distress was strongly correlated with daytime dysfunction [129], a finding that generates new 
hypotheses about whether overall symptom burden could act as a more robust predictor for 
nocturnal and daytime sleep-related impairments. 
 
 
2.5. Summary and Critique 
Admittedly, varying deficits in sleep/wake parameters may be evident in a significant part of 
this population. Regardless of whether objectively or subjectively measured, nocturnal sleep 
patterns of women can already be affected prior to chemotherapy initiation, deteriorate over 
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treatment continuation and be accompanied by daytime dysfunction, and impairments can 
persist even after the last CThC. Interestingly, whereas sleep quality and restfulness may 
become compromised, the actual use of sleep aids may be particularly low, thus revealing a 
discrepancy between how sleep/wake problems are assessed and how they are subsequently 
managed. Yet, research data are not equally distributed among the different sleep compo-
nents/parameters, or across all major time points throughout chemotherapy. Especially with 
regard to women’s circadian rhythms, daytime rest patterns, and use of sleep aids, more fo-
cused investigation is warranted. Other variables, such as night-time dreaming and feelings 
of restfulness upon arising, have been only superficially reported, with strange dreams being 
infrequent at least before treatment initiation [104], and only moderate levels of energy after 
a night’s sleep, possibly throughout treatment [134, 143]. However, the potential links be-
tween circadian rhythm parameters and feelings of restfulness upon arising [143] is worth 
further examination in future studies to identify patients at risk for non-restorative nocturnal 
sleep. 
One should be careful in evaluating the quality of the existent data. In all but two studies 
[87, 133], time after surgery was not reported, making it unclear whether evidenced sleep 
deficits could be attributed to the known effects of surgical procedures because patients 
might have been assessed too close to the time – within 2-3 weeks – after surgery. What is 
more, no study evaluated women’s past sleep history, sleep habits or concurrent use of med-
ications possibly affecting sleep, while only one study evaluated the influence of menopause 
on sleep before initiation of adjuvant chemotherapy, among those which reported data perti-
nent to participants’ menopausal status. In this study, Berger et al. [123] found that com-
pared to pre- and peri-menopausal women, post-menopausal women had lower total sleep 
time, experienced more nocturnal awakenings and spent more time awake after sleep onset. 
In three studies [8, 9, 120], researchers included a small number of women (15% of the sam-
ple sizes) scheduled to receive neo-adjuvant chemotherapy (i.e. chemotherapy given to re-
duce tumour size prior to surgery), thus leading to results that may actually not reflect sleep 
patterns of women to receive adjuvant chemotherapy. While unclear, women receiving neo-
adjuvant treatment may have been assessed closer to diagnosis, at which time sleep may be 
profoundly affected by the emotional impact of a diagnosis of a life-threatening disease. 
Lastly, data regarding subjective sleep quality might reflect slight inaccuracies due mainly to 
sleep measures’ time frames for recall: in some studies [7, 122, 130, 133] women were 
asked to reflect on their sleep patterns for the previous month, which renders it questionable 
whether data would reliably reflect the immediate period (last week) prior to treatment ini-
tiation. 
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In appraising data collected through repeated sleep assessments during chemotherapy, one 
should note the following points: (a) a large part of evidence is derived from multiple sec-
ondary analyses to clinical trials based on observations from control groups [49, 122, 123]. 
The fact that data from the same pools were repeatedly used in further studies, along with 
the possibility that women’s sleep in the control group was affected by their mere participa-
tion to a clinical trial to improve sleep, might have impacted on the reproducibility and gen-
eralisability of observations; (b) studies exist where the assessment of sleep parameters was 
conducted in an incomplete fashion, over only specific chemotherapy cycles (CThC1-
CThC3 [126], only CThC3 [129], baseline to CThC4 [9]) without baseline and/or post-
treatment data available, thus rendering comparisons limited or impossible; (c) while some 
studies have included a post-treatment assessment with relative consistency [49, 122, 123], 
they have included patients with varying adjuvant chemotherapy protocols, differing in the 
chemotherapy agents used but, most importantly, in their duration. Hence, true sleep values 
might become unclear due to a mix of data from women who might have completed chemo-
therapy protocols of different duration (≤4 CThC v. 6 or 8 CThC) or different intensity (e.g. 
anthracycline-based v. anthracycline-based followed by taxanes). For instance, in a study 
where the post-treatment assessment point was deliberately selected as being the same for 
the entire sample, the chemotherapy protocol was of a four-cycle duration only [9]. Howev-
er, several adjuvant chemotherapy regimens (e.g. FEC, CMF) may be given over a span of 
six CThC, so that the accumulated distress caused by chemotherapy-related symptoms may 
be greater and associated with more severe sleep problems. 
 
Admittedly, a host of potentially predisposing, precipitating and/or perpetuating factors can 
contribute to disruption and/or restriction nocturnal sleep and daytime dysfunction in women 
receiving chemotherapy for early stage breast cancer. Six categories of sleep-impairing fac-
tors were identified, namely demographic, medical/clinical, lifestyle/behavioural, psychoso-
cial/emotional, biological, and chemotherapy-related. To date, the most consistent findings 
relate to the precipitating/perpetuating effects of fatigue, depression and hot flashes, as well 
as the predisposing/perpetuating effects of performance status and body mass index. Whilst 
research so far has been able to identify some of these and other underlying links, many 
questions remain to be answered in future studies. 
The contribution of aging to alterations in sleep architecture has been examined in a rather 
subjective manner, and different age groups have been formed based on different premises 
as to who those persons may be that can be regarded as ‘older’. Unconvincing theories with 
regard to the role of education and race in poor sleep also have been introduced. This is 
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mainly due to the lack of evidence, given that these variables still represent two of the most 
under-represented person-related factors for disturbed sleep. Furthermore, are these 
relationships truly different in women with breast cancer compared to healthy women from 
the general population, and do the sleep-disrupting effects of the above-mentioned factors 
have any additional significance for women with breast cancer? More comparative studies 
will be required to answer this. 
The effects of prior breast surgery as well as those of chemotherapy procedures will need to 
be continually adjusted in future studies. Type of surgery, time elapsed since the operation, 
type of chemotherapy protocol, and time in-between CThC administration can all increase 
the likelihood for sleep/wake impairment. In addition, many other medications co-
administered to anti-cancer agents have known effects on nocturnal sleep architecture and 
daytime functioning [4]; however, they have never been included as covariates in the rele-
vant studies. Insomnia, lethargy and restlessness are well recognised and confirmed side ef-
fects of corticosteroids, particularly dexamethasone [173, 174], although prochloroperazine, 
metoclopramide and granisetrone (a serotonin [5-HT3] antagonist) have also been found to 
disturb sleep in patients with cancer [175, 176], having a high sedative potential. 
A pressing question is also this: How reliable are pre-treatment assessments of sleep patterns 
in the absence of data regarding sleep quality prior to cancer diagnosis? A history of dis-
turbed sleep may render individuals susceptible to sleep problems even if pre-treatment 
quality and quantity of sleep are adequate. Whereas for some women disturbed sleep may be 
a reaction to the experience of cancer, for others this may be the continuation of a pre-
existing condition that needs to be identified. The extent to which sleep hygiene practices 
and behaviours change over time, how such changes might also predict changes in the wom-
en’s sleep/wake patterns, and whether changes occur in response to experience of poor sleep 
remains to be established. 
Whilst much research has been devoted to the establishment of inter-relationships between 
fatigue, depression, and sleep, more robust designs such as day-to-day process analyses 
could allow for directionality to be clarified. Similarly, in order for the indirect effects of 
factors such as coping styles and social support to be established, comprehensive methodol-
ogies and more sophisticated statistical approaches could allow for potential mediators (e.g., 
psychological symptoms) to be co-examined. Despite the extremely important data on circa-
dian rhythm activity, it is equally important to establish whether deficits in the biological 
clock can be explicitly depicted on reports of perceived quality of sleep. In addition, contra-
ry to hot flashes, only rarely have night sweats been tested as possible contributing factors to 
disturbed nocturnal sleep in this population, and these need to be included in future studies 
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as a potential covariate. In any case, longitudinal sleep studies will need to examine how 
changes in these and other potential covariates are related to or are predictive of changes in 
the sleep/wake parameters of women during chemotherapy. This is of paramount importance 
as it goes beyond the static baseline-only assessment of significant covariates that was intro-
duced in some studies [7, 131], and acknowledges the fact that in an ever-changing situation, 
fluctuations in sleep/wake patterns are not only affected by baseline characteristics, but even 
more so by changes in these characteristics. 
Last but not least, the clinical, as opposed to the statistical, significance of the relationship 
between these triggers and sleep/wake patterns has only rarely been examined in relevant 
studies. The need to understand the magnitude of these relationships calls for the systematic 
calculation and reporting of effect sizes. Moreover, whereas a number of physical symptoms 
may independently contribute to sleep/wake impairments, their cumulative effects could 
provide a better explanation to their link with disrupted/restricted sleep and daytime dys-
function. With the advent of the concept of ‘symptom clusters’, namely groups of symptoms 
that are related one another and experienced at the same time [177], this seems to be a valid 
hypothesis. Consideration of the use of composite scores deriving from assessments of dif-
ferent sleep-impairing physical symptoms could provide a more robust measure of burden 
and a more consistent predictor of sleep/wake deficits in this population. From a clinical 
point of view, then, this approach could lead to more comprehensive assessments, which 
would increase the odds for identification of more ‘subtle’ symptoms that could nevertheless 
affect nocturnal sleep. 
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CHAPTER 3. 
Cancer Caregiving and the Experience of 
Impaired Sleep/Wake Patterns 
 
 
3.1. Informal Caregiving in the Context of (Breast) Cancer 
Women diagnosed with a curable breast cancer are frequently recognised as having pressing 
needs that emanate from the experience of a host of symptoms and concerns that arise post-
diagnosis, peak during treatment and may remain prominent during survivorship [178-180]. 
Women may have a transitory care requirement, often before, during and immediately after 
treatment; however, in their majority they will rely – in some cases, heavily – on families 
and friends for help and support [181], perhaps for an extended period of time. Throughout 
these major health transitions, families and friends offer, or in other cases are required, to 
shoulder the burden of often complex care [182-184]. Regardless of its nature, support pro-
vided by persons regarded as significant by the woman – often recognised by health profes-
sionals as her ‘informal caregivers’ – has been found to be equal to or more beneficial than 
support derived from other ‘formal’ sources [185, 186]. By providing actual and ongoing 
care for essential daily tasks to be undertaken and for an acceptable quality of life to be 
achieved [181], significant others in caregiving roles can have an important part in a wom-
an’s ability to respond to and cope with the pressure of living with breast cancer [185]. 
From the health system’s perspective, the expectation and prevalence of caregiving in signif-
icant others also is high. As social welfare costs rise in many nations and the medical man-
agement of cancer becomes more complex, there are increasing obligations placed on indi-
viduals close to the ill person to undertake caregiving responsibilities [187] and deal with 
extensive coordination of care [10]. Moreover, recent changes in health policy [188], such as 
shifting the balance of care from hospitals to the community, and the shortage of health care 
providers [184], have further impacted on the roles and responsibilities of these persons in 
providing primary and ongoing care at home [189, 190]. In fact, the use of outpatient-based 
cancer treatment means that it is often family members, partners, or friends who provide dai-
ly support to the person with cancer, not healthcare professionals [191]. According to Carers 
UK, and based on the 2001 census, around six million people in the UK (half a million in 
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Scotland) provide care on an unpaid basis for a relative, friend or neighbour in need of sup-
port due to old age, disability, frailty or illness [192-194]. Carers save the UK economy an 
estimated £87 billion a year, and economic considerations form a key element in govern-
ment policy to support carers [193]. 
Informal service providers have always been the primary source of human service care to 
individuals in need. During the past four decades, the informal provision of care to patients 
with chronic illnesses such as cancer has become so common that the meaning of the term 
‘caregiving’ is taken for granted; however, the definitions and boundaries of what is includ-
ed in it are not always clear [187, 195]. Traditionally, the concept of caregiving has been 
equated with that of the family [196]. The provision of assistance and support by one family 
member to another is a regular and usual part of family interactions, and is in fact a normal 
and pervasive activity. Thus, caregiving due to chronic illness represents something that, in 
principle, is not very different from traditional tasks and activities rendered to family mem-
bers [187, 195]. The difference, however, is that caregiving in chronic illness often repre-
sents an increase in care that surpasses the bounds of normal or usual care [187]. 
Despite the focus of empirical research on a limited inclusion of only blood relatives as 
informal caregivers, factors such as families’ nationality and race/ethnicity, and the sexual 
orientation of the ill person may dictate broader conceptualisations [197], including 
individuals “considered as family by the patient” (p. 295) [196]. In the context of cancer, 
Thomas et al. [198] broadly define the caregiver as someone who shares the experience of 
cancer with the patient. Obviously, current approaches to informal caregiving tend to be 
more inclusive of all persons who may be involved in the care of a patient with cancer, 
rather than focusing only on spouses, children or other members of the family: partners, 
close friends, even neighbours may also provide informal care to a person. This recognition 
of ‘significant others’ being involved in care explains the current shift illustrated within the 
literature towards use of the term ‘informal caregivers’ instead of the narrower one of 
‘family caregivers’ [199-201]. 
 
 
3.2. Roles of Informal Caregivers 
What the existing literature signals is that what caregivers do as individuals and/or as part of 
caregiver networks can make an essential contribution to the patient’s ‘care package’ and 
that patients’ well-being can be profoundly affected by the quality of the informal care they 
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receive [202]. This revelation implies that caregivers can be constructed as the ‘co-
caregivers’ of formal health care providers [202]. However, Thomas & Morris [202] pose a 
core question: ‘what is the informal carer role and how does it contribute to the care of the 
patient with cancer?’ (p. 178). Current knowledge or understanding about what informal 
caregiving actually involves in cancer contexts, and about the difference that this makes to 
the overall health care endeavour is based on limited information derived from a few studies. 
In general, care may be organised into numerous dimensions, each possibly consisting of 
several specific tasks and processes (Figure 3-1) [196, 198, 203-207]. Moreover, it has been 
suggested that informal caregiving roles and responsibilities may (a) occur in relation to the 
health transition experienced by the ill person during treatment [203]; (b) be fluid and ever 
changing [203]; (c) be novel and never before undertaken [206]; (d) be adopted as necessary 
[196, 208]; and (e) depend on the specific moment, setting or patient need [203]. 
 
 
Figure 3-1. Roles and tasks potentially undertaken by individuals providing informal care for people 
with cancer. Source: Kotronoulas et al. [209]. 
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Nonetheless, evidence regarding caregiving roles is confined in terms of generalizability and 
consistency with regard to type of cancer, stage of disease, phase in the cancer experience, or 
setting. For instance, it is unclear whether differences in roles assumed are influenced more 
by the type or the stage of the disease, or by who the caregiver might be (family versus non-
family member; spouse versus child); whether caregiving tasks are driven more by patient 
need (caregiving ‘on demand’) or by caregiver attitude towards provision of care; or how (or 
if) they develop/evolve across time, cultures or socioeconomic status. Whereas caregiving 
might become more significant during periods when patients are in receipt of medical treat-
ments and/or are at later critical moments in the cancer experience [198], which tasks might 
be involved in different phases have not been explored. Albeit basically useful, the afore-
mentioned broad role categorisation seems too simplistic to depict the array of caregiving 
tasks, and might imply that caregiving roles are confined in only those that happen to fall 
into these specific categories, or should be similar to every individual case. It can be argued 
that, in the case of patients who might rely more on self-care, caregiving roles might be 
more limited, or even focused on some areas rather than others. Some findings exist that 
husbands of women with breast cancer might provide less assistance with more intimate ac-
tivities such as bathing, toileting, or eating [206]. Still, whether this is a purely gender- or 
age-related behaviour needs to be confirmed. 
Given the diversity of the caregiving demands, it is equally reasonable to claim that caregiv-
ers themselves will possess different skills, capabilities and preferences for performing the 
different caregiving tasks [181], which, to a great extent, are influenced or mediated by sev-
eral endogenous (individual-related) and exogenous (environment-related) factors. In addi-
tion, it should be recognised that not all people assume a supportive role in the event of a 
diagnosis of cancer among their loved ones. Age, gender, cultural background, ethnicity, 
socioeconomic status, educational level, type of personality, coping style, personal health, as 
well as family dynamics, quality of relationships, and over time adjustment to cancer diag-
nosis and illness stage [167, 187, 195, 201, 210] may work together as integral factors in 
predicting a person’s involvement in caregiving, the extent of associated tasks, and finally, 
their reaction to this demanding role. 
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3.3. Impact of caregiving on informal caregivers 
Nowadays, caregivers are legitimised as persons affected by cancer in profound ways [202]. 
Key cancer service policy documents reflect this acceptance, acknowledging the presence of 
these ‘significant others’ and their interests as service users alongside patients [211, 212]. 
This is mainly because patient illness experience cannot be understood as an individualised, 
socially isolated phenomenon [195, 213]. Rather, a serious illness carries with it considera-
ble physical, psychological and social consequences for the family, friends and other close 
associates [202]; in particular, those individuals who assume the short- or long-term role of 
the caregiver are impacted the most. When cancer becomes a reality, spouses, partners, other 
family members and friends may actively participate in shaping the cancer experience, and 
also share in this experience. The practical and emotional involvement of these socially sig-
nificant others in patients’ journeys, however, often affects their own lives, sometimes con-
siderably [214]. Among other factors, caregivers may be forced to make changes in their 
lives, take on new roles and responsibilities, or give up past activities [206]. These life 
changes can be viewed as commonalities or stressors, which can create burden and strain, 
especially when extremely high physical and emotional demands are placed on caregivers 
[190]. 
It is generally accepted that a conceptualisation of caregiver burden contains both objective 
and subjective dimensions [187]. Objective burden can be defined as the time and effort re-
quired for one person to attend to the needs of another. Thus, it may include the amount of 
time spent in caregiving, the type of caregiving services provided, and financial resources 
expended on behalf of the ‘dependent’ person [201, 215]. Alternatively, subjective burden 
usually refers to perceived beliefs and feelings regarding the performance of caregiver tasks 
and assumptions of the caregiver role. Definitions of subjective burden are more varied than 
those of objective burden, and studies in the context of cancer care have included such ele-
ments as the extent to which caregiving causes strain with regard to work, finances, physical 
well-being, family relationships and social life, or emotional distress associated with care-
giving [187, 195, 199, 216]. 
Current hypotheses suggest that patients with cancer and their informal caregivers react to 
cancer as one emotional system [217, 218]. Based on this assumption there may be a signifi-
cant reciprocal relationship between each person’s response to the illness, with caregivers 
often reporting similar [219, 220] or greater [221] emotional distress, anxiety, or depression 
than patients do. What is more, some studies report that caregivers’ psychological distress 
reduces over time after diagnosis [222], but others suggest it increases and becomes pro-
longed [10, 223, 224]. The latter might be the case for caregivers who disregard their own 
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problems in order to focus exclusively on fulfilling patients’ needs; however, this is only one 
of several possible explanations. Along these lines, caregivers may be less likely than pa-
tients to disclose their concerns and worries, and up to only half of those with serious psy-
chological problems may actively seek help [167]. Similarly, caregivers’ family and social 
well-being might become affected, especially in relation to talking about the illness, dealing 
with deficits in sexual well-being, changing roles and assuming new responsibilities, as well 
as maintaining support systems [184]. For instance, informal caregivers may experience role 
overload when they take on a patient’s household or family responsibilities in addition to 
their own [184, 225]. Difficulty communicating their feelings and negotiating their roles can 
hinder patients’ and caregivers’ ability to support one another and decrease the dyad’s inti-
macy [226]. 
More often than not, caregivers of patients with cancer will also experience a decline in their 
own physical well-being [184, 227]. Although early on in the illness trajectory caregivers’ 
health status is similar to that of the normal population, they often report more problems 
with fatigue, alterations in habitual sleep/wake patterns, and impaired cognitive function 
than non-caregivers [219]. Over time, as caregiver burden and strain increase, caregivers’ 
physical well-being might be at stake with possible, yet not the only, reasons including little 
time to rest, engagement in fewer self-care behaviours (e.g., physical activity), or failure to 
seek medical care for themselves when sick [184, 223]. A considerable proportion of infor-
mal caregivers have chronic health problems of their own, which can be exacerbated by the 
stress of caregiving [201]. Presence or worsening of pre-existing symptoms, as well as de-
velopment of new ones may interfere with caregivers’ ability to assume roles and fulfil those 
already assumed. Furthermore, adjustments caregivers may be forced to make in their way 
of life [228] can result in added strain on their physical well-being. Eventually, both unre-
lieved symptoms and ongoing demands of caregiving may adversely affect both functional 
status and quality of life [10]. 
Excerpts of this discussion on caregiving tasks/roles and caregiving burden were published 
in a peer-reviewed journal and can be found in Kotronoulas et al. [229] (see Appendix 7). 
 
 
3.4. Sleep/Wake Patterns of Caregivers of Adults with Cancer 
Several evident and latent caregiver stressors can be a threat to individual well-being by spe-
cifically affecting the caregiver’s habitual sleep/wake patterns [230]. Sleep research in the 
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context of cancer caregiving has gained some interest in the last 15 years; yet, sleep impair-
ment remains one of the least assessed symptoms in this population [10]. In spite of the ab-
sence of a consistent method of assessment, and with evidence mainly deriving from cross-
sectional studies with non-homogeneous samples with regard to phase of cancer experience 
(palliative care, survivorship, active treatment) or duration of caregiving, it is now widely 
known that sleep of caregivers of patients with cancer can also be adversely affected [10]. 
Difficulty falling and staying asleep, experience of restless and non-restorative sleep, as well 
as development of insomnia and chronic sleep loss may be common complaints raised [43, 
231]. What is more, inconclusive evidence exists that informal caregivers of patients with 
cancer might experience restless sleep and daytime dysfunction to a greater extent compared 
to caregivers of patients with other illnesses such as acquired immunodeficiency syndrome 
(AIDS) or age-related dementias [232]; yet, studies among caregivers of patients with Par-
kinson’s [233, 234] or Alzheimer’s [234, 235] disease point to the direction of general simi-
larities in sleep-related distress. In any case, occurrence, frequency and/or severity of 
sleep/wake problems may widely vary, mainly but not solely depending on the overall care-
giving situation. Existent evidence is indicative of this variability, highlighting the need for a 
cautious interpretation when more general conclusions are to be drawn upon. 
To evaluate the sleep-related distress in caregivers of adults with cancer, a two-part critical 
review of the empiric literature was conducted. In the first part, a systematic search for pub-
lications that evaluated sleep/wake patterns among informal caregivers of adults with cancer 
was conducted. The purpose of this synthesis of evidence was to answer two questions: 
a. What do research findings report about key sleep/wake parameters of informal care-
givers of adults with cancer? 
b. What are the methodological and research gaps in this body of evidence? 
The systematic literature review aimed to identify original research studies conducted in the 
context of informal caregiving, and specifically focusing on examination of caregivers’ 
sleep/wake patterns and potential correlates of disturbed sleep. The review was conducted in 
a two-fold manner to address its two objectives. Initially, given the limited sleep research 
conducted in the context of cancer caregiving, all relevant publications were retrieved irre-
spective of disease context, study design, or primary or secondary focus on sleep patterns. 
These studies would form a large pool of evidence, especially with regard to factors affect-
ing sleep in informal caregivers of adults with cancer with findings complemented by evi-
dence deriving from caregivers of people with non-cancer illnesses. From this pool of stud-
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ies, original papers were extracted that specifically examined sleep/wake patterns of infor-
mal caregivers of adults with cancer. 
Studies were identified by systematically searching three electronic databases, namely Med-
line (1948-2011 May week 02), CINAHL (Beginning-2011), and EMBASE (1988-2011 
Week 18). An initial search strategy was devised and subsequently revised through an itera-
tive process (Appendix 5). Using a snowballing strategy, the reference lists of retrieved stud-
ies were also examined for any studies that may have been overlooked. Reference lists of 
two topical research reviews also were examined [10, 236]. Additional literature was sought 
through use of the search engine Google Scholar to locate relevant publications using the 
aforementioned key words. 
In the first stage, studies were eligible in the review if they (a) were written in the English 
language; (b) were conducted with adult (>18 years of age) individuals who were self-
identified or patient-identified as providing informal care irrespective of their relation to the 
ill person; (c) examined sleep as a primary or secondary variable; and (d) were published as 
original articles in peer-reviewed journals from January 1990 to July 2011 representing the 
period in which sleep-specific instruments were developed, and studies of sleep in informal 
caregivers emerged. Both quantitative and qualitative studies were included. In the second 
stage, studies were considered eligible if they specifically examined sleep of informal care-
givers of persons diagnosed with cancer irrespective of stage of disease, and through use of 
sleep-specific subjective and objective measures. Intervention studies also were eligible if 
they provided baseline and/or control arm sleep data. Studies were excluded from the pre-
sent review on the basis of the following criteria: (a) studies examining sleep/wake patterns 
of informal caregivers of individuals with terminal illnesses (cancer or otherwise), or con-
ducted among bereaved caregivers; and (b) unpublished studies, dissertation studies, or con-
ference presentations. 
A shortlist of papers was initially compiled, where titles and abstracts were screened to as-
sess relevance to the review. Potentially eligible papers were retrieved in full and checked 
for adherence using the afore-mentioned inclusion and exclusion criteria, thus forming a 
pool of papers reporting on sleep patterns of informal caregivers. In a second step, additional 
criteria were applied to identify studies examining sleep of informal caregivers of patients 
with cancer. Study characteristics of these latter studies were extracted using a systematic 
scheme. Due to heterogeneity of the studies retrieved, findings were only integrated in a nar-
rative synthesis. 
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The evidence categories employed by the Department of Health in the National Service 
Frameworks (DOHNSF, 2001) [116] were used for levelling evidence, and aiding appraisal 
of quality of the papers reviewed. This framework was used because it has been piloted for 
use with both peer-reviewed and non-peer-reviewed research [117]. Table 5-A2 outlines the 
levels of evidence as established using the DOHNSF validated grading hierarchy. No studies 
were excluded on the grounds of quality, given the lack of agreement in the application and 
interpretation of quality criteria [118]. 
The selected studies were analysed, summarised and synthesised to provide evidence with 
regard to the overall incidence of sleep-related problems. Sleep data were further analysed 
on the grounds of patient disease stage, which was one of the few common points of refer-
ence within this diverse sample of studies. A separate analysis was conducted for studies 
focusing on caregivers of persons with a specific type of cancer, whereas, potentially unique 
in this population, sleep findings were clustered together separately. A brief description of 
the characteristics of the included studies can be found in Appendix 5. Findings presented 
below and in Appendix 5 were published in a peer-reviewed journal and can be found in Ko-
tronoulas et al. [182] (see Appendix 7). 
 
3.4.1. Overall Incidence of Sleep-Related Problems 
Between 36% and 95% of caregivers reported altered nocturnal sleep associated with poor 
sleep quality in the studies reviewed [23, 25, 27-29, 232, 237-241], based on different sleep 
measures and cut-off scores. When examined under the prism of disease stage, prevalence 
rates ranged from 36% to 80% during the early phases of cancer [23, 30, 240-243], whereas 
they reached 95% (42%-95%) when care was provided to patients with advanced disease 
[25, 27-29, 232, 237, 238]. Such rates are somewhat comparable, but a slight trend of in-
creased frequency seems to exist as disease severity increases. Across active treatment, 
36.7% to 59% of caregivers reported sleep problems prior to treatment initiation [25, 242, 
243], whereas sleep problems were reported by more than 70% of the respondents during the 
patient’s treatment [23, 28, 30, 241]. 
 
54 
 
 
3.4.2. Caregiver Sleep/Wake Patterns in the Context of Patients with Ad-
vanced Disease 
In long-term family caregivers of patients with advanced-stage cancer, particularly disrupted 
and restricted sleep was reported: perceived sleep duration of 5.9 to 7.8 hours per night; ha-
bitual sleep efficiency ratings ranging from 74% to 80%; trouble falling and staying asleep; 
as well as restless, non-restorative sleep coupled with daytime dysfunction [27-29, 232, 237, 
244]. Where actigraphic measurements were implemented, similar trends were revealed: 
actual sleep time of even less than five hours/night (range 4.8 to 6.2 hours); sleep latency 
ranging from 11 to 45 minutes; and sleep efficiency ranging from 73% to >90% [28, 29, 
244]. Three studies aimed at examining changes in the sleep/wake patterns of caregivers, 
without, however, these being related to any major events or transitions. In the studies of 
Carter [28, 29], where observation spanned over 10 [28] and 16 [29] weeks, respectively, all 
sleep variables varied widely both within (as evidenced by high individual standard devia-
tions) and between time-points (as evidenced by different mean values). Although fluctua-
tions pointed to no specific direction, over time sleep disturbance was evident. Gibbins et al. 
[244] recorded sleep for a small interval of seven consecutive days, where, despite within 
time-points variations, caregiver sleep parameters remained relatively stable and somewhat 
disturbed across time. Of note, generally low daytime activity levels were recorded, with 
large periods of the day (28%-31% of the day) spent immobile. At this time, caregivers took 
approximately nine naps a day each lasting 9 minutes on average [244]. 
 
3.4.3. Caregiver Sleep/Wake Patterns in the Context of Patient Early Stage 
Disease 
Data on the sleep/wake patterns of this specific caregiver population are generally scant. 
Nevertheless, two recent and largely heterogeneous, cross-sectional studies using mixed 
samples of caregivers at various disease stages provided some descriptive general evidence. 
In the first study [241], 90 family caregivers providing care for an average of five months to 
patients receiving chemotherapy for different types of cancer were studied. Increased sleep 
latency and daytime dysfunction, a somewhat diminished sleep duration (6 to 7 hours per 
night), as well as multiple nocturnal disturbances were self-reported, whereas habitual sleep 
efficiency remained at a satisfactory level [241]. In a more detailed way, Dhruva et al. [243] 
reported subjective and objective sleep data of 103 family caregivers at the initiation of pa-
tients’ primary or adjuvant radiotherapy for prostate, breast, lung, or brain cancer. In this 
sample of relatively older caregivers (mean age 61.7 years), objective sleep measurements 
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indicated no major disturbances with regard to sleep onset latency (13 minutes on average), 
total sleep time (approximately 7 hours on average), sleep efficiency (84.4%), and daytime 
sleep (close to 6% of wake time). However, the number of nightly awakenings exceeded 17 
per night, leading to an increased amount of time being awake after sleep onset (12.7% of 
total sleep time) [243]. When circadian rhythm parameters were examined, all but one (ac-
rophase) were outside normal values. These results are indicative of low daytime and higher 
night-time activity; however, this trend was not found to correspond with deficits in subjec-
tive and objectives sleep variables. 
 
3.4.4. Caregiver Sleep/Wake Patterns in the Context of Specific Disease Type 
Only few studies have targeted caregivers of patients with a specific type of cancer, and their 
limited exploratory scope should deter from any attempt to generalise findings. Results from 
two reports indicated only moderate levels of sleep disturbance among female, family care-
givers of patients with prostate cancer at the initiation of radiation therapy [25, 240], espe-
cially with regard to increased nocturnal awakenings and WASO. Although the majority of 
participants were above their 60th year of age, patient and caregiver good functional status, 
as well as low treatment-related burden, might have played a role to the low percentage of 
reported sleep problems; yet, such relationships were not explored. Conversely, Cho et al. 
[23] highlighted the presence of poor sleep quality, difficulty with falling asleep and daytime 
dysfunction after CThC1 for gastric cancer. However, neither caregiving characteristics were 
reported nor detailed data with regard to key sleep parameters were provided. Whether care-
givers were recruited at different time points in the course of chemotherapy also remains 
unknown. Among 61 family caregivers of newly diagnosed women with early stage breast 
cancer, eight out of ten caregivers reported poor sleep quality [30]. Sleep latency and dura-
tion as well as daytime dysfunction were the areas predominantly affected in this group. 
However, lack of homogeneity with regard to the duration of caring period and timing of 
assessment (for some sleep was assessed during chemotherapy, while for others after the 
treatment had ended) renders these data inconclusive. 
 
3.4.5. Additional Sleep Data Relevant to Persons in Caregiving Roles 
Overestimation of self-reported sleep problems compared with objective assessment was 
suggested in two studies [240, 244]. Conversely, Carter [28] reported that caregivers typical-
ly under-rated their sleep disturbance when compared with actigraphic measures. Perhaps 
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caregivers perceived their sleep problems as less important when compared with the pa-
tient’s advanced illness [241]. Interestingly, less than 20% of caregivers were found to make 
actual use of prescribed or over-the-counter sleep medication in the majority of the studies 
reviewed [23, 27, 30, 241, 243, 244]. Authors explained this trend as reluctance, possibly 
driven from caregivers’ fear of not being alert to provide care to the patient during the night 
[23, 27, 29, 237], or from cultural beliefs surrounding the use of sleep medication [23]. Such 
attitudes can well explain why often caregivers refrain from engaging in discussions with 
clinicians, and consequently do not receive adequate care [241]. While prescription of hyp-
notics may be common among caregivers of patients with degenerative illnesses such as de-
mentia [245], caregivers in the context of cancer might not receive similar attention. None-
theless, in a Turkish study among caregivers of patients undergoing chemotherapy [241], 
seven out of ten participants were using some form of non-pharmacological strategy (e.g. 
lifestyle or behavioural practices, biological treatments) to help them get through the sleep-
deprived days. 
 
 
3.5. Sleep-Impairing Factors in Caregivers of Adults with Cancer 
Admittedly, not all caregivers develop sleep problems, and when these do occur they might 
not be easily explained or categorised. For instance, while some caregivers may complain 
about their sleep, objectively assessed sleep patterns may not replicate their complaints or 
not be significantly worse than those of non-caregivers. Altered sleep patterns in caregivers 
of adults with cancer are often presumed to be linked to night-time behaviours of the person 
they care for. Whilst important and still underresearched, this is only one source of sleep-
related distress for persons in caregiving roles. Indeed, several additional underlying factors 
may play a detrimental role to the development of sleep/wake problems, and may have dif-
ferent significance for persons with different characteristics. 
The second part of the critical review conducted gathered evidence from studies that evalu-
ated potential factors interfering with nocturnal sleep and/or triggering daytime dysfunction 
related to poor sleep in informal caregivers of adults with cancer. The purpose of this syn-
thesis of evidence was to answer two questions: 
a. What do research findings report about factors affecting sleep/wake parameters of 
informal caregivers of adults with cancer? 
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b. What are the methodological and research gaps in this body of evidence? 
Forty-four articles were identified through the systematic search undertaken (see Appendix 
5). Relevant findings were synthesised, critically analysed and categorised into two broad 
themes: factors directly relating to the person and his/her lifestyle habits or behaviours, and 
factors relating to the caregiving experience also including patient-related parameters. This 
categorisation aims at highlighting that these factors can be independent of the caregiving 
situation, as well as directly related to it [245]. In agreement with Conceptual Framework for 
Understanding Impaired Sleep [62] and Spielman’s Three-Factor Insomnia Model [63, 64], 
such factors can predispose caregivers to sleep restriction, and precipitate and perpetuate 
sleep/wake impairments, acting both interchangeably and in tandem. Figure 3-2 presents an 
overview of the identified factors theoretically classified according to the aforementioned 
models. 
 
 
Figure 3-2. Classification of identified triggers for sleep/wake impairments in informal caregivers of 
adults with cancer according to two theoretical sleep models. 
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3.5.1. Person- and Lifestyle-Related Factors 
A host of person-related characteristics have been proposed as potential triggers for 
sleep/wake deficits in informal caregivers. Importantly, while the effects of these predispos-
ing risk factors can be seen early on within the caregiving experience, in other cases it is the 
occurrence of additional precipitating factors – most probably related to caregiving itself – 
that triggers their manifestation, which in turn can perpetuate already established alterations 
in sleep patterns. 
Age – There is a lack of consistency with regard to the extent of age-related sleep problems 
in persons assuming caregiving roles. This possibly reflects methodological inadequacies as 
well as a significant variability in the caregiver samples studied. Lower habitual sleep effi-
ciency was reported among older caregivers of patients with breast cancer during chemo-
therapy [30]; however, whether this was a true association or mediated by co-existing factors 
(e.g. sharing the caregiving responsibility with others) remained unexplained. Conversely, 
other research groups failed to conclude with a significant association [27, 241]. When three 
caregiver groups were compared (providing care to patients with cancer, AIDS or dementia), 
Flaskerud et al. [232] attributed sleep restlessness evidenced in caregivers of patients with 
cancer to their younger age. Although disrupted nocturnal sleep [246, 247] and longer time 
in bed [248] have been reported in older caregivers of persons with dementia, it is in the 
younger carers that daytime dysfunction seems to be more prevalent [249]. This is perhaps 
an indication that daytime dysfunction may be of greater importance to younger, more active 
and possibly still employed caregivers, whereas the older ones can compensate their sleep 
loss through increased daytime napping. 
Gender – Disrupted sleep in the female caregivers of elderly people [250] or patients with 
Parkinson’s disease [251], and in the male caregivers of spouses with moderate to severe 
dementia [252] was reported. Nevertheless, clinical or statistical differences in sleep by gen-
der are absent among caregivers of patients with cancer [23, 27, 30, 237, 241]. Potential rea-
sons for this paucity might include potentially equally distressed male and female partici-
pants in the studies reviewed; inability of self-reported data to accurately capture salient dif-
ferences that objective data could reveal; and over-representation of female [23, 27] or male 
[30] caregivers in these caregiver samples (>77% of participants) that might have prevented 
associations from reaching statistical significance. For instance, although no differences in 
perceived sleep quality were reported in two studies, female caregivers did report greater 
frequency of depressive symptoms and fatigue severity than the males [23]. Alternatively, 
while Mills et al. [252] concluded with greater sleep disruption in male caregivers of spouses 
with moderate to severe Alzheimer’s disease, they were not able to explain this difference 
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given that this subgroup did not report disproportionately more stress overload or problem 
behaviours than all other subgroups.  
Personality – Despite some weak to moderate preliminary correlations, Carter & Acton 
[238] failed to include personality parameters (optimism, mastery or neuroticism) in a pre-
dictive model of sleep/wake patterns among caregivers of patients with cancer [238]. Im-
portantly, it remains unclear whether the actual association of type of personality with sleep 
is an indirect one, with depression and/or coping being the link between the two variables. In 
several studies among caregivers of people with cancer, dementia or Parkinson’s disease, 
personality traits emerged as a strong predictor of caregiver depression and coping [253-
256]. Thus, a more substantial hypothesis would be that personality deficits lead to increased 
levels of depressive mood and poor coping; these in turn interfere with caregiver sleep archi-
tecture. 
Past sleep history – Primary sleep disorders diagnosed in the past may be aggravated by a 
caregiving situation of tension and restlessness, but in other cases they can be fairly new in 
onset, thus greatly affecting vulnerable individuals. Similarly, a past history of unstable ha-
bitual sleep patterns also can increase susceptibility for impaired sleep. Impressively, inves-
tigation of these covariates in informal caregivers remains near to zero. Only recently, Gib-
bins et al. [244] examined the presence of a notable history of disordered sleep in caregivers 
of patients with advanced cancer; 12% of poor sleepers reported past sleep problems, 36% 
attributed sleep problems to patient diagnosis, and an additional 36% reported considerable 
aggravation of past sleep problems after patient diagnosis. However, sleep history was not 
specifically examined as a potential contributor to caregiver sleep disturbances. 
Biological and genetic factors – Until recently, research relevant to the roles of pro-
inflammatory cytokines in sleep/wake impairment in caregivers of patients with cancer was 
scant [257-260]. Findings from a longitudinal, repeated-measures study suggested that cer-
tain functional genetic variations in the tumour necrosis factor-alpha (TNF-α) [261] and in-
terleukin-6 (IL-6) genes [262] might act as co-predictors of baseline level and trajectories of 
sleep disturbances. While effect sizes were indicative of a somewhat meaningful clinical 
difference between allele homozygotes and carriers of the rare allele, mean levels of sleep 
disturbance were below cut-off points for clinically significant sleep problems [261, 262]. 
Thus, there is a requirement for additional research with larger samples and with greater var-
iability in levels of sleep disturbances to replicate such findings. 
Comorbid conditions – A number of serious health conditions can adversely impact sleep, 
including thyroid disease, hypertension, arthritis, and cardiovascular disease [245, 263]. 
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Medications used to treat these conditions may further increase the risk for development and 
maintenance of sleep problems [235], although in a study of dementia caregivers a signifi-
cant relationship was not found [264]. Overweight or obese caregivers might be at greater 
risk for sleep-disordered breathing as well as disordered bed- and wake-times [263], and this 
also might be age-related or gender-related [245]. Nonetheless, underlying complexity, lack 
of directionality, and lack of sufficiency in self-rated measures of physical health, may have 
been responsible for discrepancies in relevant evidence [241]: whereas some studies favour a 
link between health status and caregiver sleep [248, 265], others have failed to show a statis-
tical association [249, 266]. Regardless, mediators including age, health habits, gender, and 
level of psychological distress should be taken into account when the relationship between 
caregiving, health problems and sleep is examined [245]. 
Sleep hygiene – Habitual sleep routines can play a role in the deregulation of sleep/wake 
patterns in caregivers of patients with cancer [65, 267-269]. Sleep hygiene recommendations 
have been almost uniformly included as part of various cognitive-behavioural techniques 
[65] for caregivers of patients with cancer [29] and dementia [270]. Despite their overall im-
portance, sleep hygiene practices of caregivers of patients with cancer or other chronic ill-
nesses have never been assessed. Similarly, recorded attempts to explore over-time or health 
transition-related changes in sleep routines of persons in caregiving roles are absent. There-
fore, a rather theoretical than evidence-based knowledge exists.  
 
3.5.2. Factors Related to the Caregiving Experience 
Subjective caregiver burden – Relevant literature partially confirms caregivers’ increased 
vulnerability to sleep disturbance. Significant differences have been reported in caregivers of 
patients with cancer [234] or other chronic illnesses [249, 264, 271-273] compared to indi-
viduals in non-caregiving roles. There is a possibility, however, that this is a matter of sub-
jectivity, given that objectively evaluated sleep patterns might not differ according to care-
giving status [247, 248]. Caregivers’ appraisal or personal interpretation of their situation 
might be more important than their actual caregiving role [274]. Equally, it is reasonable to 
assume that not all caregivers perceive their caring role as burdensome, and even if it is felt 
as such, what might be considered to be burdensome may not necessarily be linked to sleep 
impairments. In fact, only weak to moderate [271, 273] or even absence of associations 
[248, 275] between subjective caregiver burden and sleep disturbances exist, indicating an 
increased complexity in underlying mechanisms. That said, stronger triggers such as depres-
sion might be responsible, rather than the caregiving experience itself [276]. Even in the 
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cases where a positive relationship was found, the lack of longitudinal data cannot exclude 
the possibility that the caregiver sleep problems observed might have preceded and account-
ed for burden, rather than resulted from caregiving [266, 276]. 
Objective caregiver burden – As patient needs increase, primary caregivers are expected to 
provide intensive care, which allows only for minimal periods for rest and sleep [233, 277]. 
Yet, current limited evidence only moderately supports such a hypothesis [274]. Frequency 
of engagement in caregiving activities was also associated with poor nocturnal sleep and 
excessive tiredness in caregivers of persons with Parkinson’s disease who provided daily 
care compared to those only occasionally being involved in patient care [233]. Conversely, 
the extent of caregiver involvement in patient care, as perhaps implied by the number of ac-
tivities undertaken, remained unrelated to sleep problems other than merely nocturnal sleep 
disturbances [265]. However, adaptation of the caregiver’s sleep-wake schedule to that of 
the patient’s might provide one of several explanatory links [278], with caregiver narratives 
providing support to this relationship [277]. The patient’s fatigue [275] and own sleeping 
difficulty [237, 244, 245, 277] might be additional triggers. Despite the inconclusive find-
ings, this seems to apply mainly to co-habiting patient-caregiver dyads, and to bed- or room-
sharing caregivers. 
Fatigue – The extent to which care influences caregivers’ daily schedule might be seen as a 
contributor to perceptions of fatigue [279, 280]. The interaction between fatigue and noctur-
nal sleep disruption and/or daytime sleepiness potentially flows both ways, which can lead 
to a negative feedback loop, where each symptom can be attributed to the manifestation of 
the other [111, 281]. Yet, only moderate correlations were reported in two widely dissimilar, 
cross-sectional studies after the first chemotherapy cycle for gastric cancer [23] and before 
radiotherapy for prostate cancer [25]. A causal link between the two variables was not estab-
lished. Admittedly, fatigue and sleep disturbances could co-exist and co-vary without other-
wise interacting. Indeed, relatives of patients with cancer in palliative care reported moderate 
levels of fatigue, even though they were sleeping fairly well [279]. Findings from a recent 
longitudinal study proposed baseline sleep disturbances as a significant predictor of the 
overall severity of the evening fatigue trajectories among female caregivers of patients with 
prostate cancer [239]. 
Health deficits – The caregiving situation itself may be associated with negative health ef-
fects [282, 283] that can adversely impact sleep. As a direct consequence of increased objec-
tive burden, then, caregivers may exercise less than their non-caregiving peers, a fact that 
further increases their risk for medical co-morbidity [245]. In a cross-sectional study of pre-
dominantly female family caregivers of older adults with memory impairment, objective 
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increases in total sleep time were positively, whereas increases in WASO were negatively, 
associated with caregivers’ physical functioning after adjusting for caregiver age [284]. In 
the context of cancer caregiving, female family caregivers of patients with prostate, lung or 
brain cancer at the initiation of radiotherapy were categorised into active and inactive groups 
based on physical activity estimates [240]. Increased daytime napping was recorded in the 
group of lower physical activity. Conversely, only marginal sub-clinical differences were 
observed in self-reported sleep: on average, women in the active group slept approximately 
fifty minutes more than the inactive ones, whereas inactive caregivers reported increased 
sleep latency (mean 23.3 versus 11.7 minutes) compared to the active ones. Even so, ad-
justments for age, level of depression, or concurrent illnesses were not performed. 
Sleep hygiene deficits – In theory at least, caregivers “might fall into iatrogenic sleep rou-
tines (…) to compensate for having their nightly rest disturbed” (p. 145) [245]. Such rou-
tines may include napping during the daytime, drinking coffee to stay awake or alcohol to 
help fall asleep with the ultimate result being a further decrement in their nocturnal sleep 
quality and quantity [245]. However, Aslan et al. [241] reported that a mere 7% of the par-
ticipants consciously attributed their sleep problems to their poor sleep routines. Due to the 
absence of systematic research, the extent of sleep hygiene’s contribution to poor sleep is 
still unclear. 
Emotional distress – The emotional distress associated with caring for an ill loved one may 
explain alterations in sleep/wake patterns of informal caregivers [237, 241]. Although super-
ficially examined, some moderate correlations between sleep problems, anger, and anxiety 
among caregivers of patients with advanced cancer have been reported [232]. A type of 
“anxiety from exposure to adverse effects of the therapy on the patient” (p. 372) has been 
identified by caregivers themselves as a potential reason for sleep problems [241, 277]. The 
emotional distress of illness experience may explain alterations in cancer caregivers’ sleep 
patterns as well [237, 241]. In 164 community-dwelling caregivers of people with dementia 
followed every six months for 5 years, caregiver depression was one of the most powerful 
predictors of the onset of new sleep impairment [274]. Some caregivers with depressive 
symptoms might wake up crying [237], and this can be associated with feelings of restless or 
non-restoring sleep the next morning. Moreover, depressive mood was associated with de-
creased total sleep time and sleep efficiency, and increased daytime dysfunction in cancer 
and non-cancer caregivers [27, 28, 232, 237, 265, 266, 274, 276, 285]. Depression may be a 
persistent risk factor for sleep disturbance even after adjusting for differences in caregiver 
coping strategies, type of personality [238], caregiver age, and number of sleep aids used 
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[264]. Nevertheless, additional confounding variables such as gender or patient disease sta-
tus need to be taken into consideration [28, 237]. 
Coping strategies – The way caregivers cope with their indirect illness experience can influ-
ence the manifestation of feelings of anxiety and sadness that interfere with sleep. Those 
caregivers who avoid and/or deny their situation, or are passively resigned to that may be 
more distressed [286] and depressed [287], and therefore more prone to habitual sleep altera-
tions. Perceived self-adequacy in the caregiving role was moderately associated with better 
sleep quality among 60 caregivers of persons with Alzheimer’s disease, but the role of de-
pression as a covariate in this relationship was not examined [266]. In only one study were 
the linkages between caregiver personality, coping and sleep problems explored [238]. Sig-
nificant, yet moderate, positive associations between less functional coping and sleep prob-
lems, and between neuroticism and sleep problems among caregivers of patients with ad-
vanced cancer emerged. However, in further regression analyses depression was the only 
significant predictor of caregiver sleep problems. In this small sample of overly depressed 
individuals, the indirect effects of coping and personality on sleep were possibly overshad-
owed by the most prominent effects of depression. 
Social support – Deficits in caregiver social support have been associated with ineffective 
ability to cope [288], and with greater depressive symptoms and negative affect [206, 289]. 
Hence, inadequate or unavailable social support can be claimed as indirectly related to per-
ceptions of poor sleep quality among cancer caregivers [241, 277]. Chang et al. [30] reported 
that perceived absence of someone to share the responsibility of caregiving was associated 
with poorer subjective sleep quality in persons supporting women with early stage breast 
cancer during chemotherapy treatment; however, confounding factors of this relationship 
were not examined. Using structural equation modelling, Brummett et al. [271] demonstrat-
ed that dementia caregivers with inadequate social support might be more likely to develop 
sleep problems, an association that is possibly mediated by the effects of perceived poor so-
cial support on the development of high levels of negative affect. 
 
 
3.6. Summary and Critique 
Sleep research has only begun to increase our knowledge on an area of functioning that may 
be of paramount importance for individuals assuming caregiving roles in the context of can-
cer. Current evidence confirms the variability of sleep/wake problems experienced by in-
64 
 
 
formal caregivers of people with cancer: at least four out of ten individuals may report at 
least one problem [182]. Diminished sleep duration, nocturnal awakenings, prolonged wake-
fulness after sleep onset, and daytime dysfunction seem to be the areas of greatest distress, 
irrespective of stage or type of disease; yet, circadian activity remains under-studied. In ad-
dition, despite a wide spectrum of potential triggers, no safe conclusions can be drawn upon 
that could direct clinicians’ attention to factors that can be of definite significance in the on-
set and maintenance of sleep disturbances.  
Current findings share a number of common drawbacks. First, the majority of data are 
skewed towards the more advanced stages of disease and more prolonged caring periods. 
Consequently, they mainly target persons profoundly affected by the patient’s severity and 
chronicity of illness, and needs. Second, a predominant focus on female persons in caregiv-
ing roles is noted. Third, clarification of the effects of cancer type-specific experiences on 
caregivers’ sleep/wake patterns is lacking. In other words, generalisability is limited only to 
populations with very specific demographic characteristics (Caucasian, older than 50 years 
of age, and spouses) or caregiving experiences (either very intense or rather minimal provi-
sion of actual care). Inclusion of diverse age, gender, racial and ethnic groups of informal 
family and non-family caregivers in future exploratory sleep studies is recommended. 
An additional point for debate could well be whether prevalence of sleep/wake problems in 
caregivers of patients with cancer has been reliably measured thus far, and whether preva-
lence rates reflect clinical importance. For instance, Cho et al. [23] found that 80% of care-
givers of outpatients with gastric cancer reported poor sleep quality with a mean total score 
of 5.81 (±2.20) on the PSQI, slightly over a cut-off score of 5. Very similar frequencies were 
reported by Carter et al. [27, 28, 237] in a series of studies conducted in the context of ad-
vanced cancer; however, in the latter studies, mean PSQI scores ranged between 8 and 11, 
thus indicating greatly disturbed sleep. It is possible that low specificity of the cut-off score 
selected in the study of Cho et al. [23] might have led to caregivers having been character-
ised as having poor sleep quality whereas actual perceptions might not have pointed to this 
conclusion. With respect to the use of the PSQI in populations of caregivers, insufficiently 
established self-report cut-off scores to characterise caregivers as being either those with or 
without sleep problems may propose that in some cases overall prevalence of caregiver sleep 
problems can well be virtual. Indeed, Dhruva et al. [243] reported that, within the same sam-
ple, 59% and 38.6% of caregivers were identified as poor sleepers based on cut-off scores of 
two different measures, thus confirming the need for more validation studies to take place in 
the future. 
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Several other points should be noted as well. Given the presence of only a limited number of 
longitudinal studies in caregivers of patients with cancer [28, 29, 244], trends of over time 
changes in caregiver sleep/wake patterns remain practically unexplained. The infrequent uti-
lisation of objective sleep measures in the studies reviewed means that even fewer have 
gathered data on caregivers’ sleep/wake patterns or have used combinations of self-report 
and objective sleep measures as per current recommendations [49]. One additional key find-
ing is the systematic use of a rather secluded terminology to define caregivers, thus merely 
focusing on family caregivers. Even in the studies where a broader definition was adopted, 
sampling strategies failed to include adequate numbers of non-family caregivers [231, 232]. 
Therefore, between groups comparisons to identify differences in sleep patterns of family 
and non-family members in caregiving roles are inexistent. This is a clear indication for a 
more comprehensive sampling methodology to be pursued to augment inclusion of relatively 
equal numbers of recruited family and non-family caregivers. Finally, a considerable trend 
can be noted in terms of the studies’ cultural derivation. Although the majority of studies 
have been conducted in the United States, the rest of available data derive from eastern cul-
tures (Korea, Taiwan, Turkey) [23, 30, 241]. Strong sociocultural demands for more inten-
sive and uninterrupted caregiving in some cultural/ethnic contexts can result in greater bur-
den and disrupted or restricted sleep, which however might not be replicated in studies of 
caregivers of different ethnic/cultural backgrounds. 
Clearly, more research is needed to elucidate the experience of sleep disturbances in this 
growing population. Adequately powered, longitudinal quantitative studies are needed to 
examine the onset of alterations in sleep/wake patterns, describe changes and establish asso-
ciations with time and transition points. What is more, well-designed qualitative studies are 
also warranted to shed light on the true meaning of disturbed sleep in the lives of informal 
caregivers who go through the experience of cancer, explore practices/behaviours that pre-
dispose carers to sleep loss, and enhance our understanding of what caregivers would con-
sider the most important sleep/wake deficits they would wish help for. 
 
Whilst the contribution of an array of factors is recognisable, current evidence only partially 
supports their causal relationship to sleep problems. This lack is mainly due to the cross-
sectional nature of the vast majority of studies conducted. Although links between several 
factors and disrupted sleep patterns have been reported, it is largely unknown whether this 
‘desirable’ direction of relationship is actually true. Especially for caregivers of patients with 
cancer, the limited targeted sleep research surrounds evidence with even more uncertainty. 
In turn, this lack of information often leads researchers to complement cancer-specific data 
66 
 
 
by ‘borrowing’ evidence derived from other caregiving populations, which may be true for 
cancer caregivers as well, but to what extent? Similarly, current literature has focused more 
on some rather than other effects on caregivers’ sleep; therefore, relationships between sleep 
and possible explanatory factors are in part based on either weak correlations or findings 
from the general population. Consequently, unique cancer-specific data such as those relat-
ing to the nature, frequency, severity, or patterns of occurrence of factors affecting sleep 
regulation when caring for patients in different disease stages or disease types, might still 
remain hidden. For instance, the relative risk for caregiver sleep deprivation associated with 
the various demographic/clinical/lifestyle characteristics remains to be clarified in future 
comparative studies. 
Despite the fact that advanced cancer has been linked to increased patient needs that may 
increase caregiver burden, sleep disruption/deprivation warrants exploration beyond this 
limited area. Are the current incongruous findings sufficient to establish a link between pa-
tient disease stage and caregiver sleep problems? Clearly, evidence is so limited in extent 
and so heterogeneous in terms of basic participant characteristics that drawing safe, general 
conclusions becomes impossible. Although there seems to be a trend towards greater sleep 
disruption/deprivation during caregiving for patients with advanced cancer, the nature and 
range of sleep problems experienced by caregivers may manifest themselves irrespective of 
patient disease severity, and fluctuate according to the overall caregiving situation. Several 
additional factors might contribute in complex ways to the occurrence and perception of 
sleep problems in cancer caregivers. Hence, perceptions of disturbed nocturnal sleep might 
be greatly associated with additional correlates such as caregiving or other responsibilities, 
duration of caregiving, or caregiver symptoms and concerns. Such important parameters 
have scarcely been taken into consideration in the relevant studies. In other cases, caregiver 
burden might be only temporal; closely related only to specific events rather than to the 
whole illness experience. This temporality might be related only to transient caregiver sleep 
disturbances as well; once the stressors cease, sleep patterns might return to habitual. In that 
sense, despite the temporary deficits in their sleep, caregivers in such situations might not 
perceive their sleep patterns as particularly affected. Such a hypothesis could represent an 
additional reason as to why thus far caregiver burden has not been consistently or highly as-
sociated to caregiver sleep problems. 
As previously mentioned, current evidence derives from diverse samples of individual, 
cross-sectional studies only. Whether there is a true prospective impact on sleep/wake pat-
terns, or evidence is only influenced by different characteristics of these diverse samples 
remains to be found. More longitudinal, mixed-methods and comparison studies will need to 
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explore the onset and maintenance of sleep/wake impairments based on the gravity of the 
caregiving situation in the context of diverse types of cancer and disease severity. Whether 
the relation between sleep hygiene practices and sleep can be extrapolated from other popu-
lations to caregivers of patients with cancer remains unknown. Even in the studies where 
multi-component sleep interventions were tested [29, 270], it is questionable whether their 
positive effects could also be attributed to their sleep hygiene component, or whether they 
could be attributed to sleep hygiene only. Positive sleep hygiene practices can be a powerful 
protective factor against sleep loss, and clarification of the extent to which disruptive habits 
are associated to poor sleep can be a useful adjunct to design more effective sleep interven-
tions for caregivers. 
Fatigue-related daytime dysfunction can be manifested as excessive sleepiness and pro-
longed napping that can adversely affect regulation of the sleep/wake cycle and lead to noc-
turnal arousal. Whether baseline and ongoing fatigue can be regarded as a predictor of over 
time daytime dysfunction in caregivers of patients with cancer also remains to be confirmed 
in future, adequately powered, prospective studies. Such research efforts will also be re-
quired to clarify the degree to which the relationship between fatigue and sleep is a matter of 
subjective perception, or perceived fatigue can be equally correlated to objective sleep 
measurements. The same is true for the sleep-impairing effects of psychological burden. A 
pilot study conducted over a relatively short follow-up period of ten weeks reported abrupt 
swings from week to week in both sleep and depressive symptom scores of advanced cancer 
caregivers [28]. Although overall fluctuations might have coincided in this very small sam-
ple size (n=10), a link between these two variables was not established. In such samples of 
overly burdened caregivers, both sleep disturbances and psychological distress could certain-
ly coexist without, however, their onset necessarily originating from one another. Because of 
the lack of longitudinal comparisons and associations, the direction of this relationship in 
cancer caregivers has only in part been replicated, whereas its nature in caregivers of pa-
tients with early-stage cancers, or those who provide care during specific major event-related 
periods of time, remains unclear still. Lastly, longitudinal data could clarify whether positive 
coping styles and personality traits can be regarded as truly linked to caregiver sleep quality, 
through a protective mechanism that possibly leads to reduction of caregiver psychological 
distress. To this direction, application of a comprehensive theoretical framework or model 
could effectively guide nursing research to explore the effects of sleep-impairing factors in 
this population [61]. 
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CHAPTER 4. 
Patient-Caregiver Dyads and the Experience of 
Sleep/Wake Impairments 
 
 
4.1. The Patient-Caregiver Dyad: Beyond Individualism 
In the previous discussion, there has been a conscious effort to present disparate accounts of 
concept-related and sleep-related research data pertinent to women with breast cancer and 
their informal caregivers. However, this distinction was implemented for the purposes of 
data presentation and analysis only; in reality, changes in the lives of the person receiving 
cancer care and the person providing informal care take place in partnership, and illness is 
often experienced and managed in the context of a complex network of relationships [290]. 
In the majority of early studies however, patients’ and caregivers’ experiences have been 
regarded rather independently. Schumacher [203] argues that it was the perceived frailty of 
the care receiver and resulting dependency that instilled individualism in this relationship. 
Nevertheless, research literature, now more than ever, supports the fundamental idea of dy-
adic interdependency: cancer is considered to be a shared experience that impacts upon indi-
viduals on a level that transcends mere individualistic limits and cannot be understood solely 
within person-centred models of care [290-292], but instead, through a whole-systems 
framework [290]. In that sense, interdependence between parties of close relationships may 
exist, which has been accounted as the defining feature of human relationships [293]. At the 
level of a dyad (that is to say, a pair of closely related persons), interdependence can influ-
ence the ways in which persons grow and thrive, as well as cope, in the wake of major 
events and challenges. Illingworth et al. [290] analysed patients’ and caregivers’ narratives 
within the first year of cancer diagnosis, confirming this shared nature of cancer experience: 
participants often experienced cancer at the dyadic level, where it was jointly and interac-
tionally owned and processed. A dyadic focus seems to be a more appropriate approach for 
people affected by cancer, and active-phase treatment such as chemotherapy has been pro-
posed as one – yet, not the only one – time point in a patient’s cancer trajectory, where care 
is viewed as an area of endeavour in which both patient and caregiver actively participate 
[203]. 
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4.2. The Added Value of a Concurrent Assessment of Health Outcomes in 
Patient-Caregiver Dyads 
The notion that the patient-caregiver relationship is made of two people, both of whom in-
fluence and are influenced by the other, has been stressed as particularly relevant to health 
care in general [294, 295]. Several health- and quality of life-related variables have been 
frequently conceptualised in an individualistic way; however, social contextual models argue 
that health outcomes are likely to co-vary in close relationships, as in the patient-caregiver 
relationship. For instance, any change in the functioning of one individual can affect the 
functioning of their significant others, and vice-versa [296]. Similarly, although external fac-
tors such as disease severity and social support may affect patients’ and caregiver’s physical 
and psychosocial well-being directly and uni-directionally, patient and caregiver interde-
pendence may contribute to a bidirectional situation, in which the well-being of each indi-
vidual in the dyad also affects the well-being of the other [297]. 
By accepting the probability of complex interactions in their relationship, it is reasonable to 
argue that patients and their caregivers may react to cancer as a unit; as a result, they both 
have legitimate interrelated needs for help from health care professionals [298, 299]. There 
is general consensus among clinicians and researchers that when patients and caregivers are 
treated simultaneously, important synergies can be achieved contributing to the well-being 
of each person [217, 300]. In any case, when these interrelated and often concurrent needs 
are neglected, patient-caregiver dyads are denied the opportunity to obtain optimal care. 
Therefore, Northouse et al. [298] claim that in order to provide optimal comprehensive can-
cer care, the care plan must focus on these patient-caregiver units. To address and confirm 
dyadic reciprocity and establish the effects of such dyadic approach, a shift in health re-
search is evident towards inclusion of patient-caregiver dyads rather than merely patients or 
caregivers alone. In turn, this novel approach promises to enhance care by revealing salient 
aspects lying within the mutuality of the patient-caregiver relationship. 
A scoping review of the most recent literature was undertaken, which made apparent the im-
portance attributed to concurrent evaluation of patient and caregiver health outcomes 
throughout major chronic illness/disorder experiences. A wide range of health care contexts 
was involved, including cancer [218, 224, 226, 301-309]; renal disease [295, 310] and hae-
modialysis [311]; psychiatric illness (bipolar disorder [312], schizophrenia [313]); mental 
illness (dementia [314-316], Alzheimer’s disease [317, 318]); cardiovascular diseases (heart 
failures [319, 320], stroke [321, 322]); degenerative diseases (Parkinson’s disease [323], 
multiple sclerosis [324]); as well as diabetes [325] and spinal cord injury [326]. By examin-
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ing the content of this body of literature, two important and contrasting issues emerged: di-
versity in the perspectives employed to capture and demonstrate benefits associated with 
inclusion of patient-caregiver dyads in health care, as well as wide variability in limitations 
that urges for greater consistency in future research so that benefits can irrevocably be estab-
lished. 
These methodologically diverse studies implementing a dyadic approach were classified in 
three broad clusters of sources of evidence. In the first cluster, studies were included where 
exploratory methods were employed to describe the dyadic nature of key health outcomes 
and identify key predictors of reciprocal influences [295, 310, 312, 319-322, 325]. Departing 
from these simple exploratory models, the second cluster comprised studies evaluating the 
effects and benefits of caregiver-targeted interventions on both patient and caregiver health 
outcomes [313, 314, 317]. Studies of this type evaluate effectiveness of various interventions 
such as bio-behavioural [314] or psychoeducational/support programmes [313] on patient-
caregiver dyads’ functioning, well-being and quality of life, as well as caregiver social sup-
port, confidence, and patient dependence. These interventions have been accompanied by 
some significant reciprocal improvements in outcome variables, thus proposing that en-
hancement of the caregiving qualities can have a dual benefit for both caregivers and pa-
tients. Lastly, the third cluster included studies concurrently testing interventions for both 
patients and caregivers in order to demonstrate reciprocal effects on health outcomes, as well 
as achieve greater bidirectional benefits [311, 315, 326]. 
Existing evidence in the context of chronic illnesses other than cancer is indicative of greater 
overall distress and caregiver burden in patient-caregiver dyads where life satisfaction is dis-
cordantly low, and even greater in dyads reporting concordant dissatisfaction. Interestingly, 
even caregivers satisfied with life but whose care recipients are dissatisfied, might express 
caregiver burden [321]. Similarly, partners’ abnormal personality traits might influence both 
patient and partner perceptions of the quality of their relationship, but this might be more 
evident in the context of a psychiatric disorder. Reversely, patients’ psychiatric symptoms 
might be associated with poorer intimate relationship functioning in their partners [312]. 
Other dyadic models favour associations between support behaviours and relationship satis-
faction: patients and partners who report both receiving protective buffering (i.e. hiding con-
cerns or pretending) may also report relationship dissatisfaction; this might be especially 
true for those who at the same time report receiving low active engagement (i.e. refraining 
from openly discussing or asking how the other is feeling) [325]. In-home training pro-
grammes that value care partners as well as patients might be associated with dyads thriving 
in terms of well-being and relationship quality, as opposed to training that focus merely on 
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the patient at the expense of the partner [311]. Such an approach can be viewed as particular-
ly useful in engaging patients and caregivers in open discussions that promote effective 
communication [315].  
In the cancer care context, weak evidence (r≤.20) indicates that patients’ fear of disease re-
currence might affect carers’ own fear of recurrence and distress over time [327], but re-
mains unclear whether this association extends beyond six months post-diagnosis, is influ-
enced by dyadic adjustment to illness, or is true for dyads affected by cancers other than 
head and neck cancer. Along these lines, post-traumatic growth might present with greater 
differences between individuals in female patient-male partner pairs than in the reverse sit-
uation, possibly reflecting an effect of gender and role on dyads’ interrelated experience of 
illness [309]. As discussed, examination of the intra- and inter-personal consequences of 
protective buffering among patients and their partners suggests that the more patients hide 
cancer-related thoughts and concerns from their partners, and the more they feel that their 
partner hides their own concerns, the lower their concurrent relationship satisfaction and the 
poorer their mental health might be [302]. As well, mutual avoidance and communication 
withdrawal can be responsible for poor perceived intimacy, ultimately leading to concurrent 
psychological distress in heterosexual couples in long-term relationships [303, 304]. Due to 
the absence of proven causality, however, the possibility that dissatisfied or distressed part-
ners might exclude each other from their most intimate thoughts cannot be ruled out. Be-
coming increasingly dissatisfied and not feeling privileged in taking care of the sick spouse 
have been suggested as possible mediators of incongruence in patient and caregiver percep-
tions of quality of life [328]. Drawing on some of these findings, education interventions 
[329, 330] and stress-reduction programmes [331] have targeted the dyad for possible joint 
effects. In spite of some promising concurrent improvements in psychological distress [329, 
331], mood [330, 331] and quality of life [330], there is still an outright need to establish 
superiority of dyadic interventions, not only over control groups, but also over groups where 
one member of the dyad receives the intervention (four-group designs); as inconclusive find-
ings indicate [330], this can only happen where methodological rigour supersedes the above-
mentioned limitations. 
In its vast majority, evidence derives from studies conducted in the context of breast cancer 
[218, 224, 226, 305, 306, 308, 332-335]. For instance, the nature of the patient-partner dyad 
relationship might not be of particular significance for women’s post-surgical adjustment, 
but intimate partners might be at greater risk for emotional and social adjustment issues 
compared to other family- or non-family members [306]. In any case, husband’s and wife’s 
difficulties with role adjustment one year after a diagnosis of breast disease might have a 
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direct, yet rather minimal, effect on the role adjustment of the other; very similar cross-
partner effects regarding emotional distress have been also reported [224]. Concurrent linear 
drops in reports of marital satisfaction and family functioning might be evident over time, 
whereas elevated dyadic distress and role problems at diagnosis of breast cancer are likely to 
remain high at least one year later [336]. Complex interactions in mutual constructive com-
munication between patients with breast cancer and their partners might also alleviate some 
of their concurrently experienced distress [226]. Correspondent trends and changes in wom-
en’s and their partners’ emotional well-being have been reported as well, possibly suggest-
ing close covariance [305]. In the same sense, there is some evidence that a caregiver’s im-
pression rating of the patient’s quality of life might act as a predictor of the patient’s own 
quality of life [337], possibly due to negative attitudes of family members adversely affect-
ing patients’ clinical outcome [337]. In fact, males’ relationship satisfaction has been sug-
gested as a weak predictor of self-acceptance of body image in women with breast cancer 
[308]. Due to the absence of a long-term investigation, however, a causal relationship cannot 
be implied, nor can it be established whether this is a mere indirect association, possibly em-
anating from the effects of partners’ views of the woman’s body image on the woman’s self-
acceptance. Nevertheless, several couple-based intervention studies have been conducted, 
based on the grounds of this evidence. These have aimed at demonstrating concurrent im-
provements in couples’ quality of life [335], psychosocial and physical adjustment [333, 
334], relationship satisfaction [334] and functioning [332, 334], and psychological function-
ing [332]. Although the beneficial effects of a dyadic interventional approach have been 
praised, its superiority over interventions targeting only the one member of the dyad remains 
to be established. Additionally, long-term effects over periods where major events occur, 
such as diagnosis, pre- and/or post-surgery, subsequent or initial treatment, ongoing recov-
ery, survivorship or palliative care, need to be explored. One issue to be taken into consider-
ation is the suggestion that younger women in short-term relationships who receive chemo-
therapy treatment might benefit more from a dyadic approach to their illness [335], but this 
also should be evaluated in studies where the focus shifts from married couples/partners to a 
broader patient-caregiver relationship including additional significant others such as children 
or friends. 
Despite the aforementioned efforts, several limitations still undermine reproducibility, gen-
eralisability or/and reliability of their findings. In fact, in some cases these limitations may 
well have been responsible for an inability to demonstrate significant effects of the dyadic 
approach on health outcomes [316, 318, 323], whereas in other cases directionality of signif-
icant associations may still remain unclear due to cross-sectional designs not permitting re-
peated examination and verification. In addressing duality of health outcomes, studies in-
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volving patients and their caregivers need to rely on a robust methodology and adequate de-
sign, prerequisites which have not been fully met as yet. In a largely analogous fashion and 
despite the benefits reported, dyadic research in cancer care can also be seen as suffering 
from the same methodological issues as the ones previously mentioned. Interestingly, the 
majority of studies have focused only on bi-directional associations of psychological distress 
with the dyads’ well-being, quality of life, or other external predictors, whereas potentially 
interrelated bio-behavioural symptoms such as sleep or fatigue have yet to be fully examined 
in patient-caregiver dyads. Closely related to this gap, the association between the dyad’s 
long-term adjustment and interrelated health outcomes has not been widely explored. This 
could be facilitated by conducting longitudinal, repeated-measures studies over extended 
periods of time, even one or two years after major events or transitions have taken place. 
Nonetheless, only a limited number of studies have implemented a truly adequate prospec-
tive design to test direction of associations, but this strategy does not necessarily ensure that 
generalisability is feasible. 
The sample of studies examined suggests that relevant evidence needs to be evaluated with 
caution. Careful examination makes additional methodological issues rather evident: (a) 
non-inclusion of sample size estimation analyses may be seen as responsible for sample siz-
es inadequate to support multiple statistical procedures: in fact, testing of predictors may be 
limited only to a few variables despite hypotheses of multifactorial relationships; (b) sam-
pling under-representativeness at the level of patient (for example, with regard to age, sex, 
cancer type, severity of disease, functional status, cultural background), caregiver (e.g., fo-
cus on family members only) and patient-caregiver dyad (e.g., recruitment or self-selection 
biases regarding dyads in low quality relationships, exclusion of minorities) may render 
findings relevant only to some patient-caregiver groups but not to others, especially for mid-
age, Caucasian, married couples where the woman has been diagnosed with breast cancer; 
(c) albeit highly recommended, adequate statistical analyses, such as multilevel modelling or 
structural equation modelling [293], that take into consideration the existing interdependen-
cy within the dyad have been scarcely implemented. As opposed to classic analyses assum-
ing independence of observations, appropriate dyadic data statistics treat the dyad as the unit 
of analysis. Yet, relative unfamiliarity may lead to advanced statistics being seen as the last, 
and thus avoided, resort. Sadly, such practices can lead to mishandling of dyadic data that 
may hinder statistical comparisons. Furthermore, very commonly, exploration of dyadic 
changes of outcome variables has taken place over selected time points thereby unlinked to 
transition to the different phases of cancer experience, such as prospective re-assessments 
conducted following diagnosis (e.g., 6- or 12-month follow-ups) or during survivorship or 
remission. It is, however, interesting for interrelated outcomes to be examined at time points 
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where major events occur, such as post-diagnosis and before, during and after active treat-
ment, during transition from one treatment modality to another, at relapse and related health 
care decisions, or before, during and after hospice or palliative care. Bearing in mind these 
important limitations, supporting findings need to be treated as only indicative, but certainly 
not definitive, of a complex interaction between patient- and caregiver-related outcomes in 
the context of cancer. Most importantly, the most needed longitudinal intervention studies 
that demonstrate the benefits of a dyadic approach over an individualistic one by comparing 
groups of dyads where intervention is applied to one or other member, both or none, and 
where participants are followed-up over time, have only recently begun to emerge. 
 
 
4.3. A Dyadic Approach in Sleep Research: A Novel Concept 
In Chapter 1, it was argued that onset and maintenance of sleep are dependent on the satis-
faction of a series of physiological conditions [11]. Aside from that, sleep is considered to be 
a vulnerable state that, in part, occurs, or otherwise is optimised, when one feels a sense of 
physical and emotional safety and security to down-regulate vigilance and cease alertness 
[338, 339]. Across the lifespan, such feelings are largely derived from the social environ-
ment [340]. Thus, for humans, sleep has evolved beyond its biological nature to one that is 
embedded in a social context, a fundamental attachment behaviour that may be regulated 
within and affected by close human relationships [338, 341] such as the patient-caregiver 
relationship. In that sense, the fact that the science of sleep has tended to view sleep as an 
entirely individual phenomenon can be described as a rather confined approach, impeding 
assessment and management of sleep disorders that might manifest themselves especially 
during periods of adjustment to illness. As described earlier, interdependence is a defining 
feature of relationships and it might also be a defining feature for sleep as seen in the context 
of a close patient-caregiver relationship [342]. 
Attachment theory has been implemented to provide a perspective of the link between close 
relationships and sleep [338]. This theory posits that early interactions with caregivers lead 
to the development of expectations to the degree to which a caregiver will be responsive to 
one’s needs [338, 343]. These key expectations are thought to mediate affect and arousal, 
particularly in times of real or perceived threat [340, 344]. This might suggest that the closer 
the relationship, the greater the odds of a good night’s sleep, and vice versa. Despite recog-
nition of the dyadic nature of sleep for most adults, there has been surprisingly little investi-
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gation of human sleep patterns in a paired manner. Within the scope of a broader review of 
the literature (see below), a systematic search for publications addressing the issue of con-
current examination of sleep/wake patterns in adult couples was conducted. Seventeen origi-
nal studies were retrieved, where research was focused on the nocturnal sleep patterns and 
daytime impairments of co-sleeping heterosexual couples either in the absence of a medical 
illness or in the presence of a primary sleep disorder such as obstructive sleep apnoea 
(OSA). 
In the general population, Meadows et al. [342] reported that the variables showing the most 
significant couple interdependency in co-habiting heterosexual couples were actual bed time, 
sleep latency, light/dark movement ratio (i.e. the difference between amount of movement 
during daytime and night-time), and wake bouts (i.e. the number of nocturnal awakenings). 
In addition to this interesting, yet inconclusive, evidence suggesting a close interrelation in 
couples’ sleep patterns, presence of a bed-partner has also been viewed as a potential source 
of sleep disturbance. The relevant research has demonstrated significantly lower levels of 
Stage 4 NREM sleep [345], a concomitant increase in REM sleep [345], and a greater num-
ber of movements during sleep [345, 346] on the nights when participants slept with their 
partners rather than when slept alone. In spite of this reciprocal impact on one another’s 
sleep, participants have reported less satisfaction with their sleep when sleeping alone [345, 
346]. In a sample of couples without sleep disorders, Pankhurst and Horne [346] observed 
more movements in men than in women, with women reporting that their sleep was affected 
by their partners’ sleep more than did men. Men are also more often loud snorers [347], and 
the sound of snoring can be a major disturbing factor of the sleep of their bed-partner, who 
might report symptoms of insomnia, morning headache, daytime sleepiness and fatigue 
[348]. However, whether ‘sleeping alone’ improves substantially sleep in partners of snorers 
is shrouded in ambiguity [349] and might be related to the actual duration of the interven-
tion. Similarly, several efforts have been made to identify a link between reported or ob-
served sleep disturbances within the couple with relationship functioning or quality [350-
352] and attachment behaviours [353-355]. Although a positive unidirectional association 
has been established, evidence is mainly based on either cross-sectional dyadic studies [352, 
353] or single-arm studies [350, 351, 354, 355]. In a cross-sectional study among married 
couples, attachment anxiety predicted poor sleep quality, but no cross-partner effects were 
identified [353], possibly due to non-homogeneity of the study sample and use of self-report 
sleep measures which might have been biased by participants’ levels of mood. Nonetheless, 
in a very recent longitudinal study of 29 young adult couples, Hasler and Troxel [356] 
showed the existence of some bidirectional associations between interpersonal interaction 
and sleep parameters, specifically sleep efficiency and sleep concordance (i.e. agrre-
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ment/similarity in sleep timing and onset within the couples). Women who reported more 
positive daytime partner interaction were found with greater perceived sleep efficiency, and 
this was also true for their male partners [356]. These results imply existence of interde-
pendence in night-time sleep and daytime relationships; however, aside from the small study 
sample and several inconsistencies in data derived from both objective and subjective sleep 
measures, findings also seem to be largely confined in the limited context of young, happy 
and childless couples with no concurrent illnesses, who are good sleepers. 
On the other hand, OSA has been referred to as a “disease of listeners” [357]; aside from 
snoring, increased arousals often adversely affect both the bed-partner’s and the individual’s 
sleep [348, 358]. In particular, Beninati et al. [359] observed less consolidated sleep in part-
ners of individuals with OSA, a feature which tended to correspond with the patient’s dis-
rupted sleep patterns. The effects of OSA-related features on the partner’s sleep patterns can 
be difficult to subside: in an inadequately powered pseudo-experimental study studying the 
effect of continuous positive airway pressure (CPAP) treatment of individuals with sleep 
apnoea/hypopnoea syndrome – a subtype of OSA – on sleep quality, McArdle et al. [358] 
reported improvement in partners’ subjective sleep quality after a one-month period, but no 
evidence of a benefit on objectively measured sleep quality was found. OSA has been asso-
ciated with excessive daytime sleepiness, irritability, energy deficits, and depressive symp-
toms [360], all of which might be manifested in both the individual and their spouse; as yet, 
this remains a mere prediction or hypothesis as relevant literature has not systematically as-
sessed such issues in a longitudinal, dyadic manner. Moreover, in the studies examining the 
role of CPAP in improving the sleep quality of co-sleeping couples [359, 361], no follow-up 
of home use or whether the couple continued to sleep together were reported, thus preclud-
ing knowledge on the long-term effects of the intervention. 
Excerpts from Sections 4.1 through 4.3, as well as Section 4.4 that follows, have been pub-
lished in a peer-reviewed journal and can be found in Kotronoulas et al. [209] (see Appendix 
7). 
 
 
4.4. Sleep/Wake Patterns of Patients and Informal Caregivers: A Matter of 
Dyads 
To date, attachment theory has been used to guide research models in the relationship be-
tween couples’ relationship functioning and sleep [338]. However, this theory could, to a 
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certain extent, justify the value of concurrent assessment of sleep/wake patterns of patients 
and their primary informal caregiver, either in a family [340] or a wider support context. 
Caregivers who, regardless of their actual caregiving tasks, value their role as important for 
them and for the patient they care for, might be more affectionate towards the patient; this in 
turn could lead to patients feeling more secure in their relationship and sleeping better. 
Importantly, as patients and caregivers go through the experience of illness together, their 
emotional reactions and distress affect one another in a relatively proportionate manner, add-
ing to one’s own concerns and worries when they reach a peak, or relieving from additional 
distress when they simmer down, and possibly resulting in corresponding changes in sleep 
patterns. In a similar manner, effective or dysfunctional coping strategies of the dyad might 
co-affect their sleep through a psycho-behavioural mechanism. Moreover, it is more than 
obvious that patient symptom distress can lead to increased caregiving efforts. However, 
impaired caregiver sleep patterns, coupled with daytime sleepiness and increased fatigue can 
equally lead to poor caregiving performance, which might in turn inhibit the management of 
patient symptoms influencing sleep, or disordered sleep itself. What is more, although not all 
patients and caregivers share the same bed or the same room, co-sleeping or co-habiting dy-
ads might be co-affected by poor sleep hygiene practices or by disrupted sleep patterns relat-
ed to the illness experience. Such sleep-impairing factors might well interfere with the pre-
requisites necessary for a good night’s sleep at a level that transcends the individual. 
Crossley [362] suggests that in a situation involving the co-presence of persons, the parties 
to that situation need to secure cooperation from each other to achieve their sleep ritual, 
whether this involves the choice of common bed times and sleep conditions or different but 
complementary patterns, with each party respecting the needs of the other. In co-habiting or 
co-sleeping patients and caregivers, this ‘cooperation’ becomes blurred given that patient 
symptom experience, caregiver burden and associated frustration can alter sleep hab-
its/rituals or restrict actual sleep of the dyad in a way that concordance might be no longer 
feasible. 
Drawing on the above arguments, it is more than reasonable to assume that implementation 
of this dyadic approach would augment our understanding of co-occurrence of sleep prob-
lems in patient-caregiver dyads, trends of concurrent transformation of these sleep problems 
across time, and covariates/factors that appear to contribute to these patterns within the dyad 
and across time. Some argue that this is key to the development of truly effective treatment 
strategies [278, 338, 363].  
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A systematic search for published studies that utilised concurrent examination of sleep/wake 
patterns/impairments in patient-caregiver dyads was conducted. This systematic review 
aimed to answer two questions: 
c. What do research findings report about concurrent sleep/wake pat-
terns/changes/impairments in dyads of patients and informal caregivers irrespective 
of health care context? 
d. What are the methodological and research gaps in this body of evidence? 
The literature review aimed to identify original research studies where sleep/wake patterns 
were concurrently assessed in couples or patient-caregiver dyads, either in the absence of a 
disease or in the context of chronic illness. The review was conducted in a two-fold manner 
to address its two objectives. Initially, all relevant publications were retrieved irrespective of 
presence or type of illness, study design, or primary or secondary focus on sleep/wake pat-
terns. These studies would form a large pool of evidence. From this pool of studies original 
papers were extracted that concurrently examined sleep/wake patterns of patients and infor-
mal caregivers in the context of chronic illness. 
Studies were identified by systematically searching three research and evidence databases, 
namely Medline (1948-2011 May week 02), CINAHL (Beginning-2011), and EMBASE 
(1980-2011 Week 18). An initial search strategy was devised and subsequently revised 
through an iterative process (Appendix 6). Using a snowballing strategy, the reference lists 
of retrieved studies were also examined for any studies that may have been overlooked. The 
reference list of a key topical research review also was examined [338, 364]. Additional lit-
erature was sought through use of the search engine Google Scholar to locate relevant publi-
cations using the aforementioned key words. 
Studies were eligible in the review if they were written in the English language; were con-
ducted with adult (>18 years of age) individuals; examined sleep as a primary variable in a 
concurrent fashion in couples or dyads of individuals; and were published as original articles 
in peer-reviewed journals from January 1990 to July 2011 representing the period in which 
studies of sleep within different clinical populations emerged. Both quantitative and qualita-
tive studies were included. In the second step, only studies concurrently assessing 
sleep/wake patterns in patient-caregiver dyads irrespective of the context of illness were re-
garded. Unpublished studies, dissertation studies, or conference presentations were not in-
cluded in the present review. 
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A shortlist of papers was initially compiled, where titles and abstracts were screened to as-
sess relevance to the review. Potentially eligible papers were retrieved in full and checked 
for adherence using the afore-mentioned inclusion and exclusion criteria, thus forming a 
pool of papers. Papers reporting on sleep/wake patterns of couples/dyads in the absence of a 
chronic illness were introduced in a narrative synthesis. In a second step, additional criteria 
were applied to identify studies examining sleep of patient-caregiver dyads irrespective of 
the context of illness. Study characteristics of these latter studies were extracted using a sys-
tematic scheme. Findings of the studies retrieved regarded in this step were critically ana-
lysed and categorised in major themes. However, due to heterogeneity of these studies, me-
ta-analysis of findings was not feasible. 
Studies reporting on patient-caregiver dyads’ sleep/wake patterns were evaluated for meth-
odological quality using a validated scoring system for the systematic appraisal of empirical 
studies with varied methodologies [365]. However, no studies were excluded on the grounds 
of quality, given the lack of agreement in the application and interpretation of quality criteria 
[118]. The evidence categories employed by the DOHNSF (2001) [116] were also used for 
levelling evidence, and aiding appraisal of quality of the papers reviewed. This framework 
was used because it has been piloted for use with both peer-reviewed and non-peer-reviewed 
research [117]. Table 5-A2 outlines the levels of evidence as established using the 
DOHNSF validated grading hierarchy. No studies were excluded on the grounds of quality. 
The selected studies were summarised, analysed and synthesised at a higher level. Irrespec-
tive of the illness context, evidence regarding bidirectional associations in the sleep of care 
recipient-caregiver dyads is still inconclusive and in some cases contrasting. Nevertheless, 
interesting and promising preliminary findings/associations were reported in the studies re-
viewed. These findings were organised into two broad thematic categories: sleep/wake pat-
terns/problems, and sleep-impairing factors. Table 4.1 summarises evidence according to 
the level of clarification established in the relevant literature. A brief description of the char-
acteristics of the included studies can be found in Appendix 6. Findings presented below and 
in Appendix 6 were published in a peer-reviewed journal and can be found in Kotronoulas et 
al. [366] (see Appendix 7). 
 
4.4.1. Sleep/Wake Patterns/Problems of Care Recipient-Caregiver Dyads 
In agreement with the concept of care recipients and caregivers living in close relationships, 
similarities in nocturnal and daytime sleep behaviours within dyads were reported in three 
studies, where close synchronisation of bedtimes and wake times [242, 247, 278], daytime 
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naps [278], as well as sleep duration [247] was found. Caregivers had generally later bed-
times (ranging from 35-42 minutes on average) [247, 367] and earlier awakening times 
(ranging from 4-36 minutes on average) [242, 247, 367], thus demonstrating organisation of 
their sleep routines around the patient. What is more, the notion that a caregiver’s sleep can 
be a function of the patient’s sleep, and vice versa, was investigated and partly verified in 
the studies reviewed [242, 247, 278, 285, 367, 368]. Where positive significant correlations 
emerged, these were moderate to strong [242, 247, 367], derived from dyads sharing the 
same bed/room [242, 247, 367], and were pertinent to the objectively recorded nocturnal 
sleep parameters of sleep onset latency [242], wakefulness after sleep onset [242], night-
time activity [278, 368], number of nocturnal awakenings [242], sleep efficiency [242, 367], 
and total sleep time [242, 247, 367]. In a study that involved 7 days of actigraphic record-
ings, however, sleep variables that showed the greatest night-to-night stability and variability 
were different between patients with Alzheimer’s disease and family caregivers, thus sug-
gesting that sleep deficits within the dyad are not necessarily interrelated [363]. In addition, 
the frequency and magnitude of correlations between self-reported sleep data were far less in 
the studies [242, 285], mainly regarding perceived sleep quality [242, 285], sleep duration 
[242] and early awakenings [242]. Conversely, daytime behaviours between members of the 
dyads seemed to be uncoupled, given the consistent absence of significant correlations in 
their activity levels and total daytime sleep [242, 278, 285, 367, 368]. 
Where sleep/wake disturbances were investigated [233, 242, 244, 251, 285, 363, 367], pat-
terns of frequency, concurrency, and, in some cases, comparability of nocturnal sleep prob-
lems, were described in the dyads. Similarities in the occurrence of poor sleep for care recip-
ients and caregivers were reported in the majority of the studies [233, 242, 244, 251, 285, 
367], with complaints of poor sleep accounting for approximately 30% to 50% in either 
group. Yet, two studies revealed that in only 20%-23% of the pairs both parties reported not 
sleeping well, while in 41%-45% only the patient or the caregiver reported not sleeping well 
[244, 363]. Irrespective of whether statistical significance was reached, trends of clinically 
greater sleep deficits in patients were apparent in all studies. Even though studies were split 
as some concluded with no statistical differences between patients’ and caregivers’ sleep 
deficits [242, 244, 367], whereas others reported greater sleep problems in care recipients 
than in caregivers [285, 363], nocturnal sleep problems in the caregivers were not unim-
portant and in some cases comparable to those manifested in care recipients. Conversely, 
despite the absence of perfect agreement [242], less daytime activity, increased time in im-
mobility, greater daytime dysfunction and/or higher levels of daytime sleepiness were re-
ported in care recipients than in caregivers in three studies [244, 278, 285], which might re-
flect the consequences of a restless night and/or a severe disease. Two studies revealed 
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dampened circadian rhythms (particularly, amplitude) which could explain patterns of ex-
cessive daytime inactivity in care recipients [278, 367]. Even so, caregiver reports of day-
time sleepiness and dysfunction were far from insignificant. Lastly, the infrequent use of 
sleep medications in care recipients (22-23%), but especially in informal caregivers (10-
20%), was highlighted in two studies [244, 363], with a further study confirming patients’ 
greater need to medicate for poor sleep [242]. In any case, McCurry et al. [363] reported that 
dyads of concurrent poor sleepers were more likely to include a care recipient who was us-
ing sleep aids. 
 
Table 4.1. Summary of Associations in Sleep/Wake Patterns of Care Recipient-Caregiver 
Dyads According to the Level of Clarification Established in the Literature [366] 
Probable 
/Definite As-
sociations 
 Nocturnal interactions in co-residing dyads. 
 Worse daytime activity levels/greater daytime sleepiness in care recipients ver-
sus caregivers. 
 Clinically poorer nocturnal sleep in care recipients versus caregivers. 
 Close synchronisation of bed-times/wake-times in the dyads. 
 Absence of correlation between care recipient and caregiver daytime activity 
levels/behaviours. 
 Infrequent use of sleep medications in the dyads, especially in caregivers. 
Possible 
/Inconclusive 
Associations 
 Effects of sharing a bed/room on the dyad’s sleep. 
 Organisation of a caregiver’s sleep around the care recipient. 
 Frequent/strong correlations between objective nocturnal sleep parameters in the 
dyads. 
 Infrequent/weak correlations between subjective nocturnal sleep parameters in 
the dyads. 
 Comparability in sleep fragmentation and night-time movement in the dyads. 
 Synchronisation of the dyad’s occurrence of daytime naps. 
 Occurrence of concurrent sleep disturbances in the dyads. 
 Dampened circadian rhythms in care recipients versus caregivers/infrequent, 
weak correlations in rhythm activity parameters. 
 Frequency of use of sleep aids as a predictor of dyads in ‘sleep distress’. 
 Direction of disruptive nocturnal interactions: patients’ sleep deficits affect care-
givers’ sleep. 
 Psychological/physical distress, caregiver burden, coping strategies, disease se-
verity/chronicity as predictors of poor sleep in the dyads. 
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4.4.2. Sleep-Impairing Factors in Care Recipient-Caregiver Dyads 
With night-time interactions between care-recipients and informal caregivers being apparent 
[368], two studies suggested mutuality in the way poor sleep is experienced within these dy-
ads [242, 247]. In that sense, each party could be rendered responsible for the other’s sleep 
disturbance. However, this notion was only partially examined in the studies reviewed, half 
of which provided some inconclusive evidence suggesting interactions mainly initiated by 
the care recipients [233, 244, 285, 363, 368]. Indeed, while partner’s sleep showed little abil-
ity to predict ratings of poor sleep in persons with Parkinson’s disease, it was identified as a 
slight contributor of poor sleep in female caregivers, with a four-fold increase in the relative 
risk for poor sleep among caregivers whose care recipient also experienced problems with 
their sleep [233]. Several significant, moderate-to-high inter-correlations were also reported 
in a further study in the same population: greater patient sleep disturbance and diminished 
caregiver sleep duration, as well as poorer patient sleep and greater caregiver daytime dys-
function [285]. Yet, on spontaneous reports, only a small part of caregivers (just below 30%) 
claimed to have been disturbed by the patient [244]. 
Co-habitation and room-sharing were examined in four studies as potential mediators of 
sleep impairments [278, 363, 367, 368]. Findings among the studies were similarly discrep-
ant. One study suggested that, especially in dyads who shared the same bed, and in co-
habiting pairs, it was mainly the elders who initiated nocturnal interactions; yet, it remained 
unclear whether such interactions were also truly associated with sleep interruptions in the 
dyads [368]. In a concurrent study, no significant effects of co-habitation were found for 
both daytime and night-time activity, thus implying a dissociation between elder nocturnal 
activity and caregiver sleep disruption [278]. Possible explanations might be caregivers not 
sharing the same bedroom with the elders, and caregivers not spending much time with el-
ders given that the majority of caregivers in this study were elders’ adult children [278]. In 
the context of dementia, two studies also failed to show direct effects of room-sharing on the 
dyads’ sleep [363, 367]. In the first study, sharing a room was not a significant predictor of 
dyads of concordant poor sleepers [363], whereas in the second study between-groups anal-
yses yielded no differences in either self-report or objective baseline sleep measures between 
caregivers sharing and not sharing a bedroom [367]. 
In spite of the absence of findings based on prospective inter-correlations, four studies iden-
tified psychological distress in the form of mood disturbance and anxiety as a potential con-
tributor to a dyad’s sleep deficits [233, 244, 285, 363]. In three studies, poor sleep was con-
sistently associated to one’s own poor psychological well-being [233, 244, 285], whereas in 
dyads of persons with Alzheimer’s disease and their family caregivers, patient psychological 
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co-morbidity and caregiver ineffective coping strategies were significant predictors of con-
currently manifested poor sleep [363]. However, one study concluded with less nocturnal 
interactions in pairs whose elders reported high levels of depression [368]. One possible, yet 
unexplored, explanation might be that depressed elders disengaged themselves from their 
caregivers, which in turn might have led to caregivers experiencing less sleep disrup-
tion/deprivation over-night. 
Disease severity and chronicity, heavily impacting on the patient’s physical functioning and 
rendering the caregiving situation even more demanding, especially where the situation also 
involves physically affected caregivers, was highlighted – although not explicitly confirmed 
– as a potential sleep-impairing factor in some of the studies reviewed [233, 244, 251, 363]. 
One study revealed that approximately 45% of persons with Parkinson’s disease and 30% of 
caregiving spouses claimed that their sleep had been at least moderately affected by the dis-
ease itself [251]. Among patients with advanced cancer and their family caregivers, patients’ 
bodily pain and caregivers’ global distress were associated with significant sleep deficits, 
even though potential interactions were not explored [244]. Similarly, McCurry et al. [363] 
reported that in dyads in which both the patient and the caregiver slept poorly, the overall 
caregiving situation was more difficult, co-affected by disease chronicity and patients’ lower 
physical functioning. Surprisingly enough, however, caregiver health-related outcomes were 
not significant predictors of concordant poor sleep [363], but data on predictive variables 
were collected only at baseline, thus affecting emergence of associations and limiting relia-
bility of the findings on possible changes across time. 
 
 
4.5. Summary and Critique 
Despite the dearth of studies in the field, promising findings have been yielded suggesting 
bi-directional associations in the sleep of care recipient-caregiver dyads. Concurrent and rel-
atively comparable nocturnal sleep disruption/deprivation may be evident, where poor sleep 
quality, decreased sleep duration, and multiple awakenings may correlate with each other 
within the dyad. Alternatively, daytime activity levels may be uncoupled. In any event, care 
recipients’ and caregivers’ night and day rest patterns can be synchronised, particularly in 
co-residing dyads and/or in those in which caregivers organise their sleep around the patient. 
As a potential consequence, where the illness is more severe, and the overall situation is 
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more intense, distressful, and prolonged, patient-caregiver dyads may be at greater risk of 
concurrent sleep disturbances. 
On closer look, however, evidence is largely compromised by several limitations, which un-
dermine its generalisability and question its reproducibility. Firstly, the majority of studies 
relied on relatively small to moderate sample sizes (range 6 to 60 dyads) in the absence of a 
priori power estimation analyses, a fact that in itself poses a question as to whether larger 
sample sizes would allow for emergence of more [244, 247, 278, 367] or larger [285, 363, 
368] associations between dyads’ sleep variables [244, 247, 278, 363, 367, 368] and be-
tween sleep variables and impairing factors [278, 285, 363, 367, 368]. Multiple statistical 
comparisons in the presence of such small sample sizes might have increased the risk for 
Type I errors. Even studies with more than 100 dyads were cross-sectional in nature [233, 
242, 251], thus precluding causal inferences.  
Secondly, with the exception of one study where assessment spanned over a six-week period 
[367], prospective assessments took place over a limited period of three days [247], and one 
[244, 363] or approximately one (ranging from 6 to 9 days) [278, 368] week. While the ex-
ploratory nature of these studies as well as difficulties to obtain objective data on sleep for 
extensive periods of time are certainly acknowledged, this narrow time frame of observation 
may have been inadequate to allow for latent co-variances in the sleep of dyads to emerge. 
One such example is the inconsistent findings regarding the impact of sharing a bedroom on 
the dyads’ sleep. Furthermore, in two studies, unavailability of data for all days of assess-
ment was reported, which may have produced an even more confined true assessment period 
[247, 363]; similarly, Pollak et al. [368] reported variability in the assessment period ranging 
from 6 to 8 days. It is reasonable to assume that such inconsistencies might also have inter-
fered with study findings.  
Thirdly, all but one [367] study aimed to recruit partners or family members rather than us-
ing a broader definition of the caregiver; yet, even in the study of Lee et al. [367] the final 
sample exclusively consisted of family members, in their vast majority (~80%) patients’ 
spouses. One reason for this might be the short sampling period unable to allow for inclusion 
of all possible categories of caregivers. Closely related to this trend, the majority (63%-
100%) of caregivers were women over a mean age of 55. This fact may have influenced re-
ports of incidence of sleep disturbance, as poor sleep might have been the result of associat-
ed menopausal symptoms, hyperarousability or past sleep problems, rather than just the 
caregiving experience itself or patients’ sleep patterns. Perhaps, inclusion of predominantly 
or exclusively male caregivers could result in different associations.  
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Fourthly, only one study systematically explored triggers of concurrent sleep disturbances in 
the context of dementia [363], whereas three only explored the impact of sharing a bedroom 
[367, 368] or providing care for patients versus healthy elders [278]. Another study, while 
gathering some pertinent data, never went on to explore the possible associations between 
these triggers and dyadic sleep/wake patterns [244]. Especially with regard to the latter, evi-
dence as to the nature of factors that co-affect sleep of patients with cancer and their care-
givers still remains near to zero.  
Fifthly, all studies were conducted in a phase of illness experience where no major events 
were taking place, such as diagnosis, active treatment, health-care transition, or relapse, 
while in at least two studies [242, 244], patients’ functional status was good to very good in 
the majority of the sample. In addition, in at least four studies [233, 285, 363, 367], time 
since diagnosis exceeded an average of approximately four years. Seen together, these facts 
might have led to inclusion of dyads who, in the absence of major influential situations, 
might have found a balance in their sleeping arrangements so as to avoid the considerable 
effects of possible disordered sleep patterns and overall needs on one another. Consequently, 
a gap in the relevant research seems to exist. 
Lastly, in the study of Gibbins et al. [244], inappropriate statistical methods may have ob-
structed associations from emerging, while inadequate association of the definition of day-
time naps with individuals’ inactivity may have led to overestimation of the actigraphic 
measurements. These serious limitations further limit relevant knowledge in the context of 
cancer care, but at the same time dictate the need for more systematic research. 
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CHAPTER 5. 
Study Methodology 
 
 
5.1. Introduction and Research Problem 
Thus far, analysis of current research evidence has emphasised that altered sleep/wake pat-
terns represent a highly disturbing symptom that can severely affect a person’s life in multi-
ple ways and, depending on its nature, potentially over extended periods of time (Chapter 1) 
[49]. Chapter 2 clearly demonstrated that women diagnosed with breast cancer constitute a 
patient population susceptible to sleep impairment, which can be considerably exacerbated 
throughout chemotherapy treatment. Of note, night-time restlessness and daytime sleepiness 
may be present before, maximised during, and persist even after treatment for reasons relat-
ed to a host of individualistic triggers whose underlying link to sleep disruption/deprivation 
is yet to be understood. Furthermore, Chapter 3 confirmed that persons providing informal 
care to people with cancer may also suffer from sleep loss that is possibly, yet not exclusive-
ly, related to the experience of providing continuous care during the intense period of patient 
treatment. Drawing upon theoretical frameworks (attachment theory [338]; “sleep ritual” 
theory [369]) proposing a link between close relationships and sleep regulation, it was then 
argued (Chapter 4) that within such closely related pairs as a patient-caregiver dyad, poor 
sleep may be simultaneously experienced. In a similar fashion, because important aspects of 
the care recipient’s and caregiver’s well-being – sleep functioning included – are linked 
through an interactive and dynamic process known as interdependence [370], it was postu-
lated that individualistic and dyadic triggers of sleep deprivation and/or disruption [62] may 
be concurrently present and exert important cross-partner effects on a dyad’s sleep.  
Women with early stage breast cancer and their caregivers should be able to continue their 
lives free of sleep problems and the associated discomfort. To this end, effective sleep as-
sessment methods are required that go beyond the individual: data are simultaneously taken 
into account, synthesised, and contrasted to establish a dyad’s levels of sleep quality and 
sleep disturbance [366]. Including the perspectives of both care recipient and caregiver can 
increase our understanding of dyadic processes that take place during the natural course of 
caregiving, facilitate the investigation of latent interactions, and highlight potential areas that 
may hinder or enhance implementation of interventions [371]. Moreover, if these dependen-
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cies were examined over time, trajectories of change could be charted, and individual and/or 
dyad characteristics related to change could be determined [371]. In this sense, it is im-
portant to conduct studies that provide longitudinal and simultaneous data on sleep/wake 
patterns/problems for both populations, and identify key time points and impairing, protect-
ing, and/or interacting factors to form a knowledge base for further intervention and guide 
development of effective treatments targeted to the specific needs of care dyads. 
Despite its important implications, to date, dyadic sleep research in the context of cancer 
care is scarce and less than optimal [366]. Current knowledge is lacking in that (a) 
sleep/wake pattern trajectories of people with cancer and their informal caregivers have nev-
er been concurrently investigated at distinct time points during active-phase treatment; (b) 
sleep/wake  patterns of people with cancer and their informal caregivers have never been 
prospectively assessed in true dyadic studies; (c) sleep quality and sleep disturbances of in-
formal caregivers of people with cancer has never been prospectively assessed; (d) interact-
ing sleep-impairing factors and their patterns of change over time have not yet been explored 
in women with breast cancer and their caregivers; (e) sleep history and sleep hygiene have 
never been explored as covariates of alterations in the sleep patterns of people with cancer 
and their informal caregivers; and (f) sophisticated statistical procedures to analyse dyadic 
sleep data have only scarcely been used in previous studies of care dyads, but never in the 
context of cancer care. 
In light of the aforementioned limitations, this Chapter will discuss issues pertinent to the 
design of a dyadic sleep study and the analysis of dyadic data. Furthermore, rationale for the 
selection of variables and relevant measures used in the research project conducted also will 
be provided. 
 
 
5.2. Deciding upon the Research Method and Design 
Whilst the necessity for mixed-methods studies integrating quantitative and qualitative data 
to aid clarification of underlying mechanisms in the development of dyadic sleep disturb-
ances has been previously acknowledged [366], unforeseen budget restrictions in the current 
study (see also Section 8.2) prevented inclusion of both quantitative and qualitative compo-
nents as well as purchase of important measurement equipment (i.e. wrist actigraph devices) 
[49], and inevitably led to re-examination of all initial methodological and design plans. 
Therefore, it was decided that for this exploratory, observational study only quantitative 
89 
 
 
methods based on collection of self-reported sleep data would be used as a first step to in-
vestigate and compare trajectories of change in different sleep and wakefulness parameters, 
and explore relationships that could point to statistically and clinically significant predictors 
of sleep impairment in care dyads. In line with the study’s aims and research questions, self-
reported quantitative sleep data were regarded to be appropriate for testing inter-
relationships among key variables within a certain time point, between the time points of 
observation, and between the two groups of participants. In any case, study limitations aris-
ing as a consequence of the afore-mentioned developments/decisions are explicitly acknowl-
edged in the Chapter 8. 
With the amount of dyadic sleep research being sparse, a descriptive, correlational research 
design was pursued, which allowed for factor-isolating (“what is this?”) and factor-relating 
(“what is happening here?”) questions to be asked as originally proposed in Dickoff and 
James’ hierarchy of researchable questions [372]. Moreover, in line with current recommen-
dations for sleep research [10, 43, 49], distinct assessment points over the course of chemo-
therapy were identified to allow for potential changes in the care dyads’ sleep/wake patterns 
to be explored. This prospective, repeated-measures design was considered to be particularly 
useful in order to support inferences regarding the role of sleep correlates in the develop-
ment of sleep deficits in the dyads, as well as to allow the directionality of the relationships 
to be tested. Four time points have been regarded as critical for the examination of a pa-
tient’s sleep patterns throughout adjuvant chemotherapy for breast cancer [119]: the period 
close to treatment initiation; the week after the first CThC; the weeks after the third and/or 
fourth CThC; and the period following the end of treatment. These time points were consid-
ered for inclusion in the present study. Adopting time points similar to those reported in the 
literature was also viewed as a means to increase the study’s external validity, including 
comparability with relevant research and generalizability [373].  
Importantly, the present study was conceptualised as a true dyadic one [371], where both 
members of the care dyad would be invited to provide data, and dyads rather than individu-
als would be used as the unit of analysis (see Section 5.5) [293, 371]. Lyons and Sayer [371, 
374] argue that methods that fail to address the hierarchical nature of the dyad also fail to 
demonstrate variation, both within and between dyad processes that are paramount to under-
stand them [371, 374]. What is more, the standard dyadic design was adopted, in which each 
person is linked to one, and only one, other person; in other words, each person is member 
of one and only one dyad [293]. In the standard dyadic design, not only both persons are 
measured, but also, at least for some of the variables, both are measured on the same varia-
bles (i.e. reciprocal design) and with the same (or equivalent) measures [293]. Where feasi-
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ble, measurement of a variable of common interest was conducted using versions of the 
same questionnaire for patients and caregivers. In addition, in longitudinal models points of 
assessment must be the same for both members of the dyad so that comparisons between 
patients’ and caregivers’ variables can be tested. Given the scarcity of longitudinal sleep re-
search in caregivers of people with cancer [10], time points for the assessment of informal 
caregivers’ sleep/wake patterns were selected to be the same as those for the patients. 
 
 
5.3. Selecting Outcome and Predictor Variables 
Outcome Variables: Sleep/Wake Parameters 
Drawing upon current recommendations [43, 49], data on the dyad members’ subjective 
sleep quality, subjective sleep efficiency, sleep latency, total sleep time, nocturnal awaken-
ings, wakefulness after sleep onset, daytime sleepiness, and use of sleep aids were planned 
to be collected. As analysed in Paragraph 1.4, information on individuals’ need for napping 
in the daytime, duration of daytime naps, leg restlessness, early morning awakenings, and 
feelings of restfulness upon wakening is considered equally important to adequately describe 
impaired sleep and wake patterns, therefore they were also included as outcome variables to 
be explored. 
 
Predictor Variables and Covariates: Health Outcome Parameters 
The following physical and psycho-behavioural parameters were considered for inclusion in 
the final set of predictors: sleep hygiene, nocturnal disturbance, physical symptom burden 
(patients), psychological burden, coping strategies, and caregiver burden (caregivers). All 
analyses were also adjusted for the effects of demographic/clinical covariates, for which a 
link to sleep/wake patterns has been proposed, such as past sleep history, performance status 
and physical activity. Predictor variables and covariates were selected based on findings of 
recent literature reviews [119, 182, 366], and according to the theoretical frameworks of 
sleep/wake impairment analysed in Chapter 1 in line with current guidelines [61]. First, ac-
cording to Lee et al.’s Conceptual Model of Impaired Sleep [62], a number of triggers were 
considered that may lead to sleep deprivation (e.g. inadequate sleep hygiene, caregiving bur-
den etc.) or disruption (e.g. psychological and physical burden, nocturnal disturbance), and 
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eventually result in sleep loss. Second, Spielman’s Three-Factor Insomnia Model [64] guid-
ed the selection of predisposing (e.g. sleep hygiene), precipitating (e.g. psychological and 
physical burden, nocturnal disturbance, caregiver burden), and perpetuating (e.g. sleep hy-
giene, psychological burden, coping styles) predictors of sleep loss. The same model was 
used to form the set of covariates (confounding variables): predisposing (e.g. age, past sleep 
history), precipitating (e.g. treatment-related stressors), and perpetuating (e.g. reduced phys-
ical activity) were considered. Third, in line with the dyadic paradigm [293, 294, 366, 374], 
not only individualistic but also dyadic covariates were considered (e.g. sharing the same 
house/bedroom, type and duration of relationship). Importantly, the ever-changing and pos-
sibly non-linear nature of sleep-impairing factors was acknowledged [61], which informed 
the inclusion of both time-invariant (measured once) and time-varying (measured repeated-
ly) predictors [375, 376].  
 
 
5.4. Screening for Adequate Measures 
Whilst it was anticipated that demographic and clinical information would be provided by 
the participants themselves, or extracted from patient case notes, completion of a set of vali-
dated questionnaires was planned to form the basis of data collection activities. Two pa-
rameters have been identified as being particularly important in this context [377]. First, 
psychometric efficiency (i.e. validity, reliability, responsiveness to change) of the selected 
questionnaires is required to ensure that internal validity of a study is preserved. Second, 
proved acceptability and feasibility (i.e. readability, length) are paramount to prevent data 
collection from creating unwanted burden to participants. Therefore, a systematic search for 
available measures according to variable category was performed. The questionnaires identi-
fied were contrasted and compared taking into consideration the afore-mentioned criteria, 
which ultimately led to the selection of the most appropriate measure per variable category. 
Of note, given the multi-factorial nature of the study which posed the requirement for use of 
a number of different questionnaires, it was decided that, where possible, brief rather than 
lengthy psychometrically fit questionnaires would be preferably selected. 
 
Performance Status 
In oncology, the two most commonly used scales to assess performance status (PS) are the 
Karnofsky Performance Status scale (KPS) [378] and the Eastern Cooperative Oncology 
92 
 
 
Group Performance Status scale (ECOG PS) [379]. Compared to the KPS which is a 10-item 
measure, ECOG PS is simpler (5 items) and can be more easily used by patients and care-
givers [380]. Although the scale is generally completed by health professionals [380-382], 
research has shown that patients can make reliable self-assessments of their PS, thus further 
enhancing assessment precision [381]. Therefore, in line with current recommendations, 
self-assessments of PS were planned to be performed in this study via use of the ECOG PS 
scale. 
 
Physical Activity 
Methods to measure physical activity are classified as direct or concurrent (e.g. measure-
ment of bodily movements or energy expenditure) and indirect or surrogate [383]. Indirect 
or surrogate methods include physiologic measures (e.g. cardiorespiratory fitness, percent-
age of body fat) and self-report measures such as surveys, multi- or single-item question-
naires, activity diaries, and recall interviews [383]. In this context, questionnaires are inex-
pensive, do not have a large participant burden, and can provide prevalence estimates of in-
tensity, frequency and duration of physical activity that can be used to categorise respond-
ents into activity categories [383]. Admittedly, these questionnaires share the weaknesses of 
introducing recall bias and of being unable to account for all types of activity performed 
[383, 384]. However, well-established and validated questionnaires can be usefully intro-
duced in observational studies. Over fifteen physical activity scales exist [384-389], the ma-
jority are lengthy ones and are used infrequently with patients with cancer or informal care-
givers. As previously mentioned, to prevent participant burden, focus was directed on the 
shorter scales, preferably those comprised of one item. Nine studies were identified in the 
relevant literature where single items were used to rate frequency and intensity of moderate 
and/or vigorous physical activity [240, 390-397]. However, a series of limitations, including 
lack of proper validation [240, 390-396], unclear definition of ‘inactive versus active’ [240, 
390], and exclusive focus on either moderate [391] or vigorous [394, 395] physical activity, 
led to the retention of a psychometrically fit (validity, test-retest reliability) [398], single-
item scale (Appendix 10) previously used in a study of survivors of Hodgkin’s lymphoma 
[397]. Although this scale has not been used previously with patients with breast cancer or 
informal carers, it is not disease- or context-specific and therefore it was deemed appropriate 
in this context. 
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Sleep/Wake Parameters 
Although sleep/wake patterns can be assessed objectively by a number of different modali-
ties, including polysomnography, sleep latency testing, and actigraphy, self-reported sleep 
measures serve as a non-invasive substitute that have been validated and verified to be use-
ful instruments for research purposes [43, 49]. To ensure that all available options in the col-
lection of subjective sleep data had been examined, the use of daily sleep diaries or sleep 
questionnaires, or a combination of the two, was taken into consideration. Daily recorded 
sleep diaries/logs can be usefully implemented to monitor sleep/wake patterns over a week’s 
period; yet, they are not always standardised as research tools and also can be much harder 
to keep for prolonged periods than standardised questionnaires [182]. This burden is of im-
portance to studies implementing a longitudinal design, and seeking to recruit people other-
wise occupied during an active treatment period. Therefore, to prevent participant burden 
and avoid high rates of missing data, the option of using validated sleep questionnaires 
seemed more feasible, practical and reasonable. As previously mentioned, self-report re-
search questionnaires are easy to obtain, administer and complete [4]. They also measure 
perceptions; hence, they can provide data on the more qualitative features of sleep such as 
sleep quality, feelings upon arising, or daytime sleepiness and dysfunction [49]. Certainly, 
several limitations in their use exist (e.g. potential for recall bias; lack of flexibility due to 
time frames for recall; unclear psychometric properties), which are acknowledged and ex-
plicitly discussed in Chapter 8. However, as subjective sleep data may correlate more strong-
ly with self-reports of health-related outcomes, data deriving from sleep questionnaires can 
allow for intra- and inter-personal relationships to be more thoroughly examined. Therefore, 
in the context of this exploratory study, their inclusion has been instrumental in the explicit 
investigation of (inter-) relationships within and between the dyads. 
Numerous sleep questionnaires have been identified in the relevant literature [13, 43, 49, 
251, 399-403], which can be generally classified into two broad categories: generic 
measures of sleep/wake parameters and measures of daytime sleepiness (such as the Ep-
worth Sleepiness Scale [404], the Functional Outcomes of Sleep Questionnaire [405], and 
the Stanford Sleepiness Scale [406]). Given that the present study aimed to explore a wide 
range of sleep/wake patterns rather than merely focusing on daytime sleepiness/dysfunction, 
only generic sleep measures were taken into consideration. Of these, ten questionnaires had 
been used in previous studies with patients with cancer, and were further examined (Table 
16-A2). Comparisons revealed that the Pittsburgh Sleep Quality Index (PSQI) [407], the 
Medical Outcomes Study-Sleep Scale (MOS-SS) [408] and the Insomnia Severity Index 
(ISI) [409] had undergone the most extensive psychometric evaluation. These instruments 
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have been used in diverse clinical populations and are similar in length and ease of use. 
Originally, the PSQI and the MOS-SS assess sleep over the past 28 to 30 days, whereas the 
ISI has a shorter recall time frame (past 14 days). However, the ISI does not elicit infor-
mation on the person’s bed/wake-times, sleep efficiency, sleep latency, and sleep duration as 
the PSQI and partly the MOS-SS do. Therefore, it was excluded from further consideration. 
Conversely, the PSQI was found to have a stronger established validity, reliability, respon-
siveness and interpretability, whereas the MOS-SS has minimal data on responsiveness and 
no available data on interpretability. In addition, the PSQI is the most widely used self-
report questionnaire among patients with breast cancer [119] and caregivers of adults with 
cancer [182]. Given that psychometric soundness for a self-report sleep measure is of utmost 
importance, and that comparability of similar studies in this context is highly desirable, the 
PSQI was considered to be the most appropriate instrument for this study. 
Bearing in mind that no perfect self-report sleep measure exists, a number of questions were 
also considered to assess additional essential sleep parameters reported in the literature 
[119], but not covered or not thoroughly addressed in the PSQI. In brief, these questions ad-
dressed the following sleep parameters: (a) need for daytime napping and average duration 
of naps per day; (b) feelings of restfulness upon arising in the morning regarding the extent 
of restfulness; (c) occurrence and frequency of leg restlessness; (d) early, unplanned awak-
enings in the morning; (e) extent of daytime sleepiness; and (f) average number of nocturnal 
awakenings per night. These parameters were combined to formulate a separate form that 
was administered to participants alongside the PSQI. 
 
Sleep History 
Sleep history questionnaires are commonly used in clinical practice to elicit information re-
garding an individual’s past and current sleep habits, and can be a useful adjunct in identify-
ing persons at risk for disordered sleep [410]. Numerous, and in most cases considerably 
extensive, sleep history questionnaires are available online, with their content reflecting the 
needs of different professionals caring for clinically different individuals in different sleep 
clinics. This abundance suggests that development of these questionnaires to date has been 
largely arbitrary; hence, no questionnaires with definitely established properties exist. For 
the purposes of the present study, six questions were extracted from a standardised sleep his-
tory used in a previous study of people with advanced cancer and their informal caregivers 
[244]. Questions referred to past sleep history, sleep problems due to cancer diagnosis, nico-
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tine/alcohol consumption, and sleeping arrangements. Although validity remains questiona-
ble, it was nevertheless believed that comparability between the studies could be promoted.  
 
Sleep Hygiene 
Sleep hygiene questionnaires are useful diagnostic tools for patients and their partners [411]; 
yet, no studies have tested the use of such instruments with people with cancer and their in-
formal caregivers [182]. Upon systematically searching for reliable and valid tools, four in-
struments addressing sleep hygiene practices were identified that have been used with 
healthy individuals, insomniacs, or people with post-traumatic stress disorder [412-415]. 
These tools were compared regarding their brevity, suitability, and psychometric properties 
(Table 17–A2). Admittedly, each of these measures has problematic features, and question-
able reliability and validity. Nonetheless, the Sleep Hygiene Index (SHI) was deemed the 
most appropriate questionnaire for the purposes of this study for its brevity, ease of use, and 
acceptable psychometric properties. What is more, the SHI yields a global score that can be 
usefully implemented in statistical analyses. 
 
Physical and Psychological Burden 
Current guidelines suggest that symptom assessment instruments should be comprehensive 
capturing symptom prevalence, severity and distress, easy to understand and complete, accu-
rate, reliable, repeatable, and sufficient for decision-making [416]. Yet, no questionnaire 
exists that meets all criteria for an ideal instrument, hence the final choice very much de-
pends on the purpose of each individual study [416]. In a recent systematic review of cancer 
symptom assessment instruments, Kirkova et al. [416] identified twenty-one tools appropri-
ate for use in cancer care practice. Selection of the most appropriate tool for the present 
study was informed by the results of this review. Seven instruments were symptom-targeted 
and/or included less than five items, thus they were not taken into further consideration. 
Moreover, since this study aimed at collecting data based on patient and caregiver self-
reports, two instruments (Reduced Expanded Support Team Assessment Schedule [417], and 
Pain and Symptom Assessment Record [418]) were excluded as they are observer-rated. One 
tool (A Computerized Symptom Assessment Instrument [15]) was excluded as completion is 
computer-assisted rather than paper-and-pencil, and is recommended for use in the radio-
therapy setting. Two more instruments (Cambridge Palliative Assessment Schedule [419], 
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and The Symptom Monitor [420]) were excluded as they had been developed for use in the 
palliative care setting only. Therefore, nine instruments (Symptom Distress Scale [421], Rot-
terdam Symptom Checklist [RSCL] [422], Edmonton Symptom Assessment Scale [423], 
Memorial Symptom Assessment Scale [MSAS] [424], Oncology Treatment Toxicity As-
sessment Tool [425], Worthing Chemotherapy Questionnaire [426], M. D. Anderson Symp-
tom Inventory [MDASI] [427], The Symptom Experience Scale [428], and the Canberra 
Symptom Score Card [429]) were deemed appropriate for the purposes of this study and 
their properties were fully examined. Of these, it was determined that the RSCL, the MSAS, 
and the MDASI had undergone the most extensive psychometric validation and were com-
prehensive, yet not too long to cause participant burden. However, the MSAS had a stronger 
established validity, reliability, responsiveness and interpretability than the RSCL, and it 
covered more areas of symptom burden and was easier to understand than the MDASI. In 
addition, the MSAS addressed all three important symptom parameters (i.e. duration, severi-
ty and distress) compared to only one (distress) addressed by the RSCL and two (frequency, 
severity) addressed by the MDASI. For these reasons the MSAS was considered to be most 
appropriate for this study. 
It should be stated here that a separate systematic search was initially conducted for validat-
ed measures of psychological burden, namely measures of anxiety and depression. The 
State-Trait Anxiety Inventory (STAI) [430], the Center for Epidemiologic Studies-
Depression (CES-D) [431], the Beck Anxiety Inventory [432], the Beck Depression Invento-
ry [433], and the Hospital Anxiety and Depression Scale (HADS) [434] emerged as the most 
frequently used measurement tools in studies with people affected by cancer [435]. Whereas 
the psychometric properties of the STAI and the CES-D have been extensively tested in this 
population [435, 436], the scales are lengthy (measuring 40 and 20 items, respectively) and 
may prove burdensome. Therefore, the need for a more brief measure led to the retention of 
the HADS, which has acceptable validity and reliability [435, 437], and also benefits from a 
concurrent assessment of individuals’ levels of anxiety and depression. Nevertheless, during 
ethical approval review of the current study, the Research Ethics Committee (REC) raised 
concerns to the use of a measure of emotional distress in the specific context on the grounds 
of emotionally evocative questions possibly increasing the levels of distress of vulnerable 
patients and carers at a sensitive point after cancer diagnosis. To avoid unwanted participant 
distress and to meet the REC’s requirements, it was decided that the HADS be removed 
from the study’s instrumentation set. Psychological burden was measured through the 
MSAS psychological subscale instead. 
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Coping Strategies 
Livneh and Martz [438] point out that despite the gradual improvement of conceptual, 
structural and psychometric aspects of the available coping scales, many inadequacies still 
remain. Lack of conceptual clarity, questionable factor structure, and inappropriate 
reliability estimates are only a few of the aspects criticised in the literature [439], which may 
in part stem from inconsistencies inherent in the definition and conceptualisation of coping 
itself [438, 440]. For instance, dispositional (or trait-like) and situational (process or state-
like) views of coping can result in two types of assessment tools [438]. As previously stated, 
selection of the coping scale to be used in this study was based on a measure’s brevity, 
comprehensiveness, and psychometric soundness [440]. A situation-oriented instrument was 
regarded to be most suitable for the prospective nature of the study. In addition, and in 
agreement with previous research, the selection process favoured instruments which can 
provide measures of approach or engagement coping, and avoidance or disengagement 
coping that have been associated with salutary and poor psychosocial outcomes, 
respectively. Seventeen instruments were identified as being commonly used to assess 
individual coping styles. Three of them had been originally developed to evaluate responses 
or adjustment to cancer (Mental Adjustment to Cancer [441], Mini-Mental Adjustment to 
Cancer [442]) and mastery skills (Mastery Scale [443]) rather than coping, whereas the 
Coping Strategies Questionnaire [444] assesses coping strategies exclusively related to pain. 
Hence, these measures were not taken into further consideration. Thirteen measures 
underwent full examination of their properties (Table 18-A2). In order to avoid increasing 
participant burden, six instruments (Ways of Coping Checklist [445], Ways of Coping 
Questionnaire [446], Coping Strategies Inventory [447], Measure of Daily Coping [448], 
COPE Inventory [449], Jalowiec Coping Scale [450]) were excluded as they were deemed 
too long (ranging from 55 to 72 items). Moreover, due to their dispositional orientation, 
three instruments (Brief Approach/Avoidance Coping Questionnaire [451], Coping Strategy 
Indicator [452], Coping Inventory for Stressful Situations [453]) were not deemed suitable 
for this study. Similarly, the Life Situations Inventory [454] was disregarded because it only 
addressed a hypothetical situation and had no established psychometric data in populations 
of people affected by cancer. Because of the lack of validation data in cancer populations 
and of an ambiguous scoring system, the Coping Responses Indices scale [455] was also 
excluded. Of the two remaining instruments, the Cancer Coping Questionnaire [456] uses a 
patient-oriented format rather than a neutral one, thus rendering administration to informal 
caregivers difficult without prior vast adaptation, which might influence criterion validity. 
Therefore, the Brief COPE scale [457] was considered to be the most appropriate for use in 
the present study. 
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Caregiving Burden 
Over the last three decades, caregiver burden has evolved as one of the most rigorously re-
searched areas in the caregiving experience [458]. Closely related to this trend, development 
of burden assessment instruments has grown in terms of theoretical soundness, complexity 
and rigour of psychometric testing [458]. Two systematic reviews of the relevant literature 
identified seventeen burden instruments for use with informal caregivers of chronically ill 
people, developed between 1980 and 2002 [216, 458]. Considerable variation, strengths and 
limitations of these instruments were reported, which informed selection of the most appro-
priate measure for this study. A measure assessing both objective and subjective aspects of 
burden was regarded most desirable. However, none of these few instruments (Caregiver 
Subjective and Objective Burden Scale [459], Burden Assessment Scale [460]) had under-
gone rigorous testing, and selection of a generally poor measure of burden was definitely 
unwanted. Therefore, all available measures were examined irrespective of their specific 
focus. Upon initial inspection, eight instruments were deemed to be the least psychometri-
cally sufficient and/or feasible to be taken into further consideration. Yet, of the remaining 
nine measures, seven instruments were also excluded for various additional reasons includ-
ing the following: 
 Absence of data on the instrument’s factor structure (Zarit Burden Interview [461], 
Caregiver Appraisal Scale [462], Burden Assessment Scale [460], Caregiver Burden 
Scale [463]) 
 Uni-dimensionality in the assessment of subjective burden (Zarit Burden Interview 
[461]) 
 Dichotomous response format that limited sensitivity of the instrument (Caregiver 
Strain Index [464], Caregiver Perceived Burden Scale [465]) 
 Questionable content validity (Caregiver Perceived Burden Scale [465], Burden 
Assessment Scale [460]) 
 Instrument length exceeding 50 items, possibly increasing participant burden 
(Caregiver Experience Assessment [466]) 
 Questionable scoring system (Caregiver Experience Assessment [466]). 
After the Caregiver Reaction Assessment Scale (CRAS) [467] and the revised Bakas’ 
Caregiving Outcomes Scale (BCOS) [468] having been thoroughly examined, it was 
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determined that only minimal data on the BCOS’s psychometric properties in caregivers of 
patients with cancer were available. Therefore, the CRAS was retained for use in the present 
study. 
In sum, the final instrumentation set for the current study comprised the following measures: 
the ECOG performance status scale; a single-item physical activity scale; the PSQI; a study-
specific form addressing additional sleep/wake parameters; a sleep history inventory; the 
SHI; the MSAS; the Brief COPE; and the CRAS. 
 
 
5.5. Analysing Data from Dyadic Studies 
There are a number of challenges to consider when analysing data deriving from dyads. 
First, observations from individuals within the same dyad are most likely non-independent 
[371]. This is because members of the care dyad are likely influenced by similar contextual 
factors, or influence one another directly [293, 371, 469]. Kenny et al. [293] defined dyadic 
non-independence as follows: if two scores from the two members of the dyad are compared 
and found to be non-independent, then those scores are likely to be more similar to (or dif-
ferent from) one another than are two scores from two people who do not belong to the same 
dyad. In this case, there is less unique information than the total sample size would suggest 
[371]. Ignoring the nested structure of this type of data leads to bias in the estimates of the 
error variance, which in turn distorts the estimates of standard errors, p-values, confidence 
intervals and effect sizes [293, 371, 469]. 
Second, ordinary least squares (OLS) procedures used to measure dyads such as bivariate 
correlations, intraclass correlations, paired samples t-tests, analysis of variance (ANOVA) 
and repeated measures ANOVA have limitations in processing dyadic data, basically be-
cause they create measures of dyadic properties from individual level data [370, 374]. What 
is more, standard errors can be underestimated in these procedures, especially as variance 
within dyads increases, thus leading to biased estimates of coefficients and a greater risk of 
Type I errors. Therefore, the use of analytic methods that take into consideration (and con-
trol) for the shared variance within the dyad has been emphasised as being critical [293, 
374]. 
Multilevel modelling (MLM) (that is to say, hierarchical linear modelling) provides a power-
ful and flexible framework for analysing dyadic data [293, 374]. As the name suggests, in a 
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multilevel data structure, there are multiple levels within the data; in other words, there is a 
hierarchy of units, with one set of units nested within another [293]. In MLM for dyads the 
responses of the members of the dyad are conceived as Level 1 units nested within the Level 
2 unit, the dyad [371, 374]. In over-time data from dyads, there is one additional factor: 
time. However, the two-level structure of the data is retained, given that time and person are 
usually crossed, not nested [293]. This means that, for a given dyad, the level of time is the 
same for the two persons at each time point [293] (see Figure 5-1). 
 
 
Figure 5-1. A two-level statistical model for patient-caregiver dyads (Note: Pt – patient; Cg – care-
giver; L1 – level 1; L2 – level 2; t – assessment point). Adapted from: HLMs for dyadic data: Multi-
variate Outcomes Approach. School of Psychology; UMass Amherst. http://www.psych.umass.edu/ 
uploads/people/79/Dyads_with_Multivariate_Outcomes.pdf 
 
 
The multivariate hierarchical linear model (MHLM) proposed by Raudenbush et al. [376] is 
a combination of the cross-sectional model for matched pairs and the longitudinal model for 
individual change. This longitudinal matched-pairs model is fit to the repeated assessments 
of the outcome variables for both members of the dyad, and compares patterns of change in 
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trajectories for both of them [374]. This approach uses indicator variables to identify patient 
and caregiver variables within one model so that it can demonstrate how dyad members may 
change differently over time while controlling for the non-independence of scores among the 
dyad members [371]. 
There are compelling advantages in the use of MLM when estimating longitudinal trajectory 
models for dyads over the more traditional OLS procedures [370, 374]. First, each member 
of the dyad can have a unique trajectory, specified to differ in pattern (e.g., change can be 
linear for patients and nonlinear for caregivers) and magnitude (e.g., the rate of change can 
be steeply negative for patients and flat for caregivers) [374]. MLM allows the incongruence 
of the average trajectories for each member of the dyad to be directly tested for significant 
differences at the intercept (the predicted score at a specific occasion of measurement), the 
slope (rate of change), or both, using a generalised multivariate hypothesis test [370, 374]. 
Second, MLM takes into consideration non-independence within dyads, controls for the au-
tocorrelation among the repeated measures, and adjusts the error variance for the interde-
pendence of member outcomes within the same dyad. This adjustment results in more accu-
rate standard errors and their associated hypothesis tests [370, 374]. Third, the model allows 
for unbalanced study designs in models for dyadic data and permits inclusion of data from a 
dyad even when one partner is missing data points under missing at-random assumptions 
[371, 376]. Conversely, repeated measures ANOVA requires a full dataset with no missing 
values, whereby any data missing lead to the automatic listwise deletion of cases. With 
MLM it is possible for only one member of the dyad to contribute data or for the pattern of 
missing responses to be different for each partner; however, no cases are excluded due to 
incomplete data. Fourth, MLM allows for uneven spacing between assessment points and 
variation in the number of assessments completed by participants [470]. Last but not least, 
MLM allows for variables that might affect dyads’ trajectories to be investigated. Given the 
importance of longitudinal MLM in the estimation of dyadic models over time [293], this 
statistical method was chosen to facilitate interpretation of changes in the sleep patterns of 
dyads in the present study. 
 
 
5.6. Summary 
A number of instrumental methodological issues were taken into consideration that shaped 
overall design procedures for this study. Identification of gaps in the current relevant re-
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search was a crucial first step. Findings deriving from comprehensive literature reviews (rig-
orously analysed in the previous chapters and recapitulated here) constituted the basis upon 
which theories were applied and hypotheses were generated. The correlational nature of the-
se hypotheses, the dyadic nature of the relationships to be investigated and the requirement 
for robust procedures to measure change over time and grasp relationship direction subse-
quently informed decisions about the appropriateness of the research design to be employed. 
Identification of the outcome (dependent) and predictor (independent) variables was the next 
important step. This was followed by careful consideration of measurement issues (e.g. cur-
rent recommendations, feasibility, acceptability, reliability, validity, comprehensiveness) 
that guided the screening process for the selection of adequate available measures. Inextrica-
bly linked to all afore-mentioned issues, a data analytic strategy was devised that took into 
consideration advantages and disadvantages of different analytic approaches in answering 
the questions posed in the current study. 
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CHAPTER 6. 
Study Aims and Methods 
 
 
Reporting of this study was conducted in accordance to guidelines contained within the 
STROBE Statement [141, 142]. The Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) recommendations were developed to improve the quality of 
reporting of observational studies, to enable strengths and weaknesses of a study to be re-
vealed, as well as sound interpretation and application of study results to be facilitated [141]. 
Table 7-A2 provides a checklist of the twenty-two items required to be addressed in reports 
of observational studies as included into the STROBE Statement. 
 
 
6.1. Aims & Research Questions 
The primary aim of this PhD study was to longitudinally explore sleep/wake patterns of dy-
ads of women with early stage breast cancer and their informal caregivers throughout adju-
vant chemotherapy treatment, thus identifying interrelations in their sleep/wake parameters. 
Related hypotheses included the following: 
Hypothesis 1: In patient-caregiver dyads living in a close caring relationship, similarities in 
the shape of their trajectories of sleep/wake parameters exist as dyads go through the dif-
ferent stages of adjuvant chemotherapy for breast cancer. 
Hypothesis 2: In patient-caregiver dyads living in a close caring relationship, sleep/wake 
parameters and/or changes in sleep/wake parameters are moderately correlated as dyads go 
through the different stages of adjuvant chemotherapy for breast cancer. 
Hypothesis 3: In patient-caregiver dyads living in a close caring relationship, sleep/wake 
impairments of caregivers are comparable (in terms of frequency/severity) to that of pa-
tients going through the different stages of adjuvant chemotherapy for breast cancer. 
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Based on existing literature, a secondary aim was to examine how different sleep-impairing 
factors may affect patients’ and caregivers’ sleep/wake patterns over time, also taking into 
consideration the complexity of mechanisms interfering with a dyad’s sleep quality, where a 
woman’s sleep may not only be influenced by her own distress but also by her carer’s, and 
vice versa. Relevant hypotheses included the following: 
Hypothesis 4: Increases in own physical and psychological burden, disruptive sleep hy-
giene behaviours, nocturnal sleep disturbance, and maladaptive coping strategies, con-
trolled for significant demographic/clinical covariates, are independently predictive of poor 
sleep/wake outcomes in women receiving adjuvant chemotherapy for breast cancer. 
Hypothesis 5: Increases in own psychological burden, caregiving burden, disruptive sleep 
hygiene behaviours, nocturnal sleep disturbance, and maladaptive coping strategies, con-
trolled for significant demographic/clinical covariates, are independently predictive of poor 
sleep/wake outcomes in informal caregivers of women receiving adjuvant chemotherapy 
for breast cancer. 
Hypothesis 6: Cross-partner effects of the afore-mentioned sleep-impairing factors exist, 
where dyad members’ sleep/wake patterns not only are influenced by own distress but also 
by their care partners’. 
 
Thus, the research questions for this study were: 
1. What are the trajectories of change of patients’ and caregivers’ sleep/wake parameters 
throughout the period of adjuvant chemotherapy for breast cancer? 
 How similar or dissimilar are patients’ and caregivers’ trajectories of change of their 
sleep/wake patterns? 
 Which sleep/wake parameters show the greatest interdependence across the dyads? 
2. How are changes in triggers of sleep deprivation associated with changes in the pa-
tient’s and caregiver’s sleep quality adjusted for own demographic/clinical covariates 
emerging at both the individual and dyadic level? 
a. Are changes in women’s physical burden, caregiver’s health burden, and dyads’ 
sleep hygiene practices and psychological burden associated with changes in their 
own sleep/wake parameters? 
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b. Are there cross-care-partner effects of the aforementioned triggers on the dyad 
members’ sleep/wake parameters? 
 
 
6.2. Study Design 
This was a descriptive, observational, repeated-measures dyadic study, conducted to explore 
sleep/wake patterns and sleep-impairing factors in patients with early stage breast cancer and 
their informal caregivers throughout adjuvant chemotherapy treatment. 
 
 
6.3. Setting 
Women diagnosed with early stage breast cancer and scheduled to receive adjuvant chemo-
therapy on an outpatient basis at four ambulatory oncology NHS clinics in Scotland were 
screened for eligibility and invited to take part in the present study along with their primary 
informal caregiver. 
 
 
6.4. Population and Sample 
A convenience sample of all newly diagnosed women with early stage breast cancer and 
their primary informal caregiver – as nominated by the patient – upon their consultation ap-
pointment for chemotherapy planning were considered as possible candidates, based on pre-
specified eligibility criteria (see below). 
In order to promote sample homogeneity, only those women scheduled to receive adjuvant 
chemotherapy were considered for inclusion in this study; women scheduled to receive neo-
adjuvant treatment were excluded. Specifically, it was postulated that differences in the de-
gree of distress (mainly due to women with adjuvant chemotherapy having also undergone 
surgery, and women receiving neo-adjuvant treatment being closer to diagnosis) would ren-
der these groups not exactly comparable in terms of sleep problems. 
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For the purposes of the study, the term ‘informal caregiver’ was also chosen to encourage 
patient self-identification of an individual, who had an important role in providing support 
post-diagnosis and during chemotherapy experience. This term acknowledges the variety of 
individuals that may have a primary caregiving role and may include family members, 
friends or neighbours [229]. 
 
6.4.1. Patient Eligibility Criteria 
Patients eligible to this study were adult (>18 years of age) women recently diagnosed with 
clinical stage I-IIIA (TNM-UICC) [71] breast cancer, at least 2 weeks post-initial breast sur-
gery, with no previous cancer diagnosis or previous administration of chemotherapy, and 
scheduled to receive ≥6 cycles of adjuvant chemotherapy. Changes in chemotherapy doses 
or regimens were allowed in this study. Women were also required to have adequate 
knowledge of English and a satisfactory level of communication and to be able to provide 
written informed consent. Patients with inflammatory locally advanced or metastatic disease, 
with a diagnosed or clinically suspected primary sleep disorder (such us primary insomnia, 
narcolepsy, or sleep apnoea), and/or cognitive or mental impairment, were excluded from 
this study. 
 
6.4.2. Informal Caregiver Eligibility criteria 
Primary informal caregivers eligible to this study were nominated by patients as the person 
who the woman felt closest to, and who provided most physical and emotional care and sup-
port to her during that period of time. In this sense, participating caregivers could be a wom-
an’s husband/partner, parent/child, other family member, friend, or neighbour. Caregivers 
were required to be adults (>18 years of age), have adequate knowledge of English and a 
satisfactory level of communication, and to be able to provide written informed consent. 
Similarly to patients, individuals with a diagnosed or clinically suspected primary sleep dis-
order (such us primary insomnia, narcolepsy, or sleep apnoea), and/or cognitive or mental 
impairment were excluded from this study. 
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6.5. Data Collection Scheme 
Repeated assessments of each woman and her caregiver took place starting prior to initial 
chemotherapy (T0; baseline), during active-phase treatment (T1-T2), and at the end of 
treatment (T3), three weeks post-completion of the last chemotherapy cycle. Detailed infor-
mation about each time point and its purpose is given below. A data collection schedule in-
cluding the four time points of assessment is outlined in Figure 6-1. 
 Time point T0: Baseline assessment prior to Treatment 1 (CThC1). Data collection 
was conducted the week before a woman’s first appointment for chemotherapy, where 
participants were asked to reflect on the study variables for the past 15 days. Baseline 
data served as a starting point, to which subsequent changes in the dyads’ sleep/wake 
patterns during and after chemotherapy were compared. 
 Time point T1: Post-administration of Treatment 1 (CThC1). Data collection was con-
ducted two weeks after administration of CThC1, where participants were asked to re-
flect on the study variables for the past 15 days. Data collected at this time point al-
lowed for the initial impact of chemotherapy administration on patients’ sleep/wake 
patterns, as well as that of caring for patients who had experienced chemotherapy for 
the first time, on caregivers’ sleep/wake parameters to be examined. 
 
 
 
Figure 6-1. Schematic of data collection points (Note: CThC – Chemotherapy cycle). 
 
 
 Time point T2: Post-administration of Treatment 4 (CThC4). Data collection was con-
ducted two weeks after administration of CThC4, where participants were asked to re-
flect on the study variables for the past 15 days. Data collected at this time point al-
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lowed for assessing patients’ and caregivers’ sleep/wake impairment during chemother-
apy continuation, at a period where cumulative distress reaches a peak after successive 
cycles of chemotherapy [119, 128]. 
 Time point T3: Three weeks post-administration of the last cycle of chemotherapy 
(≥CThC6). Participants were asked to reflect on the study variables for the past 15 days. 
T3 was selected at 3 weeks after the end of treatment to avoid possible confounding 
variables (e.g. anticipatory anxiety) from interfering with sleep assessment by including 
patients (and their caregivers) scheduled to initiate radiation therapy 3 or more weeks 
after chemotherapy was complete. Data collected at this time point allowed for as-
sessing patients’ and caregivers’ sleep/wake patterns at the end of chemotherapy and 
before patients go ahead with additional adjuvant treatment modalities [119]. 
 
 
6.6. Research Ethics 
The study protocol was granted approval by the Tayside Committee on Medical Research 
Ethics A (10/S1401/41) (see Appendix 8), and the study was undertaken in accordance with 
the guidelines of the Declaration of Helsinki and its current revision [471]. 
 
 
6.7. Recruitment and Participation Procedures 
Based on the fundamental principles of research ethics of beneficence, non-malfeasance, 
respect for individuals’ autonomy, and justice [472], recruitment and consent procedures 
aimed to protect eligible individuals by ensuring that: 
1. Information and consent documents were readily understandable by all individuals. 
2. Each individual understood the nature and purpose of the study, and consented volun-
tarily. 
3. Each individual had the opportunity to ask questions. 
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4. Individuals were free to take part, if they so wished, but they were equally free to de-
cline, and subsequently withdraw, if they changed their minds, without this affecting in 
any way the quality of care they received. 
5. The researcher was aware of verbal and nonverbal cues of the patient/caregiver imply-
ing that they felt uncomfortable during the initial approach, and was flexible during this 
assessment to each individual’s needs. 
6. The individual wished to continue in the study prior to follow-up assessments. 
 
A local collaborator was identified at all recruitment NHS sites involved in the present 
study. Clinical collaborators were also the researcher’s clinical supervisors at the specific 
site, allowing for the researcher to establish a relationship with each site and be able to ac-
cess clinical areas and patient case notes. Local collaborators were responsible for identify-
ing newly diagnosed patients with early stage breast cancer, for whom a plan to commence 
adjuvant chemotherapy had been settled. 
Upon their appointment for consultation and chemotherapy treatment planning, the local 
collaborator checked patient eligibility and was the first to approach the patient and invite 
her to participate in the study through the use of a one-page invitation flyer (Appendix 9). 
No formal training of the local collaborators was required as they only handed flyers out to 
patients; however, they all were aware of the procedures of recruitment to be followed. 
Patients interested in the study were given a Participant Information Sheet – Patient (PIS-P) 
(Appendix 9) to read at home and consider their willingness to take part in the study. In ad-
dition, patients were asked to nominate their primary informal caregiver. If the caregiver was 
present, they were also given a caregiver information sheet (PIS-C) to read (Appendix 9); if 
not, patients were asked to give a PIS-C to their caregiver. In three study sites, clinical col-
laborators handed patients and caregivers the respective PIS. In the fourth site, the researcher 
met in person with the potential candidate and handed the PIS, under the clinical collabora-
tor’s supervision. 
Patients were informed that the researcher was intending to contact them after no less than 
24 hours to confirm their consent to participate, therefore they were asked for their permis-
sion for this to be done. The researcher contacted patients and briefly explained the purpose 
of the call, ensuring that they understood the purpose of the study, the voluntary nature of 
their participation, and their liberty to withdraw at any time, as well as re-enforcing the is-
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sues of confidentiality and anonymity with them. He then answered possible queries and 
confirmed whether patients agreed to take part in the study or not. If they wished to take part 
in the study, they were informed that a questionnaire pack would be mailed to them within 
the following two days. Patients were also asked to provide the contact details of their care-
giver. Similarly, the researcher contacted nominated caregivers after no less than 24 hours 
after they were invited to the study so as to confirm eligibility, answer all possible queries, 
and find out whether they wished to participate in the study or not. 
It was anticipated that not all eligible individuals would agree to take part in this study. Con-
sequently, four different situations would occur: 
1. Both agreed to participate; 
2. Both refused to participate; 
3. Patient agreed, whereas caregiver refused; 
4. Patient refused, whereas caregiver agreed. 
In situations 1, 3 and 4, all individuals who agreed to participate were sent an informed con-
sent form to sign (two copies) (Appendix 9). All patients were also asked to provide consent 
for their General Practitioner (GP) to be notified about their participation in the study. Those 
patients who returned a signed copy were considered to be participants in the study thereaf-
ter. Although the study aimed to recruit dyads of patients and their caregivers, there was no 
specific reason as to why to exclude individuals who still wished to take part in the study, 
even if their caregiver refused participation or no caregiver was identified, and vice versa. 
Data derived from these individuals were planned to be used as supplemental material in 
secondary within-group analyses and presented as part of future publications. In situation 2 
(as well as in situations 3 and 4, where refusal occurred), patients and/or caregivers were 
thanked for their time and again reassured that their decision would in no way compromise 
their rights and standard of care they received. 
Furthermore, it was recognised that some participants would drop out during this study. In 
the case that a patient or a caregiver did drop out of the study, their relevant data for time 
points already completed were still included in the analysis. If a patient withdrew from the 
study at any point, their carer was still considered to be participant in the study, and vice 
versa. To effectively deal with a large number of withdrawals undermining the study’s sta-
tistical power, a plan for recruitment of additional patient-caregiver dyads was put in place, 
taking into consideration the associated timelines. 
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Table 6.1 provides a summary of measurement procedures at each time point and for both 
groups of participants. At each assessment point, patient and caregiver case report forms 
(CRF) were mailed to participants at their home address. Patients and caregivers were given 
adequate time to complete the questionnaires, but were asked to refrain from sharing their 
responses with each other. They were then asked to return the CRFs via mail to the research-
er himself at a time most convenient to them. If queries were posed by the participants dur-
ing baseline completion of the questionnaires, they were invited to contact the researcher, 
who then provided explanations in such a manner that prevented both manipulation of re-
sponses and occurrence of missing data due to participants skipping questions because of 
becoming perplexed. 
 
Table 6.1. Data Collection Timetable 
 Time-points 
 T0 T1 T2 T3 
Participant Group & Measure Pre-treatment 
Two weeks 
post CThC1 
Two weeks 
post CThC4 
End-
treatment 
Patients 
DCF-PT ×    
CCF-PT × × × × 
Brief Sleep History-PT ×    
SHI × × × × 
PSQI × × × × 
Additional Sleep/Wake parameters 
Form × × × × 
MSAS-PHYS and PSYCH × × × × 
Brief COPE scale-PT × × × × 
Caregivers 
DCF-CG ×    
CCF-CG × × × × 
Brief Sleep History-CG ×    
SHI × × × × 
PSQI × × × × 
Additional Sleep/Wake parameters 
Form × × × × 
MSAS-PSYCH × × × × 
Brief COPE scale-CG × × × × 
CRAS × × × × 
Abbreviations: PT – Patient; CG – Caregiver; CThC – Chemotherapy cycle; DCF – Demographic Characteristics 
Form; CCF – Clinical Characteristics Form; SHI – Sleep Hygiene Index; PSQI – Pittsburgh Sleep Quality Index; 
MSAS-PHYS – Memorial Symptom Assessment Scale-Physical symptoms subscale; MSAS-PSYCH – Memorial 
Symptom Assessment Scale-Psychological symptoms subscale; CRAS – Caregiver Reaction Assessment Scale. 
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The researcher maintained regular contact with patients and caregivers during the study by 
sending short updates of the project and brief informal reminders throughout their involve-
ment to prevent missing data due to non-response. In addition, in those cases where not all 
questionnaires had been returned two months after a dyad’s anticipated final assessment, a 
letter was sent to participants as a final reminder regarding the study. Whilst all reminders 
posed a request to participants to complete and return questionnaires, or return any complet-
ed questionnaires (final letter), they explicitly acknowledged the voluntary nature of partici-
pation in this study and participants’ right to withdraw at any time. 
 
6.7.1. Risks, Burdens and Benefits 
Patients affected by cancer and their caregivers constitute potentially vulnerable populations; 
hence, considerable care was taken to avoid causing any distress to them during the study. 
However, it was recognised that completion of questionnaires could encourage patients 
and/or carers to focus more on their experiences than if they had not been asked to complete 
them, as well as lead to discussions about illness, treatment and associated experiences 
which some participants could find distressing. At each assessment point, a Macmillan Can-
cer Relief support flyer with contact information was sent to all participants along with study 
questionnaires should anyone have felt the need to receive consultation. Should they desired 
additional support, patients were also reminded to report to their GP, who was previously 
formally informed of the patient’s participation in the study (Letter to GP; Appendix 9). 
Moreover, at each assessment point, the researcher reinforced with participants that should 
they desire to withdraw from the study, they were absolutely free to do so without being re-
quired to give a reason about this decision. Similarly, it was recognised that the prospective 
nature of the study involving repeated measures of health outcomes could become tiresome 
for some participants. Given that participation was voluntary, willingness to continue in the 
study was reconfirmed at each contact point throughout the study. 
Although they may have not directly benefited from taking part in this study, participants 
may have found their participation beneficial in an indirect manner. Through completing the 
questionnaires, participants had the opportunity to reflect on their experience, which might 
have urged them to discuss their feelings with members of the health care team, and thus 
seek and receive more help. In addition, the goal of this study was to inform and educate 
health care professionals involved in patients’ and their caregivers’ care regarding the expe-
rience of sleep problems during chemotherapy in order for them to provide increasingly bet-
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ter care. Given the study’s goal to inform new strategies for the improvement of sleep in pa-
tients with cancer and their caregivers, participants could benefit from these in the future.  
 
6.7.2. Issues of Confidentiality and Data Handling 
All research data recorded throughout this study were regarded as confidential. Contact 
details provided were only used by the researcher to contact participants so as to invite them 
in the study, to reconfirm participation during the study and to send short update reports on 
the progress of the project. These contact details were stored separately and securely in a 
locked cabinet and they will be destroyed following 6 to 12 months after the last assessment 
contact, according to University of Dundee policy. Participants were reassured that their 
details would be kept confidential at all times. 
All research data collected were stored securely in a separate locked cabinet in the School of 
Nursing and Midwifery at the University of Dundee, and were only available to members of 
the research team (i.e. the PhD student and his supervisors), who needed access for data 
analysis purposes. These data were transferred to an electronic password-protected database, 
which again was accessed by the research team for data collection and analysis purposes. 
Following the completion of data collection, all demographic and clinical data and complet-
ed questionnaires were archived, and will be stored securely for 5 years, according to Uni-
versity of Dundee policy. 
No identifiable information was associated to any of the data generated from the study. Nei-
ther patients nor caregivers were asked to fill out their name in any questionnaire. A partici-
pant-specific code number was matched to respondents’ actual name and this was used 
throughout their participation in the study. These code numbers had already been applied to 
the questionnaires given to the participants at each time point, along with a plain envelope. 
Patients and carers were returning their completed questionnaires in the sealed envelope to 
the researcher himself. Participants had been informed at the start of the first assessment of 
this intention, but it was stressed that this code number would in no way be associated to 
their own name and would be used only when referring to their experience within the con-
text of the project. 
If queries were posed by the participants during completion of the questionnaires, the re-
searcher provided explanations in such a manner that prevented manipulation of their re-
sponses. Finally, participants were assured that any conversations they possibly had with the 
researcher would remain confidential between the participant and the researcher – for exam-
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ple, if a patient was involved, they were assured that details of the conversations would not 
be revealed to their carer, and vice versa. 
 
 
6.8. Study Variables 
Outcome variables 
A number of sleep parameters were used as outcome variables in all analyses in order to ex-
plore within-groups longitudinal changes, examine between-groups interrelations, and iden-
tify predictors of poor sleep in both the women and their caregivers. Outcome variables in-
cluded the following 8 sleep parameters: perceived sleep quality (PSQf); daily disturbance 
(DDISTf), habitual sleep efficiency (HSE); sleep latency (SL); total sleep time (TST); wake-
fulness after sleep onset (WASO); daytime napping duration (NAPTIME); and overall 
sleep/wake impairment (GSQI; based on global PSQI scores). 
Two sleep parameters, bedtime and wake time, were only descriptively explored given limi-
tations in the multilevel modelling software package functionality to manage time/date vari-
ables. Additional sleep parameters, including need for daytime napping, nocturnal awaken-
ings, early morning awakenings, daytime sleepiness, restless legs, feelings of restfulness up-
on arising in the morning, and sleep aid use were also descriptively explored but they were 
not entered into multivariate models with the aim of limiting the number of statistical anal-
yses. 
 
Predictor variables 
To address the study’s secondary aim, a number of physical and psycho-behavioural pa-
rameters were used as independent variables based on results from recent literature reviews 
[182, 366]. Potential predictors of poor sleep in the women and their caregivers included the 
behavioural variables of sleep hygiene (SHPT/CG; frequency of sleep disruptive practic-
es/behaviours), patient physical burden (PHYSPT; aggregated frequency, severity and dis-
tress levels), caregiving burden focussing on impact on health and disruption in schedule 
(CRACBCG), psychological burden (PSYCHPT/CG; aggregated frequency, severity and 
distress levels), negative/maladaptive coping strategies (COPNEGPT/CG; frequency of use), 
and nocturnal sleep disturbance (SDSTRBPT/CG; frequency of occurrence). 
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Covariates (confounding variables) 
Predictive models were adjusted for the effects of important socio-demographic and medical 
covariates of sleep/wake impairment based on results from a preliminary correlational analy-
sis. Covariates included (a) person variables: age (AGEPT/CG); caregiver gender (SEXCG); 
employment status (EMPLOYPT/CG); educational background (EDUCPT/CG); patient 
body mass index (BMIPT); time since patient diagnosis/surgery (DIAGNTM; SURGTM); 
disease stage (BCSTAGE); type of surgery (SURGTYP); chemotherapy protocol 
(REGIMTYP); patient menopausal status (MENOPPT); presence of comorbid illnesses 
(CMRBDTPT/CG); past history of sleep problems (SLPAST); sleep affected by cancer di-
agnosis (SLCA); performance status (PSPT/CG); physical activity (PAPT/CG); smoking 
(SMKNGPT/CG); and alcohol consumption (ALCHLPT/CG); and (b) dyadic variables, in-
cluding type of relationship (RELTYPE); duration of relationship (RELDUR); and sharing 
of the same house/room (SLSROOM; SLSHOUS). 
 
 
6.9. Instrumentation 
Data pertinent to the outcome and predictor variables were collected through the use of a set 
of well-established and valid questionnaires as part of the study CRFs. These questionnaires 
were selected from a pool of available measures after a comprehensive review of the rele-
vant literature was performed (see Chapter 5). Measures regarded for inclusion were those 
which were relatively brief in order to prevent participant burden, were psychometrically 
sound, and had been previously tested in studies with people with (breast) cancer and infor-
mal caregivers. 
All questionnaires asked or were set to ask participants to reflect on the past 2 weeks at all 
time-points. This is a critical time period for the assessment of sleep: it is neither too narrow 
(e.g. past week) to neglect features of sleep/wake patterns that manifest themselves earlier 
than one week before assessment, nor too wide (e.g. past month) making it difficult for the 
participants to reflect on their sleep/wake patterns thus providing inaccurate or inadequate 
information. 
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6.9.1. Demographic and Clinical data 
A patient demographic characteristics form (DCF-P) was used to collect information on age 
(years), educational background (high school versus college/university), marital status, and 
household yearly income (£) (Appendix 10). A similar caregiver DCF-C was used to collect 
information on age (years), gender, educational background (high school versus col-
lege/university), marital status, household yearly income (£), relation to patient, and duration 
of relationship (months; except for a parent-to-child relationship) (Appendix 10). 
A patient clinical characteristics form (CCF-P) was used to collect information on menopau-
sal status (pre-; peri-; or post-menopausal), comorbid diseases (yes/no), use of dexame-
thasone (yes/no), and use of alternative/complementary therapies (yes/no) (Appendix 10). 
Additional disease- and treatment-related clinical data– body mass index (kg/m2); time since 
diagnosis/surgery (days); disease stage (I, IIA/B, IIIA according to TNM-UICC [71]); type 
of surgery (mastectomy v. lumpectomy); chemotherapy protocol – were file sourced through 
use of patient case notes. A caregiver CCF-C was used to collect information on concurrent 
diseases (yes/no) and use of prescribed and over-the-counter medications (yes/no) (Appen-
dix 10). 
 
6.9.2. ECOG Performance Status 
At all time-points, patients and caregivers were asked to indicate their level of functional 
capacity on the Eastern Cooperative Oncology Group Performance Status scale (ECOG PS) 
(Appendix 10) [379]. The scale allows assessment of the individual’s actual level of function 
and ability of self-care, ranging from 0 (fully active) to 4 (completely incapable and depend-
ent on others) [379]. The scale’s clinimetric properties have been widely established [382, 
473]. 
 
6.9.3. Level of Physical Activity Scale 
Levels of physical activity were evaluated through use of a single-item scale (Appendix 10) 
previously used in survivors of Hodgkin’s lymphoma [397], which addressed two levels of 
activity. The first described duration of activities at a low level, such as walking; the other 
described duration of activities at a high level that leads to sweating and breathlessness. Ac-
cording to their combined levels of physical activity, participants were divided into two 
groups, namely those minimally active (i.e. independent of the duration of low-level activity, 
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no high level activity or < 1 hour per week) and those highly active (i.e. independent of the 
duration of low-level activity, high level activity ≥ 1 hour per week) [397]. Validity and re-
peatability of the scale have been established through comparisons with direct measures of 
physical activity [398]. 
 
6.9.4. Pittsburgh Sleep Quality Index (PSQI) 
The PSQI consists of four open-ended questions regarding sleep timing and multiple-choice 
questions regarding sleep quality, and takes approximately 10 minutes to complete. 
Although the scale assesses quality of sleep patterns over the past month, in order to 
measure with greater precision the sleep quality of participants during this study, the scale 
was modified to measure changes from the past 2 weeks. A similar approach has been 
successfully followed in previous studies [21, 474-476]. 
Nineteen multiple-choice and free-text questions are used to elicit information pertinent to 
sleep/wake parameters (Appendix 10). These questions can be used to generate the 
following seven component scores: sleep quality (C1), sleep latency (C2), sleep duration 
(C3), habitual sleep efficiency (C4), sleep disturbances (C5), use of sleep medications (C6), 
and daytime dysfunction (C7). The seven components can be added together to give a global 
score (GSQI) ranging from zero to 21 [407]. Higher scores signify greater overall 
sleep/wake impairment. A GSQI score > 5 indicates possible sleep pathology. This score has 
yielded a diagnostic sensitivity of 89.6% and specificity of 86.5% in distinguishing good and 
poor sleepers. However, in patients with breast cancer a cut-off score of 8 has been 
suggested as a more valid criterion for identifying bad sleepers [477]. Overall, good 
measures of internal homogeneity, consistency (test-retest reliability), and validity have been 
obtained on the questionnaire’s wide psychometric testing [478]. In women with breast 
cancer, Cronbach’s alpha for the GSQI was .80 [33]. In the present study, internal 
consistency was α=.78, .79, .76, and .69 for the patient group, and α=.75, .60, .73, and .73 
for the caregiver group. Nevertheless, recent reports argue on the instrument’s 
multidimensional scoring system compared to the traditional one-factor structure [479-483]. 
Confirmatory factor analysis has supported a three-factor model with Perceived Sleep 
Quality (PSQf; C1, 2, 6), Sleep Efficiency (SEf; C3, 4), and Daily Disturbances (DDISTf; 
C5, 7) as separate indices of sleep quality in an attempt to improve the questionnaire’s 
sensitivity [480]. 
For the purposes of the current study, ten outcome variables and one predictor variable were 
created that derived from free-text questions and aggregation of components of the PSQI. 
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Table 6.2 provides an overview of the variables created based on the PSQI, and how these 
were derived. 
 
Table 6.2. Sleep/wake variables created based on PSQI data 
Variable PSQI source Metric 
Outcome   
HSE Calculated as the ratio of TST divided by the total 
time spent in bed (x100); Free-text items 1, 3, 4 
Per cent (%) 
SL Free-text item 2 Minutes 
TST Free-text item 4 Minutes 
WASO Calculated by subtracting TST and SL from the 
total time spent in bed (free-text items 1, 3) 
Minutes 
PSQf Components 1, 2, 6 Numerical scale 0-9 
DDISTf Components 5, 7 Numerical scale 0-9 
GSQI Sum of Components 1-7 Numerical scale 0-21 
BEDTM Free-text item 1 24-hour time 
WAKETM Free-text item 3 24-hour time 
SAU Item 6 Numerical scale 0-3 (convert-
ed to binary variable: yes/no) 
Predictor   
SDSTRB Items 5b-5j Numerical scale 0-27 
Abbreviations: HSE – Habitual sleep efficiency; SL – Sleep latency; TST – Total sleep time; WASO – Wakeful-
ness after sleep onset; PSQf – PSQI Factor 1 indicating Perceived Sleep Quality; DDISTf – PSQI Factor 3 in-
dicating Daily Disturbances; GSQI – Global Sleep Quality Index (indicating sleep/wake impairment); 
SDSTRB – Nocturnal sleep disturbances; BEDTM – Bedtime; WAKETM – Wake time; SAU – Sleep aid use; 
PSQI – Pittsburgh Sleep Quality Index 
Notes: With the the exception of HSE, TST, BEDTM and WAKETM, higher values are indicative of poorer 
sleep/wake outcomes. 
 
 
A number of questions were also used to assess additional essential sleep/wake parameters 
reported in the literature [119], but not addressed in the PSQI. These included need for day-
time napping (NAPNEED) and average duration of naps per day (NAPTIME; minutes); 
feelings upon arising in the morning regarding the extent of restfulness (MORNFEEL); oc-
currence and frequency of leg restlessness (RSTLSSLG); early, unplanned awakenings in 
the morning (EARLAW); extent of daytime sleepiness (SLPNSS); and average number of 
nocturnal awakenings per night (NOCAW). These questions and their response format are 
presented in Appendix 10. Questions were adapted from existing sleep questionnaires (Ta-
ble 16-A2). Where appropriate, their original response format was retained the same; in all 
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other cases, the multiple-choice response format of the PSQI was implemented to enhance 
consistency. 
 
6.9.5. Sleep History 
For the purposes of the present study, six relevant questions were extracted from a standard-
ised sleep history used in a previous study of people with advanced cancer and their informal 
caregivers [244]. In that way, comparability between the studies could be promoted. Ques-
tions included asked participants to give information on the following (Appendix 10): (a) 
past history of sleep problems (yes/no); (b) sleep problems as a result of the diagnosis of 
cancer (yes/no); lifestyle habits, i.e. (c) smoking (yes/no) and (d) alcohol consumption (nev-
er/only occasionally/every day); and sleeping arrangements, i.e. patient/caregiver sharing (e) 
the same bedroom (yes/no) and/or (f) house (yes/no). 
 
6.9.6. Sleep Hygiene Index (SHI) 
The SHI is a brief (13-item) self-report scale designed to assess the presence of behaviours 
that comprise sleep hygiene (Appendix 10) [415]. Individuals are asked to indicate how fre-
quently they engage in specific sleep behaviours. Each item is rated on a 5-point scale. Item 
scores are summed to provide a global assessment of sleep hygiene, and higher scores are 
indicative of more maladaptive sleep hygiene status, with total scores ranging from 0 to 52. 
The scale has moderate internal consistency (Cronbach’s α = .66), but test-retest reliability 
over a 5 week interval is good [415]. In addition, it has acceptable content validity, while 
construct validity has been established through its positive correlation with all of the associ-
ated features of inadequate sleep hygiene as determined by the American Sleep Disorders 
Association [484], as well as with self-report measures of sleep quality and daytime sleepi-
ness [415]. In the present study, internal consistency was α = .63, .61, .59, and .60 for the 
patient group, and α = .61, .57, .58, and .63 for the caregiver group. 
 
6.9.7. Memorial Symptom Assessment Scale (MSAS) 
The MSAS is a self-report questionnaire designed to measure the multidimensional experi-
ence of symptoms (Appendix 10). It has been widely used in the context of cancer care [244, 
485, 486]. The original version of MSAS evaluates 32 physical and psychological symp-
toms, according to their frequency, severity and distress/bother to the person. Respondents 
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are asked to indicate whether or not they have experienced each symptom (in the past 2 
weeks). If they have, they are asked to rate its severity, frequency of occurrence, and dis-
tress. Symptom severity is measured using a five-point Likert scale (i.e., 0 = not at all, 1 = 
mild, 2 = moderate, 3 = severe, 4 = very severe) [424]. This measure has shown high corre-
lation with quality of life and clinical status. Internal consistency of the scale is high with 
Cronbach’s alphas ranging from .83 to .88. The MSAS questionnaire takes approximately 20 
minutes to complete [424]. 
For the purposes of the present study, 14 physical symptoms with direct effect on sleep 
(PHYS) and 4 psychological symptoms (PSYCH) were selected from the MSAS. A similar 
approach has been successfully followed in previous studies as well [485, 487]. The physical 
symptoms assessed included pain, lack of energy, cough, dry mouth, nausea, numb-
ness/tingling in hands/feet, feeling bloated, problems with urination, vomiting, shortness of 
breath, diarrhoea, sweats, itching, and dizziness. Psychological symptoms included worry-
ing, feeling nervous, feeling sad, and feeling irritable. The PSYCH subscale was also given 
to caregivers to assess impact of psychological symptoms on their sleep. Total scores pro-
duced from these subscales were used as predictors of the patient’s sleep. In the present 
study, internal consistency was α = .79, .83, .85, and .85 for the PHYS subscale. For the 
PSYCH subscale, alphas were .66, .71, .72, and .70 for the patient group, and .73, .77, .76, 
and .69 for the caregiver group. 
 
6.9.8. Brief COPE scale 
The Brief COPE scale is a self-report measure proposed to assess a broad scope of coping 
behaviour among adults for all conditions, illnesses or non-illnesses [457]. It is an abbreviat-
ed version of the COPE Inventory [449]. Although the Brief COPE scale is conceived as a 
dispositional measure, it is flexible and a situational version of it can be used after rephras-
ing items to denote a real-life experience and asking individuals to recall a specific time pe-
riod [449]. A situational format was used in this study (Appendix 10). The instrument com-
prises 28 items rated on a 4-point Likert scale, ranging from “I haven’t been doing this at 
all” (1) to “I have been doing this a lot” (4). A higher score represents greater coping strate-
gies used by the respondents [449, 457]. In total, 14 dimensions (two items for every dimen-
sion) are put forward by this scale, assessing 14 conceptually different ways people respond 
to stress. They are self-distraction, active coping, denial, substance use, use of emotional 
support, use of instrumental support, behavioural disengagement, venting, positive refram-
ing, planning, humour, acceptance, religion and self-blame. 
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A rigid factor structure of the coping strategies assessed by the Brief COPE does not exist 
[440], therefore researchers are invited to choose to flexibly and creatively use all or a sub-
set of the dimensions according to the purposes of their research [457]. The Brief COPE 
scale does not produce an overall score. However, it has been recommended that researchers 
create second-order factors from among the items or dimensions based on own data, and use 
the extracted factors as predictors [449]. However, previous research using factor analysis 
favours a two-factor structure format of adaptive/engagement and maladap-
tive/disengagement coping strategies [488-490]. This factor structure was used in the present 
study, where two separate scores were calculated by aggregating scores of adaptive 
(COPPOS) and maladaptive coping styles (COPNEG); however, only maladaptive coping 
strategies were considered as a potential predictor of sleep alterations in further analyses 
given that past research has failed to conclude with significant association between adaptive 
coping and sleep [110]. Brief COPE has been successfully used in previous breast cancer-
related [488-494] and caregiver [495] research, where good reliability (internal consistency 
and stability) has been shown. In the original report the Brief COPE Scale exhibited ac-
ceptable internal consistencies across its dimensions with six dimensions exceeding .70, five 
dimensions exceeding .60, and three dimensions exceeding .50 [457]. In the present study, 
acceptable alphas were found for COPNEG in the patient (.66, .69, .66, .61) and caregiver 
groups (.62, .60, .67, .65). 
 
6.9.9. Caregiver Reaction Assessment Scale (CRAS) 
The CRAS is a self-rating scale assessing informal caregivers’ reactions regarding providing 
care to a family member with a chronic physical and/or mental impairment (Appendix 10) 
[467]. There are 24 items with 5-point Likert-type response alternatives in the original ver-
sion. It consists of five subscales that quantify negative as well as positive experience of 
caregivers when providing care. The subscale ‘Disruption of Schedule’ (CRADoS) quanti-
fies to what extent caregiving interrupts the caregiver’s activities (5 items). ‘Impact on Fi-
nances’ assesses the impact of caregiving upon the caregiver’s financial situation and to 
what extent caregiving puts a strain on the financial situation in the family (3 items). ‘Lack 
of Family Support’ quantifies to what extent the caregiver receives help with caregiving and 
the caregiver’s experience of being abandoned (5 items). The subscale ‘Impact on Health’ 
(CRAIoH) consists of items concerning the caregiver’s health and experience of vigour in 
relation to caregiving (4 items). Finally, the subscale ‘Caregiver Esteem’ quantifies to what 
extent the caregiver experiences feelings of enjoyment and reward, or whether the situation 
arouses feelings of resentment (7 items) [467]. Of note, no total summary score is to be cal-
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culated; instead, reporting of subscale total scores should be reported. For the purposes of 
this study, CRADoS and CRAIoH subscale scores were aggregated to yield an overall care-
giving burden score (CRACB) that was considered to be a potential trigger of sleep disturb-
ances. The CRAS has been used in research to assess experiences of caregivers to individu-
als with different types of cancer [200, 216, 496-498]. Satisfactory construct and convergent 
validity, internal consistency (subscale Cronbach’s α = .82, .90, .85, .80, .81, respectively) 
and test-retest reliability, and sensitivity to change have been reported [499, 500]. In the pre-
sent study, internal consistency of CRACB was good (α = .78, .77, .79, .76). 
 
 
6.10. Potential Sources of Bias 
The likelihood of research biases interfering with the present study was acknowledged early 
when the project was planned. Bias is a systematic deviation from the truth; it is typically 
introduced during the design or implementation of a study and it can threaten its internal and 
external validity [141]. Of the different sources of bias, three types – inclusion bias, response 
bias and attrition bias – were specifically assessed for this study with regard to their magni-
tude and direction. 
Whilst every attempt was made for all eligible patients to be invited to take part in the study, 
the researcher and his collaborators were free to evaluate whether a patient was not psycho-
logically fit to take part in a research study and choose not to introduce the study to them. 
Although this practice was introduced in only a few cases, it might have favoured patients 
with less psychological distress, more effective coping strategies, and therefore less likely 
sleep disturbances. Yet, the associated ‘inclusion bias’ was rather small. 
Furthermore, in view of the moderate rates of patients who refused to participate in the 
study, the possibility of ‘response bias’ was examined by testing for differences in demo-
graphic and/or clinical characteristics between those who agreed and those who declined 
participation in the study. 
As this was a prospective study involving the collection of data at several time points, a test 
for ‘attrition bias’ – that is, the non-random loss of participants from the study over time 
[501] – was performed. More specifically, the demographic characteristics of participants 
who remained in the study were compared with those of participants who withdrew (see 
Chapter 7). 
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A final potential source of bias could be patients and carers colluding over completion of the 
sleep and health outcome measures. Although participants were reminded at every time 
point to complete questionnaires independently from one another, it is possible that some of 
them did not fully comply. However, it is believed that the associated bias has been kept to a 
minimum. 
 
 
6.11. Sample Size Estimation 
Sample size for this study was estimated via a sample size analysis using the G*power gen-
eral power analysis programme [502]. During the early design stages of this study, an initial 
analysis plan was devised that anticipated use of a Repeated Measures Analysis of Variance 
(RM-ANOVA) to answer the primary research question (i.e., over-time similari-
ties/differences in sleep/wake patterns within each group) with GSQI scores selected as the 
main outcome variable. However, the data analytic strategy was revised during the study 
when more appropriate/flexible data analytic techniques came to the researcher’s knowledge 
(see below); therefore, power estimation for this study was reconfirmed. 
Initial sample size calculations were conducted to meet the requirement for a RM-ANOVA 
with time points as the within-subjects factor (time effect); based on means of global PSQI 
scores (i.e. measure of SQ in the study) of 6.03-8.29 with SD=2.31-3.62 from previous stud-
ies in patients with breast cancer [7, 122, 123, 125, 130] and for the anticipated time points, 
effect size to be tested was estimated as f2=.02 (within-group ratio of effect variance to error 
variance) [503]. Cohen’s guidelines [504] for univariate repeated measures analyses define 
effect sizes (f2) as .01=small, .0625=medium, and .16=large, indicating that a relatively 
small effect size would be detected for the present study. Furthermore, magnitude of correla-
tion among repeated measurements has been found to be .82 based on previous test-retest 
reliability analysis in patients with cancer for a 14-21 days interval [482]. Assuming that 
correlations between adjacent pairs are greater than correlations between more distant pairs 
[Autoregressive of order 1, AR(1)] [505], correlations between T1 and T2 were estimated to 
be 5% lower than .82, and between T2 and T3 10% lower than .82, thus giving an overall 
mean correlation of ρ=.80. Given that correlations are expected to differ between time 
points, the sphericity (ε) assumption is violated. To correct this, an adjustment to the degrees 
of freedom of the numerator (m-1) and the denominator [N*(m-1)] was used (Greenhouse-
Geisser epsilon, <ε>), where m=4 (number of levels of repeated factor, i.e. time points). 
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Choosing the worst case scenario, epsilon was considered as conservatively low as 
<ε>=ε/(m-1), where ε=1 (i.e. sphericity assumed), i.e. <ε>=0.33. The non-centrality parame-
ter was λ=N*m*f2/(1-ρ), where N is the size of the sample for the study. The technical point 
to be aware of is that G*power computes lambda as λ=Ν*f2, where f2 is the label of the effect 
size slot in the programme. Therefore, an estimated corrected effect size was calculated as 
<ε>*m*f2/(1-ρ)=.133. Again, in factorial designs, Cohen [506, 507] defines f2 of .10, .25, 
and .40 as small, medium, and large effects, respectively. Based on the aforementioned data, 
sample size estimation indicated that n=61 consecutive patients would need to be recruited 
in order to achieve a power (1–β) of 80% (actual power achieved: 80.05%) for the study 
with a level of significance of .05. Since sleep/wake patterns in patients and caregivers were 
to be explored in a paired fashion, n=61 caregivers would also need to be recruited. Since 
this was a prospective study, issues of attrition needed to be co-estimated. With an anticipat-
ed overall 10% of attrition for the study (approximately 3% for each time point T1, T2, T3), 
the final total sample size for each group rose to 68 participants to preserve power of the 
study to the predetermined level even in the case of possible withdrawals. 
As mentioned above, with inclusion of multilevel modelling as the main data analytic strate-
gy, power calculations were re-run to ensure that a sample of 68 dyads would be adequate 
enough to permit the emergence of statistical associations. Previous dyadic sleep research 
has concluded with an aggregated moderate correlation (r=.30) between patient and caregiv-
er GSQI scores [242, 285] (the aggregated Pearson’s correlation coefficient was produced by 
converting individual r’s to Z scores, calculating mean score, and reverting the aggregated Z 
score back to r). According to sampling tables presented in Kenny et al. [293], a sample of 
90 dyads (adjusted for 10% attrition rate) would be required to detect this medium effect size 
of non-independence. Nevertheless, a sample size of 68 dyads would provide acceptable 
power to the study (70%) to detect a medium effect size of non-independence, but sufficient 
power (>80%) to detect a statistical difference between patients’ and caregivers’ GSQI 
scores [293] (adjusted effect size Cohen’s d=.75 [285]). In light of these favourable results, 
and also taking into consideration budget constraints as well as challenging recruitment is-
sues during the study’s feasibility phase (see Paragraph 6.13) but mainly beyond that, no 
major amendment to this study was sought. 
 
6.12. Data Analysis 
The data analytic strategy for this study involved a combination of preliminary ordinary least 
squares (OLS) analyses and multilevel modelling (hierarchical linear modelling) techniques 
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to examine longitudinal change in the sleep patterns of patients and caregivers, as well as 
explore the effects of individual and dyadic correlates on the dyads’ quality of sleep. 
 
6.12.1. Data quality 
Patient and caregiver raw data were first entered into Microsoft Excel® spreadsheets and 
coded into ‘item-score’ variables, thus creating an electronic database which was next trans-
ferred into IBM SPSS 17 (SPSS Inc.: An IBM Company; Chicago, IL) for a preliminary in-
spection. In this stage, data were first scanned for incomplete responses in the questionnaires 
returned, as well as for inaccurate responses possibly reflecting errors in data entry that re-
quired correction. To determine the extent of missing values in the questionnaires returned, 
frequency distributions were examined on a variable-by-variable basis [501]. Overall, in-
formation on almost all variables was found to be missing sporadically, accounting for less 
than 2% of the total amount of data. Missing values were treated with mean substitution by 
replacing a missing value with the mean of a given variable, calculated from all participants 
with non-missing data. Although mean substitution may lead to underestimation of variance, 
it can be used as an effective means to manage missing values when the percentage of miss-
ing values is very small [501]. Subscale and total scores were calculated and ‘subscale-
score’ and ‘total scale-score’ variables were subsequently created. Next, data were re-
examined for the presence of outliers through use of numerical summaries and graphs such 
as boxplots to identify whether they were legitimate values. An outlier was defined as mild if 
its data value laid between 1.5 and 3.0 times the variable’s interquartile range (IQR) below 
quartile 1 (Q1) or above quartile 3 (Q3), and as extreme if its data value was more than 3.0 
times the IQR below Q1 or above Q3 [501]. Only mild outliers were identified for certain 
variables; however, as they were legitimate values, they were not removed from further 
analyses. 
In longitudinal research, data values can also be missing due to non-response (i.e. no 
questionnaires received). This often creates unbalanced datasets that may further complicate 
already complex analyses [376]. As this was a prospective study involving repeated 
measures, the extent of missing responses at each time point was specifically examined 
through use of the Missing Values Analysis (MVA) module within SPSS. One definite 
advantage of the analytic strategy employed in the main analyses part is that it produces 
efficient or unbiased estimates of all parameters under the assumption that data are missing 
at random (MAR). This assumption implies that missing data are ‘conditionally random’ 
[508], given that their status as missing is dependent on observed variables included in the 
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analysis [508, 509]. In other words, “the missing data for a variable are MAR if the 
likelihood of missing data on the variable is not related to the participant’s score on the 
variable, after controlling for other variables in the study” (p. 1014) [508]. These other 
variables are considered to provide the mechanism for explaining the pattern of missingness 
and so can be used to impute the missing data. Among common mechanisms education, age, 
gender, or psychological well-being are those more often cited [508]. In longitudinal 
analyses, preceding values of the outcome also can predict missing data [509]. Within this 
context, MAR renders missingness as ignorable because of controlling for all earlier 
measures related to a participant’s missing data. The crucial distinction is that predictors of 
missing data are observed and included in the analysis [509], and in most large exploratory 
studies several of these predictor variables are included [508]. Of note, these variables may 
or may not be part of the theoretical model employed in the study to explain the outcome 
variable [508]. Previsouly, it has been shown that in many realistic cases even an erroneous 
assumption of MAR may often have only a minor impact on model estimates [510]. Yet, 
Raudenbush et al. [376] suggest that in longitudinal research the relationship between a 
measured covariate and the probability of a missing value is nevertheless examined to 
confirm randomness of missing data. To examine whether attrition introduced systematic 
bias in this study, unpaired t-tests (or Mann-Whitney U tests; non-parametric data) were 
performed (see Paragraph 6.10). Specifically, respondents and non-respondents at each 
follow-up time point were compared in terms of their demographic characteristics and their 
baseline and T1 scores on outcome (perceived sleep quality; overall sleep/wake impairment) 
and predictor variables for significant differences. A dummy-coded missingness variable 
(coded 0 for observed and 1 for missing) was created to examine patterns of missingness 
throughout the study. 
 
6.12.2. Descriptive analysis 
In the second stage, descriptive statistics were computed to summarise patient and caregiver 
socio-demographic and clinical data, and to explore sleep patterns and covariates at each 
time point, using mean and standard deviations for parametric data, and median and range 
for non-parametric data. Distribution of continuous or interval-scale variables was confirmed 
through examination of histograms and a series of Shapiro-Wilk tests (especially recom-
mended for datasets with < 50 cases) [511]. Where data were plausibly normal, parametric 
methods were chosen during preliminary analyses to test relationships; in cases of deviations 
from normality or examination of ordinal/categorical variables, non-parametric methods 
were used instead. Relative to outcome variables, only very modest deviations from normali-
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ty (skewness index twice the value of its standard error [501]) were observed for some vari-
ables, but these were deemed plausibly normal through histogram examination. Yet, moder-
ate deviations were found for SL (negatively skewed) and NAPTIME (positively skewed). 
In order to increase normality of these variables, square root and reversed square root trans-
formations were used, respectively. Variable transformation is often recommended in the 
context of multilevel modelling when normality assumptions fail in the case of a continuous 
dependent variable [512]. However, due possibly to the small study sample, transformation 
did not considerably improve distribution, and in other cases even reversed the direction of 
skewness. In addition, Tabachnick and Fidell [513] argue that MLM results based on trans-
formed and untransformed versions of a variable do not differ substantively. Therefore, in 
the interest of interpretability all variables were used untransformed in further analyses. 
A series of bivariate tests was pursued to facilitate preliminary analyses. First, to compare 
sociodemographic and clinical data, and explore over-time similarities and/or differences in 
outcome and predictor variables between patients and caregivers, a series of ordinary least 
squares (OLS) statistical procedures such as paired t-tests (or Wilcoxon Signed Ranks tests), 
chi-square tests, Friedman tests, and Cochran’s Q tests were used. With respect to Friedman 
and Cochran’s Q tests, ‘last observation carried forward’ was used as an effective, yet 
somewhat conservative, method to impute missing values [501]. Second, inter-dyad correla-
tions between sleep variables were tested to examine for the presence of non-independence 
[293], which would further support the use of dyadic data analytic techniques. Third, corre-
lation coefficients were used to assess stability over time of each construct for each dyad 
member. Fourth, both within-patient and within-caregiver correlations between outcome and 
predictor variables (aggregated over 4 assessment points) were also investigated to establish 
whether they could be considered as distinct constructs, thus further supporting the use of 
separate growth curve models for further analyses. A similar correlational analysis was con-
ducted between outcome variables (aggregated over 4 assessment points) and demograph-
ic/clinical variables to select important covariates for which final multivariate models would 
be controlled. Finally, within-person correlations between predictor variables and demo-
graphic/clinical covariates (repeatedly measured variables aggregated over 4 assessment 
points) were used to assess the presence of collinearity (see below). 
A series of graphs and scatter plots were constructed within SPSS to complement multilevel 
modelling results, and illustrate and compare patterns of change in sleep variables across 
time and between members of the dyads. 
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6.12.3. Multilevel modelling 
In the main analysis stage, multilevel modelling techniques were employed to investigate 
change over time (growth trajectories) in the sleep patterns of the dyads and examine the 
effects of covariates [512]. Analyses were conducted using the HLM 7 computer software 
(Scientific Software International, Inc.; Skokie, IL) [514] and employed the dyadic data ana-
lytic approaches described by Kenny et al. [293] and Lyons et al. [371]. The analytic strate-
gy employed maximises data from all participants who have provided at least one wave of 
data, thus allowing interpretation of results as if no missing data were present [375, 512]. 
HLM 7 uses Maximum Likelihood to estimate parameter values based on all existing data 
across assessment points and data available at Level 2. Maximum Likelihood uses all avail-
able information in the data to obtain unbiased parameter estimates of change for each par-
ticipant that have been adjusted for missingness. Importantly, the amount of data available 
for each participant only affects the reliability of the prediction, not the ability to estimate 
the trajectory. HLM 7 weights each estimated coefficient by this reliability so that those par-
ticipants with less data have estimates closer to the mean. Through this process, HLM 7 not 
only effectively manages missing values in longitudinal data, but also eliminates the need 
for implementation of a missing values replacement technique and the associated risks of 
incorrect estimation of standard errors in analyses that may increase the chance of unwanted 
statistical errors [375]. 
Specifically, the multivariate two-level model for longitudinal dyadic data (multivariate hi-
erarchical linear model [MHLM]) described by Raudenbush et al. [371, 376] was employed 
to enable simultaneous estimation of the average sleep pattern trajectories of the dyad mem-
bers, as well as own and cross-partner predictor effects, while controlling for interdependen-
cies in the data (see Paragraph 5.5). All dyads participating in at least one wave of assess-
ment were included in the analysis. The MHLM involves two separate levels of analysis, a 
within-dyad model at Level 1 and a between-dyad model at Level 2. Figure 5-A1 illustrates 
the organisation of data for analysis at Level 1. Two basic MHLMs were tested for each out-
come variable: a Baseline/Unconditional MHLM, where trajectories of change in sleep pa-
rameters were examined; and an Explanatory MHLM, where the relation of these trajectories 
with time-varying and time-invariant covariates/predictors was explored. These were com-
pared with each other and with a means-only model, namely a model containing only inter-
cepts but no main predictor variables, to identify the most appropriate one for modelling the 
effects of time. 
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Baseline/Unconditional MHLM 
Level 1 model: The Level 1 model represents change over time for both patients and care-
givers described by dyad member-specific growth parameters (i.e. intercepts and slopes) that 
are allowed to vary across dyads, plus a residual term, e, that captures measurement error 
which is considered to be constant both within and across dyads. Separate Level 1 models 
were created for PSQf, DDISTf, HSE, SL, TST, WASO, SDSTRB and NAPTIME. As an 
example, a model where PSQf is considered to change in a linear fashion over time was 
specified as follows: 
PSQftp = (patient)[β1p + β2p(timelintp)] 
           + (caregiver)[β3p + β4p(timelintp)] 
           + etp,      (1) 
 
where PSQftp represents perceived sleep quality (t=1, …K responses per dyad and point of 
assessment) for dyad p; β1p and β3p represent the intercepts for patient and caregiver (initial 
levels of sleep quality); and β2p and β4p represent the time effect (linear) for the patient and 
caregiver of perceived sleep quality, respectively. The indicator variable (patient) takes on a 
value of “1” if the response is obtained from the patient and “0” if it is obtained from the 
caregiver. The opposite is true for the (caregiver) indicator variable. The first set of brackets 
contains the latent growth parameters (coefficients) β1p and β2p characterising the trajectory 
for the patient; the second set contains the latent growth parameters (coefficients) β3p and β4p 
that characterise the trajectory for the caregiver. Seen together, each dyad has four coeffi-
cients that represent the true growth parameters for the dyad. The etp are the within-dyad re-
siduals, which are assumed to be normally distributed, with a mean of 0 and variance σ2. 
Within the statistical package HLM 7, the general intercept was removed and replaced with 
the dummy coded variables ‘patient’ and ‘caregiver’ [293, 515]. 
Definition of ‘time zero’ has been described as being of utmost importance in growth curve 
analyses [293, 371]. The intercept represents the predicted value of the outcome for time 
zero, that is to say, when time equals 0 or the origin [293, 371]. Often, time zero is set at the 
time of the first measurement; however, considerable flexibility exists so that alternatives in 
determining time zero can and should be considered depending on the nature of the research 
[293]. Because time zero affects the average intercept, the variance in the intercepts and the 
covariance of the slope and intercept [293], it can profoundly affect interpretation of the 
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growth curve trajectory parameters, and therefore should be weighed carefully [371]. Typi-
cally, the original recorded value of time is rescaled. In the present study, 1 was subtracted 
from each time point (i.e. 1, 2, 3 and 4) so that the intercept (time 0) was at the initial or 
baseline assessment (i.e. prior to chemotherapy initiation). The value 1 indicated the next 
assessment point, which took place two weeks post-CThC1, and the value 2 indicated the 
third point of assessment, which occurred two weeks after administration of CThC4. Finally, 
the value 3 indicated the final assessment point. Thus, a one-unit change in time represents 
the interval between one assessment point and the following one. 
Previous research in women with breast cancer has shown that sleep disturbances gradually 
increase in prevalence and severity after initial administration and during continuation of 
adjuvant chemotherapy, with a tendency for slight improvement towards and/or close after 
the end of treatment [119]. A curvilinear pattern of change is therefore possible. What is 
more, the lack of longitudinal research in caregivers of women with breast cancer precludes 
any conclusions to be drawn with regard to the trajectories of their own sleep patterns [182], 
and warrants detailed examination. Therefore, alternative quadratic models were also esti-
mated to identify the best fit to the data. MHLM for longitudinal data typically requires 4 or 
more waves of data to estimate quadratic effects so that the within-dyad measurement error 
variance can be estimated [376]. An example model where PSQf was considered to change 
in a curvilinear (i.e. quadratic) fashion over time was the following: 
PSQftp = (patient)[β1p + β2p(timelintp) + β3p(timequadtp)] 
           + (caregiver)[β4p + β5p(timelintp) + β6p(timequadtp)] 
           + etp,        (2) 
 
where the β3p and β6p coefficients represent the time effect (quadratic) for the patient and 
caregiver of perceived sleep quality, respectively. In a quadratic model, the linear compo-
nent is usually interpreted as the average velocity, whereas the quadratic component explains 
the curvature of growth [470, 512]. For instance, a negative linear term followed by a posi-
tive quadratic term may indicate the presence of a decline in a sleep parameter that levels off 
as time elapses. Conversely, a positive linear term and a negative quadratic term may indi-
cate that there was an increase in a sleep parameter, which again decelerates over time. 
Univariate hypothesis testing (t ratio) was performed to indicate whether, on average, patient 
and caregiver intercepts and slopes differed significantly from zero on the basis of values of 
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unstandardised coefficients calculated via the HLM 7 programme. To facilitate interpretation 
of these coefficients, effect sizes rES were calculated based on the formula rES=√[t2/(t2+df)], 
where t refers to the value of the t-test and df are the degrees of freedom associated with the 
particular test. Small, medium and large effects were designated by rES of .10, .30, and .50, 
respectively [507]. In addition, since separate scores for each dyad member were obtained in 
the same model, multivariate hypothesis testing was conducted within the HLM 7 software 
to examine significant differences between average patient and caregiver trajectories, i.e. 
baseline status and rates of change over time [371, 376]. 
Level 2 model: The Level 2 model (between-dyad model) aggregates the person-level esti-
mates thus providing estimates for the entire sample of patients and caregivers, respectively. 
At Level 2, growth parameters from Level 1 are modelled as outcomes to be explained by 
characteristics of the dyad. They are permitted to vary across all Level 2 units (i.e. dyads) 
and can take on different values for each dyad. In this stage, the first step is to fit an uncon-
ditional Level 2 model (i.e. a model with no predictor variables at Level 2), which for a 
quadratic change is specified as follows: 
β1p = γ10 + u1p   (3) 
β2p = γ20 + u2p   (4) 
β3p = γ30 + u3p   (5) 
β4p = γ40 + u4p   (6) 
β5p = γ50 + u5p   (7) 
β6p = γ60 + u6p   (8) 
 
This unconditional model provided estimates of the population averages (known as the fixed 
effects of the model) for each growth parameter for the patient (γ10, γ20, and γ30) and for the 
caregiver (γ40, γ50, and γ60) across dyads. The Level 2 random effects u1p, u2p, u3p, u4p, u5p, 
and u6p represent the deviation of each dyad from the respective population average growth 
parameter. The variances of these random effects (τ00, τ11, τ22, τ44, τ55, τ66) represent the het-
erogeneity across dyads, and were estimated to test whether they were significantly different 
from zero in the population. Any significant results are indicative of significant variability 
across dyads, hence time-invariant predictors (variables that do not change or were measured 
only once) can be introduced to explain this variability in a conditional MHLM model [371, 
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376]. In addition, relationships among these Level-2 variance components were examined in 
an attempt to identify notable correlations representing the extent of shared variance in each 
outcome variable for the members of a care dyad. Tau-correlation coefficients and 95% con-
fidence intervals were produced for this purpose. Not only can tau-correlations reveal the 
relationship in trajectories of the dyad members, but also provide support for one’s decision 
to use multilevel modelling in the first place [374, 376]. 
 
Explanatory MHLM 
In longitudinal dyad models, not only time-invariant predictors (variables that are enduring), 
but also time-varying covariates/predictors (variables change over time) may be incorporated 
to control for the effects of a predictor that is measured over time, and examine more com-
plex associations with the outcome. In the present study, changes in sleep parameters and 
psychosocial variables were measured (‘sleep’ and ‘behavioural’ predictors), whose associa-
tion with the outcome variables was decomposed into two parts. As an example, this decom-
position allowed the effects of sleep hygiene (SH) on perceived sleep quality (PSQf) to be 
separated into (a) the relationship between changes in SH and changes in PSQf (time-
varying), and (b) the relationship between mean SH and mean PSQf scores for both mem-
bers of the dyad (time-invariant). 
Level 1: The Level 1 model includes the time-varying component of specific time-varying 
predictor. In the quadratic Level 1 model for PSQf (2), the time-varying component of SH is 
specified as follows: 
PSQftp = (patient)[β1p + β2p(timelintp) + β3p(timequadtp) + β4p(SHPTtp – S̅H̅P̅T̅.p)] 
           + (caregiver)[β5p + β6p(timelintp) + β7p(timequad) + β8p(SHCGtp – S̅H̅C̅G̅.p)] 
           + etp,          (9) 
 
In model (9), PSQftp represents perceived sleep quality (t=1, …K responses per dyad and 
point of assessment) for dyad p; β1p and β3p represent the intercepts for patients and caregiv-
ers; β2p and β6p represent the linear slopes for patients and caregivers; and β3p and β7p repre-
sent the quadratic slopes for patients and caregivers, respectively. The values for sleep hy-
giene (SH) at each time are deviations from the individual’s mean on that variable, which 
capture the fluctuations in SH over the study period. Therefore, β4p and β8p represent the 
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time-varying effect of the patient’s SH (SHPT) and the caregiver’s SH (SHCG) on their re-
spective PSQf score over time. Within-person centring – deviations at each time point of 
each individual’s SH score from own mean SH score (averaged over four assessment points) 
– is used to create the time-varying component. This procedure was followed in the present 
study for each repeatedly measured predictor. 
Level 2: The aforementioned model has eight coefficients (β1p … β8p), which can take on 
different magnitudes within and across dyads, and become outcome variables at Level 2. In 
this stage, the time-invariant component of the example predictor (SH) is included, which 
represents the degree to which mean SH scores averaged over time (four assessment points) 
relate to mean PSQf scores. The time-invariant component is modelled at Level 2 grand 
mean centred. Hence, the following initial explanatory Level 2 model is specified: 
β1p = γ10 + γ11(MEAN SHPT) + u1p  (10) 
β2p = γ20 + u2p     (11) 
β3p = γ30 + u3p     (12) 
β4p = γ40     (13) 
β5p = γ50 + γ51(MEAN SHCG) + u5p  (14) 
β6p = γ60 + u6p     (15) 
β7p = γ70 + u7p     (16) 
β8p = γ80     (17) 
 
The between-dyad model provides estimates of the population averages for the intercept 
(γ10), linear (γ20) and quadratic change (γ30) in PSQf scores for the patient, and for the inter-
cept (γ50), linear (γ60) and quadratic change (γ70) in PSQf scores for the caregiver. Mean SH 
(MEAN SHPT/CG) is included here with γ11 and γ51 representing the effect of each individ-
ual’s mean SH score on own level of mean PSQf score. Coefficients γ40 and γ80 capture the 
average time-varying effect of SH across dyads. The random effects (u1p, u2p, u3p, u5p, u6p, 
u7p) represent the deviation of each individual from the average intercept, linear and quadrat-
ic effect for patients and caregivers, respectively. Again, significant variability in these pa-
rameters allows for the introduction of additional predictors in an effort to explain this vari-
ability. Random effects for the time-varying covariates were not included (γ40 and γ80 are 
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specified as fixed) because the six βs already in the Level 1 model completely saturate the 
temporal component of variation [376]. 
After testing models including the effect of an individual’s own predictor scores on their 
own outcome variables, cross-care-partner effects were tested. Each of these models includ-
ed two additional time-varying covariates for each predictor (Level 1) representing (a) the 
effect of patient predictor changes on caregiver outcome variables and (b) the effect of care-
giver predictor changes on patient outcome variables, as well as two time-invariant effects 
(Level 2) representing (c) the effect of mean patient predictor scores on mean caregiver out-
come variables and (d) the effect of mean caregiver predictor scores on mean patient out-
come variables. For the example model of the effects of SH on PSQf, the Level 1 model is 
specified as: 
PSQftp = (patient)[β1p + β2p(timelintp) + β3p(timequadtp) 
           + β4p(SHPTtp – S̅H̅P̅T̅.p) + β5p(SHCGtp – S̅H̅C̅G̅.p)] 
           + (caregiver)[β6p + β7p(timelintp) + β8p(timequad) 
           + β9p(SHCGtp – S̅H̅C̅G̅.p) + β10p(SHPTtp – S̅H̅P̅T̅.p)] 
           + etp,        (18) 
 
Whereas the Level 2 model is specified as: 
β1p = γ10 + γ11(MEAN SHPT) + γ12(MEAN SHCG) + u1p  (19) 
β2p = γ20 + u2p       (20) 
β3p = γ30 + u3p       (21) 
β4p = γ40       (22) 
β5p = γ50       (23) 
β6p = γ60 + γ61(MEAN SHCG) + γ62(MEAN SHPT) + u6p  (24) 
β7p = γ70 + u7p       (25) 
β8p = γ80 + u8p       (26) 
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β9p = γ90       (27) 
β10p = γ100       (28) 
 
All explanatory models were adjusted for the effects of significant demographic/clinical co-
variates of sleep/wake impairment based on the results of preliminary correlational analyses. 
As previously stated, before they were entered at Level 2, all predictors and covariates were 
examined for multicollinearity. In cases where inter-correlations between predic-
tors/mediators were particularly high (r>.85) [501], only selected covariates were entered 
into the Level 2 model based on examination of the magnitude of within-patient and within-
caregiver correlations between the outcome and predictor variables. Interval-scale predictor 
variables/covariates were centred around the sample grand mean before entered into the 
model [293]; ordinal-scale variables were dummy-coded (0-1) before entered in the model 
(e.g. PS); and nominal-scale variables were entered in the models with no further recoding. 
All predictors/covariates were entered into the Level 2 models simultaneously to examine 
their association with variation in the patient’s and caregiver’s trajectories of sleep patterns. 
Multivariate hypothesis testing was conducted within the HLM 7 software to examine dif-
ferences in the strength of the relationship between patient and caregiver predictors and out-
come variables. As previously, unadjusted effect sizes rES were calculated for predictors and 
covariates based on the formula rES=√[t2/(t2+df)], where t refers to the value of the t-test and 
df are the degrees of freedom associated with the particular test. Small, medium and large 
effects were designated by rES of .10, .30, and .50, respectively [507]. From the above-
mentioned formula it can be inferred that rES is always positive in sign; however, by conven-
tion, rES was positively or negatively signed in this study to match the corresponding t ratio. 
All tests were conducted with a two-tailed level of significance of .05. However, due to the 
exploratory nature of the study, trends towards significance (.10>p≥.05) were also showed. 
 
Model fit 
For each individual outcome variable, the linear model’s (1) fit to the data was first com-
pared to the means-only model. The means-only model outputs the deviance statistic (–2 log 
likelihood or –2LL) as a baseline that can be used for comparisons with later, more complex 
models [516]. In addition, it provides information for the calculation of the intraclass corre-
lation coefficient (ICC), which is the usual test of whether multilevel modelling is needed 
[516]. ICC ranges from +1.0 (i.e. group means differ but there is no within-group variation) 
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to –1/(N–1) (i.e. no between-group variation but very large within-group variation). When 
ICC approaches 0 or is negative, multilevel modelling is not appropriate [516]. In this study, 
the magnitude of ICC was calculated as the intercept variance component in the null model 
divided by the total of variance components (intercept plus residual). 
Model (1) and Model (2) fit to the data was also compared through their deviance statistics. 
The change in the deviance statistic is distributed as χ2 and can be tested relative to the 
change in the degrees of freedom. The model with the best fit to the data was considered as 
the Baseline MHLM for a specific outcome variable. When predictor (own and cross-care-
partner) and covariate effects were tested, a similar procedure was followed but with com-
parisons between the deviance statistic of Explanatory MHLMs (9) and (18). These adjusted 
models were compared not only with each other but also with the aforementioned unadjust-
ed/baseline ones to identify their fit to the data. Analyses were performed with full maxi-
mum likelihood estimation (FML) using all available data from all patients and caregivers. 
The FML method provides deviance statistics that, as stated, are useful in describing the fit 
of the entire model (fixed and random effects) [470]. However, FML may produce biased 
estimates of variances with small, unbalanced datasets [293]; therefore, all models were also 
estimated with restricted maximum likelihood estimation (REML). The effects estimated 
with FML and REML were very similar, thus only results produced with FML are presented 
here. 
 
 
6.13. Study Feasibility Phase 
In order to ensure that any inconsistencies in the research design were effectively managed 
and problems in the implementation of the research plan were timely tackled, a study feasi-
bility phase was planned to precede the actual study phase [517]. Feasibility studies are 
pieces of research done before a main study to estimate important parameters that are needed 
to design or verify the design of the main study. Yet, they are different from pilot studies, 
which are regarded as miniatures of large studies to be conducted. With feasibility studies, 
researchers are able to evaluate several key parameters: standard deviation of the outcome 
measure, which is needed in some cases to estimate sample size; number of eligible patients; 
appropriateness of eligibility criteria; willingness of participants to participate; willingness 
of clinicians to recruit participants; characteristics of the proposed outcome; appropriateness 
of the data collection plan; response rates to questionnaires and adherence/compliance rates; 
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or adequacy of financial resources [517]. Feasibility of the plan for this study was verified 
drawing on data derived from the first four dyads recruited. The feasibility phase spanned 
over three months from 1st November 2010 to 31st January 2011, after the study was granted 
R&D Management Approval to proceed at the first participating NHS site (Appendix 8). A 
number of methodology-, design-, and procedure-related parameters were evaluated for ef-
fectiveness. Table 6.3 outlines all relevant parameters reviewed and evaluated for their ef-
fectiveness. 
 
Table 6.3. Summary of key parameters evaluated during the project’s feasibility phase 
Parameter Evaluation* 
Identification of patients easy?  
Eligibility criteria realistic?  
Availability of individuals?  
Study design feasible?  
Missing data rates satisfactorily low?  
Data collection plan effective?  
Time-points realistic?  
Time-points acceptable to patients?  
Time-points acceptable to health professionals?  
Recruitment rates satisfactory?  
Questionnaire mailing system effective?  
Collaboration with the clinical team effective?  
Recruitment strategy effective?  
Patients willing to take part in the study?  
Caregivers willing to take part in the study?  
Rates of withdrawals low?  
Financial resources adequate?  
Note:  Yes;  Unclear;  No 
 
 
In all, eligibility criteria proved realistic, also facilitating the identification of potential pa-
tients during the clinics. Similarly, the patient and caregiver recruitment strategy was re-
garded as effective, leading to four participating dyads out of a total of five approached. Not 
only were patients and caregivers willing to take part in the study, but they also freely ex-
pressed their eagerness to provide as much relevant information as possible throughout the 
study. In that sense, rates of withdrawals for the first four dyads were zero, while missing 
data rates were more than satisfactorily low as < 0.5% of variables were missing. Moreover, 
the study design was feasible and the data collection plan was effective, with time-points 
regarded as being both realistic and acceptable by both patients and clinicians. In spite of 
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some minor delays over the Christmas period (December 2010), the questionnaire mailing 
system was more than effective, with participants receiving questionnaires in a timely man-
ner, and no questionnaires going missing. 
The afore-mentioned positive outcomes signalled that the study could proceed to its actual 
phase. Yet, the availability of patients with early-stage breast cancer scheduled to receive 
adjuvant chemotherapy seemed to be unclear. Given the increased number of clinical trials 
concurrently taking place as the present study, only a small proportion of the total of diag-
nosed women eventually entered this study. As well, collaboration with the clinical team 
proved to be more than challenging because tight time schedules and increased overload 
prevented clinicians from giving the study the attention required; in conjunction with clini-
cians’ unwillingness to overload patients with information on several different clinical trials, 
recruitment rates dropped considerably by the end of the third month of recruitment, leading 
to only three additional dyads entering the study out of five approached. In light of these de-
velopments, a decision was made to bring more recruitment sites on board to meet the 
study’s timelines and deadlines. Therefore, contact was made with clinicians from February 
to June 2011 at three additional NHS sites, and R&D approval was granted for the study to 
take place at each site. 
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CHAPTER 7. 
Results 
 
 
7.1. Accrual Rates 
From November 2010 to April 2012, 97 newly diagnosed women with early stage breast 
cancer were approached at the participating sites after eligibility to the study had been con-
firmed by local collaborators. All women received information on the study’s purposes and 
goals and were subsequently invited to consider participation. Twenty women refused par-
ticipation due to a variety of reasons, as outlined in Figure 7-1. For 7 more women no con-
tact was made, either because they could not be reached over the phone (5 individuals) or 
because of a delay in the researcher’s notification of a new eligible patient that eventually 
resulted in insufficient recruitment time before chemotherapy treatment initiation. Prelimi-
nary analyses indicated no statistical differences between women who refused (n=20) and 
those who gave verbal consent to the study (n=70) with regard to demographic (i.e. age) and 
clinical characteristics (i.e. breast cancer stage, type of surgery) (all p>.05). 
Seventy women were contacted by the researcher, were fully informed on the study’s proce-
dures, were invited to identify their primary informal caregiver, and provided initial verbal 
consent; yet, two women called back before any data had been provided and requested to 
withdraw their consent. Consent forms were sent to the remaining 68 individuals. However, 
7 women never returned written consent forms nor provided data to the study, and were con-
sequently eliminated from the study. The remaining 61 women (62.9% of the eligible indi-
viduals) provided written informed consent, but only 52 were also able to identify a caregiv-
er for the purposes of the study. Reasons for not being able to identify a carer are outlined in 
Figure 7-1. Preliminary analyses indicated no statistical differences between women who 
identified a carer (n=52) and those who did not (n=9) with regard to demographic and clini-
cal characteristics (all p>.05), except for a statistical difference according to marital status: 
married women were more likely to identify a carer compared to those single, widowed or 
divorced/separated (89% v. 60%; χ2(3)=9.276; p=.026). 
Informal caregivers were approached either at the clinic during the patient’s appointment or 
contacted at a later point over the phone. All 52 carers provided initial verbal consent; how-
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ever, 3 individuals failed to return a written consent form as well as data to the study. In ad-
dition, one patient also failed to provide data at any assessment point. Hence, in total, 60 
patients and 49 caregivers participated in at least one wave of assessment. As the study fo-
cused on care dyads, women with breast cancer and their respective family caregivers were 
excluded from further analyses if no caregiver had been identified, or if the patient or the 
carer did not complete at least one wave of data collection. Therefore, the final sample con-
sisted of 48 care dyads, who participated in at least one wave of assessment. 
 
 
7.2. Attrition Rates and Patterns of Missingness 
Information about the number of patients, caregivers and dyads who completed study ques-
tionnaires at each time of assessment is presented in Figure 7-2. Although 48 dyads partici-
pated in baseline assessments, data from only 42 patients, 37 caregivers and 36 dyads were 
received at the end of the study. These results are translated as an attrition rate of 12.5%, 
22.9% and 25% for patients, caregivers and dyads, respectively. Across all assessment 
points, reasons for loss to follow-up included busy patient and caregiver schedules, family 
member’s illness, preliminary termination of chemotherapy due to toxicity, caregiver work-
ing abroad, and caregiver death. Attrition in this repeated measures study created an unbal-
anced dataset, with unequal numbers and timing of assessments from individual to individu-
al and from dyad to dyad. The structure of missingness is displayed in Figure 7-3, where a 
variety of missing data patterns is shown; in all, 34 dyads (70.8% of total) had complete data 
(four assessments for the patient and four for the caregiver). 
In light of the aforementioned small to moderate attrition rates, separate analyses were pur-
sued to examine the possibility of attrition bias interfering with the data. Firstly, participants 
who completed all four assessments (n=40 patients; n=34 caregivers) were contrasted with 
those who did not (n=8 patients; n=14 caregivers) in terms of baseline demographic and 
clinical characteristics. The only significant associations were found with regard to duration 
(t45=3.14; p=.003) and type of relationship (p=.040; Fisher’s exact test) for patients, and du-
ration (t45=2.36; p = .023) and type of relationship (χ2(1)=9.71; p=.002) for caregivers. In 
other words, patients and caregivers completing all four assessments were more likely to be 
in a long-standing relationship and be married/partnered. 
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Figure 7-1. Summary of accrual rates. 
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Figure 7-2. Summaries of patient, caregiver and dyad participation and attrition rates throughout the study. 
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Secondly, participants who completed the study irrespective of number of completed as-
sessments (n=42 patients; n=37 caregivers) were similarly contrasted with those who did not 
(n=6 patients; n=11 caregivers). No statistical differences emerged (all p>.05). On the other 
hand, dyads who completed all four assessments (n=34) and those who did not (n=14) were 
contrasted. Significant differences were found with regard to patient employment status 
(χ2(1)=4.55; p=.033), duration of relationship (t45=2.36; p=.023), type of relationship 
(p=.003; Fisher’s exact test), and patient sleep affected by diagnosis (χ2(1)=4.55; p=.033). 
Dyads completing all four assessments were more likely to include retired or unemployed 
patients, individuals in long-standing relationships, spouses or partners, and patients whose 
sleep had not been affected by the diagnosis of breast cancer. 
 
 
Figure 7-3. Patterns of missingness in the current study (Note: Each lightly-coloured cell indicates 
the number of assessments that members of a dyad completed in the study; numbers in these cells 
indicate the total number of dyads for a specific pattern of missingness). 
 
 
Finally, when dyads who completed the study (irrespective of number of completed assess-
ments) (n=36) and those who did not (n=12) were contrasted, the only significant difference 
that was found related to type of relationship (p=.036; Fisher’s exact test); hence, dyads 
completing the final assessment were more likely to be those in a long-standing relationship. 
Overall, these non-significant findings provided good support to the assumption that data 
were not affected by attrition. 
When baseline and T1 scores on PSQf, GSQI and predictor variables were similarly com-
pared between completers and non-completers, no significant differences were found (all 
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p>.05). In conjunction with covariates for which significant differences emerged being ac-
counted for in later analysis stages, the above analyses supported the assumption of missing-
at-random data and, therefore, justified the use of multilevel modelling in the main analyses 
section. 
 
 
7.3. Sample Characteristics 
Demographic characteristics of the 48 care dyads are outlined in Table 7.1. The typical pa-
tient was 55 years old, had received high school education, was married and employed, with 
average to high yearly income. The typical caregiver was male, 54 years old, had received 
high school education, was married and employed, with average to high yearly income, and 
was the patient’s spouse or heterosexual partner. The sample mainly consisted of wife-
husband dyads (n=30; 62.5%), although heterosexual partners (n=10; 20.8%), mother-child 
dyads (n=7; 14.6%), and one dyad of friends were also present. Care dyads, on average, had 
well-established relationships, the mean length of which was 356.1 months (SD=161.3; 
range=18-624), or approximately 30 years. Analysis of variance indicated that mean length 
of relationship was greater in the spouse or mother-child dyads compared to the partner dy-
ads (F3, 43=22.15; p<.001). No differences were found between the patient and caregiver 
groups in terms of their demographic features, except for a significant difference in marital 
status: the patient group comprised of more divorced/separated or widowed women com-
pared to the caregiver group in which individuals were more likely to be single (χ2(3)= 9.01; 
p=.029). 
Table 7.2 summarises the clinical characteristics of the participating dyads. On average, 
women had been diagnosed 75 days and underwent breast surgery 41 days prior to 
chemotherapy initiation. In their majority, women were diagnosed with stage II breast 
cancer (62.5%) and underwent breast conserving surgery (58.3%) with axillary node 
clearance. Sixty-five per cent of the women received 21-day cycles of FEC (Fluorouracil, 
Epirubicin 75 or 80 mg/m2, Cyclophosphamide). For 9 additional women, FEC was 
complemented by additional cycles of Paclitaxel or Docetaxel. Other chemotherapy 
regimens included AC (Adriamycin, Cyclophosphamide), CAF (Cyclophosphamide, 
Adriamycin, and Fluorouracil) or TC (Paclitaxel, Cyclophosphamide) of diverse length. In 
line with administration guidelines for highly emetogenic chemotherapy regimens, prior to 
each cycle women received intravascular pre-medication consisted of a combination of 
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corticosteroid (e.g. dexamethasone 8 mg) and anti-emetic (e.g. granisetron 8 mg, 
ondansetron 8 mg) and/or anti-histaminic agents (e.g. ranitidine); they were also prescribed 
dexamethasone to be taken orally for the first 3-4 days after chemotherapy administration. 
Three women were excluded from this medication scheme as they had also been diagnosed 
with Type II diabetes. Whereas the majority of patients completed treatment without 
breaches in the chemotherapy protocol, three women experienced haematological toxicity 
that caused one week’s delay in treatment continuation, whereas one additional woman 
experienced severe cardiotoxicity which required her treatment to change to another 
regimen. 
 
Table 7.1. Participant demographic characteristics (n=48 dyads). 
Variable/Category 
Patients Caregivers Test statistic 
(df) M (SD); Range M (SD); Range 
Age (years) 55.44 (8.89); 38-74 53.81 (14.51); 18-89 1.05 (47)ns,a 
 n (%) n (%)  
Gender    
Male  43 (89.6) NA 
Female 48 (100.0) 5 (10.4)  
Marital status    
Married/partnered 39 (81.3) 40 (83.3) 9.01 (3)*,b 
Single 0 (0.0) 5 (10.4) 
Divorced/separated 6 (12.5) 3 (6.3) 
Widowed 3 (6.3) 0 (0.0) 
Educational background    
High school 32 (66.7) 33* (70.2) .14 (1)ns,b 
College/university 16 (33.3) 14 (29.8) 
Employment status    
Employed 
(FTM/PTM) 
30 (62.5) 33 (68.8) .42 (1)ns,b 
Unemployed/retired 18 (37.5) 15 (31.3) 
Yearly household income    
≤ £10,000 6* (13.0) 6* (12.8) .12 (3)ns,b 
£10,001-20,000 8 (17.4) 9 (19.1) 
£20,001-50,000 22 (47.8) 21 (44.7) 
> £50,000 10 (21.8) 11 (23.4) 
Relation to patient    
Husband/partner  40 (83.3) NA 
Child  7 (14.6) 
Friend  1 (2.1) 
Abbreviations: FTM – full-time; PTM – part-time; NA – not applicable; df – degrees of freedom; SD – Standard 
Deviation. 
a Paired samples t-test.; b Chi-square test. 
*Valid percentages accounted for missing values 
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Table 7.2. Participant baseline clinical characteristics (n=48 dyads). 
Variable 
Patients Caregivers Test statistic 
(df) M (SD); Range  
Time since diagnosis (days) 74.7 (26.7); 21-155  NA 
Time since surgery (days) 41.0 (14.7); 13-87  NA 
BMI (kg/m2)ǂ 29.2 (7.6); 18.6-49.2  NA 
 n (%) n (%)  
Breast cancer stage    
I 6 (12.5)  NA 
II 30 (62.5)   
IIIA 12 (25.0)   
Type of surgery    
Mastectomy 20 (41.7)  NA 
Wide local excision 28 (58.3)   
Chemotherapy regimen    
FEC 31 (64.6)  NA 
FEC + Taxanes 9 (18.8)   
Other 8 (16.6)   
Menopausal status    
Pre-menopausal 15 (31.3)  NA 
Peri-menopausal 8 (16.6)   
Post-menopausal 25 (52.1)   
Number of comorbidities    
0 17 (35.4) 22 (45.8) –2.22ns,a 
1-2 23 (48.0) 22 (45.8) 
≥ 3 8 (16.6) 4 (8.4) 
ECOG Performance status    
0 21 (43.7) 39 (81.3) –2.80**,a 
1 26 (54.2) 6 (12.4) 
2 1 (2.1) 3 (6.3) 
Physical activity    
Minimally active 23 (47.9) 23 (47.9) .00 (1)ns,b 
Highly active 25 (52.1) 25 (52.1) 
Smoking status (Yes) 5 (10.4) 17 (35.4) 8.49 (1)**,b 
Alcohol consumption    
Never 5 (10.4) 5 (10.4) .39 (2)ns,b 
Only occasionally 38 (79.2) 36 (75.0) 
Daily 5 (10.4) 7 (14.6)  
Pain medications use (Yes) 15 (31.3)  NA 
Alternative therapies use (Yes) 4 (8.3)  NA 
Prescribed medications use (Yes)  24 (51.1)* NA 
OTC medications use (Yes)  6 (12.5) NA 
Abbreviations: NA – not applicable; df – degrees of freedom; FEC – Fluorouracil, Epirubicin, Cyclophosha-
mide; BMI – Body mass index; ECOG – Eastern Cooperative Oncology Group; OTC – Over-the-counter; SD 
– Standard deviation. 
a Wilcoxon signed ranks test.; b Chi-square test.; ǂ n=45 
*Valid percentages accounted for missing values 
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The majority of women in this sample were either overweight (24.4%; BMI=25.0-29.9 
kg/m2) or obese (44.5%; BMI≥30 kg/m2). At baseline, 52.1% of women self-reported as 
being in menopause, whereas the remaining described themselves as either pre- (31.3%) or 
peri-menopausal (16.6%). At the end of the study (T3), only six women self-reported as 
being pre-menopausal, whereas 24.4% and 62.2% of the sample were either peri- or post-
menopausal, respectively. This was a statistically significant change with more women 
moving into or close to menopause as a result of chemotherapy compared to pre-treatment 
(McNemar (2)=9.00; p=.011). In addition, 31.3% of women reported the use of pain 
medications at baseline. Figure 7-4 illustrates changes in the frequency of pain medication 
use. Cochran’s Q test revealed a statistically significant difference (Q3=9.17; p=.027) with 
prevalence of pain medication use steadily increasing from T0 through T2 and then 
decreasing at T3. Examples of agents with analgesic properties throughout the study 
included paracetamol, ibuprofen, diclofenac, codeine and tramadol. What is more, Figure 7-
4 presents changes in the patient frequency of complementary/alternative (CAM) therapies 
use, which for this study was particularly low (8.3%-16.3%) at every time-point. Although 
frequency of CAM use showed a slight increase at T1 and T2, this was not statistically 
significant (Q3=5.40; p=.145). Examples of CAM therapies used included reflexology, self-
hypnosis, aromatherapy, Reiki, and acupuncture. Approximately half of the caregivers 
(51.1%) indicated the use of prescribed medications at baseline. Yet, over-the-counter 
medication use was particularly low (12.5%) at this time-point. 
As a group, the majority of women (64.6%) were experiencing at least one concurrent 
chronic health condition to breast cancer. These ranged from hypothyroidism, hypertension, 
and hypercholesterolaemia to arthritis, asthma, diabetes, diverticular disease, fibromyalgia, 
and systemic lupus erythematosus. Similarly, 54.2% of informal caregivers were experienc-
ing at least one chronic health condition, including hypertension, hypercholesterolaemia, 
angina, arthritis, chronic obstructive pulmonary disease, diabetes, benign prostatic hyper-
plasia, and HIV infection. Paired groups analyses indicated that statistically significantly 
women suffered from more chronic health conditions compared to their caregivers (Z=–
2.22; p=.026). 
In spite of these chronic conditions, the majority of both patients and caregivers maintained 
high levels of leisure time physical activity at baseline (Table 7.2), with at least 3 hours of 
mild activity and at least 1 hour of moderate to strenuous activity per week. This seemed to 
be analogous to the infrequent smoking and the occasional consumption of alcohol per week 
in both groups. No significant fluctuation in patients’ (Q3=.94; p=.816) and caregivers’ 
(Q3=4.86; p=.183) activity levels was found throughout the study. Moreover, no significant 
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between-group differences were found at any of the four assessment points (all p>.05; chi-
square analyses not shown), thus suggesting that patients and caregivers maintained similar 
levels of leisure time physical activity throughout the patient’s treatment. 
 
 
Figure 7-4. Over-time fluctuations in pain medication and CAM therapies use in the 
patient group over the chemotherapy treatment period (n=40-48 individuals). 
 
In terms of overall physical functioning, women reported good (54.2%) to excellent (43.7%) 
performance status at baseline; conversely, in their vast majority (81.3%) caregivers indicat-
ed excellent performance status at the same time-point. At baseline, caregivers had statisti-
cally significantly better performance status than the women they were caring for (Z=–2.80; 
p=.005). Although a decline in performance status was apparent for both groups (especially 
for patients) from T0 to T1 and from T1 to T2, this was statistically significant only for pa-
tients (Friedman test; χ2(3)=24.30; p<.001) but not for caregivers (Friedman test; χ2(3)=4.15; 
p<.246) (Figure 7-5). However, throughout the study performance status of caregivers was 
consistently better than that of women they were caring for (all p<.001; Wilcoxon Signed 
Rank test analyses not shown). 
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Figure 7-5. Graphical representation of fluctuations in patient and caregiver performance status 
throughout the study (Note: Higher scores indicate poorer performance status). 
 
 
7.4. Descriptive Analysis of Dyadic Sleep and Predictor Variables 
Tables 7.3 and 7.4 provide an overview of means, standard deviations and ranges for all pa-
tient and caregiver sleep and predictor variables as these were measured throughout the 
study. At all time-points, mean GSQI scores for both patients and caregivers exceeded an 
established cut-off score of 5 for clinically significant sleep/wake impairment. Based on this 
cut-off point, 52.1-76.7% of patients and 35.1-48.7% of caregivers could be identified as 
experiencing impaired sleep/wake patterns throughout the study (Figure 7-6). At T1 and T2, 
mean patient GSQI scores also exceeded a cancer-specific threshold of 8. Based on this 
threshold, 33.3-44.7% of the women were classified as having clinically significant sleep 
disturbance throughout the study. Figure 7-7 presents results similar to the afore-mentioned 
findings seen from a dyadic standpoint. It is apparent that, at baseline, 65% of the dyads 
consisted of one or two poor sleepers. However, over treatment continuation, dyads with one 
poor sleeper exceeded 45%, whereas for an additional 35%, both the patient and the caregiv-
er experienced poor sleep. 
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Table 7.3. Descriptive data of patient and caregiver outcome variables throughout the study. 
 Patients Caregivers 
 T0 (n=48) T1 (n=47) T2 (n=43) T3 (n=42) T0 (n=48) T1 (n=46) T2 (n=39) T3 (n=37) 
Bedtime (24h time)         
M (SD) 22:47 (0:45)ns 22:36 (0:56)ns 22:27 (0:55)* 22:34 (0:57)* 22:51 (0:59) 22:49 (0:58) 22:45 (0:55) 22:45 (0:50) 
Range 21:30-01:00 19:45-01:00 20:30-01:00 20:00-01:00 21:00-01:00 21:00-02:00 21:00-01:00 21:00-00:00 
Wake time (24h time)         
M (SD) 07:49 (1:00)*** 07:54 (1:02)** 07:51 (1:00)* 07:53 (0:55)*** 07:00 (1:15) 07:12 (1:34) 07:12 (1:25) 07:03 (1:12) 
Range 06:00-11:00 05:00-10:00 05:00-10:00 06:00-10:00 04:00-10:00 04:00-12:00 03:30-11:00 04:30-09:00 
GSQI (0-21)         
M (SD) 6.58 (4.25)ns 8.19 (4.03)*** 8.47 (4.18)** 7.29 (3.34)* 5.54 (3.48) 5.50 (3.26) 5.82 (3.77) 5.19 (3.41) 
Range 0-18 1-17 2-17 1-13 1-15 1-15 0-14 1-14 
PSQf (0-9)         
M (SD) 2.73 (2.20)† 3.32 (2.16)** 3.26 (2.40)* 2.60 (1.52)* 2.08 (1.61) 1.91 (1.56) 2.28 (1.70) 1.81 (1.53) 
Range 0-9 0-8 0-9 0-6 0-6 0-6 0-6 0-6 
DDISTf (0-6)         
M (SD) 1.90 (.97)ns 2.23 (.91)ns 2.63 (1.00)*** 2.57 (1.17)** 1.96 (1.05) 2.02 (1.15) 1.85 (.96) 1.95 (1.10) 
Range 0-4 1-5 1-5 1-5 0-4 0-5 0-4 0-5 
HSE (%)         
M (SD) 75.95 (13.54)* 71.15 (16.43)*** 72.09 (12.41)** 75.33 (12.11)* 81.88 (12.77) 82.52 (11.69) 80.03 (11.99) 81.82 (10.32) 
Range 41.38-96.77 33.33-94.73 45.00-95.65 48.00-100.00 37.04-100.00 50.00-100.00 50.00-100.00 56.25-94.73 
SL (minutes)         
M (SD) 26.06 (17.76)* 32.00 (29.27)** 30.74 (20.33)ns 24.74 (18.07)ns 20.54 (13.02) 18.70 (15.61) 29.03 (35.43) 20.59 (12.63) 
Range 2-90 1-150 2-90 5-90 2-60 5-90 5-185 5-60 
TST (minutes)         
M (SD) 408.75 (70.79)ns 396.51 (97.75)ns 407.09 (96.25)ns 417.86 (76.81)ns 404.67 (85.50) 420.00 (98.74) 405.00 (88.88) 407.84 (73.98) 
Range 180-480 150-570 150-660 300-600 90-600 90-720 120-600 180-540 
WASO (minutes)         
M (SD) 105.08 (73.10)** 130.74 125.65 (67.39)** 112.95 (66.09)** 68.60 (50.95) 67.50 (54.57) 73.54 (57.54) 70.49 (50.37) 
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 Patients Caregivers 
 T0 (n=48) T1 (n=47) T2 (n=43) T3 (n=42) T0 (n=48) T1 (n=46) T2 (n=39) T3 (n=37) 
(93.37)*** 
Range 0-320 10-375 20-315 0-352 0-195 0-210 0-220 10-195 
NAPTIME (minutes)         
M (SD) 22.00 (29.25)† 35.34 (44.29)* 45.19 (51.77)* 33.64 (36.78)** 11.88 (19.64) 16.91 (32.09) 20.69 (35.88) 15.78 (19.42) 
Range 0-120 0-240 0-300 0-120 0-75 0-180 0-180 0-60 
NOCAW (0-3)         
M (SD) 1.42 (.85)ns 1.68 (.76)* 1.58 (.70)† 1.60 (.73)ns 1.46 (.90) 1.33 (.94) 1.31 (.77) 1.41 (.80) 
Range 0-3 1-3 1-3 0-3 0-3 0-3 0-3 0-3 
EARLAW (0-3)         
M (SD) 1.38 (1.10)ns 1.36 (1.13)† 1.58 (1.12)ns 1.48 (1.02)ns 1.21 (1.25) 0.91 (1.09) 1.33 (1.33) 1.11 (1.17) 
Range 0-3 0-3 0-3 0-3 0-3 0-3 0-3 0-3 
SLPNSS (0-3)         
M (SD) .83 (.59)ns 1.06 (.60)† 1.33 (.61)** 1.19 (0.59)** .79 (.74) .85 (.56) .85 (.67) .76 (.60) 
Range 0-2 0-2 0-3 0-3 0-3 0-2 0-2 0-2 
RSTLSSLG (0-3)         
M (SD) .50 (1.01)ns .40 (.88)ns .58 (.96)ns .52 (.99)ns .56 (1.01) .41 (.83) .38 (.82) .54 (1.02) 
Range 0-3 0-3 0-3 0-3 0-3 0-3 0-3 0-3 
MORNFEEL (0-3)         
M (SD) 1.23 (.83)ns 1.26 (.82)ns 1.44 (.88)ns 1.64 (.69)* 1.40 (.96) 1.33 (.92) 1.23 (.93) 1.22 (.89) 
Range 0-3 0-3 0-3 0-3 0-3 0-3 0-3 0-3 
NAPNEED Yes % 50.0ns 74.5** 76.7† 66.7ns 41.7 47.8 56.4 56.8 
SAU Yes % 18.8† 19.1ns 23.3ns 7.1ns 6.3 10.9 10.3 5.4 
Abbreviations: GSQI – Global Pittsburgh Sleep Quality Index score; PSQf – Perceived Sleep Quality factor; SEf – Sleep Efficiency factor; DDISTf – Daily Disturbances factor; HSE – Habitual 
Sleep Efficiency; SL – Sleep Latency; TST – Total Sleep Time; WASO – Wakefulness after Sleep Onset; TIMENAP – Duration of Daytime Napping; NOCAW – Nocturnal Awakenings 
score; EARLAW – Early Awakenings score; SLPNSS – Daytime Sleepiness score; RSTLSSLG – Restless Legs score; MORNFEEL – Feelings Upon Morning Awakening score; NAPNEED 
– Need for Daytime Napping; SAU – Sleep Aid Use. 
Note: Whilst sample size varies for each assessment time-point, sample sizes are the same for all sleep variables because missing values were treated with mean substitution given the very low 
extent of missing data due to non-response. Paired samples t-tests and Wilcoxon Signed Ranks tests were used to compare patients and caregivers on different sleep variables at each time 
point, except for NAPNEED and SAU where χ2 tests were used instead: nsp> 10; †p<.10; *p<.05; **p<.01; ***p<.001. 
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Table 7.4. Descriptive data of patient and caregiver ‘behavioural’ predictor variables throughout the study. 
 Patients Caregivers 
 T0 (n=48) T1 (n=47) T2 (n=43) T3 (n=42) T0 (n=48) T1 (n=46) T2 (n=39) T3 (n=37) 
SH (0-52)         
M (SD) 10.60 (4.73)ns 8.47 (4.92)ns 8.60 (5.44)ns 8.74 (5.16)ns 10.33 (6.78) 10.52 (8.30) 9.92 (6.75) 8.30 (6.75) 
Range 0-23 0-22 0-22 0-19 1-29 0-42 0-26 0-24 
PHYSPT (0-4)         
M (SD) .382 (.284) .663 (.385) .856 (.495) .746 (.478) 
– – – – 
Range .000-1.119 .110-1.786 .109-2.309 .000-2.352 
PSYCH (0-4)         
M (SD) 1.20 (.83)ns .72 (.79)** .81 (.79)ns .93 (.85)ns 1.43 (.79) 1.12 (.81) .97 (.89) .92 (.92) 
Range .00-2.87 .00-3.17 .00-2.85 .00-3.13 .00-3.00 .00-2.99 .00-2.83 .00-2.77 
COPNEG (12-48)         
M (SD) 18.73 (4.29)** 17.09 (3.36)ns 16.51 (3.47)ns 15.93 (2.99)ns 15.73 (3.97) 16.09 (4.49) 15.87 (5.49) 15.84 (5.46) 
Range 12-37 12-23 12-23 12-24 12-30 12-32 12-37 12-38 
CRACB (9-45)         
M (SD) 
– – – – 
18.65 (6.02) 19.35 (6.15) 19.13 (5.82) 18.41 (5.80) 
Range 9-33 9-31 9-30 9-31 
SDSTRB (0-27)         
M (SD) 8.02 (4.58)ns 8.79 (4.30)* 9.51 (5.13)** 9.52 (4.75)** 7.79 (4.61) 7.07 (4.33) 6.41 (4.13) 6.38 (4.40) 
Range 0-19 1-19 1-24 2-20 0-20 0-21 0-15 0-19 
Abbreviations: SH – Sleep Hygiene Index total score; PHYSPT – Patient Physical Distress score from MSAS; PSYCH – Psychological Distress score from MSAS; COPNEG – Negative Cop-
ing score from COPE; CRACB – Caregiver Burden score from CRAS; SDSTRB – PSQI Sleep Disturbance Score. 
Note: Whilst sample size varies for each assessment time-point, sample sizes are the same for all sleep variables because missing values were treated with mean substitution given the very low 
extent of missing data due to non-response. 
Paired samples t-tests and Wilcoxon Signed Ranks tests were used to compare patients and caregivers on different predictor variables at each time point: nsp>.10; †p<.10; *p<.05; **p<.01; 
***p<.001. 
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Figure 7-6. Percentages of patients and caregivers scoring above 5 on GSQI (indicating 
impaired sleep/wake patterns) at different time points throughout chemotherapy (n=36-48 
dyads). 
 
 
 
Figure 7-7. Percentages of patient-caregiver dyads with two good sleepers (both ≤5 on 
GSQI), one poor sleeper (one >5 and one ≤5 on GSQI), or two poor sleepers (both >5 on 
GSQI) at different time points throughout chemotherapy (n=36-48 dyads). 
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Mean habitual sleep efficiency was reported as lower than a cut-off score of 80% by patients 
and marginally above this score by caregivers, irrespective of timing of assessment; this was 
also true for mean sleep latency and mean sleep duration values, which were greater than 20 
minutes and lower that 420 minutes, respectively, at all time-points for patients and caregiv-
ers (except for T1). Regardless of over-time fluctuations, on average, patients were awake 
during the night for at least one-and-a-half hour, with caregivers being awake for at least one 
hour. 
Evidence of disrupted sleep patterns was further corroborated by reports of frequency of 
nocturnal awakenings, which for 35.4-51.1% of patients and 30.4-39.6% of caregivers ex-
ceeded 3 per night throughout the study; reports of early morning awakenings, where 16.7–
27.9% of patients and 13.0-30.8% of caregivers awoke early and could not go back to sleep; 
and feelings of being only a little bit or not at all rested upon waking up in the morning in 
39.6-57.1% of patients and 29.7-39.6% of caregivers. Yet, only 7.1-23.3% of patients and 
5.4-10.9% of caregivers reported the use of sleep aids during the study. These included the 
benzodiazepine agent lorazepam, the non-benzodiazepine agents zolpidem and zopiclone, 
and the antidepressant drugs fluoxetine and citalopram. 
The degree of sleepiness was only moderate with 10.4-30.3% of patients and 8.1-15.4% of 
caregivers feeling quite a bit or very sleepy during the day. However, the need for napping 
in the daytime was prominent for both groups (patients 50.0-76.7%; caregivers 41.7-56.8%). 
Mean duration of daytime naps exceeded 20 and 15 minutes for patients and caregivers, re-
spectively. Of note, duration of daytime naps was reported to be greater than 30 minutes by 
23.9-44.2% of patients and 10.4-18.9% of caregivers throughout the study. 
At least half of the patients (58.3%) and the caregivers (50%) had experienced some prob-
lem with their sleep in the past, which, however, did not lead to a formal diagnosis of a sleep 
disorder. Interestingly, 62.5% of the women indicated that their sleep had been affected by 
the diagnosis of breast cancer, whereas 40.4% (n=19) of caregivers also admitted so. In 
terms of their sleeping arrangements, 87.5% (n=42) of dyads indicated sharing the same 
house, and 77.1% (n=37) also shared the same bedroom. 
Analysis of SH scores indicated that sleep hygiene behaviours of patients and caregivers 
were, on average, favourable of a good night’s sleep. Using the third quartile of obtained 
baseline scores as the cut-off score, 16.3-25% of patients (SH>13.75) and 16.2-28.2% of 
caregivers (SH>14) were classified as with inadequate sleep hygiene. Trends of reduction in 
mean SH scores (i.e. less sleep disruptive behaviours) were also noted from baseline to T3 
for both patients and caregivers. In contrast, patient SDSTRB scores increased steadily from 
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baseline to end of study, possibly following the manifestation of chemotherapy toxicities. 
Indeed, throughout the study, mean patient PHYS scores were relatively low, but increased 
steadily from T0 to T1 and from T1 to T2, only showing a slight reduction towards the end 
of the study (end of treatment). Conversely, caregiver SDTRB scores decreased steadily 
throughout the study despite the fact that mean caregiver burden (moderate in magnitude 
throughout the study) increased during treatment and restored back to baseline levels only 
towards the end of study. In a somewhat inverse fashion, mean dyad psychological burden, 
albeit fluctuating between mild and moderate, was reported as relatively high prior to treat-
ment initiation with a reduction during treatment, which was steady for caregivers but not 
for patients: after an initial reduction at T1, patient psychological distress showed trends for 
constant increase at T2 and T3. Finally, use of maladaptive coping strategies was generally 
infrequent in this sample. However, patients endorsed more negative coping strategies at the 
beginning of the study, which were gradually diminished to levels similar to those of care-
givers, for whom COPNEG scores showed no major fluctuations throughout the study. 
 
 
7.5. Preliminary Bivariate Correlation Analyses 
Preliminary inter-dyad correlational analyses yielded some significant, yet sporadic and 
modest, associations between patients’ and caregivers’ sleep/wake patterns across time. Rel-
ative to the outcome variables, at different time-points during the study, patient and caregiv-
er SL (T0 .37; T2 .36), PSQf (T0 .30), DDISTf (T1 .37; T2 .36; T3 .49), WASO (T2 –.24), 
GSQI (T0 .27), WAKETM (T0 .30; T3 .32), MORNFEEL (T0 .32), SLPNSS (T0 .30), and 
SAU (T2 .37) were also found to be linearly related. Bedtime was the only variable where 
patient and caregiver patterns were consistently correlated throughout the study (.35-.41). 
When relationships between patient and caregiver predictor variables were examined, further 
positive, yet moderate, correlations were found. Dyads’ sleep hygiene scores (.21-.37) were 
moderately associated throughout the study. Associations between dyads’ psychological dis-
tress were also low-to-moderate and emerged at the second half of the study (T2 .21; T3 
.37). At T1 (.22) and T2 (.25), positive between groups correlations were observed for 
SDSTRB. Lastly, positive associations between dyads’ maladaptive coping strategies were 
recorded from T1 until the end of the study (.23-.41). Despite their limited number, to a cer-
tain extent these significant results (or trends towards significance) suggest the presence of 
non-independence in the dyads’ outcome and predictor variables, thus supporting use of dy-
adic data analyses. 
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Intra-group correlation analyses revealed the presence of consistent and moderate-to-strong 
associations between time-points of assessment for the majority of repeatedly-measured out-
come and predictor variables. Moderately to highly stable over-time sleep constructs includ-
ed caregiver BEDTM (.68-.85) and WAKETM (.70-.76), caregiver SLPNSS (.53-.75), pa-
tient SAU (.57-.76), patient SH (.50-.69), and caregiver COPNEG (.52-.57). Low to moder-
ate stability was found for patient SDSTRB (.21-.54), caregiver DDISTf (.10-.73), patient 
NAPTIME (.17-.44) and NAPNEED (.06-.40), patient SLPNSS (.16-.50), NOCAW (.03-
.38) and EARLAW (.09-.58), caregiver SAU (.06-.47), and patient PSYCH (.22-.55). Stabil-
ity of all other variables was at least moderate (coefficients >.30) at all assessment points. 
Preliminary within-patient and within-caregiver correlational analysis revealed overall low 
to moderate associations between outcome and predictor variables (Table 7.5). However, in 
general, outcome and predictor variables were adequately related, yet they were sufficiently 
distinct to consider variables as distinct constructs, a fact that further supported the use of 
growth curve analyses with these data. When inter-correlations between outcome and demo-
graphic/clinical covariates were examined, only some modest associations were found (Ta-
ble 19-A2). Irrespective of participant group, the most consistent associations between co-
variates and outcome variables were recorded for age, type of relationship, duration of rela-
tionship, presence of comorbidities and performance status, and past sleep history and sleep 
affected by cancer diagnosis with affected individuals reporting greater sleep impairment. Of 
note, physical activity, patient menopausal status and whether dyads were sharing the same 
house/bedroom were not or hardly correlated with any of the outcome variables. Finally, in 
terms of collinearity evaluation, no correlation coefficients exceeded the selected cut-off 
score of .85; indeed, in their majority inter-correlations among predictors, demograph-
ic/clinical covariates and their combinations were low to moderate. 
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Table 7.5. Within-patient and within caregiver associations between outcome and predictor 
variables. 
Predictor variables 
Outcome variables 
PSQf DDISTf NAPTIME TST SL HSE WASO GSQI 
Patients 
Patients SH .26* .23* .23* .01ns .16ns –.13ns .10ns .31* 
PHYS .29** .47*** .22* –.15ns .21* –.17† .12ns .52*** 
PSYCH .29** .41*** .10ns –.08ns .18† –.10ns .05ns .37** 
COPNEG .23* .35** .03ns .01ns .11ns –.01ns –.03ns .33* 
SDSTRB .39*** NA .19† –.17† .23* –.22* .19† NA 
 
 Caregivers 
Carers SH .24* .40*** .02ns .01ns .13ns .06ns –.12ns .30* 
CRACB .20* .37*** .17† –.07ns .05ns .09ns .05ns .45** 
PSYCH .29** .55*** .28** .04ns .14ns –.06ns –.04ns .48*** 
COPNEG .25* .47*** .18† .10ns .08ns .04ns –.09ns .44** 
SDSTRB .35** NA .19† –.13ns .12ns –.32** .31** NA 
Abbreviations: PSQf – Perceived Sleep Quality factor from PSQI; DDISTf – Daily Disturbances factor from 
PSQI; NAPTIME – Daytime napping duration (minutes); TST – Total Sleep Time (minutes); SL – self-reported 
Sleep Latency (minutes); HSE – self-reported Habitual Sleep Efficiency (%); WASO – Wakefulness after sleep 
onset (minutes); GSQI – Global Sleep Quality Index score (denotes overall sleep/wake impairment); NA – Non 
applicable. 
Notes: nsp>.10; †p<.10; *p<.05; **p<.01; ***p<.001; Kendall's tau-b correlation coefficients. Coefficients in bold 
denote predictor variables that were entered into each separate multivariate model. 
 
 
 
7.6. Multilevel Modelling of Over-Time Changes in the Sleep/Wake         
Patterns of Care Dyads 
Eight baseline (unconditional) MHLMs assessing the effect of time in a linear and curviline-
ar pattern were estimated for each sleep parameter/outcome variable (Table 7.6). Compara-
tive analyses provided support for modelling the effect of time using the quadratic model for 
PSQf, NAPTIME, SL, SE, WASO, and GSQI, whereas for DDISTf the linear model was 
found to be a better fit to the data and was adopted as the baseline model. Of note, for TST, 
neither the linear nor the quadratic models were a significantly better fit to data than the 
means-only model. Unavoidably, this result limited examination of over-time changes in the 
dyads’ total sleep time to a descriptive analysis only. 
Based on estimation of variance components in the means-only models, intraclass correla-
tion coefficients (ICC) were calculated for each outcome variable and participant group. For 
the patient variables, ICCs were as follows: ICCPSQf=.60; ICCDDISTf=.38; ICCNAPTIME=.57; 
158 
 
 
ICCTST=.55; ICCSL=.48; ICCHSE=.59; ICCWASO=.59; and ICCGSQI=.61. The respective ICCs 
for the caregiver variables were as follows: ICCPSQf=.43; ICCDDISTf=.48; ICCNAPTIME=.42; 
ICCTST=.62; ICCSL=.38; ICCHSE=.53; ICCWASO=.42; and ICCGSQI=.56. Given that all patient 
and caregiver intercept components were statistically significant (all p<.001), ICCs were 
also significant, indicating that MHLMs were both appropriate and needed for these data 
[516]. In addition, the overall moderate magnitude of the ICCs suggested that not only group 
means were different but also that there was enough variation within each group. 
 
Table 7.6. Deviance statistics and comparison tests for the selection of baseline MHLMs 
Outcome 
variable 
Means-only  Linear model  Quadratic model 
Deviance     
Statistic  
Deviance 
Statistic χ
2,a  Deviance 
Statistic χ
2,b
 
PSQf 1317.8  1316.4 1.46ns  1275.5 42.30** 
40.85*** 
DDISTf 955.9  921.3 34.67***  906.01 27.46* 
15.29ns 
NAPTIME 3385.7  3369.3 16.49†  3278.5 107.22*** 
90.73*** 
TST 3978.6  3975.9 2.69ns  3962.9 15.64ns 
12.95ns 
SL 3065.4  3051.2 14.18ns  3015.3 50.05*** 
35.88*** 
HSE 2661.8  2658.9 2.89ns  2639.0 22.75* 
20.13* 
WASO 3809.9  3802.4 7.53ns  3770.6 39.31* 
31.42** 
GSQI 1787.5  1780.9 6.49ns  1744.8 42.65** 
36.15*** 
Abbreviations: PSQf – Perceived Sleep Quality factor from PSQI; DDISTf – Daily Disturbances factor from 
PSQI; NAPTIME – Daytime napping duration (minutes); TST – Total Sleep Time (minutes); SL – self-
reported Sleep Latency (minutes); HSE – self-reported Habitual Sleep Efficiency (%); WASO – Wakefulness 
after sleep onset (minutes); GSQI – Global Sleep Quality Index score (denotes overall sleep/wake impairment); 
MHLM – Multivariate Hierarchical Linear Model. 
Notes: aComparison test with means-only model (df=9); bComparison test with means-only model is presented 
first (df=22), and with linear model second (df=13). Deviance statistics in bold indicate selected baseline (un-
conditional) MHLMs for each outcome variable. nsp>.10; †p<.10; *p<.05; **p<.01; ***p<.001 
 
 
Table 7.7 presents the FML parameter estimates and standard errors of the fixed and random 
effects for the MHLMs that were fit to the data for each sleep/wake parameter and for both 
members of the dyads. 
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Table 7.7. Estimates of intercepts, linear change, quadratic change, and variance in dyads’ sleep/wake parameters 
 Fixed Effects  Random Effects Variance 
Parameter Effects b SE t (47) rES  VC χ2 (39) 
PSQf PT intercept, β10 2.73 .31 8.82***   3.58 155.74*** 
 CG intercept, β20 2.03 .23 8.75***   1.68 85.21*** 
 PT linear, β30 .97 .38 2.58* .35  4.03 88.28*** 
 CG linear, β40 .20 .23 .86ns .12  .61 30.40ns 
 PT quadratic, β50 –.34 .11 –3.03** .40  .32 78.32*** 
 CG quadratic, β60 –.07 .07 –.97ns .14  .05 29.21ns 
 Level-1 residual      1.10  
DDISTf PT intercept, β10  1.96 .13 15.63***   .41 104.49*** 
 CG intercept, β20  1.97 .15 12.73***   .80 129.54*** 
 PT linear, β30  .25 .06 4.30*** .53  .06 74.65** 
 CG linear, β40  .04 .07 .58ns .08  .08 81.21** 
 Level-1 residual        
NAPTIME PT intercept, β10  21.16 4.41 4.80***   683.94 146.04*** 
 CG intercept, β20  11.63 2.90 4.02***   247.70 69.61** 
 PT linear, β30  21.78 8.34 2.61* .36  2584.90 211.98*** 
 CG linear, β40  7.37 3.91 1.88† .26  363.74 28.57ns 
 PT quadratic, β50  –5.49 2.72 –2.02* .28  271.92 225.85*** 
 CG quadratic, β60  –1.85 1.24 –1.49ns .21  35.58 20.72ns 
 Level-1 residual      262.41  
TST PT intercept, β10  404.87 9.82 41.22***   3782.33 257.30*** 
 CG intercept, β20  408.04 11.21 36.39***   5103.32 332.17** 
 Level-1 residual      3089.78  
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 Fixed Effects  Random Effects Variance 
Parameter Effects b SE t (47) rES  VC χ2 (39) 
SL PT intercept, β10  26.16 2.55 10.25***   169.48 49.13ns 
 CG intercept, β20  19.42 1.91 10.18***   26.87 26.87ns 
 PT linear, β30  8.39 3.25 2.57* .35  157.80 59.48* 
 CG linear, β40  3.87 4.39 .88ns .13  478.77 48.29ns 
 PT quadratic, β50  –2.87 1.06 –2.72** .37  17.71 62.69* 
 CG quadratic, β60  –.90 1.27 –.71ns .10  37.78 38.60ns 
 Level-1 residual      203.35  
HSE PT intercept, β10  75.82 1.97 38.48***   130.30 124.04*** 
 CG intercept, β20  82.17 1.84 44.70***   106.43 86.40*** 
 PT linear, β30  –6.59 2.37 –2.78** .38  112.82 78.01*** 
 CG linear, β40  –1.16 1.78 –.65ns .09  11.46 32.12ns 
 PT quadratic, β50  2.09 .75 2.78** .38  10.74 77.67*** 
 CG quadratic, β60  .30 .53 .57ns .08  .89 29.81ns 
 Level-1 residual      59.32  
WASO PT intercept, β10  106.15 10.65 9.97***   4207.04 188.63*** 
 CG intercept, β20  68.05 7.26 9.38***   1538.01 73.28*** 
 PT linear, β30  33.09 13.12 2.52* .35  4771.87 107.57*** 
 CG linear, β40  2.95 8.08 .37ns .05  317.85 38.14ns 
 PT quadratic, β50  –10.43 4.12 –2.53* .35  445.28 99.97*** 
 CG quadratic, β60  –.64 2.62 –.24ns .03  33.91 39.99ns 
 Level-1 residual      1299.05  
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 Fixed Effects  Random Effects Variance 
Parameter Effects b SE t (47) rES  VC χ2 (39) 
GSQI PT intercept, β10  6.58 .60 10.98***   13.31 154.43*** 
 CG intercept, β20  5.52 .51 10.93***   8.63 101.37*** 
 PT linear, β30  2.55 .68 3.77*** .48  11.31 84.99*** 
 CG linear, β40  .55 .42 1.31ns .19  1.34 30.90ns 
 PT quadratic, β50  –.76 .20 –3.81*** .49  .82 74.21*** 
 CG quadratic, β60  –.18 .12 –1.49ns .21  .05 26.65ns 
 Level-1 residual      4.13  
Abbreviations: PSQf – Perceived Sleep Quality factor from PSQI; DDISTf – Daily Disturbances factor from PSQI; NAPTIME – Daytime napping duration (minutes); TST – Total Sleep Time 
(minutes); SL – self-reported Sleep Latency (minutes); HSE – self-reported Habitual Sleep Efficiency (%); WASO – Wakefulness after sleep onset (minutes); GSQI – Global Sleep Quality 
Index score (denotes overall sleep/wake impairment); SE – Standard error; PT – Patient; CG – Caregiver; rES – Effect Size; VC – Variance component. 
Notes: nsp > .10; †p < .10; *p < .05; **p < .01; ***p < .001. 
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Presentation of findings in the following sections is in line with research hypotheses posed 
in Chapter 6 (Section 6.1) as part of the primary research question for this study. Hence, 
each of these sleep/wake parameter-specific sections aims to provide evidence with regard to 
whether (a) similarities in the shape of trajectories of patients and carers were recorded; (b) 
whether at least moderate correlations in average and change patterns emerged within dyads; 
and (c) whether the sleep/wake impairments reported in these care dyads were of compara-
ble magnitude between dyad members. 
 
Perceived Sleep Quality (PSQf) 
A curvilinear pattern of change was evident for patient-perceived sleep quality, supported by 
a significant positive linear (β30=.97) and a significant negative quadratic slope over time 
(β50=–.34). Patient PSQf scores showed steady increase from prior to treatment to mid-
treatment (indicated by an increase in mean scores from 2.73 to 3.32 and 3.26), with restora-
tion to levels close to baseline towards the end of the study (three weeks post-treatment). In 
contrast, there was no significant linear or quadratic trend for caregivers, thus suggesting 
that, on average, caregiver PSQf scores showed no particular change over time. Despite non-
significance, a trend for slight deterioration in caregiver-perceived sleep quality may be pos-
tulated at mid-treatment (T2) (Figure 7-8). 
A multivariate hypothesis test indicated that average curves for the dyad members were sig-
nificantly different (χ2=15.50, df=3, n=48; p=.002), with patient-perceived sleep quality 
more affected than that of caregivers. More specifically, at baseline, average perceived sleep 
quality was worse for patients than for caregivers (χ2=4.75, df=1, n=48; p=.027). Accelera-
tion in deterioration of perceived sleep quality was greater for patients than for caregivers 
(linear trends: χ2=5.01, df=1, n=48; p=.024), whereas deceleration was also significantly dif-
ferent towards the end of the study (quadratic trends: χ2=5.91, df=1, n=48; p=.014). 
However, random effects tau correlations indicated a modest association between average 
baseline patient and caregiver perceived sleep quality (.42; 95% CI [.15, .63]), and strong 
correlations between the linear and quadratic rates of change (.91; [.84, .95] and .82; [.69, 
.89], respectively) for patient- and caregiver-perceived sleep quality. Hence, within the same 
dyads, members’ average perceptions of their sleep quality and especially changes in their 
sleep quality were closely related. 
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Figure 7-8. Average perceived sleep quality trajectories for patients and caregivers 
over the chemotherapy treatment period (n=36-48 dyads). Higher scores indicate 
worse perceived sleep quality with a possible range of 0-9. 
 
 
Daily Disturbance (DDISTf) 
A linear pattern of change in patients’ daily disturbance scores was evident, which was sup-
ported by a significant positive, yet modest, linear slope over time (β30=.25). In contrast, 
there was no linear trend for caregivers (β40=.04). Figure 7-9 shows that although patients 
reported increasingly more daily disruption during treatment (mean scores of 1.90 at base-
line to 2.23 at T1, 2.63 at T2, and 2.57 at T3), caregivers’ own daily disruption remained 
generally unaffected. 
Overall, average DDISTf curves for patients and caregivers were significantly different 
(χ2=12.77, df=2, n=48; p=.002). However, prior to treatment initiation average daily disturb-
ance was similar for patients and caregivers (χ2=.00, df=1, n=48; p>.05) (Figure 7-9). Yet, 
the linear trends were significantly different between patients and carers (χ2=6.52, df=1, 
n=48; p=.01), indicating greater acceleration rates (increasing frequency of daily disturb-
ances) for women than for caregivers. Figure 7-9 clearly illustrates patient and caregiver 
curves fanning out from T1 through T2 to T3. 
Within the same dyad, members’ average perceptions of and changes in daily disruption 
were somewhat, yet not closely, related to each other. Random effects tau correlations indi-
cated a modest association between average baseline patient and caregiver DDISTf scores 
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(.37; 95% CI [.10, .59]), but only a weak and non-significant relationship between the linear 
rates of change (.21; [–.08, .47]). 
 
 
Figure 7-9. Average daily disturbance trajectories for patients and caregivers over the 
chemotherapy treatment period (n=36-48 dyads). Higher scores indicate greater daily 
disruption with a possible range of 0-6. 
 
 
Daytime Napping Duration (NAPTIME) 
A curvilinear pattern of change was evident for patient daytime napping duration, which was 
supported by a significant positive linear slope over time (β30=21.78) and a significant nega-
tive quadratic slope over time (β50=–5.49) (Figure 7-10). On average, patient napping dura-
tion increased by at least 10 and 20 minutes at T1 and T2, respectively, and despite some 
degree of restoration remained close to these levels even at the end of the study. In conjunc-
tion with similar evidence on daily disturbance, it can be inferred that considerable daytime 
dysfunction was evident for women even after the end of chemotherapy treatment. Caregiver 
average trajectories were not very dissimilar from patients’. Average napping during the day 
increased after CThC1 and reached a maximum after CThC4, with restoration to baseline 
levels at the end of chemotherapy (Figure 7-10). However, albeit marginally, neither the 
linear nor the quadratic trend for caregivers reached statistical significance. 
Average curves for patients and caregivers were significantly different (χ2=10.32, df=3, 
n=48; p=.016), with patients spending more time napping in the daytime throughout the 
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study. However, although from a clinical point of view patients spent more time napping 
during the day than caregivers, on average, both dyad members were similarly affected by 
demands posed during the treatment period. Indeed, neither the average (χ2=2.71, df=1, 
n=48; p=.095) nor the linear (χ2=2.43, df=1, n=48; p=.115), nor the quadratic trends 
(χ2=1.54, df=1, n=48; p=.212) trends of daytime napping duration were significantly differ-
ent between patients and caregivers. 
Random effects tau correlations indicated a modest, yet negative, association between aver-
age patient and caregiver napping duration (–.30; 95% CI [–.54, –.02]), and only very weak 
and non-significant associations between the linear and quadratic rates of change (.00; [–.28, 
.29] and .07; [–.22, .35], respectively) between patients and caregivers. Seen together, these 
results are indicative of major discrepancies in the napping duration of dyad members; with-
in the same dyad, duration of time in napping of patients remained practically unrelated to 
that of caregivers. 
 
 
Figure 7-10. Average daytime napping duration trajectories for patients and caregiv-
ers over the chemotherapy treatment period (n=36-48 dyads). 
 
 
Total Sleep Time (TST) 
Throughout the study, no particular pattern of change in either patients’ or caregivers’ total 
sleep time at night was found. In addition, at baseline, there was no statistical or clinical dif-
ference in average reported total sleep time between patients and carers (χ2=.05, df=1, n=48; 
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p>.05). A two-way repeated measures analysis of variance also confirmed this absence of 
over-time change patterns. Due possibly to the presence of wide variability in individual 
TST reports for both patients and caregivers, univariate within-subjects effects of time were 
also non-significant (trajectories plotted in Figure 7-11). In agreement with univariate 
paired t-tests presented in Table 7.3, significant over-time differences between the two 
groups (patients v. caregivers) were also absent (Wilks’ Lambda=.97, F=1.108, df=3; 
p=.35). Nevertheless, 38% and 28% of patients, and 35% and 26% of caregivers experienced 
reduction in their total sleep time at T1 and T2, respectively, compared to baseline. At the 
same time-points, 50% and 49% of dyads included one or both members, whose actual sleep 
time during the night had been adversely affected. Interestingly, total sleep time of patients 
dropped by an average of 12 minutes the weeks following administration of CThC1 com-
pared to baseline, whereas for caregivers an inverse trend was apparent (average increase in 
TST by 16 minutes). 
A rather weak and not significant, positive tau correlation between average patient and care-
giver reports of total sleep time emerged (.13; 95% CI [–.16, .40]). Whilst within some dy-
ads average patient TST may have been positively and linearly linked to caregiver TST, and 
vice versa, on the whole one member’s lower TST only minimally was followed by a re-
spective reduction in the other’s TST. 
 
 
Figure 7-11. Average daily disturbance trajectories for patients and caregivers over the 
chemotherapy treatment period (n=36-48 dyads). A reference (faint dotted) line indi-
cates the minimum normal TST of 420 minutes (≥7 hours) for healthy adult individuals. 
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Sleep Latency (SL) 
As with perceived sleep quality, a curvilinear pattern of change was evident for patient sleep 
latency (Table 7.7). Increase in patient sleep latency from baseline to mid-treatment (indi-
cated by increases in mean sleep latency from 26 to 32 and 30 minutes) was evident, which 
levelled off with restoration to levels close to, but slightly lower than, baseline towards the 
end of the study (25 minutes). In contrast, whereas a somewhat similar pattern was observed 
(Figure 7-12), there was no significant linear or quadratic trend for caregiver sleep latency. 
On average, caregivers required approximately the same time to fall asleep at all assessment 
points throughout the study. 
Multivariate hypothesis testing indicated that average curves for patients and caregivers 
were significantly different (χ2=9.70, df=3, n=48; p=.021). Indeed, on average, patients spent 
more time until falling asleep than caregivers did (χ2=6.24, df=1, n=48; p=.012). However, 
no difference emerged for either the linear (χ2=1.27, df=1, n=48; p=.259) or the quadratic 
(χ2=2.62, df=1, n=48; p=.102) trends. These findings are in agreement with OLS results for 
matched groups presented in Table 7.3, where no between-groups differences in mean sleep 
latency were found at T2 and T3. From a clinical point of view, at T2 (mid-treatment) pro-
longation of average caregiver sleep latency to levels close to those reported from patients at 
the same time-point (29 v. 32 minutes) – and certainly higher than previous own (29 v. 20 v. 
19 minutes) – was evident. Whereas early in the course of treatment dyad members’ sleep 
latency was greater for patients than caregivers, as time elapsed (post-CThC1 to end treat-
ment), differences in sleep latency patterns started to fade out; caregivers found falling 
asleep increasingly more difficult, thus assimilating patients’ own difficulty. From T2 to end 
of study, dyad sleep latency curves became parallel, showing somewhat similar patterns of 
deceleration and restoration of sleep latency to pre-treatment levels. 
Random effects correlations indicated a modest association between average patient and 
caregiver sleep latency (.36; 95% CI [.08, .58]). Yet, correlations between the linear and 
quadratic rates of change were particularly strong (.77; [.62, .86] and .80; [.67, .88], respec-
tively), thus suggesting that within the same dyad, patient and caregiver changes in their 
sleep latency were positively and closely related. 
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Figure 7-12. Average sleep latency trajectories for patients and caregivers over the 
chemotherapy treatment period (n=36-48 dyads). A reference (faint dotted) line indi-
cates the minimum normal SL of 20 minutes for healthy adult individuals. 
 
 
Habitual Sleep Efficiency (HSE) 
As with other sleep parameters, a curvilinear pattern of change was evident for patient habit-
ual sleep efficiency as well (Table 7.7). Average patient HSE declined from baseline to mid-
treatment (indicated by a steady decrease in mean sleep efficiency percentages from 78% to 
71% and 72%), with restoration to levels close to baseline three weeks after the end of 
chemotherapy. In contrast, caregiver linear (β40=–1.16) and quadratic (β60=.30) trends of ha-
bitual sleep efficiency fell short of significance, thus suggesting absence of a particular pat-
tern of change in average HSE in this sample of caregivers. However, a trend for slight dete-
rioration in caregiver HSE from 82% at treatment initiation to 80% at mid-treatment is 
shown in Figure 7-13. 
Multivariate hypothesis testing suggested that average HSE curves for patients and caregiv-
ers were significantly different (χ2=17.31, df=3, n=48; p<.001); patients’ HSE was more af-
fected than that of caregivers throughout the study. Indeed, baseline average HSE was worse 
for patients than for caregivers (χ2=6.40, df=1, n=48; p=.011). Although no statistically sig-
nificant difference was found between either linear (χ2=3.11, df=1, n=48; p=.074) or quad-
ratic (χ2=3.52, df=1, n=48; p=.057) patient and caregiver trends, rates of decrease and accel-
eration in patient HSE were also consistently greater than those for the caregivers. 
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The random effects associated with the quadratic growth model for HSE revealed the extent 
to which patients’ trajectory of change was related to that of their caregivers. A weak tau 
correlation coefficient for initial HSE status was found (.19; 95% CI [–.10, .45]). This disso-
ciation in dyads’ HSE was further confirmed by modest, but negative, correlations for linear 
(–.38; [–.60, –.11]) and quadratic change (–.48; [–.67, –.23]). Thus, within the same dyad, 
patient and caregiver reports of average HSE were found to be only weakly related, but more 
importantly, rates of change were found to be inversely related: steeper declines in a pa-
tient’s HSE were correlated with steeper increases in caregiver HSE, and vice versa. 
 
 
Figure 7-13. Average habitual sleep efficiency trajectories for patients and caregivers 
over the chemotherapy treatment period (n=36-48 dyads). A reference (faint dotted) line 
indicates the minimum normal HSE of 80% for healthy adult individuals. 
 
 
Wakefulness After Sleep Onset (WASO) 
A curvilinear pattern of change was also evident for patient wakefulness after sleep onset. 
Average patient WASO increased from baseline to mid-treatment (proposed by a steady in-
crease in mean time in wakefulness from 105 minutes to 131 and 126 minutes), and then 
levelled off close to baseline three weeks after the end of chemotherapy. The effect sizes for 
the linear and quadratic trends were modest to large (.35 and –.35, respectively). As with 
other sleep parameters, caregiver linear (β40=2.95) and quadratic (β60=–.64) trends of WASO 
fell short of significance. Yet again, average dyad trajectories were indicative of a trend to-
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wards slight deterioration in caregiver WASO by approximately 6 to 7 minutes on average 
baseline to mid-treatment (Figure 7-14). 
The average WASO curve for patients was significantly different (greater) from caregivers’ 
(χ2=20.69, df=3, n=48; p<.001). Additional univariate tests revealed that baseline WASO 
was more prolonged for patients than for caregivers (χ2=9.49, df=1, n=48; p=.002). No sta-
tistically significant differences were found between either linear (χ2=3.21, df=1, n=48; 
p=.069) or quadratic (χ2=3.44, df=1, n=48; p=.060) patient and caregiver trends; however, 
rates of increase and deceleration in patient WASO were again consistently greater than 
those for the caregivers. 
Cross-dyad member tau correlations revealed a rather weak patient-caregiver association in 
baseline WASO (.12; 95% CI [–.17, .39]). As with dyads’ HSE, dissociation in dyads’ 
WASO was further confirmed by negative, yet strong, between groups correlations for linear 
and quadratic change (–.77; [–.86, –.62] and –.69; [–.81, –.50], respectively). Thus, within 
same dyads, patient and caregiver rates of change were found to be inversely related: steeper 
increases in a patient’s WASO were correlated with steeper declines in caregiver WASO, 
and vice versa. 
 
 
Figure 7-14. Average wakefulness after sleep onset trajectories for patients and care-
givers over the chemotherapy treatment period (n=36-48 dyads). 
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Overall Sleep/Wake Impairment (GSQI) 
A significant curvilinear pattern of change was evident for patients with large effect sizes for 
the linear and quadratic trends (.48 and –.49, respectively). Average patient GSQI scores 
increased from baseline (6.58 at T0) to mid-treatment (8.19 and 8.47 at T1 and T2, respec-
tively), and then levelled off but remained higher than baseline three weeks after the end of 
chemotherapy. Consistent with previously reported findings, caregiver linear (β40=.55) and 
quadratic (β60=–.18) trends of overall sleep/wake impairment fell short of significance with 
small to medium size effects (.19 and –.21, respectively). However, the typical caregiver 
exceeded a cut-off GSQI score of 5 suggesting potential sleep/wake impairment. What is 
more, average dyad trajectories illustrated in Figure 7-15 are indicative of a trend for slight 
deterioration in average caregiver sleep/wake patterns as dyads entered mid-treatment; in 
other words, average caregiver sleep/wake impairment reached its peak at the same time as 
patients’. As a result, dyads half way through the patient’s chemotherapy treatment were 
more sleep-impaired than at any other point over this period. 
Multivariate hypothesis testing revealed that the average sleep/wake impairment curve for 
patients was overall greater than for caregivers (χ2=18.74, df=3, n=48; p<.001). On average 
however, dyad members about to enter the experience of chemotherapy treatment were sim-
ultaneously sleep-impaired (χ2=2.64, df=1, n=48; p=.100). In contrast, as treatment pro-
gressed, care dyad members’ sleep/wake patterns were affected differently. Rates of increase 
(χ2=8.12, df=1, n=48; p=.005) and deceleration (χ2=7.06, df=1, n=48; p=.008) in patient 
sleep/wake impairment were consistently greater than those for the caregivers. 
Cross-dyad member tau correlations revealed a moderate patient-caregiver association in 
baseline overall sleep/wake impairment (.42; 95% CI [.15, .63]). This finding was supported 
by fairly strong correlations for linear (.76; [.61, .86]) and quadratic change (.84; [.73, .91]). 
In all, within same dyads, not only was average sleep/wake disruption found to be linearly 
related between a woman and her caregiver, but more importantly, rates of change were 
found to be positively and strongly related: steeper increases in a patient’s sleep/wake im-
pairment were correlated with steeper increases in their caregiver’s own sleep/wake impair-
ment, and vice versa. In other words, despite the differences in the magnitude of sleep im-
pairment, within care dyads, deterioration or amelioration (i.e. change) in dyad members’ 
sleep/wake impairment was very similar. 
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Figure 7-15. Average sleep/wake impairment trajectories for patients and caregivers 
over the chemotherapy treatment period (n=36-48 dyads). Two reference (faint dotted) 
lines indicate established cut-off scores of >5 and >8 for possible sleep/wake impair-
ment. 
 
 
 
7.7. Multilevel Modelling of the Effects of Sleep–Impairing Factors 
Inclusion of time-varying and time-invariant predictors led to the formation of separate con-
ditional MHLMs for each of the outcome variables, which were adjusted for the effects of 
additional covariates. Significant variation around the average and/or linear and/or quadratic 
patient and caregiver trajectories of sleep/wake parameters indicated whether it was appro-
priate to examine predictors at Level 2 (Table 7.7). 
As previously, presentation of findings in the following sections is in line with research hy-
potheses posed in Chapter 6 (Section 6.1) as part of the secondary research question for this 
study. Hence, each of these sleep/wake parameter-specific sections aims to provide evidence 
with regard to the (a) average (enduring) and change-related (contextual) effects of the se-
lected predictors on patients’ own sleep/wake parameters, such that greater burden is associ-
ated with poorer sleep/wake outcomes; (b) average (enduring) and change-related (contextu-
al) effects of the selected predictors on caregivers’ own sleep/wake parameters, such that 
greater burden is associated with poorer sleep/wake outcomes; and (c) average (enduring) 
and change-related (contextual) cross-partner effects of the selected predictors, such that 
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greater burden on the patient’s part is associated with poorer caregiver sleep/wake outcomes, 
and vice versa. 
 
Perceived Sleep Quality (PSQf) 
Both enduring and contextual effects of nocturnal disturbance were found. Indeed, own 
mean nocturnal disturbance significantly predicted own mean perceived sleep quality for 
both patients (γ111=.15, SE=.07, p=.03; rES=.36) and caregivers (γ29=.09, SE=.04, p=.019; 
rES=.37) (Table 20-A2). Moreover, increases in own nocturnal disturbances were followed 
by increases in reports of poor sleep quality for both patients (γ70=.18, SE=.04, p<.001; 
rES=.46) and caregivers (γ80=.12, SE=.05, p = .01; rES=.27). Additional important associa-
tions emerged: increase in own psychological distress was related to worse perceived sleep 
quality for women (γ120=.45, SE=.21, p=.032; rES=.23), while increase in caregiving burden 
was associated with worse perceived sleep quality for caregivers (γ111=.08, SE=.03, p=.005; 
rES=.30). Quite surprisingly, more frequent use of negative coping strategies by caregivers 
was found to be associated with better perceived sleep quality (γ111=–.13, SE=.05, p=.007; 
rES=–.28) (Figure 7-16). 
Some interesting cross-partner effects were also found flowing predominantly from patients 
to caregivers. More specifically, patients’ mean physical distress (γ24=1.57, SE=.55, p=.007; 
rES=.45), mean psychological distress (γ26=.75, SE=.30, p=.019; rES=.40), mean negative 
coping strategies (γ211=.14, SE=.06, p=.03; rES=.37), and mean nocturnal disturbance 
(γ213=.14, SE=.05, p=.014; rES=.41) were associated with worse mean PSQf scores in the 
caregivers. Interestingly, increase in patients’ psychological distress was also associated 
with positive change (worsening) in caregivers’ perceived sleep quality (γ190=.42, SE=.18, 
p=.023; rES=.26). In addition, increase in caregiver burden throughout treatment was found 
to be related not only to own decline (γ250=.06, SE=.03, p=.003; rES=.23), but also to decline 
in patients’ perceived sleep quality (γ260=.09, SE=.03, p=.041; rES=.33). 
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Figure 7-16. Statistically significant (p<.05) enduring (mean) and contextual (change) own and cross-
partner effects of the sleep-impairing factors examined on patients’ and caregivers’ perceived sleep 
quality (PSQf). Faint arrows indicate associations where trends towards significance emerged 
(.10>p≥.05). All models were controlled for the effects of SLPAST, SLCA, AGE, RELATDUR, 
CMRBDT, PS, and BCSTAGE for patients; and SLPAST, SLCA, AGE, and RELATDUR for care-
givers. Where no arrows are shown, no statistically significant associations (or trends towards signifi-
cance) emerged. Numbers next to arrows denote the MHLM parameter estimates (coefficients) for 
each predictor variable; negative values indicate an inverse relationship between predictor and out-
come variable (see Table 20-A2). 
 
 
Daily Disturbance (DDISTf) 
Significant enduring effects of own mean patient physical burden/caregiver burden on own 
mean daily disturbance for both patients (γ14=.96, SE=.28, p=.002; rES=.49) and caregivers 
were found (γ24=.04, SE=.02, p=.036; rES=.34) (Table 21-A2). In addition, mean caregiver 
psychological distress was positively associated with mean daily disturbance (γ25=.37, 
SE=.15, p=.016; rES=.39). In terms of change, increase in own use of poor sleep behaviours 
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was significantly associated with more daily disruption for both patients (γ50=.05, SE=.02, 
p=.012; rES=.39) and caregivers (γ60=.04, SE=.02, p=.009; rES=.40). Additional important 
associations emerged: increase in own physical distress (γ70=.74, SE=.19, p<.001; rES=.54) 
and more frequent use of maladaptive coping strategies (γ100=.06, SE=.03, p=.037; rES=.33) 
was related to more daily disruption for patients. Moreover, increase in caregiver burden was 
found to be associated with increased own daily disturbance (γ120=.05, SE=.02, p=.006; 
rES=.42). Overall, results suggest that the effects of the predictors tested on daily disturbance 
were primarily contextual for both dyad members (Figure 7-17). 
In further analyses, only an enduring cross-partner effect emerged: poorer caregiver sleep 
hygiene was associated with increased patient daily disruption (γ19=.04, SE=.02, p=.042; 
rES=.35), after controlling for potential own effects. It can be inferred that one’s own daily 
disturbance in this sample was primarily influenced by own sleep-impairing factors. Never-
theless, a hint of intra-dyad influence suggested that sleep disruptive behaviours on the care-
givers’ part may have triggered patient restlessness during the night and subsequent disrup-
tion in the daytime. 
 
 
Daytime Napping Duration (NAPTIME) 
Two significant and positive own enduring effects were found for patients, with mean physi-
cal distress (γ14=31.63, SE=14.63, p=.038; rES=.35) and disruptive sleep hygiene (γ16=2.75, 
SE=1.03, p=.012; rES=.42) predicting prolonged own mean napping duration (Table 22-A2). 
In addition, mean caregiver psychological distress was positively associated with own mean 
daytime napping duration (γ25=15.94, SE=6.08, p=.013; rES=.41). In terms of contextual pre-
dictor effects, increase in caregiver frequency of nocturnal disturbances was associated with 
more time spent in napping (γ80=1.47, SE=.67, p=.032; rES=.23). For patients, increase in 
own psychological distress was related to increase in daytime napping (γ120=11.74, SE=4.05, 
p=.005; rES=.30) (Figure 7-18). 
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Figure 7-17. Statistically significant (p<.05) enduring (mean) and contextual (change) own and cross-
partner effects of the sleep-impairing factors examined on patients’ and caregivers’ daily disturbance 
(DDISTf). Faint arrows indicate associations where trends towards significance emerged (.10>p≥.05). 
All models were controlled for the effects of SLPAST, SLCA, AGE, RELATDUR, CMRBDT, PS, 
and BCSTAGE for patients; and SLPAST, SLCA, AGE, and RELATUR for caregivers. Where no 
arrows are shown, no statistically significant associations (or trends towards significance) emerged. 
Numbers next to arrows denote the MHLM parameter estimates (coefficients) for each predictor vari-
able; negative values indicate an inverse relationship between predictor and outcome variable (see 
Table 21-A2). The SDSTRB predictor variable was removed from this model as data used to create it 
were also used to create the DDISTf outcome variable. 
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Figure 7-18. Statistically significant (p<.05) enduring (mean) and contextual (average) own and 
cross-partner effects of the sleep-impairing factors examined on patients’ and caregivers’ daytime 
napping duration (NAPTIME). Faint arrows indicate associations where trends towards significance 
emerged (.10>p≥.05). All models were controlled for the effects of SLSROOM, SLSHOUS, AGE, 
RELDYAD, RELATDUR, PS, and BMI for patients; and SLSROOM, SLSHOUS, RELDYAD, 
RELATUR, and SEXCG for caregivers. Where no arrows are shown, no statistically significant asso-
ciations (or trends towards significance) emerged. Numbers next to arrows denote the MHLM param-
eter estimates (coefficients) for each predictor variable; negative values indicate an inverse relation-
ship between predictor and outcome variable (see Table 22-A2). 
 
 
Two enduring cross-partner effects flowing from patients to caregivers were also revealed 
(Figure 7-18). First, greater patient psychological distress was associated with shorter care-
giver napping (γ26=–13.63, SE=5.94, p=.029; rES=–.39). Second, increased patient use of 
negative coping strategies was associated with lengthier caregiver napping (γ213=3.27, 
SE=1.41, p=.028; rES=.39). In terms of contextual cross-partner effects, increases in caregiv-
er burden were significantly associated with an increase in patient napping over the study 
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duration (γ260=1.91, SE=.60, p=.002; rES=.34). In a counteracting fashion and albeit margin-
ally non-significant, increases in dyad members’ psychological distress were linked to de-
cline in the other party’s napping duration. Yet, as previously identified, increases in pa-
tients’ psychological distress were still significantly associated with increases, rather than 
decreases, in own daytime napping after controlling for potential cross-partner effects 
(γ170=10.49, SE=4.30, p=.017; rES=.27). A similar own-effects association for caregivers fell 
short of statistical significance. These results may nevertheless be suggestive of a link be-
tween mood and napping, the direction of which may depend on the point of view from 
which it is examined, namely own (positive) or cross-partner (negative) effects. 
 
 
Total Sleep Time (TST) 
No significant own effects were found for either patients or carers except that a trend to-
wards lengthier actual sleep at night was found for those caregivers whose own nocturnal 
disturbance was, on average, lower (γ27=–5.33, SE=2.86, p=.070; rES=–.28). Although simi-
larly expected, the respective association for patients fell short of significance (γ110=–2.98, 
SE=2.72, p=.281) (Table 23-A2). 
Own and cross-partner effects analyses revealed only a trend towards an enduring cross-
partner effect flowing from caregivers to patients: greater caregiver burden was linked to 
shorter patient total sleep time (γ14=–3.80, SE=2.10, p=.080; rES=–.31) (Figure 7-19). To-
gether with a similar (in both direction and magnitude) trend emerging for caregiver burden 
effects on own TST (γ23=–4.73, SE=2.61, p=.078; rES=–.29), it can be inferred that in dyads 
where caregivers felt more burdened, not only they themselves might have experienced sleep 
deprivation, but also patients’ actual sleep duration might have been adversely affected, with 
caregiver burden equally related to dyad members’ mean TST. 
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Figure 7-19. Statistically significant (p<.05) enduring (mean) own and cross-partner effects of the 
sleep-impairing factors examined on patients’ and caregivers’ total sleep time (TST). No contextual 
(change) effects were investigated as the means-only model was found to be a better fit to the data. 
Faint arrows indicate associations where trends towards significance emerged (.10>p≥.05). All mod-
els were controlled for the effects of SLPAST, SLCA, RELDYAD, CMRBDT, PS, and ALCHL for 
patients; and SLPAST and RELDYAD for caregivers. Where no arrows are shown, no statistically 
significant associations (or trends towards significance) emerged. Numbers next to arrows denote the 
MHLM parameter estimates (coefficients) for each predictor variable; negative values indicate an 
inverse relationship between predictor and outcome variable (see Table 23-A2). 
 
 
Sleep Latency (SL) 
No significant associations between changes in any of the predictors and changes in sleep 
latency were found for either patients or carers; yet, contextual trends towards significance 
were recorded for two predictors (see Table 24-A2). First, increases in patient use of mala-
daptive sleep practices (i.e. declines in sleep hygiene) were linked with increases in own 
sleep latency (γ90=.71, SE=.40, p=.082). The size of this effect was only small to medium 
(rES=.19). Second, change in caregiver burden was positively linked to own sleep latency 
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(γ160=.43, SE=.24, p=.080; rES=.19) (Figure 7-20). Thus, as caregivers became increasingly 
burdened during the patients’ treatment they were more likely to find difficulty in falling 
asleep at night. 
 
 
Figure 7-20. Statistically significant (p<.05) contextual (change) own and cross-partner effects of the 
sleep-impairing factors examined on patients’ and caregivers’ sleep latency (SL). No enduring (own) 
effects were investigated as not enough variability in the model’s intercepts was found to allow inclu-
sion of average effects. Faint arrows indicate associations where trends towards significance emerged 
(.10>p≥.05). All models were controlled for the effects of SLPAST, RELATDUR, CMRBDT, and 
BCSTAGE for patients; no covariates were entered for caregivers due to lack of significant variabil-
ity. Where no arrows are shown, no statistically significant associations (or trends towards signifi-
cance) emerged. Numbers next to arrows denote the MHLM parameter estimates (coefficients) for 
each predictor variable; negative values indicate an inverse relationship between predictor and out-
come variable (see Table 24-A2). 
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As with own effects, no significant cross-partner effects emerged (Figure 7-20). Neverthe-
less, increases in caregiver burden were linked to increase in patient sleep latency over the 
study duration (γ260=.44, SE=.24, p=.068; rES=.21). At the same time, as previously identi-
fied, increase in caregiver burden was still linked to worsening sleep latency after control-
ling for potential cross-partner effects (γ250=.90, SE=.53, p=.092; rES=.19). Multivariate hy-
pothesis testing suggested that the effects of increasing caregiver burden on the dyads’ 
changes in sleep latency were somewhat different, as patients seemed to become more af-
fected than caregivers themselves (χ2=6.94, df=1; p=.029). 
 
 
Habitual Sleep Efficiency (HSE) 
A trend towards worse patient HSE with greater nocturnal disturbance was recorded (γ19=–
.69, SE=.36, p=.060; rES=–.30). Quite unexpectedly, a positive association was also found 
between patient mean negative coping and own mean HSE (γ18=1.20, SE=.53, p=.030; 
rES=.43), suggesting that greater use of maladaptive strategies was related to better sleep dur-
ing the night for patients. Conversely, mean caregiver burden was inversely associated with 
own mean HSE (γ23=–.97, SE=.30, p=.002; rES=–.54), as was own mean nocturnal disturb-
ance (γ28=–.88, SE=.31, p=.007; rES=–.42), and own mean sleep hygiene (γ25=–.63, SE=.24, 
p=.013; rES=–.39). Consistent associations between changes in predictors and the outcome 
variable were found for patients only. More specifically, increases in patient nocturnal dis-
turbance (γ70=–.86, SE=.25, p<.001; rES=–.35), increases in patient disruptive sleep hygiene 
practices (γ90=–.96, SE=.23, p<.001; rES=–.41), and increases in patient physical distress 
(γ110=–4.61, SE=2.31, p=.049; rES=–.21) were independently related to declines in HSE dur-
ing treatment. Medium effect sizes were found for both enduring and contextual effects for 
patients, with magnitude of contextual effect sizes greater than those of the enduring ones 
(Table 25-A2). 
Investigation of this MHLM revealed a number of interesting cross-partner effects. Greater 
mean caregiver psychological distress was significantly associated with poorer patient HSE 
(γ15=–5.09, SE=2.08, p=.020), an effect that was medium in size (rES=–.39). A trend towards 
worse patient HSE with greater mean caregiver burden (γ12=–.51, SE=.26, p=.056; rES=–.33) 
also was evident. In addition, changes in caregiver nocturnal disturbance (γ100=–.56, SE=.32, 
p=.083; rES=–.20), caregiver sleep hygiene behaviours (γ140=–.39, SE=.18, p=.035; rES=–
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.24), and caregiver burden (γ260=–.37, SE=.20, p=.067; rES=–.21) were negatively linked to 
changes in patient habitual sleep efficiency over the study duration (Figure 7-21). 
 
 
Figure 7-21. Statistically significant (p<.05) enduring (mean) and contextual (change) own and cross-
partner effects of the sleep-impairing factors examined on patients’ and caregivers’ habitual sleep 
efficiency (HSE). Faint arrows indicate associations where trends towards significance emerged 
(.10>p≥.05). All models were controlled for the effects of SLPAST, RELATDUR, CMRBDT, and PS 
for patients; and SLPAST, SLCA, RELATUR, EDUCCG, and ALCHLCG for caregivers. Where no 
arrows are shown, no statistically significant associations (or trends towards significance) emerged. 
Numbers next to arrows denote the MHLM parameter estimates (coefficients) for each predictor vari-
able; negative values indicate an inverse relationship between predictor and outcome variable (see 
Table 25-A2). 
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Wakefulness After Sleep Onset (WASO) 
A wealth of enduring own effects emerged (Table 26-A2). More frequent use of maladap-
tive coping strategies was related to greater WASO for patients (γ18=6.05, SE=2.75, p=.034; 
rES=.34). More severe caregiving burden was positively related to prolonged time in wake-
fulness for caregivers (γ23=3.12, SE=1.46, p=.038; rES=.33). For both patients and caregivers, 
poorer own sleep hygiene behaviours, and more nocturnal disturbance were independently 
associated with poorer own outcomes. Whereas enduring effects of own nocturnal disturb-
ances were comparable in size (rES=.34 v. .35), enduring effects of own sleep hygiene on 
WASO were significantly greater for caregivers than for patients (χ2=5.66, df=1; p=.033). 
Not only enduring, but also contextual effects of own sleep hygiene practices were recorded. 
Increases in the use of disruptive sleep practices was associated with prolongation in WASO 
for both patients (γ90=3.47, SE=1.48, p=.021; rES=.24) and caregivers (γ100=1.94, SE=.63, 
p=.003; rES=.31), although the size of these effects was again greater in magnitude for carers 
than for patients (rES=.31 v. .24). Similarly, as patients experienced more nocturnal disturb-
ance during treatment, they spent more time awake during the night, and vice versa 
(γ70=6.36, SE=1.70, p<.001; rES=.38) (Figure 7-22). These results suggest that accumulation 
of disruption caused by triggers acting at the early (sleep hygiene) and later phases (noctur-
nal disturbance) of sleep particularly increased the risk of both dyad members for a sleepless 
night during the patient’s treatment. 
Only a few, yet particularly interesting, mean and time-varying cross-partner effects that 
flowed from caregivers to patients also emerged. After controlling for own effects, caregiver 
mean psychological distress was significantly, but negatively, associated with increased pa-
tient WASO (γ15=–30.76, SE=13.48, p=.029; rES=–.37), thus indicating that women, whose 
caregivers were, on average, less emotionally affected, spent more time awake at night dur-
ing the treatment period. Increases in caregiver nocturnal disturbance throughout the study 
period were significantly associated with increases in patient WASO (γ100=4.98, SE=1.83, 
p=.008; rES=.30), after controlling for own effects. Seen in conjunction with own effects, 
patients spent more time in wakefulness, not only as a result of their own nocturnal disturb-
ance, but also as a result of their caregivers’. Yet, own effects (rES=.41) had a greater impact 
on patient WASO than the cross-partner ones (rES=.30). In addition, a contextual cross-
partner effect from caregiver sleep hygiene practices to patient WASO was also apparent 
(γ140=3.39, SE=1.00, p=.001; rES=.36). In this case, however, multivariate hypothesis testing 
indicated that the emerging significant difference was in favour of the cross-partner effects; 
that is, after controlling for own effects, patients were impacted more by the caregivers’ dis-
ruptive sleep hygiene behaviours than by their own (χ2=6.88, df=1; p=.017). 
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Figure 7-22. Statistically significant (p<.05) enduring (mean) and contextual (change) own and cross-
partner effects of the sleep-impairing factors examined on patients’ and caregivers’ wakefulness after 
sleep onset (WASO). Faint arrows indicate associations where trends towards significance emerged 
(.10>p≥.05). All models were controlled for the effects of SLPAST, CMRBDT, and PS for patients; 
and SLPAST, SLCA, and EDUC for caregivers. Where no arrows are shown, no statistically signifi-
cant associations (or trends towards significance) emerged. Numbers next to arrows denote the 
MHLM parameter estimates (coefficients) for each predictor variable; negative values indicate an 
inverse relationship between predictor and outcome variable (see Table 26-A2). 
 
 
Overall Sleep/Wake Impairment (GSQI) 
A few enduring effects were contemplated by significant contextual effects in this MHLM 
(Table 27-A2). Mean caregiving burden was positively and significantly associated with 
own sleep/wake impairment for caregivers (γ24=.18, SE=.08, p=.04; rES=.30), and mean 
physical distress was linked to greater own sleep impairment for patients (γ14=3.17, SE=1.43, 
p=.032; rES=.34). Deterioration in patient physical distress (γ90=2.80, SE=.67, p<.001; 
rES=.42) and in caregiving burden (γ140=.12, SE=.05, p=.026; rES=.30) was also related to 
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worsening in overall sleep/wake patterns for both dyad members (Figure 7-23). Moreover, 
confirming previous findings, changes in own sleep hygiene practices were also positively 
related to changes in sleep/wake patterns for both patients (γ70=.32, SE=.08, p<.001; rES=.41) 
and caregivers (γ80=.09, SE=.03, p=.002; rES=.28). Effect sizes were significantly larger for 
patients than for caregivers (χ2=16.12, df=1; p<.001), thus suggesting that during the chemo-
therapy period patients’ sleep/wake patterns were more susceptible to deterioration due to 
own disruptive sleep behaviours than those of caregivers. 
 
 
 
Figure 7-23. Statistically significant (p<.05) enduring (mean) and contextual (change) own and cross-
partner effects of the sleep-impairing factors examined on patients’ and caregivers’ overall sleep/wake 
impairment (GSQI). Faint arrows indicate associations where trends towards significance emerged 
(.10>p≥.05). All models were controlled for the effects of SLPAST, SLCA, AGE, RELATDUR, 
CMRBDT, and PS for patients; and SLPAST, SLCA, AGE, RELATDUR, and EDUC for caregivers. 
Where no arrows are shown, no statistically significant associations (or trends towards significance) 
emerged. Numbers next to arrows denote the MHLM parameter estimates (coefficients) for each pre-
dictor variable; negative values indicate an inverse relationship between predictor and outcome varia-
ble (see Table 27-A2). The SDSTRB predictor variable was removed from this model as data used to 
create it were also used to create the DDISTf outcome variable. 
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Finally, investigation of this MHLM revealed the potential for only one contextual cross-
partner effect: changes in use of negative coping on the caregivers’ part were significantly 
and positively related to changes in patients’ overall sleep/wake impairment (γ200=.18, 
SE=.09, p=.042; rES=.22) (Figure 7-23). Interestingly, changes in patients’ sleep were more 
likely to be predicted by caregivers’ change in negative coping rather than their own fluctua-
tion. Conversely, patients’ negative coping remained unrelated to either own or partner sleep 
impairment as no cross-partner effect emerged. 
 
187 
 
 
 
CHAPTER 8. 
Discussion and Future Implications 
 
 
8.1. Overall Appraisal of Findings 
The present study implemented a longitudinal, dyadic approach to explore sleep/wake pat-
terns of patient-caregiver care dyads in the context of adjuvant chemotherapy for early stage 
breast cancer. In order to operationalize the generic term of ‘sleep/wake patterns’, this study 
specifically focussed on a number of distinct sleep/wake parameters as these have been iden-
tified in the literature [49]. Eight sleep/wake parameters (perceived sleep quality, habitual 
sleep efficiency, sleep latency, total sleep time, wakefulness after sleep onset, daily disturb-
ance, daytime napping duration, and overall sleep/wake impairment) served as outcome var-
iables throughout all analyses. By collecting and examining additional data on dyads’ noc-
turnal and early morning awakenings, restless legs episodes, feelings of restfulness upon 
morning awakening, daytime sleepiness, and need for daytime napping it is believed that a 
comprehensive sleep assessment has taken place. 
Two main research questions were addressed in the current study. The first research question 
examined trajectories of change in patients’ and caregivers’ sleep parameters, as well as rela-
tionships, similarities and interdependence in these parameters across the care dyads. Three 
hypotheses were posed and investigated. As discussed in the following paragraphs, results 
provided partial confirmation to these hypotheses in that whereas overall trajectories of 
change for patient sleep/wake patterns followed a significant curvilinear pattern (a linear 
pattern in the case of daytime disturbance), carers’ perceptions of their own sleep did not 
follow this same pattern, or this was clinically important for some parameters only, such as 
daytime napping duration, or overall sleep/wake impairment (Hypothesis 1). However, at 
pre-treatment, wake variables, total sleep time, and overall sleep/wake impairment were not 
significantly different between members of dyads; after CThC4, there was a similar pattern 
for total sleep time and sleep latency, possibly suggesting that then both patients and carers 
had diminished sleep duration and had similar difficulty to fall asleep (Hypothesis 3). In 
terms of interdependence, analyses showed that changes in perceived sleep quality, sleep 
latency and overall sleep/wake impairment in the women were followed closely by similar in 
direction changes in their caregivers. Daytime wake variables remained uncoupled. Quite 
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interestingly, an inverse relationship was found for sleep efficiency, total sleep time and 
wakefulness after sleep onset: increases in patients were followed by decreases in caregivers, 
and vice versa (Hypothesis 2). 
As with previous research [119, 518], women represented a highly sleep-deprived group of 
individuals even before initiation of chemotherapy treatment: over half of the sample were 
classified as with altered sleep at baseline. With at least 60% of women possibly reporting 
waking up in the middle of the night or early in the morning [7], this finding confirms previ-
ous research. Hence, any further disruption in sleep architecture seems to only lead to the 
accumulation of already existing sleep problems. In fact, at post-treatment, 65% of the 
women still complained of poor sleep based on PSQI cut-off scores. Possibly adding to this 
finding, daily disturbance in this patient group showed a linear trend of positive change 
(worsening) throughout the duration of chemotherapy treatment [518], remaining high in 
prevalence even at post-treatment. Previous research has also revealed that the initial period 
(first 2 days to 2 weeks) after intravenous chemotherapy for breast cancer may be character-
ised by sleep fragmentation that disrupts the maintenance of habitual sleep/wake patterns [7, 
126-128]. At mid-treatment (CThC3 and CThC4), the cumulative discomfort reaches a peak 
[128, 518] and the impact on a woman’s sleep is exacerbated. Indeed, current results re-
vealed statistically significant curvilinear patterns of change for most of the patient 
sleep/wake parameters throughout chemotherapy. Although objective sleep data might not 
corroborate these findings [120, 518], perceived sleep quality, sleep latency, habitual sleep 
efficiency, WASO, daytime napping duration, and overall sleep/wake impairment showed a 
pattern of increase/worsening from pre-treatment to post-CThC1; reached a peak after ad-
ministration of CThC4; and returned to (or close to) pre-treatment levels 30 days after the 
end of chemotherapy. Effect sizes were generally modest to large (.35 to .48), thus indicat-
ing at least moderate clinical changes on average. Nevertheless, frequency of sleep aid use 
remained low, close to pre- (14-20%) and mid-treatment rates (23-32%) reported in previous 
studies [136, 137]. Whether this result reflects reluctance on the women’s part to receive 
hypnotic treatment, or failure on the clinicians’ part to adequately manage such problems, 
can only be hypothesised. In this patient sample, habitual sleep efficiency was below normal 
limits, and this stands in contrast with previous findings [119]. Habitual sleep efficiency is 
the ratio of total actual sleep time divided by the total time spent in bed [3]; therefore, reduc-
tions in total sleep time can offer a possible explanation for this discrepancy. However, as a 
group, patients manifested no particular pattern of change in their total sleep time. Ko-
tronoulas et al. [119] concluded with a similar absence of a pattern in this context. An alter-
native explanation could be that women increased their time spent in bed. Indeed, during 
chemotherapy, patients reported earlier bedtimes and later wake times. Thus, on average, 
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whereas time asleep remained the same, time awake while lying on the bed increased, and 
this was translated into a decrease in HSE. 
The current study was among the first to longitudinally explore sleep/wake patterns of in-
formal caregivers in relation to patient health transition phases [366, 519], and the first to do 
so in the context of cancer care. A considerable proportion of caregivers were identified with 
sleep problems (35-49%), which is in agreement with past research revealing sleep/wake 
impairment in at least 4 out of 10 carers of patients with cancer irrespective of type or phase 
of disease [182]. In a different cultural context that might have increased caregiving de-
mands, eight out of ten family caregivers of newly diagnosed women with early stage breast 
cancer reported poor sleep quality [30]. Current findings are similar to studies among indi-
viduals providing informal care prior to [520], during [30, 521] and after [522] chemothera-
py: sleep latency and duration, nocturnal disturbance and WASO, daytime dysfunction were 
those areas most greatly affected. Unlike patients, however, caregiver sleep/wake parameters 
did not significantly change during and after chemotherapy, thus suggesting that overall 
caregiver self-reported sleep quality and quantity was not considerably affected as patients 
progressed through chemotherapy. Given the effects of caregiving on sleep documented in 
previous studies [182, 523], this might seem as a striking finding. Another possible way to 
interpret this result would be to acknowledge the fact that in this caregiver group, already 
established sleep problems showed no trend towards improvement, either. For instance, 
caregiver overall sleep/wake impairment, total sleep time, and WASO remained adversely 
affected throughout treatment. In spite of the absence of major significant change, a con-
sistent slight trend towards worsening in caregiver-perceived sleep quality, habitual sleep 
efficiency, WASO, and overall sleep/wake impairment was apparent at mid-treatment (post-
CThC4), possibly suggesting accumulation of the disruptive effects of caregiving at that 
time point. In contrast with nocturnal sleep, a borderline significant upward linear trend in 
daytime napping duration did emerge, which was extended until mid-treatment. Seen in con-
junction with a similar increase in need for daytime napping reports, it can be inferred that 
caregivers’ wake patterns were particularly affected by the demands posed to them during 
chemotherapy. Current results confirmed caregiver reluctance to use sleep medications, as 
documented in previous studies [23, 27, 30, 244, 521-523]. A possible explanation for this 
outcome relates to caregiver concerns about the potential side effects of these medications 
that might interfere with a carer’s ability to timely respond to patient need at night or in the 
daytime [182]. Another explanation could relate to caregivers’ perceived temporality of 
sleep/wake impairment, which might have prevented them from seeking help in the hope 
that once the intense treatment period was over, so would be their sleep problems. 
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From a dyadic point of view, comparability in frequencies of poor self-reported sleep be-
tween patients and caregivers has been suggested [233, 242, 244, 251, 524], but was only 
confirmed for pre-treatment data in this study. Importantly, current results also revealed 
alarming percentages of dyads of at least one poor sleeper that reached 65% even before 
chemotherapy initiation. These further increased as patient treatment progressed. Indeed, at 
mid-treatment, approximately 49% and 39% of this dyad sample consisted of one or two 
poor sleepers, respectively. Baseline findings are somewhat comparable to previous re-
search. Over a one-week period of observation of 60 patients with advanced cancer and their 
family caregivers, Gibbins et al. [244] reported that in 23% of the dyads, both members re-
ported not sleeping well, whilst in an additional 45%, either the patient or the carer com-
plained about poor sleep. Discrepancy in the prevalence rates reported in this and in previous 
studies may well be due to contextual effects of ever changing demands posed during chem-
otherapy continuation; conversely, the Gibbins et al. study offered a snapshot of the experi-
ence of care dyads attending cancer clinics for follow-up purposes [244]. 
The use of longitudinal multilevel modelling techniques in this study allowed for a simulta-
neous account of dyad members’ sleep/wake parameters. Except for total sleep time, the sig-
nificant differences in average curves of all outcome variables were indicative of a generally 
greater impact on patients’ rather than caregivers’ sleep during the chemotherapy period, 
which persisted into the initial post-chemotherapy period. Similar overall results were yield-
ed among 23 dyads of chronically (9.3±6.0 years) ill individuals with Parkinson’s disease 
and their primary caregiver [285]; yet, in a recent bright light trial, only sleep efficiency was 
negatively affected in memory-impaired individuals than in their caregivers [525]. What is 
more, rates of acceleration in the deterioration of perceived sleep quality, habitual sleep effi-
ciency, WASO, daily disturbance, and overall sleep/wake impairment were consistently 
steeper for patients during the administration of chemotherapy cycles as suggested by be-
tween-groups differences in their linear and quadratic trends. These findings were not only 
complemented by a consistent clinical difference in the frequency of sleep aid use, nocturnal 
awakenings, daytime sleepiness, and need for napping in the daytime between the two 
groups, but also by evident differences in the shape of average trajectories: whereas patients’ 
sleep/wake parameters changed in a significant curvilinear fashion during chemotherapy, for 
the most part, caregiver parameters did not follow. Prospective studies in the context of de-
mentia [363] and cancer care [244] have also suggested greater problems with sleep mainte-
nance [363] and daytime functioning [244] for patients than for caregivers. Gibbins et al. 
[244] found that activity levels were consistently higher for caregivers and time immobile in 
the daytime was greater for patients. In the current study, however, physical activity levels 
were, overall, similar between dyad members. Therefore, patient-caregiver differences in 
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napping duration do not seem to be due simply to differences in activity; it is more possible 
that nocturnal sleep loss and physical symptom burden urged women for more prolonged 
napping in the daytime. 
Additional diverse perspectives can be examined to interpret the afore-mentioned between-
groups differences. As women with breast cancer constitute a highly independent patient 
population, over-night caregiving demands might have been kept to a minimum. In contrast, 
caregivers of people with advanced cancer or with different types of cancer may be required 
to actively respond to patients’ needs at night and become more sleep deprived [28, 182, 
277, 520, 526]. In other studies, co-habiting caregivers changed their sleeping arrangements 
so that nocturnal alertness on the patients’ part left them unaffected [368]. Yet, a recent sys-
tematic review of studies conducted with care recipient-caregiver dyads, irrespective of 
health context, concluded with only partial evidence suggesting nocturnal interactions be-
tween the dyad members [366]. Conversely, caregivers in the current study went to sleep at 
night an average of 4-18 minutes later than patients and woke up in the morning an average 
of 39-50 minutes earlier throughout the study period. This finding is consistent with previ-
ous dyadic studies in which, irrespective of context of illness, caregivers had generally later 
bedtimes and earlier awakening times, possibly in an attempt to organise their sleep routines 
around the patient [242, 247, 367]. In the current study, an alternative explanation of this 
trend might be that, due possibly to adverse chemotherapy effects, women simply felt the 
need to rest earlier than usually, and also extended the time they spent lying on the bed, even 
if they were not actually sleeping. 
Despite these differences, at specific time points and for certain variables, dyad members’ 
sleep patterns tended also to converge. At baseline, daily disturbance, daytime napping dura-
tion, total sleep time, and overall sleep/wake impairment were no different between patients 
and caregivers. In preliminary analyses, no differences also emerged for bedtime, restless 
legs, nocturnal and early morning awakenings, feelings of restfulness upon morning awaken-
ing, sleepiness, and need for daytime napping, thus suggesting that to a certain extent dyads 
shared similar degrees of sleep/wake impairment at pre-treatment. With the exception of 
nocturnal awakenings, these results confirm similar evidence reported by Carney et al. [242] 
in a sample of 102 patient-caregiver dyads one week prior to primary or adjuvant radiation 
therapy for diverse non-metastatic cancers. Among the unique findings of this study stands 
the fact that over treatment continuation, rates of change in sleep latency and duration of 
daytime napping were not significantly different between patients and caregivers, with re-
spective increases in the dyad members’ sleep latency (indicating more difficulty in falling 
asleep) and napping duration (indicating the need for more rest in the daytime). Especially 
192 
 
 
with regard to sleep latency, average patient and caregiver trajectories almost coincided at 
mid-treatment, where difficulty to fall asleep became equivalent for both dyad members (pa-
tients, 31 minutes versus caregivers, 29 minutes). However, one of the most clinically im-
portant observations in this study was that deterioration in caregiver sleep/wake variables 
reached its highest as dyads reached mid-treatment, a time point where patient sleep/wake 
impairment also peaked. Even though severity of impairments may not have been compara-
ble, this trend gives credence to the hypothesis that not only patients with breast cancer [9] 
but also caregivers show progressive impairments in their sleep/wake patterns, which can be 
translated in dyad members concurrently manifesting sleep deficits at specific time points. 
In agreement with the concept of patients and caregivers living in a close relationship [366], 
multilevel modelling techniques also supported examination of the notion that a caregiver’s 
sleep can be a function of the patient’s sleep, and vice versa. Even in the presence of non-
cohabiting dyads in this sample (n=6), moderate positive correlations emerged between pa-
tient and caregiver perceived sleep quality, sleep latency, daily disturbance, and overall 
sleep/wake impairment at pre-treatment. Two cross-sectional studies conducted with dyads 
in the context of cancer [242] and Parkinson’s disease [285] reported relationships of a simi-
lar magnitude in the dyad members’ perceived sleep quality. Of note, patterns of change in 
these variables were strongly correlated between dyad members throughout the study, thus 
indicating that deterioration in patient sleep parameters was followed by a similar worsening 
in the respective caregiver variables, and vice versa. Preliminary correlational analysis also 
suggested close synchronisation of patient and caregiver bedtimes and wake times through-
out the study, in agreement with past research [366]. This finding underpins the notion of 
dyadic ‘sleep rituals’ [369], which might be more common in dyads similar to the ones par-
ticipated here: spouses/partners in well-established relationships. In addition, a few moderate 
correlations between patient and caregiver feelings of restfulness upon morning awakening 
and daytime sleepiness at baseline were found, which, however, faded out over treatment 
continuation. Similarly to Carney et al. [242], nocturnal disturbance at pre-treatment re-
mained unrelated in the dyads, although weak correlations did emerge during treatment. 
Moreover, analyses in the models indicated only minimal, or even inverse, relationships be-
tween average patient and caregiver total sleep time, habitual sleep efficiency, and WASO 
curves; this finding stands in contrast with existing evidence suggesting moderate-to-strong 
positive relationships depending on objective recordings [242, 247, 367], but also supports 
similar weak associations based on self-reports [242]. It can certainly be hypothesised that 
these results reflect differing degrees of burden posed to dyad members during chemothera-
py that have ultimately blurred or weakened such relationships. Whether, however, this 
might also be the result of limitations in self-report sleep assessments is an equally valid 
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question, as external influences and variability might have affected accuracy (see below); in 
any case, this remains to be answered in future studies. Finally, it is noteworthy that trajecto-
ries of daytime behaviours (i.e. need for daytime napping and daytime napping duration) of 
members of the dyads remained widely uncoupled throughout this study, as also has been 
shown in the past [242, 278, 285, 367, 368]. The reason for this outcome can possibly be 
because of differences in daytime schedules in this sample of young and employed dyads, 
compared to older adults who may share their daytime activities more closely. 
 
The second research question examined whether changes in patients’ physical burden, care-
givers’ burden, and dyads’ sleep hygiene, nocturnal disturbance, psychological burden, and 
maladaptive coping strategies were associated with own changes in sleep/wake impairment. 
In addition, the potential for more complex interrelations within a dyad’s sleep patterns was 
explored, as suggested by the presence of additional cross-partner effects. Briefly, analyses 
revealed that increased physical burden, greater use of sleep disruptive behaviours and more 
nocturnal sleep disturbances were the variables that most consistently predicted poorer out-
comes in the patients’ own sleep/wake patterns (Hypothesis 4). Similarly, increased caregiv-
ing burden, more nocturnal sleep disturbances, and poorer sleep hygiene were the variables 
that most consistently predicted poorer outcomes in the caregivers’ own sleep/wake patterns 
(Hypothesis 5). Evidence for cross-partner effects most frequently emerged with regard to 
the dyads’ psychological burden, as well as for caregiving burden, although some additional 
links might be suggested for own poor sleep hygiene and worse partner outcomes on day-
time functioning, sleep efficiency, or WASO (Hypothesis 6). 
Inadequate sleep hygiene can be an important predisposing and/or perpetuating factor for 
impaired sleep patterns [65]. In the current study, dyads who exercised more sleep inhibitory 
practices during the chemotherapy period spent more time awake at night, reported less effi-
cient sleep, and experienced more dysfunction in the daytime. According to Lee’s model 
(Figure 1-1) [62], it can be thus postulated that sleep hygiene of dyad members was related 
mainly to sleep deprivation and secondarily to sleep disruption. Using a daily process ap-
proach, Rumble et al. [527] prospectively investigated sleep/wake patterns in 41 survivors of 
early stage breast cancer who complained of insomnia post-completion of primary treatment. 
Sleep inhibitory behaviours in the previous day and night significantly predicted poorer 
sleep quality and less efficient sleep the same night [527], a finding that was partly replicat-
ed in this study. Indeed, whereas no significant associations with perceived sleep quality 
were found for either patients or caregivers, increases in the frequency of sleep impairing 
behaviours did predict decreases in patients’ sleep efficiency. In addition, carers with poorer 
194 
 
 
sleep hygiene at pre-treatment reported significantly less efficient sleep on average. Whether 
similar results for patients’ mean and contextual effects were also present for caregivers 
could not be established in this study due to a lack of significant variability in this sample’s 
reports. An at least moderate (rES=.39) association is nevertheless proposed here, which 
stands in contrast with qualitative findings derived from a cross-sectional study of 90 care-
givers of patients with cancer during active chemotherapy treatment: only a very small part 
of respondents consciously recognised poor sleep hygiene as a contributing factor to their 
overall poor sleep quality [521]. Interestingly, the only cross-partner effects that emerged 
were uni-directional flowing from caregivers to patients; this finding may strike one as odd 
because sleep hygiene practices were not significantly different between dyad members at 
any time point. However, in dyads comprised of caregivers with poor and fluctuating sleep 
hygiene behaviours, patients remained sleepless for longer at night (decreased HSE, in-
creased WASO), and experienced greater disturbance in the daytime. Moreover, cross-
partner effects were at least comparable in size with own effects. What this result suggests is 
that in a highly susceptible to sleep deprivation patient population, not only own poor sleep 
hygiene but also (and possibly equally) that of carers living in close relationship can be held 
responsible and perpetuate problems with sleep maintenance and daytime dysfunction once 
these arise. These findings partly confirm previous hypotheses for the existence of complex 
interrelationships [366] and can potentially be of importance in clinical practice. 
Similarly to sleep hygiene, own nocturnal sleep disturbance in the form of night time awak-
enings, the need to use the bathroom, feeling hot/cold, snoring, nightmares, and other poten-
tial disrupting events, consistently and significantly predicted poorer outcomes in own per-
ceived sleep quality, habitual sleep efficiency, and WASO for both patients and caregivers. 
Dyads who were more affected by sleep disrupting events at night reported poorer sleep 
quality and more problems with sleep maintenance as suggested by more time spent in 
sleeplessness at night. What is more, increases in patients’ own nocturnal sleep disturbance 
also predicted lengthier naps in the daytime, possibly in an attempt to compensate for the 
previous night’s poor sleep. Seen in conjunction, nocturnal sleep disturbances in this dyad 
sample were related to both sleep restriction and fragmentation [62]. These results give sup-
port to past cross-sectional and longitudinal research demonstrating a relationship of sleep to 
hot flashes in patients with breast cancer [148, 172, 528], as well as to findings from studies 
where nocturnal awakenings, toilet use, occurrence of bad dreams, and snoring were self-
reported as reasons for sleep difficulty by patients [7, 529] and caregivers [23, 237, 521]. 
Utilising similar methodology and instrumentation, Sanford et al. [529] longitudinally as-
sessed sleep quality of 80 women before, during (CThC4), and approximately 6 months after 
adjuvant chemotherapy for breast cancer. Although changes in snoring, having to get up to 
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use the bathroom, and feeling too hot were not consistent with over-time changes in the 
sleep/wake parameters investigated [529], patterns of change were similar to the current 
study. Importantly, bidirectional cross-partner effects were found in this study, which, de-
spite their limited number, support the existence of nocturnal interactions between patients 
and caregivers [368]. In agreement with a study conducted among patients with Parkinson’s 
disease and their partners [233], average patient nocturnal sleep disturbance predicted worse 
perceived sleep quality in their caregivers. In a similar population, greater patient sleep dis-
turbance was related to diminished caregiver sleep duration [285]; yet, this finding was not 
replicated in the current study. Albeit smaller in magnitude than the respective own effects, 
significant reverse cross-partner effects were also apparent, especially with regard to sleep 
maintenance. In the Happe et al. study, such effects fell short of significance [233], but this 
discrepancy may be attributed to differences in clinical characteristics and the nature of the 
disease between the two study samples. 
A wealth of evidence exists with regard to the effects of chemotherapy-related physical 
symptoms on sleep/wake patterns of women with breast cancer [134, 145, 146, 530]. Past 
research has confirmed that pain, fatigue, shortness of breath, and gastrointestinal symptoms 
can be adversely related to disruptions in sleep architecture and subsequent sleep deprivation 
[104, 120, 123, 125-127, 129, 143, 147, 148, 165, 172]. In the current study, frequency, se-
verity and associated distress of 14 physical symptoms were taken into consideration in an 
attempt to estimate overall physical symptom burden for patients. As with past research 
[531, 532], preliminary analyses indicated moderate burden that increased from baseline to 
mid-treatment and remained elevated even 30 days post-chemotherapy. Nevertheless, in the 
current study no associations were found between patient physical symptom burden and own 
perceived sleep quality, sleep latency, total sleep time, or WASO; thus, no evidence for 
sleep fragmentation in this dyad sample emerged [62]. This is a hard to explain finding, 
which might possibly be a function of the actual method of physical symptom measurement, 
that is to say, the use of a generic rather than symptom-specific measure. Yet, sleep re-
striction was evident. More severely affected patients were found with poorer sleep efficien-
cy and greater overall sleep/wake impairment, with changes in physical burden being fol-
lowed by modest changes in these sleep variables throughout the study. In addition, patient 
physical burden was consistently, significantly and strongly associated with greater daytime 
dysfunction. Despite their small sample size, Kuo et al. [129] concluded with a similar, yet 
even stronger, relationship. One explanation might be that as chemotherapy progresses and 
patient distress peaks, the link between physical burden and daytime sleepiness/dysfunction 
becomes even more apparent. Indeed, in Kuo et al.’s study, patients were evaluated at mid-
treatment, between CThC 3 and CThC4, which, as previously stated, are key time points 
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where sleep/wake impairment reaches a peak [119, 128]. Conversely, absence of cross-
partner effects was noted in the current study. It can be postulated that, despite a hypothe-
sised association of caregiver sleep/wake impairment to patient physical burden, there seems 
to be no direct link between the two concepts. One alternative explanation could be that 
whatever link might have existed between the two variables was blurred by the inclusion of 
both cohabiting and non-cohabiting dyads. Yet, preliminary analyses showed that no effect 
of cohabitation for the majority of sleep variables arose, whereas multilevel modelling anal-
yses were adjusted to partial out this confounding. Therefore, unless patient symptoms liter-
ally disrupt caregiver sleep (e.g. constant and heavy patient coughing in cohabiting dyads), it 
can be hypothesised that patient physical symptom only mediates the path between caregiv-
ing burden and subsequent caregiver sleep deprivation, or between patient sleep disturbance 
and caregiver sleep quality. Such hypotheses warrant replication in future studies through 
adequate analytic techniques (see below). The only exception to the afore-mentioned find-
ings pertains to a significant relationship between patient physical burden and caregiver per-
ceived sleep quality: in dyads comprised of patients severely affected by chemotherapy-
related symptoms, their caregivers perceived their own quality of sleep as poor. In the con-
text of dementia, McCurry et al. [363] also reported that where patient physical functioning 
was poor and affected the caregiving situation, dyads were more likely to consist of concur-
rently poor sleepers. 
The current study examined another yet unexplored territory by evaluating caregiving bur-
den as a potential predictive factor of poor sleep in the patient-caregiver dyads [366]. With 
existing cross-sectional literature offering only ambiguous evidence [182, 519, 523], the 
emergence of consistent moderate-to-strong associations (rES ranging from .20 to .56) be-
tween subjective caregiving burden and the majority of caregiver sleep/wake parameters is 
an intriguing finding, especially since adjustment for potentially even stronger triggers such 
as psychological burden also took place. Similarly, two prospective studies among caregiv-
ers of memory-impaired individuals concluded with caregiving burden being one of the 
strongest predictors of sleep problems in the long run [274, 519]; however, in these studies 
caregivers’ objective rather than subjective burden was considered, which was assessed at 
baseline only. Through repeatedly evaluating caregiving burden, the current study goes a 
step further by proposing that fluctuations in caregiving burden can be consistently related to 
analogous fluctuations in caregiver sleep initiation and maintenance, as well as daytime 
functioning, thus reinforcing the links between caregiving burden and sleep disruption (pri-
marily) and deprivation (secondarily) [62]. Somewhat differently, significant cross-partner 
effects were limited to associations with patient perceived sleep quality, total sleep time, and 
daytime napping duration. Additional cross-partner effects only marginally fell short of sig-
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nificance possibly due to sample size limitations. Overall, in dyads where caregivers were 
more burdened with deficits in their own health and disruption in their schedule, patients 
suffered additional negative impact from fluctuations in the caregivers’ burden, and reported 
greater sleep/wake impairment. As with patient physical burden, the exploratory nature of 
this study dictates that these results are viewed with caution. Nevertheless, these analyses 
suggest that examining the effects of caregiving burden – mainly those contextual ones – 
offers increased understanding of its impact on dyads’ sleep/wake patterns during the intense 
period of chemotherapy treatment, and therefore have important clinical implications. 
Psychological/emotional distress has long been recognised as a contributing factor for 
sleep/wake impairment in people with cancer [1, 3, 533], their informal caregivers [182, 
520, 524, 534], and patient-caregiver dyads [366]. Existing evidence suggests that anxiety 
and depressed mood are the strongest predictors of alterations in self-reported sleep/wake 
patterns of women receiving adjuvant treatment for breast cancer, with effect sizes ranging 
from .28 to .44 [7, 121, 123, 131, 136, 143, 144, 165], and from .36 to .52 [7, 8, 120, 121, 
123, 125, 131, 136, 143-147, 165, 166], respectively. On the other hand, caregiver psycho-
logical burden – especially depressive mood – has been associated with poor sleep quality, 
decreased total sleep time and sleep efficiency, and increased daytime dysfunction irrespec-
tive of health care context [27, 28, 232, 237, 265, 266, 270, 274, 276, 285, 519, 521]. Hence, 
in the current study, the almost absolute absence of significant own effects of psychological 
burden on the dyad members’ nocturnal sleep patterns stands as a striking finding, which 
renders relevant effects on sleep deprivation and/or disruption unclear [62]. A possible ex-
planation, yet not the only one (see below), could be that, overall, dyads’ psychological bur-
den levels were only low-to-moderate, also following a downward trend from baseline to 
end of treatment, which, when coupled with low variability in responses, might have pre-
cluded the emergence of statistical significance in this small sample. Among the very few 
notable own effects, fluctuations in patients’ mood throughout treatment did predict similar 
changes in their perceived sleep quality, whereas a trend for poorer habitual sleep efficiency 
in caregivers reporting more psychological burden was also recorded; both of these findings 
are in agreement with existing literature [8, 27, 120, 144, 166, 237]. Similarly, only a few 
inconsistent cross-partner effects relating to perceived sleep quality, habitual sleep efficien-
cy, and WASO also emerged, which, however, warrant additional future research. Converse-
ly, more consistent associations of psychological burden with daytime functioning were 
found for both dyad members, thus suggesting that, prior to and during chemotherapy treat-
ment, psychologically burdened dyad members were more likely to report spending more 
time napping and greater dysfunction in the daytime. These results were complemented by a 
few additional bidirectional cross-partner effects, showing that, as psychological burden 
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peaked, dyad members’ wake patterns were increasingly and mutually affected. Although a 
link between depressive mood and increased daytime dysfunction has been proposed in the 
literature [535], it has only been minimally investigated in previous dyadic studies with evi-
dence being unclear [285, 366]; this fact renders the particular finding unique and calls for 
replication in future research. 
Coping strategies are described as a person’s cognitive or behavioural efforts to manage the 
demands of a situation that is appraised as stressful, such as breast cancer or treatment [536], 
and changes in response to these stressors have been proposed [537]. In that sense, maladap-
tive coping strategies can interfere with effective stress management and affect an individu-
al’s sleep. Whether maladaptive coping processes were associated with alterations in 
sleep/wake trajectories of patient-caregiver dyads was another novel concept that the current 
study aimed to investigate [366]. Existing literature is limited to a few cross-sectional stud-
ies of individual samples of women with breast cancer during primary treatment [110, 133, 
538] or informal caregivers [238], which, nevertheless, have reported on preliminary find-
ings suggestive of a link between increased use of negative coping strategies and poorer 
sleep/wake outcomes in either population group. In that sense, the fact that in the current 
study, more dysfunctional coping on the patients’ part was associated with greater own 
sleep/wake impairment, further supports past sleep research [110, 133, 538], and also con-
firms that avoidance coping is predictive of poor psychological adjustment in patients with 
chronic illness [539]. The findings of this study however were unsupportive of a similar ex-
isting link in informal caregivers. In fact, the only significant association related to increases 
in use of maladaptive coping strategies predicting the perception of better, rather than worse, 
sleep quality. Maladaptive coping strategies might yield a protective effect, but only in the 
short term [540, 541]. Whether avoidance/denial, substance use, venting or behavioural dis-
engagement practices were seen by caregivers as an alternative means to let some steam off 
and be distracted from worries during a highly demanding period that subsequently led to 
better sleep at night, can only be hypothesised for now and possibly explored in future re-
search employing both quantitative and qualitative methodologies. Seen under the prism of 
Lee’s model [62], maladaptive coping strategies in this dyad sample were linked to sleep 
fragmentation – but not restriction – for patients, whereas no such links became apparent for 
caregivers. What is more, despite the fact that cross-partner effects were kept to a minimum, 
the potential for interactions pertinent to sleep between dyad members due to maladaptive 
coping does exist. Interestingly, whereas own coping was practically unrelated to own 
sleep/wake trajectories, not only caregivers’ sleep quality and daytime napping was affected 
by the patients’ own ways of coping, but also, increased use of own negative coping ad-
versely impacted on patients’ sleep. Although the effects of dyadic coping on psychological 
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well-being have been discussed [542], no similar evidence exists in the relevant literature 
[366], thus urging for additional dedicated sleep research; the implications for clinicians are 
nonetheless very important. 
The present study acknowledged the potential effects of various patient, caregiver and dyad 
demographic and clinical covariates on sleep, and appropriately controlled for these in ex-
planatory models. Explicit investigation of each covariate goes beyond the purposes of this 
study. However, it can be noted that past history of sleep problems, presence of comorbid 
illnesses, poor performance status, and short relationship duration were the covariates most 
consistently related with sleep/wake impairment in the dyad members during chemotherapy. 
The current study is one of the few sleep studies in the context of cancer care [136, 244] 
where past sleep history was formally assessed as well as examined as a potential covariate 
in adjusted models. Six out of ten patients and four out of ten caregivers reported troubled 
sleep in the past; to a similar extent, participants also linked sleep problems to the diagnosis 
of breast cancer. Earlier, Gibbins et al. [244] reported comparable prevalence rates in pa-
tients (42%) with incurable advanced cancer and their family caregivers (38%). What is 
more, the presence of comorbid illnesses and lower physical functioning were also related to 
the dyads’ sleep, thus confirming existing positive findings [144, 248, 521] and hypotheses 
[366]. Novel in this area, results on the effects of relationship duration and, less consistently, 
the effects of the type of dyadic relationship on the dyads’ nocturnal sleep patterns, are par-
ticularly intriguing. Several efforts have been made to establish a link between reported or 
observed sleep/wake disturbances and relationship functioning or quality [350-352] and at-
tachment behaviours [353-355] in healthy couples. Although evidence is mainly based on 
either cross-sectional dyadic studies [352, 353] or single-arm studies [350, 351, 354, 355], a 
positive unidirectional association has been reported. What can be proposed here is that, 
aside from the dyad’s quality of relationship, the length and stability of the relationship itself 
can (both independently and in conjunction) exert protective effects on the dyad’s 
sleep/wake patterns, even during intense/challenging periods such as the one of chemothera-
py treatment. Patient-caregiver cohabitation and room sharing has received some attention in 
the context of dementia care [278, 363, 367, 368], but as yet findings are discrepant; thus, 
clarification in future studies is still pending. If such a relationship does exist, it seems to be 
more related to patients’, rather than to caregivers’, sleep/wake patterns [367]; this might 
suggest that sleep/wake impairment in informal caregivers possibly goes beyond the mere 
distinction that sleeping arrangements pose. Alternatively, whether cohabitation/room shar-
ing actually plays a role in patients’ sleep patterns might also be a matter of gender. In a 
sample of heterosexual couples without sleep disorders, Pankhurst and Horne [346] ob-
served more movements in men than in women, with women reporting that their sleep was 
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affected by their partners’ sleep more than did men. Men are also more often loud snorers 
[347], and the sound of snoring can be a major disturbing factor of the sleep of their 
bed/room-partner, who might report symptoms of insomnia, morning headache, daytime 
sleepiness and fatigue [348]. In any case, no associations between the dyad members’ own 
sleep/wake patterns and caregiver gender, employment status, time since diagnosis/surgery, 
type of surgery, patient menopausal status, and physical activity were found, which are con-
sistent with past ambiguous evidence for patients with breast cancer [7, 121, 123, 125-127, 
131, 136, 137, 143, 144, 146-148] and informal caregivers [23, 27, 30, 234, 235, 237, 240, 
246-252, 284, 521]. 
 
 
8.2. Study Strengths and Limitations 
This study has a number of strengths. First, the current study employed a dyadic methodolo-
gy, thus introducing a unique and novel way to examine sleep/wake disturbances in the con-
text of cancer care, and advancing existing research in the field [242, 244]. Previous sleep 
research in cancer care has been characterised as predominantly individualistic [209, 366], 
an approach rather secluded and unable to reveal sleep-related processes and sources/triggers 
of sleep problems in patients and their carers who, due to cancer-related circumstances – but 
not exclusively because of them – live in a close relationship and are co-affected within and 
because of it. Conversely, the dyadic methodology utilised here acknowledges the potential 
for interrelations in the sleep of cancer care dyads, and allows for a simultaneous investiga-
tion of sleep/wake parameters of individuals, however, seen within the context of their 
unique relationship. Second, this sleep study employed a longitudinal, repeated measures 
design, along with the assessment of concurrent changes in sleep-impairing factors; this de-
sign has long been recommended in relevant literature as a highly sought-after way of pro-
spectively exploring trajectories of sleep/wake parameters and establishing (direction of) 
relationships between sleep and sleep-impairing factors [3, 10, 49]. In conjunction with the 
aforementioned methodological approach, this study provides unique findings, whose appli-
cation in clinical practice goes beyond individuals. As Rumble et al. [527] argue, such 
knowledge can be instrumental to the development of future sleep interventions for patients 
with breast cancer and their caregivers. Third, the selection of assessment points in the cur-
rent study was informed by previous longitudinal research in women receiving neo-/adjuvant 
chemotherapy for breast cancer [119], therefore is in line with and further extends relevant 
literature. Yet, this study makes a significant addition in regard to our knowledge of 
201 
 
 
sleep/wake patterns/disturbances of caregivers of patients with cancer. Indeed, the need for 
systematic longitudinal research so that the previously documented disruption in caregivers’ 
sleep/wake patterns is more consistently and thoroughly explored has been highlighted in 
previous key papers [3, 10, 534]. Knowledge derived from this study can usefully inform 
sleep interventions in cancer caregiver populations (see below). Fourth, careful and system-
atic procedures for the selection of sleep and behavioural measures were pursued in an at-
tempt to increase methodological rigour, while at the same time preserving comparability 
with existing literature. In addition, measures used in this study adopted similar time frames 
in order to avoid the attenuation of relationships between sleep and predictor variables. Last, 
the current study utilised sophisticated multilevel modelling techniques to analyse data 
[376], an approach that, to the best of the researcher’s knowledge, has only recently been 
employed in past sleep research with patients with breast cancer [146, 518, 527], but never 
used in previous sleep studies with informal caregivers or care dyads in the context of cancer 
care. 
This study also has several limitations. From a statistical standpoint, a definite disadvantage 
of the current study is its small sample size, which may have reduced statistical power, com-
promised inferences, and affected generalisability to similar populations. With a sample size 
of 48 dyads, a post-hoc power analysis revealed a power ranging from < 50% (WASO) to 
80% (GSQI scores) to detect small-to-medium effect sizes of non-independence (tau correla-
tion coefficients ranging from .12 to .42) in patient and caregiver pre-treatment sleep/wake 
parameters [293]. Similarly, power to detect a significant difference between overall 
sleep/wake impairment of patients and caregivers ranged from 50% to > 80% (effect sizes 
ranging from d = .42 to 1.15) [293]. Therefore, caution is necessary when interpreting results 
of this exploratory study. This is especially true for findings pertinent to potential predictors 
of sleep/wake impairment in the dyads. Since a priori, no formal sample size estimation 
analysis was undertaken, it is sensible to hypothesise that power to detect significant rela-
tionships may have been low. Hence, current findings can only be viewed as preliminary and 
requiring replication in future studies. Of note, multiple statistical analyses with this small 
sample have elevated the statistical error Type I rate for the study overall. An effective way 
to deal with this problem is to reduce the level where statistical significance is assumed 
[513]. As this was an exploratory study, it was decided to keep α at the .05 level to include 
as many emergent relationships as possible. However, by testing effects within the MHLMs, 
the number of p values that were computed per dependent variable was kept to a minimum; 
to a certain extent, this method outbalanced the potential for type I errors. What is more, 
moderate attrition rates in this study created an unbalanced dataset. Attrition-related missing 
data were effectively managed during multilevel modelling analyses under the assumption of 
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MAR [508]. As it was shown, there was reliable evidence that the MAR assumption held 
and systematic bias did not interfere with the current study; nevertheless, Schafer and Gra-
ham [543] argue that, in general, there is no way to prospectively test whether MAR holds in 
a dataset, and that in most cases departures from MAR should be expected [543]. In any 
case, the fact that current findings converge with those of previous studies using self-report 
measures suggests that they are not spurious. 
The decision to rely on subjective sleep measures for the collection of sleep data in the cur-
rent study warrants commenting. As previously discussed, current recommendations for 
measuring sleep-wake patterns in people affected by cancer are to consider combining self-
reported and objectively recorded sleep data [49]. In line with these guidelines, initial plan-
ning of this study did include the use of wrist actigraphs to complement data gathered 
through sleep questionnaires. To accommodate simultaneous use with twenty dyads partici-
pating at any time during the study, forty actigraphs were estimated as a necessary require-
ment for the purposes of this project. However, an unforeseen cut-back in the study’s fund-
ing rendered purchase of these devices practically impossible, whereas restrictions in the 
PhD timeline prevented further funding from being sought. In view of these events, a deci-
sion was made to proceed with inclusion of self-report sleep measures only. Although a val-
id and reliable sleep measure was used, absence of objective evaluation to corroborate self-
reports in itself constitutes a limitation of this study. In addition, due to their retrospective 
nature, self-reported sleep measures are subject to introducing recall bias [366], which, when 
combined with arguments posing that “patients are notoriously bad at estimating the dura-
tion of sleep and wakefulness, particularly when they have a problem with sleep” (p. 868) 
[244], may have affected measurement accuracy in the current study. An example could well 
be an inability to test trajectories in the dyads’ changes in total sleep time: despite wide vari-
ation between individuals being present (Figure 7-11), within-individuals variability was 
limited, which may suggest that participants were not able to retrospectively report changes 
in their sleep duration on PSQI during the study, even if these actually took place. In an at-
tempt to deal with the potential of recall bias, the time frame for recall in all sleep-related 
measures was reduced to the previous 15 days, which, it is believed that to a certain extent, 
reduced the magnitude of measurement inaccuracies. It can certainly be argued that relying 
on sleep diaries instead of sleep questionnaires could have diminished the magnitude of the 
aforementioned issues. Although there is some truth in this statement [544], as it will be ar-
gued further below, use of diaries/logs in sleep research is not always feasible or even advis-
able for several reasons; for instance, in the current study, prolonged use of sleep diaries 
could have possibly led to participants becoming overburdened and potentially increased 
attrition. 
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The absence of consistent associations between physical burden and sleep/wake patterns, as 
well as between psychological burden and sleep in this sample, was a somewhat unexpected 
finding, and inadequate statistical power in this study may have been a contributing factor 
that is readily acknowledgeable. Measurement issues, however, may have also played a role. 
Increased physical burden in women receiving chemotherapy for breast cancer may be the 
result of several individual physical symptoms such as pain, fatigue, nausea, and breathless-
ness among the most frequently cited in the relevant literature [90, 531, 545]. Critically, 
such symptoms may be experienced simultaneously [545-547]. Therefore, it was decided 
that for the purposes of this study, a cumulative index of physical burden (i.e. MSAS-PHYS) 
would offer a more comprehensive measure of a range of potentially concurrently manifest-
ed physical symptoms with sleep-disruptive properties. Unavoidably, this decision led to the 
inclusion of symptoms of differing individual magnitudes of prevalence/frequency, severity, 
distress and relationship to sleep, which might have blurred overall correlation to sleep/wake 
patterns. Presumably, relying on symptom-specific measures of selected physical symptoms 
(e.g. use of the Brief Pain Inventory [548] to test the relationship of pain severity to sleep 
latency) could have allowed for more consistent and/or larger in magnitude associations to 
be obtained. For reasons already explained (see Chapter 5), measurement of the dyads’ psy-
chological burden was conducted via the use of a global cumulative, yet non-specific, index 
(i.e. MSAS-PSYCH) to avoid increase in the participants’ reporting burden. It can certainly 
be argued that psychological burden was not optimally measured in this study and that inclu-
sion of anxiety- (e.g. State-Trait Anxiety Inventory [430]) and/or depression-dedicated (e.g. 
CES-Depression [431]) self-reported measures might have resulted in less unwanted varia-
bility/noise, greater specificity, and perhaps more and stronger associations with sleep/wake 
patterns. 
Despite current limited evidence [265], it has been hypothesised that as patient needs in-
crease, primary informal caregivers are expected to undertake several activities and provide 
intensive care, which allows only for minimal periods for rest and sleep [182]. Whereas in 
the current study caregiving burden was measured as disruption in schedule and impact on 
personal health status, this may have been more about how carers perceived their being af-
fected by living closely with a woman receiving chemotherapy treatment. No specific as-
sessment of objective burden was undertaken with regard to whether carers were actually 
involved in patients’ care, for how long, and what the number and nature of caring activities 
might have been. In addition, as the current sample involved highly independent women 
with breast cancer, there is the possibility that caring activities might have been infrequent; 
nevertheless, subjective caregiving burden was far from negligible in this study. 
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Although assessments of type and duration of relationship were employed, dyads’ relation-
ship quality, either compromised or empowered during treatment for breast cancer [218, 
549], was not measured in the current study. As a fundamental attachment behaviour [338], 
sleep may be regulated within and affected by close human relationships in the sense that the 
closer/better the relationship, the greater the odds of a good night’s sleep, and vice versa 
[209, 338, 366]. It has been argued that caregivers who, regardless of their actual caregiving 
tasks, value their role as important to them and the patient they care for, might be more af-
fectionate towards the patient, thus leading to patients feeling more secure in their relation-
ship and sleeping better [209, 366]. Fluctuations in relationship quality may be predictive of 
changes in the sleep quality and quantity, as well as daytime dysfunction of patient-caregiver 
dyads and future longitudinal research is warranted. 
Sleeping arrangements in the form of dyads sharing the same house/bedroom were assessed 
only at pre-treatment. With dyads exhibiting dissimilar changes in their sleep trajectories and 
sleep impairment of differing magnitude during and after treatment, the possibility cannot be 
ruled out that, once patient symptom severity increased and nocturnal disturbances manifest-
ed themselves, some of the dyads changed their sleeping arrangements as well. This may 
have led to patients and caregivers spending more (e.g. if children caring for mothers had to 
move into the patient’s home) or less time together at night (e.g. if caregivers stopped shar-
ing the same bedroom with the patient). Consequently, the extent to which such practices 
may have influenced inferences relating to comparisons between patient and caregiver 
changes in sleep patterns, as well as to the effects of sleeping arrangements themselves re-
mains unknown. Along these lines, dysfunctional thoughts about sleep may constitute anoth-
er potentially important predictive factor for disturbance [527]; hence, the fact that no such 
evaluation in this study was undertaken must be regarded as an additional limitation. 
Demographic/clinical homogeneity of the sample population studied may limit the generali-
sability of the current findings in relation to a number of domains. The patient sample in this 
study consisted of female individuals only. Although breast cancer incidence in men is ex-
tremely low (1% of all breast cancer cases), treatment is similar to that for women [550]. 
Whether sleep/wake patterns in this very small population during chemotherapy treatment 
bare any resemblance to those of women reported here and elsewhere [119] is unknown. The 
same is true for this caregiver sample, which, in its majority (90%), consisted of male care-
givers. Past research has mainly focused on examining sleep patterns of predominantly fe-
male caregiver populations [182]; therefore, discrepancies are to be expected. Indeed, it has 
been argued that with caregiver samples included in previous studies involving women over 
a mean age of 55, reports of sleep disturbance incidence may be associated with menopausal 
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symptoms, hyperarousability or past sleep problems, rather than just the caregiving experi-
ence itself or patient sleep patterns [250]. Perhaps the inclusion of predominantly or exclu-
sively male caregivers can result in different associations [209]. In addition, given that all 
participants in the current study were white Caucasian, and almost all Scottish, findings may 
not apply to patient-caregiver dyads of different racial/ethnic background. What is more, 
with the majority of dyads consisting of spouses/long-term partners, current findings seem 
applicable to such dyad populations only. Along these lines, generalisability to other cancer 
populations and/or other cancer treatments should be considered similarly low. 
Data collection in the current study spanned over a 16-week period, where patients and their 
caregivers provided information at four clinically important time points throughout chemo-
therapy treatment. Whereas this prospective design facilitated the investigation of outcomes 
on different occasions, it still constitutes only a snapshot of the whole experience of patient-
caregiver dyads dealing with a diagnosis of early stage breast cancer. It should be thus 
acknowledged that since no assessments took place at the period following diagnosis and 
before and after primary surgery, it still remains unknown how such processes may have 
impacted on the dyads’ sleep/wake processes and adjustment mechanisms before they en-
tered this study. In the past, anxiety and intrusive thoughts about surgery were linked to di-
minished sleep duration the night prior to primary breast surgery [551]. Also, patients with 
higher preoperative levels of sleep disturbance have been identified as being at increased 
risk for persistent breast pain following breast cancer surgery [552], and which can further 
interfere with own sleep architecture, and increase caregiving demands. The same is true for 
the period after chemotherapy, given the absence of long-term assessment as patients and 
dyads may go through radiation or hormone therapy, or into survivorship, in more general 
terms. Berger et al. [122, 131] investigated the effects of a behavioural therapy intervention 
with a similar sample of patients with breast cancer up to one year after administration of the 
first CThC. Global sleep quality considerably improved in both the intervention and control 
groups; baseline higher fatigue, higher anxiety and better educational background were still 
associated with poorer sleep at one year [131]. 
Of note, whereas patients and carers were asked to complete study questionnaires inde-
pendently from each other, it is unclear whether this actually happened in all of the cases. 
Therefore, the possibility cannot be ruled out that some dyads discussed their responses, and 
this might have affected the way they responded in subsequent assessment points. In addi-
tion, carers were not excluded from the study if they were providing additional care to other 
family members. It can be hypothesised that in those carers who were parents of young chil-
dren, sleep impairments might have been magnified by their increased parenting responsibil-
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ities as well. Moreover, in the current study, no standardised diagnostic interviews to deter-
mine if patients met eligibility criteria in terms of sleep and psychiatric disorders were em-
ployed [553, 554]. Local collaborators – all of them clinicians with over 15 years of clini-
cal/research experience – were instructed to exclude patients with a prior history of such 
medical issues, based on careful examination of medical case notes and confirmation by the 
patient herself; however, the potential that women manifesting such symptoms but never 
being formally diagnosed cannot be confidently ruled out. In addition, exclusion of informal 
caregivers for the same reasons was based on self-reports only, therefore reliability of this 
caregiver sample’s characterisation can be questioned. 
Finally, the use of demographic/clinical data from patients who were approached but refused 
to take part in the study warrants comment. Although only limited non-identifiable data were 
collected under the clinical collaborators’ supervision (i.e. age, but not date of birth; breast 
cancer stage; type of surgery), regarded as confidential and stored anonymously and securely 
based on the principles stated in Chapter 6, no formal ethics approval was sought, which in 
itself constitutes a limitation of this study. It is, however, acknowledged that for such proce-
dures specific Caldicott Guardian Approval is required following ethical approval of a re-
search project to improve the way the NHS handles and protects patient information [555]. 
 
 
8.3. Implications for Future Research 
Future (dyadic) sleep research among diverse cancer populations could be enhanced by con-
sidering inclusion of (a) longitudinal study designs spanning over health/treatment transition 
phases; (b) repeated measures of sleep/wake parameters, ideally continuous or daily; (c) 
combinations of objective and self-reported sleep measures [49, 556], which (d) are validat-
ed and realistically selected; and (e) careful consideration of measures of sleep-impairing 
factors and/or health outcomes. These should be complemented by (a) robust diagnos-
tic/eligibility methods; (b) sophisticated data analysis techniques; (c) systematic procedures 
to minimise attrition; and (d) novel methods to test already established interventions to man-
age sleep/wake problems in patients with cancer and their carers [366]. Thus, it is to be ex-
pected that the goals of future dyadic sleep research – also reflected on the current study – 
are met (Table 8.1) [209, 366]. 
First and foremost, replication of the current findings in future research should be regarded 
as an absolute priority. Future studies will be required to re-examine associations between 
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patients’ and caregivers’ sleep, confirm similarities (e.g. perceived sleep quality, sleep laten-
cy) and dissimilarities (e.g. daytime napping duration, daily disturbance), and resolve ambi-
guity (e.g. total sleep time, WASO) with regard to dyads’ sleep/wake trajectories, as well as 
re-investigate the magnitude of dyads’ sleep/wake impairment during treatment for breast 
cancer in the long-run. How are these associations/patterns affected by differences in the 
type/stage of cancer, phase of illness/treatment, or the caregiver’s or dyad’s circumstances? 
Perhaps with more rigorous and comprehensive measurement of sleep/wake patterns, inves-
tigation of whether changes in sleep/wake parameters of women with breast cancer can pre-
dict changes in those of caregivers, and vice versa, could shed more light to possible inter-
dependencies. What may be the effects of additional sleep/wake parameters of clinical inter-
est such as daytime sleepiness, feelings of restfulness upon awakening in the morning, rest-
less legs, or early awakenings? The presence of only unilateral cross-partner effects, such as 
the effects of caregiver poor sleep hygiene on women’s sleep maintenance, but not vice ver-
sa, also deserves additional investigation. Is this a population-specific effect? Women are 
known to be susceptible to sleep loss [557, 558], especially distressed women receiving 
chemotherapy for breast cancer, whereas caregivers (in their majority, males) might remain 
unaffected in this regard. Sleep research in the context of prostate cancer, where patients are 
men but caregivers are mainly women, could possibly allow examination of whether this 
cross-partner effect takes place in a reverse order. Similarly, the absence of cross-partner 
effects with regard to sleep initiation (i.e. sleep latency) that was apparent in the current 
study is puzzling and requires further exploration. 
 
Table 8.1. Summary of Important Associations Yet to Be Explored in the Sleep/wake Pat-
terns of Care Recipient-Caregiver Dyads [366] 
 Longitudinal effects of the dyad’s psychological and/or physical distress on the dyad’s 
sleep/wake patterns. 
 Longitudinal effects of historical relationship quality on the dyad’s sleep quality. 
 Longitudinal effects of sleep hygiene practices and/or past history of poor sleep on the dyad’s 
sleep quality. 
 Longitudinal effects of the dyad’s poor sleep on the dyad’s health-related quality of life and 
functioning. 
 Longitudinal measurement of daytime/night-time blood pressure and diurnal cortisol rhythms 
to understand the effects of sleep deficits on the dyads physical health. 
 Salient neurobiological mechanisms or pathways that mediate development of poor sleep in 
the dyads. 
 Differences in sleep/wake patterns/problems between dyads of female care recipients/male 
caregivers versus dyads of male care recipients/female caregivers. 
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To date, and for methodological/practical reasons that are perfectly understandable, sleep 
research in patients with breast cancer has been limited to longitudinal investigation of snap-
shots only of the illness/treatment experience [119]. Admittedly, considerable knowledge 
has been gained with regard to sleep/wake trajectories of women during breast surgery [528, 
551, 552, 559], chemotherapy [7, 8, 104, 120, 121, 123, 125-129, 133, 136, 137, 143-148, 
165, 166, 172], radiotherapy [110, 153, 560-563], or survivorship [33, 100, 527, 564-572]. 
However, and in conjunction with a striking absence of similar longitudinal data for infor-
mal cancer caregivers, there is still a pressing need for long-term sleep studies that follow 
individuals/dyads through major health/treatment transitions, and bring together different 
phases to provide a unified perspective of the breast cancer experience. One might question 
feasibility and acceptability of such studies especially at long periods, where patients and 
caregivers may be considerably burdened. However, previous research has confirmed feasi-
bility with acceptable attrition rates [131, 528, 573], whereas alternative ways to paper-and-
pencil data collection may improve participant acceptability and adherence/retention to the 
study (see below). 
The combined use of objective and self-reported sleep measures has been advocated as nec-
essary for the comprehensive investigation of sleep/wake impairments [49]. Yet, inherent 
conceptual differences have rendered comparison of objective and subjective sleep data frus-
tratingly difficult in studies, where both the aforementioned sleep assessment methods were 
employed [49, 574-576]. These difficulties suggest that data of a different nature be treated 
in a way that acknowledges inherent differences, accounts for disadvantages, and co-
visualises rather than synthesises deriving information. With their ability to record continu-
ously, objective sleep measures can provide more abundant data on several sleep variables, 
including sleep latency, sleep duration, nocturnal awakenings, WASO, and circadian 
rhythms than subjective measures do [577]. Polysomnography remains the ‘gold standard’ 
for the detection of specific sleep and wake states [49, 364, 578], especially with the latest 
advances of ambulatory devices [49]. Apart from its obvious advantage of being less expen-
sive than its laboratory counterpart, in-home polysomnography has also facilitated recording 
of sleep in the individual’s habitual sleeping environment [579, 580], even for patients with 
advanced disease [581]. In addition, actigraphy has been implemented in various studies 
[120, 121, 126, 127, 131, 159, 577, 582] as a relatively inexpensive, ambulatory method of 
objective sleep assessment. Actigraphy has been shown to be particularly good in the eval-
uation of circadian rhythm disorders too [577], and can be useful in examining dyads’ habit-
ual sleep patterns in their naturalistic environments for long periods of time [338]. On the 
other hand, self-reported research instruments measure perceptions [49]; hence, they can 
provide data on the more qualitative features of sleep such as sleep quality, feelings of rest-
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fulness upon arising, or daytime sleepiness and dysfunction [583]. Psychometrically suffi-
cient instruments include the Insomnia Severity Index, the Pittsburgh Sleep Quality Index, 
the Sleep Assessment Questionnaire, and the Athens Insomnia Scale [3, 399, 402, 403, 584] 
(see Table 16-A2), whereas the Pittsburgh Sleep Diary can allow prospective monitoring of 
sleep parameters in longitudinal studies [584]. In addition, subjective sleep data may corre-
late more strongly with self-reports of health-related outcomes, thus allowing for intra- and 
inter-personal relationships to be more thoroughly examined. In any case, specific research 
hypotheses rather than a priori assumptions of a technique’s superiority over another should 
guide selection of the methods to assess sleep in care recipient-caregiver dyads [338]. 
Although it is true that having more sleep interaction data over time would increase the 
power for looking at care recipient-caregiver sleep relationships (and correlates), some con-
siderable challenges in collecting such data should nevertheless be acknowledged. For in-
stance, given their retrospective nature, self-reported sleep measures are prone to introducing 
recall bias, which, when combined with their being influenced by the respondent’s situation-
al mood, can affect accurate interpretation of a person’s – let alone a dyad’s – sleep patterns 
[49]. In addition, not all self-report sleep measures have been extensively tested in all pa-
tient/caregiver populations, while even fewer are suitable for use as outcome measures given 
an absence of data to prove their ability/sensitivity to detect significant/meaningful changes 
in sleep patterns. Similar comments could be made about daily sleep logs/diaries. Sleep dia-
ries have been regarded as the ‘gold standard’ for subjective sleep assessments in the clinical 
practice [544]; however, they are not always standardised and they are much harder to keep 
for prolonged periods than is generally acknowledged in the literature. New attempts have 
been made to develop and validate core sleep questionnaires based on cutting-edge valida-
tion techniques [585, 586], and standardise prospective sleep self-monitoring through devel-
opment of the Consensus Sleep Diary [544]; yet, additional research is required to confirm 
their psychometric properties. Objective measurement of sleep can be similarly challenging. 
While wrist actigraphy is considered a relatively easy to implement and adhere to method, 
some patients and/or caregivers cannot tolerate wearing the devices for prolonged periods of 
time, hence the risk for missing data increases [364]. With in-home polysomnography, par-
ticipant burden can increase even more [364]. Equipment failures are not insignificant either. 
Furthermore, simple collection of more data might not completely solve the problem since 
there are no gold standards for which actigraph type to use, or which data collection or scor-
ing protocols to follow [577]. Given that actigraphy works by detecting movement, it may 
be unable to differentiate between a patient who is asleep and a patient who is awake but not 
moving [587]. Therefore, it is likely to overestimate levels of sleep efficiency and total sleep 
time [579, 583, 587], and has a low ability to pick up wakefulness in sleep-disordered indi-
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viduals [587], possibly leading to an overestimation of daily napping as previously evi-
denced in a study of patients with advance cancer and their family caregivers [244]. When 
sleep interaction data are considered, the aforementioned issues can be of particular im-
portance so as to enhance accuracy in sleep measurement, promote adherence to sleep as-
sessment methods, and prevent unnecessary burden to the dyad. Such issues also pose sever-
al implications for care dyads in the context of advanced cancer, possibly elder ones, and/or 
stressed by requirements of active anti-cancer treatment and everyday living. 
The investigation of correlates of co-occurring sleep problems in care recipient-caregiver 
dyads is both intriguing and challenging. In a recent review of the literature, this area 
emerged as a rather under-studied one [366]. Yet, current available findings can be usefully 
employed to form a model of complex interrelationships between sleep and sleep-correlates. 
This model suggests that a dyad’s sleep is a dynamic field of interference of several com-
pounding and interacting variables, which affect and are affected by sleep so that an infinite 
loop of chronic sleep loss and dysfunction can be established as the dyad moves in time and 
across health transitions. Whilst the mediating effects of co-habitation and bedroom-sharing 
remain to be explicitly established, a dyad’s sleep quality seems to be largely compromised 
by how parties are co-affected once sleep disturbances are manifested in one or both of 
them. Hence, frequency and severity of one’s sleep deficits can be potentially strong corre-
lates of the other’s, possibly influenced by the effects of a history of poor sleep or of an in-
adequate sleep hygiene. In dyads then where physical functioning and/or psychological well-
being are also compromised, sleep/wake patterns can be further impacted. Disease severity 
and chronicity, aging, caregiver burden, dysfunctional coping strategies, and unavailability 
of external support can pave the way towards this direction by interfering with sleep either 
directly or through their physical and psychological impact. Albeit unexplored in this con-
text, historical relationship quality, as influenced by the degree of attachment, the dyad’s 
age, and the impact of a demanding health situation, can possibly affect (and be affected by) 
the dyad’s sleep. A number of psychological, behavioural, and neurobiological mechanisms 
have been also suggested to mediate this relationship in married couples [338], which may 
be similar for dyads of care recipients and caregiving spouses, but warrant further explora-
tion. 
However comprehensive the quest for identification of potential sleep-affecting factors may 
be, it is true that additional triggers may exist. Arousability, or hyperarousal, and decreased 
homeostatic sleep drive are among the predisposing factors most often hypothesised for in-
somnia [60, 99]. Combined with a pre-existing homeostatically altered regulation of sleep, 
these manifestations might render individuals susceptible to disordered sleep during cancer 
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experience [99]. Dupont et al. [156] found that although intrusive thoughts and hyperarousal 
predicted worse sleep adequacy post-completion of breast cancer treatment, the effects van-
ished 12 months later; thus further research is warranted to confirm the magnitude of such 
associations. Moreover, conditions perpetuating sleep problems may be maladaptive or dys-
functional beliefs and wrong attitudes towards sleep and insomnia that an individual devel-
ops at the onset of sleep disorders and to which likes to refer later on [409]. In patients with 
cancer, such dysfunctional thoughts may include concerns of relapse or recurrence of cancer 
(or pain) due to lack of sleep, or beliefs that malfunctioning sleep will prevent treatment or 
even control of the disease [155, 409]. The positive results of cognitive-behavioural therapy 
interventions for insomnia in women with non-metastatic breast cancer [122, 131, 161, 588-
590] suggest that this population is prone to developing such dysfunctional attitudes. Quite 
reasonably, similar dysfunctional thoughts can adversely impact caregivers’ sleep too. 
Reversely, the effects of a dyad’s nocturnal sleep loss on daytime wakefulness/fatigue, func-
tional ability and work presenteeism/productivity, especially when this becomes a constant 
situation, are not insignificant, and may be selected as outcomes for evaluation in other re-
search. In the long run, perpetuated sleep deprivation can lead to deficits in care dyads’ qual-
ity of relationship and subsequently quality of life. In long-term survivors of breast cancer 
complaining of insomnia, poorer sleep quality the previous day predicted increased pain, 
fatigue and hot flashes the next day, and less efficient sleep was related to increased fatigue 
and hot flashes, and lower levels of positive mood the next day [527]. Quality of life can 
also be put at risk [518]. During treatment for breast cancer, symptoms of insomnia predict 
greater cognitive impairments [591, 592], which may further impact on daily functioning 
and return to work [593]. A longitudinal study among caregivers of people with advanced 
cancer also revealed that prospective sleep disturbance had analogous negative effects on 
their functional status and quality of life [28]. Links to lowered immune function have also 
been proposed [594, 595]. It is obviously intriguing to investigate the unilateral or bilateral 
effects of prolonged sleep loss in patient-caregiver dyads on important health outcomes, in 
an attempt to better understand inter-linked processes, identify important endpoints and pri-
mary outcomes, and plan sleep promoting interventions that target the care dyad. This quest 
needs to include not only care dyads during survivorship from (breast) cancer, whose health 
outcomes might be compromised by prolonged sleep loss [244], but also care dyads during 
health transitions and/or during the patient’s active cancer treatment when stress peaks [242] 
and situational sleep deprivation might interfere with a host of dyad members’ health out-
comes. 
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As argued above, to date, data regarding correlates of co-occurring sleep problems in care-
recipient/caregiver dyads remain scarce and at times discrepant. The same is true when the 
reverse of this relationship is investigated: the question about what health outcome measures 
would be most appropriate is still pending. Of relevance to the latter, wide variability (or 
otherwise, inconsistency) in the use of measures of sleep-correlates has been reported in the 
literature pertinent to dyadic sleep research [366]. For instance, Kotronoulas et al. [366] 
found that five different instruments were used across the studies reviewed to assess for the 
sleep-impairing effects of depression. Conversely, other constructs were only partially (e.g., 
burden, coping) or not at all (e.g., attachment) investigated [366]. This lack of standardisa-
tion in the measurement of key constructs can be seen as a confounding factor that hinders 
comparability of relevant outcomes. On a closely related matter, psychometric insufficiency 
of some instruments may result in compromised findings. Clearly, there is a need for con-
crete evidence- and research-based guidelines for the use of psychosocial assessment 
measures in this context. To this end, the Patient-Reported Outcomes Measurement Infor-
mation System (PROMIS) Network has been funded to establish a publicly available re-
source of standardised, accurate and efficient outcome measures for clinical research [596]. 
A wealth of comprehensive literature reviews also exists that can assist researchers to select 
the most sound measures to assess outcomes related to or affected by sleep/wake deficits in 
patient-caregiver dyads living with cancer [435, 597-604]. Importantly, researchers will need 
to rely on instruments with proven psychometric properties, preferably those for which re-
sponsiveness (otherwise, sensitivity to change over-time) has also been established. Exami-
nation of measures’ psychometric properties should lead to a rational approach to selecting 
those appropriate as well as promote consistency in their use. This common language will 
allow for comparable, reproducible and wide in scope data to be collected. 
Attrition rates reported in the current study should also be taken into consideration. The 
mail-based data collection system utilised served as a basic means to send and receive ques-
tionnaires in paper format. This system can be useful for low-budget and/or cross-sectional 
studies, but it cannot efficiently manage data collection that occurs in multiple waves. For 
instance, it is unclear whether some missing data were due to failures to the mail system 
alone, or because participants simply forgot to return completed questionnaires. To enhance 
participant adherence and retention in similar sleep studies, implementation of more effec-
tive data collection systems is required, complemented by additional methods such as per-
sonal telephone contact and/or home visits. The use of technology can be a particularly use-
ful adjunct to that end. Rumble et al. [527] used an automated telephone-based system for 
the daily collection of sleep log data from women with breast cancer. Moreover, electronic 
systems such as handheld computers, mobile phones or web-based platforms could prove 
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useful to automatically generate alerts/reminders for participants at each assessment point, 
and also to securely store self-reported and objectively recorded sleep data. With current 
efforts to produce and validate electronic versions of already existing paper-and-pencil sleep 
[585] and health outcome questionnaires [605], data collection and retention in future sleep 
studies are expected to improve considerably [606]. 
Whilst demographic/clinical diversity of the study samples is to be sought to increase repre-
sentativeness and, consequently, generalisability of findings, bias introduced by including 
patients/caregivers with undiagnosed and/or uncontrolled sleep/wake and/or psychiatric dis-
orders should be prevented. Standardised screening procedures, including structured diag-
nostic interviews for sleep/wake (e.g. the Duke Structured Interview for Sleep Disorders 
[607]) and current mood, anxiety, alcohol or substance abuse, or psychotic disorders (e.g. 
the Structured Clinical Interview for DSM-IV Axis I Disorders [608]), need always be con-
sidered in sleep research. In this way, sleep/wake impairment can be attributed to cancer ex-
perience alone. What is more, cognitive functioning evaluation of potential participants 
(possibly via the High Sensitivity Cognitive Screen [609]) can enhance self-report sleep data 
accuracy in the long run by excluding individuals with cognitive deficits. This is of particu-
lar importance for patients with cancer receiving chemotherapy treatment because recent 
evidence suggests cognitive disruption (referred to as ‘chemobrain’) associated with system-
ic administration of specific anti-cancer agents [610].  
Longitudinal sleep studies that make use of predictive models of statistical associations are 
highly advisable [49]. Analysis of dyadic data on sleep/wake patterns, sleep-impairing co-
variates, and/or related health outcomes with sophisticated, state-of-the-art statistical models 
such as the multivariate two-level model for matched pairs’ data [371], or the Actor-Partner 
Interdependence Model [293], could permit adequate exploration of inter-dyad effects. Al-
ternative types of dyadic MLM analyses for binary and/or ordinal data could further increase 
the scope of such investigations. Structural equation modelling (SEM) can also be used in 
dyadic research as an alternative data analytic strategy [293]. Albeit more complicated, SEM 
has been advocated as a particularly useful technique when dyads are distinguishable (e.g. 
dyads of patients and caregivers) [293]. Moreover, future use of latent class growth analysis 
[611] could facilitate identification of subgroups of dyads (e.g. both poor sleepers versus 
both good sleepers versus one poor sleeper) and allow a comparative investigation of over-
time changes in sleep/wake patterns. Moreover, testing mediation in multilevel modelling 
could well answer some of the questions generated in this study: “is there a mediating effect 
of patient symptom burden in the relationship between caregiver burden and caregiver sleep 
disruption/restriction?” and “is there a mediating effect of coping strategies in the relation-
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ship between depression/anxiety and own sleep problems?” According to the method pro-
posed by Kenny et al. [293], in separate MLM analyses, effects of predictor variables on 
outcome variables, and of predictor variables on mediators are estimated first. Next, the ef-
fects of predictor and mediator variables are simultaneously estimated. Mediation is estab-
lished when in this step mediators are significantly related with outcomes, whereas at the 
same time predictors are no longer associated with a given outcome variable [293]. Last but 
not least, mixed-methods studies integrating quantitative and qualitative data [612] could be 
particularly useful in the clarification of sleep behaviours and beliefs, as well as underlying 
mechanisms in the development of dyadic sleep disturbances. Such information could well 
inform future observational and intervention studies, also pointing at previously unearthed 
issues that could lead to better management in clinical practice. 
The potential to move sleep research beyond the care dyad and consider wider ‘family’ net-
works is an intriguing one. According to the family systems perspective [613], an individu-
al’s behaviour cannot be investigated “apart from the interpersonal behavioural systems in 
which he or she is embedded” (p. 224) [293]. Sleep research in triads or wider groups in-
cluding the patient, primary (e.g. spouse/partner) and secondary caregivers (e.g. friends), as 
well as additional care recipients (e.g. children or parents) is now feasible. One of the most 
comprehensive methods to investigate patterns and dynamics of such groups is the Social 
Relations Model (SRM) [293]. Based on the principles of SEM for data analysis, the SRM 
can be used to evaluate change over time and relationships at multiple levels of analysis, and 
measure reciprocity in the triad and group members [614]. 
Finally, although RCTs of hypnotic medication use for patients with cancer is “noticeably 
absent” [615], a considerable amount of work has been conducted since 2000 with regard to 
the efficacy of non-pharmacologic interventions for sleep/wake impairment in this popula-
tion [616, 617]. Of note, to date, an assortment of interventions based on exercise or educa-
tion, but mainly on CAM therapies and cognitive-behavioural therapy (CBT), have been 
tested in RCTs predominantly with women with breast cancer [616]. Conversely, only two 
similar intervention approaches have been reported for informal caregivers of people with 
cancer [29, 618]. Even worse, the absence of interventions aimed at helping both the patient 
and the carer is striking [615, 616]. However, results of the current and previous studies 
[242, 244, 363, 367, 525] make explicit the need for future non-pharmacologic intervention 
studies that go beyond the individual, thus attempting to document sleep-promoting effects 
when interventions are jointly provided to care dyads [366, 616]. Designing a dyadic sleep 
intervention study is an intriguing and challenging task, which requires careful selection of 
the intervention component itself, as well as of the mode, dose and duration of delivery. Cur-
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rent findings favour a behavioural therapy intervention (stimulus control, sleep restriction, 
relaxation and sleep hygiene) augmented by education on coping strategies/stress reduc-
tion/caregiver task planning (BTE) for patient-caregiver dyads in the context of adjuvant 
chemotherapy for breast cancer. Face-to-face delivery of this BTE intervention over at least 
10-12 weeks (2 weeks per chemotherapy cycle) and with a weekly dose of at least 5 hours 
could be crucial first steps [616]. Importantly, such an intervention should not target dyads 
of poor sleepers only; the ability to show no deterioration in the sleep/wake patterns of dyads 
of good sleepers during treatment is equally important. Hence, a three-group pilot RCT (dy-
adic BTE intervention versus individualistic BTE intervention versus standard care) can be 
designed to document the added value of targeting dyads instead of individuals in order to 
improve sleep/wake impairment and associated health deficits. 
 
 
8.4. Implications for Clinical Practice 
Implications for clinical practice arising from this study are also numerous. With latest ap-
proaches to support patients and caregivers urging for early identification of and ongoing 
assessment for sleep disturbance [3, 49, 364], the finding that at least 25% to 48% of care 
dyads may at the same time meet criteria for sleep/wake impairment throughout chemother-
apy treatment for early stage breast cancer clearly calls for a proactive management of sleep 
complaints in this population. Together with similar percentages of dyads with one poor 
sleeper, this renders the quest to simultaneously manage sleep/wake impairment in dyads of 
patients and caregivers even more compelling. One important message for clinicians is that 
even in dyads of one poor sleeper, good sleepers may represent a source of disturbance for 
the member prone to sleep deprivation, additional to potential own sleep-impairing factors. 
Even if this is not the case, dyads of both poor sleepers, particularly those closely interact-
ing, may be at risk for ‘sleep distress’ when diminished sleep duration, multiple nocturnal 
awakenings, wakefulness after sleep onset, or daytime sleepiness co-occur. 
With pressing requirements for improved psychosocial cancer care [184, 619-621], 
healthcare teams are now expected to view the patient-caregiver dyad as the unit of care 
[184] and provide support that meets concurrent and interdependent needs, and promotes the 
combined well-being of the dyad. With sleep/wake assessments in clinical practice still 
being infrequent and/or inadequate [622], engagement of health professionals is a crucial 
first step to implement dyadic sleep assessments. Communication of the findings of studies 
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as the present ones in open workshops and seminars, as well as inclusion health 
professionals in clinical educational programmes and research projects could well enhance 
their set of skills and the actual delivery of such assessments. Evaluation of sleep from a 
dyadic perspective also requires that clinicians engage in a systematic and ongoing 
investigation that goes beyond the individual: data are simultaneously taken into account, 
synthesised and contrasted to establish a dyad’s levels of sleep quality. These will need to be 
complemented by additional information regarding past sleep problems, present sleeping 
arrangements, sleep hygiene behaviours, and current use of sleep aids that can help 
clinicians identify potentially vulnerable dyads for sleep problems. Incorporation of 
screening tools for organised sleep assessments in routine clinical practice is thus 
recommended. Screening tools for the detection of sleep-wake disturbances, such as the 
Insomnia Severity Index, the Clinical Sleep Assessment for Adults, the Medical Outcomes 
Study Sleep Scale, and the Epworth Sleepiness Scale, are recommended for use in clinical 
practice [49, 364, 402, 584].  
Once problems are suspected and/or complaints are raised, evaluation of the onset, duration 
and severity of sleep deficits, as well as daytime dysfunction can reveal potentially evolving, 
co-occurring and/or interrelated problems. During assessment sessions clinicians need to 
explore in-depth the possibility of interactions that lead to sleep disturbance in the dyads by 
incorporating targeted questions such as “Would you say that your sleep is being influenced 
by that of your family member’s/by symptoms or habits of your family member? If yes, in 
what way?” This is a key question in dyadic sleep assessment that prompts dyad members to 
consider another potential source of sleep disruption. Current research suggests that clinical 
assessment of cross-partner effects should not rely on patients’/caregivers’ spontaneous re-
ports only. Indeed, findings of this and previous studies [237, 244, 521] reveal that, when 
asked in general terms about potential sleep-impairing factors, only fewer than three out of 
ten patients/carers spontaneously admitted to have been disturbed by the other dyad member. 
Importantly, whether this assessment should be introduced to dyad members jointly (to al-
low discussion) or separately (to prevent conflict) is an issue that needs to be tailored to spe-
cific dyads. Nevertheless, a plan of practical suggestions to reduce disturbing nocturnal in-
teractions of cohabiting dyads can be usefully devised, including use of twin beds or sepa-
rate rooms for sleep, separation of sleeping quarters, the use of alarms, readjustment of the 
patient’s caregiving routines, and synchronisation of positive sleep hygiene behaviours 
[368]. Such actions can prove instrumental in addressing the predisposing and perpetuating 
cross-partner effects of sleep hygiene, as well as the precipitating and perpetuating cross-
partner effects of nocturnal disturbance, and patient physical and caregiver burden that the 
current study demonstrated during the chemotherapy period. 
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Moving beyond the dilemma of dyad co-habitation or not, clinicians are faced with the chal-
lenge to identify and treat triggers for sleep/wake impairment before treating sleep problems 
themselves. To a certain extent, this indirect approach may be enough to effectively deal 
with sleep/wake problems in patient-caregiver dyads in the cancer care context. Optimisa-
tions in patient symptom control and caregiver health deficits management can prove bene-
ficial [364], especially when the shared needs of the dyads are taken into consideration. 
Women with breast cancer can benefit from the early assessment and management of can-
cer/chemotherapy-related physical symptoms such as pain, nausea/vomiting, loss of energy, 
mucositis, and hot flashes that can interfere with own sleep patterns. Nowadays, a wide 
range of effective pharmacologic and non-pharmacologic approaches to the management of 
chemotherapy toxicity are available for use in clinical practice [623-628]. Timely health 
screening for informal caregivers is equally important as it can prevent increase in burden 
and therefore alterations in sleep architecture [182]. Clinicians could usefully implement 
formal assessments for caregivers, including identification of pre-existing comorbidities; 
deterioration in symptomatology associated with known illnesses; confirmation of adherence 
to/efficacy of current treatment plan; and exploration of new symptoms, the onset of which 
may be associated with caregiving responsibilities. Moreover, psychosocial adjustment of 
couples/dyads to breast cancer and adjuvant treatment may be instrumental to the prevention 
of sleep deficits. Clinicians will need to plan comprehensive education assessments and offer 
tailored information to women and their carers. Results of the current study suggest that of-
fering dyads more information about the prognosis of illness and clarifying what it is to be 
expected during chemotherapy could lead to alleviation of distress and fear, which in turn 
could help women to fall asleep more easily and have better quality sleep, and to carers en-
joying less disrupted/restricted sleep during the night. In addition, dyadic evaluation of psy-
chological well-being and coping throughout chemotherapy treatment could well identify 
dyad members/dyads in distress or susceptible to distress. Health professionals will also 
need to evaluate the dyad’s support environment, and advise on the benefits for caregivers of 
carefully planning their everyday tasks to minimise disturbance, and of having a support 
person to share caregiving responsibilities with, whether this person is a family member or a 
hired attendant. The availability of respite care services should also be explored as it can 
lead to improvements in sleep quality of both the care recipient and their informal care pro-
vider [367]. Referrals to specialist health services could be a useful adjunct for dyads of poor 
sleepers, where relationship quality is compromised and complicated by dysfunctional cop-
ing and psychological distress [338, 339]. 
The pharmacologic treatment of sleep deficits in patient-caregiver dyads requires careful 
consideration of a number of issues. To begin with, necessity of pharmacotherapy should 
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always be confirmed. In the context of breast cancer treatment where sleep loss may be only 
temporal and restoration to normal may be achieved as dyads enter the survivorship phase, 
the gain from using hypnotic medications may be outbalanced by potential adverse effects. 
However, in cases where a history of past sleep problems is present and/or insomnia 
symptoms manifest early and persist over consecutive weeks, pharmacologic treatment may 
be advisable, particularly in dyads sharing the same bed/room and especially if all other 
indirect methods have failed. Yet, patients and caregivers may be reluctant to make use of 
pharmacological agents to help them sleep even if sleep deprivation is constant and/or 
causes considerable distress [27, 136, 137, 521]. This reluctance may be due to either 
avoidance (“I am already taking so many medications; I believe I can manage without 
another one”) or fear of adverse effects (“I may be overly sleepy in the morning and cannot 
attend to the patients’ needs”). Such concerns may be legitimate. In the context of cancer 
care/treatment, there is considerable uncertainty concerning the efficacy but mainly the 
safety of pharmacologic sleep agents [622, 629]. Indeed, to date, no randomised controlled 
trials of hypnotic therapy for sleep disturbance in patients with cancer exist [615, 622, 629]. 
Hence, valid concerns have been raised regarding the possibility that hypnotic agents might 
be hazardous for patients receiving systemic treatment due possibly to interference with the 
metabolism of chemotherapy agents. For instance, a melatonin receptor agonist, ramelteon, 
may be used for sleep-onset problems [630]; however, its pharmacokinetics in 
chemotherapy-treated individuals remain unknown. Another issue might be that 
pharmacologic agents (especially if used without proper consultation) may be accompanied 
by serious adverse effects that can do more harm than good in situational (rather than true) 
poor sleepers such as the majority of patients with cancer or their caregivers; indeed, 
hypersomnolence is a documented adverse effect of most sleep agents [4]. Even in the cases 
of sleep agents where half-life is short (e.g. zaleplon), thus suggesting less sustained 
hypnotic effects [631], daytime disruption may not be insignificant. The same is true for 
over the counter medications and supplements to treat insomnia symptoms, especially those 
including antihistamines as their major ingredients. In addition, variability in efficacy (e.g. 
melatonin) and risk for severe hepatotoxicity (e.g. Kava Kava) have been reported, which 
have led to these agents being regarded as not recommended for patients receiving 
chemotherapy [3, 632] and/or cautiously used depending on individual characteristics. 
Current basic principles call for the use of hypnotics in conjunction with non-pharmacologic 
interventions [3, 49, 622, 629]; consideration of the overall medical situation with particular 
focus on comorbid conditions that may influence the choice of agent; initiation with a low 
dose and titration; avoidance of long-term administration of benzodiazepines; consideration 
of past abuse history; and the initiation of a tapering schedule to prevent withdrawal 
insomnia when stopping the agent [632]. 
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Consideration of efficacious non-pharmacologic sleep interventions for patients with cancer 
and informal caregivers as complementary or alternatives to the pharmacological treatment 
of sleep/wake problems is paramount. In the past two decades, over 20 RCTs have been pub-
lished reporting on the effectiveness of non-pharmacologic interventions for women with 
breast cancer at various phases during the illness trajectory [49, 616]. CBT for insomnia 
symptoms has been the most widely implemented approach in this patient population; how-
ever, additional types have been investigated including exercise interventions, a wide range 
of complementary/alternative therapy (CAM) interventions, and education/information in-
terventions [3, 49, 616, 629]. Overall, positive outcomes have been associated with CBT, but 
evidence regarding other types of non-pharmacologic interventions is less consistent [615]. 
CBT seems to be similarly effective for informal carers of patients with cancer [29], but rel-
evant evidence is considerably limited [616]. Nevertheless, clinicians clearly have an array 
of available sleep interventions to choose from. What is important and proposed here is that 
the effectiveness of these non-pharmacologic interventions for sleep disturbances needs to 
be re-examined, this time at a dyadic level. Whereas therapeutic interventions such as CBT, 
home-based walking, education, mindfulness-based stress reduction, hypnosis, expressive 
writing, massage, or guided imagery have previously been shown to improve sleep and cor-
relates in patients and informal caregivers [3, 49, 616, 633-637], concurrent delivery to dy-
ads rather than merely individuals could be ‘twice as effective’ resulting in combined im-
provement in sleep [233] and other health outcomes. Davidson [615] and Langford et al. 
[616] argue in favour of an approach that looks at helping both the patient and the caregiver; 
since they may share a bed, “the sleep of one is bound to affect the sleep of the other”. How-
ever, there is much more to it: even dyads that do not interact at night may manifest 
sleep/wake problems at the same time. Concurrent ‘sleep distress’ may put dyad members 
living in this close caring relationship at greater risk for concurrent health deficits, concur-
rent quality of life deficits, and inability to cope and function both independently and togeth-
er. Joint provision of the aforementioned sleep interventions to patients and caregivers may 
have an additive effect to the benefit that they can gain from them as individuals. For in-
stance, since CBT interventions for insomnia can be conducted either one-on-one or in 
groups of individuals (e.g. patients) [616], devising a plan to offer CBT to dyads should not 
be a difficult task to accomplish. Importantly, the target would be to produce components of 
CBT (usually, cognitive, behavioural, and educational) that promote individualised goal-
setting for patients (possibly focusing more on restructuring maladaptive thoughts about 
sleep or exercising relaxation techniques, or avoiding maladaptive coping strategies) and 
caregivers (possibly focusing on planning caregiving tasks and on stimulus control), and for 
dyads by concentrating on a concurrent sleep hygiene plan to avoid disruptive behav-
iours/habits that may interfere with sleep [366]. 
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8.5. Conclusions 
As confirmed in the current study, alterations in the habitual sleep/wake patterns of women 
with breast cancer and their informal caregivers is a widely prevalent symptom, the perva-
sive and debilitating effects of which can severely affect health and quality of life [49]. 
However, it has been argued that patient sleep/wake problems during chemotherapy treat-
ment still go unrecognised and under-treated [622]. For some, these might be secondary 
problems that women need to endure, and which will go away once treatment is over. Sel-
dom is this the case. In addition, informal caregivers often experience sleep loss and daytime 
dysfunction that might not be readily visible to the healthcare team [182, 534]. For others, 
these might erroneously be seen as symptoms that carers are used to dealing with and know 
how to overcome. Complemented by the fact that whereas sleep not only is a biological [2] 
but also a social phenomenon [338], which however only rarely has been examined as such 
[366], it can be assumed that researchers’ and healthcare providers’ understanding of com-
plex sleep interaction may often be inadequate and care may fall short. 
The current study has taken dyadic sleep research a step forward by examining the interrela-
tions in the sleep/wake patterns of women receiving chemotherapy for early stage breast 
cancer and their informal caregivers, and by acknowledging the individualistic and dyadic 
nature of sleep-impairing factors that should be addressed by future sleep interventions. Cur-
rent results revealed alarming percentages of dyads consisting of at least one poor sleeper 
prior to chemotherapy initiation, which further increased as patient treatment progressed. 
However, for the majority of sleep/wake parameters, impairment was generally greater for 
patients rather than caregivers during the chemotherapy period, which persisted into the ini-
tial post-treatment period. Despite these differences, at baseline, daily disturbance, daytime 
napping duration, total sleep time, and overall sleep/wake impairment tended also to con-
verge. In addition, over treatment, continuation rates of change in sleep latency and duration 
of daytime napping were not significantly different between patients and caregivers. Patterns 
of change in perceived sleep quality, sleep latency, daily disturbance, and overall sleep/wake 
impairment were strongly correlated between dyad members throughout the study. These 
findings suggest that deterioration in patient sleep parameters was followed by a similar 
worsening in the respective caregiver variables, and vice versa, and confirms interdepend-
ence. Further analyses revealed that increased poor sleep hygiene behaviours and nocturnal 
sleep disturbances, and caregiving burden were the variables that most consistently predicted 
poorer outcomes in the sleep/wake patterns of the dyads. Conversely, evidence for cross-
partner effects most frequently emerged with regard to the dyads’ psychological burden, as 
well as for caregiving burden. Whereas more dysfunctional coping on the patients’ part was 
221 
 
 
associated with greater own sleep/wake impairment, caregiver use of maladaptive coping 
strategies was found to predict better, rather than worse, perceived sleep quality. 
Nevertheless, research has only begun to gain an understanding of the bi-directional associa-
tions in the sleep/wake patterns of patients with cancer and their caregivers [366]. Unravel-
ling the complex underlying pathways that lead to the development of sleep/wake impair-
ments in these dyads and exploring how interventions can support people affected by cancer 
in every-day practice are questions that future researchers and clinicians will be required to 
give answers to in an attempt to find innovative and more effective ways to provide better 
care to patients and their caregivers. 
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Appendix 1. Figures & Schematics 
 
 
 
Figure 1-A1. Normal electroencephalographic (EEG) characteristics (left panel) and sleep architecture 
(right panel) in a young adult. Source: Kandel et al. (1991) [638]. 
 
 
 
Figure 2-A1. The two process model of sleep regulation (SWA – Slow-wave activity; TST – Total 
sleep time). Source: Borbely (1982) [40] 
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Figure 3-A1. The “roller-coaster” experience of the treatment pathway. Source: Corner & Bailey (2008) [84] 
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Figure 4-A1. Mathematical definition of the weighted mean. 
 
 
  
  260
 
 
Figure 5-A1. Organisation of data for HLM analysis at Level 1.
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Appendix 2. Tables 
 
 
Table 1-A2. Commonly used sleep-related terms and definitions [4, 11] 
Apnoea Cessation of airflow at the nostrils and mouth lasting at least 10 seconds; the 
three types of apnoea are obstructive, central, and mixed. Obstructive apnoea 
is secondary to upper-airway obstruction, central apnoea is associated with a 
cessation of all respiratory movements, and mixed apnoea has both central 
and obstructive components. 
Arousal An abrupt change (i.e., over 3-14 seconds) from a deeper stage of non-rapid 
eye movement sleep to a lighter stage or from rapid eye movement sleep to 
wakefulness 
Deep sleep A common term for non-rapid eye movement sleep stages 3 and 4 (also called 
delta or slow wave sleep) 
Entrainment Synchronization of a biologic rhythm by a forcing stimulus such as an envi-
ronmental time cue (zeitgeber) 
Excessive daytime 
sleepiness 
Difficulty in maintaining the alert-awake state usually accompanied by a rapid 
entrance into sleep when the person is sedentary; results in somnolence and 
hypersomnia 
Insomnia Difficulty in initiating or maintaining sleep 
Periodic limb 
movement 
A rapid partial flexion of the foot at the ankle, extension of the big toe, and 
partial flexion of the knee and hip that occurs during sleep; the movements 
occur with a periodicity of 5-90 seconds and last 0.5-5.0 seconds. 
Periodic limb 
movement dis-
order 
A disorder characterised by periodic episodes of repetitive and highly stereo-
typed limb movements that occur during sleep 
Restless legs syn-
drome 
A waking dysaesthesia, most often localised to the calves, which occurs pri-
marily in evening hours; its major manifestation is an irresistible urge to 
move the legs; it may interfere with sleep onset and maintenance, as well as 
cause the sufferer great torment while waking. 
Sleep apnoea syn-
drome 
A disorder characterised by repetitive episodes of reduced or absent respiratory 
airflow that occur during sleep and that usually are associated with a reduc-
tion in blood oxygen level 
Zeitgeber An environmental time cue, such as sunlight, noise, social interaction, or an 
alarm, that usually helps an individual entrain to the 24-hour day 
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Table 2-A2. The nine recommended key sleep parameters [43] 
Sleep parameter Normal characteristics 
Total sleep time while in bed: number of minutes of 
sleep while in bed 
Adults normally attempt to sleep 7-9 hours 
(420-540 minutes) in 24 hours, whereas ado-
lescents 13-18 years old normally sleep 8.5-
9.25 hours in a 24-hour period. 
Latency: number of minutes between when someone 
lays down to bed and actually goes to sleep 
Adult latency normally is less than 20 
minutes. 
Awakenings during sleep period: the number of 
awakenings during a sleep period 
Adults normally awaken two to six times 
during a typical night’s sleep of 420 minutes. 
Wake after sleep onset (WASO): number of minutes 
awake or percentage of time awake after sleep on-
set during the sleep period 
Adult WASO time normally is less than 10% 
of the total sleep minutes, or 42 minutes if 
the person sleeps 420 minutes (seven hours) 
during the night. 
Napping during the day: total number of minutes of 
sleep during the daytime; can be intentional or un-
intentional sleep 
Adult napping normally can vary from five 
minutes to two hours. 
Excessive daytime sleepiness: episodes of lapses into 
sleep of short duration, usually in situations in 
which the person is inactive for even brief periods; 
excessive daytime sleepiness can result from acute 
or chronic sleep deprivation or loss or other patho-
physiologic causes. 
Adults normally have a minimal chance of 
dozing while engaged in routine activities. 
Quality of perceived sleep: multidimensional percep-
tions of length and depth of sleep and feelings of 
being rested upon awakening; subjective assess-
ment of sufficiency of sleep for daytime function-
ing 
Adults normally feel satisfied or very satis-
fied with their usual sleep patterns and be-
lieve that their sleep enhances their daily 
functioning. 
Circadian rhythm: bio-behavioural phenomenon 
associated with fluctuations in light, hormones, eat-
ing, or socializing that repeats approximately every 
24 hours (see also Table 3-A2) 
Circadian rhythm peaks and troughs within a 
24-hour period. 
Sleep efficiency: the number of minutes of sleep di-
vided by the total number of minutes in bed, multi-
plied by 100 
In adults, 95% sleep efficiency indicates a 
good night’s sleep; less than 80% indicates a 
bad night’s sleep; in a night’s sleep of 420 
minutes (7 hours), this would be equivalent 
to 20 minutes to fall asleep and three awak-
enings of 10 minutes each. 
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Table 3-A2. Circadian activity rhythm parameters obtained through actigraphic measure-
ments [9, 49, 121, 577, 639] 
Circadian 
parameter Definition Meaning 
Measure-
ment 
Healthy 
adult values 
Mesor 24-h adjusted mean of the 
activity counts; the mean 
of the rhythm; half-way 
between minimum and 
maximum activity 
 
Higher values represent a 
more robust activity; mean 
activity level 
Movements/ 
minute 
150.3 (± 17.7) 
[640, 641] 
~138 [642] 
Up-mesor The time of day when an 
individual switches from 
low to high activity, i.e., 
from below the mesor to 
above the mesor 
 
Higher values suggest a later 
starting time of activity; the 
time an individual “gets 
going” in the morning 
Clock time – 
Down-mesor The time of day when an 
individual switches from 
high to low activity, i.e., 
from above the mesor to 
below the mesor 
 
Higher values suggest a later 
time of decline of activity; 
the time an individual “set-
tles down” for the evening 
Clock time – 
Amplitude Peak-to-nadir difference 
(peak minus the mesor) 
the height of the rhythm 
Represents the rhythmic 
change of an individual’s 
activity during a 24-h peri-
od; lower values suggest a 
dampened circadian rhythm 
 
Movements/ 
minute 
109.0 (± 23.4) 
[640, 641] 
~110 [642] 
Peak activity Sum of the mesor and 
amplitude values 
Index of maximum activity 
for a 24-h period; favourable 
because it represents more 
robust circadian rhythms 
 
Movements/ 
minute 
Approximately 
250-260 [127] 
Acrophase Actual clock time of the 
peak amplitude 
A later time suggests more 
phase delay 
Clock time Early afternoon 
(14:00-15:00) 
[640, 641] 
 
Circadian quo-
tient 
Determined by dividing 
the amplitude by the 
mesor 
Strength of the circadian 
rhythm; higher values repre-
sent an assessment of degree 
of activity/sleep consolida-
tion throughout the day 
 
Ratio Closer to 1.00 
[639, 643] 
24-h Autocor-
relation 
The internal correlation 
of the regularity and con-
sistency of the rhythm 
from one day to the next 
 
High autocorrelation at or 
near 24-hours indicates a 
robust/stable circadian 
rhythm. 
Ratio Range –1 to 
+1; optimal = 
+1.0 [639, 643] 
Goodness of fit 
(R2 cosinor fit; 
F statistics) 
The reduction in squared 
error from using a model 
to summarise data com-
pared to using the mean; 
variance explained by the 
cosine fit; percentage of 
variance in the data ex-
plained by the fitted co-
sine curve; the correlation 
between the fitted curve 
and the actual data 
A measure of how well the 
data fits into the 24-hour 
circadian pattern; indicates 
that the circadian rhythm 
accounts for a % of the vari-
ability in an individual’s 
activity; higher values sug-
gest a more robust rhythm 
– – 
264 
 
 
Table 4-A2. UICC staging system combined with the TNM classification for breast cancer 
[67, 71] 
UICC 
Stage 
TNM classi-
fication Characteristics 
Commonly 
used terms 
0 Tis, N0, M0 Carcinoma in situ, no regional lymph node metastasis, 
no distant metastasis 
Carcinoma in 
situ; non-
invasive carci-
noma 
I T1, N0, M0 Tumour < 2 cm, no regional lymph node metastasis, 
no distant metastasis 
Early stage 
breast cancer 
IIA T0, N1, M0 No evidence of primary tumour, metastasis to mova-
ble ipsilateral axillary node(s), no distant metastasis 
T1, N1, M0 Tumour ≤ 2 cm, metastasis to movable ipsilateral axil-
lary node(s), no distant metastasis 
T2, N0, M0 Tumour > 2 cm but ≤ 5 cm, no regional lymph node 
metastasis, no distant metastasis 
IIB T2, N1, M0 Tumour > 2 cm but ≤ 5 cm, metastasis to movable 
ipsilateral axillary node(s), no distant metastasis 
T3, N0, M0 Tumour > 5 cm, no regional lymph node metastasis, 
no distant metastasis 
IIIA T0, N2, M0 No evidence of primary tumour, metastasis to fixed 
ipsilateral axillary node(s), no distant metastasis 
T1, N2, M0 Tumour ≤ 2 cm, metastasis to fixed ipsilateral axillary 
node(s), no distant metastasis 
T2, N2, M0 Tumour > 2 cm but ≤ 5 cm, metastasis to fixed ipsilat-
eral axillary node(s), no distant metastasis 
T3, N1, M0 Tumour > 5 cm, metastasis to movable ipsilateral axil-
lary node(s), no distant metastasis 
T3, N2, M0 Tumour > 5 cm, metastasis to fixed ipsilateral axillary 
node(s), no distant metastasis 
IIIB T4, any N, 
M0 
Tumour of any size with direct extension to chest wall 
or skin, any N, no distant metastasis Locally ad-
vanced carcino-
ma IIIC Any T, N3, 
M0 
Any T, metastasis to ipsilateral internal mammary 
lymph nodes, no distant metastasis 
IV Any T, any N, 
M1 
Any T, any N, distant metastasis present Metastatic breast 
cancer 
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Table 5-A2. Evidence categories used by the Department of Health in the National Service 
Frameworks (DOHNSF) (2001) [116] 
Level of 
Evidence Evidence Source 
A1 Systematic reviews, which include at least one randomised controlled trial (RCT), e.g. 
systematic reviews from Cochrane or NHS, centre for reviews and dissemination 
A2 Other systematic and high-quality reviews, which synthesise references 
B1 Individual RCTs 
B2 Individual non-randomised, experimental/intervention studies 
B3 Individual well-designed non-experimental studies, controlled statistically if appropri-
ate. Includes studies using case control, longitudinal, cohort, matched pairs or cross-
sectional random sample methodologies, and well-designed qualitative studies; well-
designed analytical studies including secondary analysis 
C1 Descriptive and other research or evaluation not in B (e.g. convenience samples) 
C2 Case studies and examples of good practice 
D Summary review articles and discussions of relevant literature and conference pro-
ceedings not otherwise classified 
 
 
Table 6-A2. Systematic search results: sleep/wake patterns in women with non-metastatic 
breast cancer 
 N N 
Medline – EMBASE 3,558  
CINAHL 508  
Total all databases 4,066  
Duplicates 721  
Total papers extracted 3,345  
Papers rejected on title  3,120 
Papers rejected on abstract  95 
Papers obtained in full  130 
Papers extracted through snowballing  6 
Papers excluded after review  115 
Papers retained and included in review  21 
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Table 7-A2. STROBE Statement – checklist of items that should be included in reports of 
observational studies [644] 
 
Item 
No. Recommendation 
Title and abstract   
 
1 (a) Indicate the study’s design with a commonly used term in the title or 
the abstract 
(b) Provide in the abstract an informative and balanced summary of what 
was done and what was found 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being 
reported 
Objectives 3 State specific objectives, including any pre-specified hypotheses 
Methods 
Study design 4 Present key elements of study design early in the paper 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and meth-
ods of selection of participants. Describe methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and 
methods of case ascertainment and control selection. Give the rationale for 
the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and 
methods of selection of participants 
(b) Cohort study—For matched studies, give matching criteria and number 
of exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the 
number of controls per case 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, 
and effect modifiers. Give diagnostic criteria, if applicable 
Data sources/ measure-
ment 
8* For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods 
if there is more than one group 
Bias 9 Describe any efforts to address potential sources of bias 
Study size 10 Explain how the study size was arrived at 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If appli-
cable, describe which groupings were chosen and why 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for 
confounding 
(b) Describe any methods used to examine subgroups and interactions 
(c) Explain how missing data were addressed 
(d) Cohort study—If applicable, explain how loss to follow-up was ad-
dressed 
Case-control study—If applicable, explain how matching of cases and 
controls was addressed 
Cross-sectional study—If applicable, describe analytical methods taking 
account of sampling strategy 
(e) Describe any sensitivity analyses 
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Item 
No. Recommendation 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—e.g. numbers 
potentially eligible, examined for eligibility, confirmed eligible, included 
in the study, completing follow-up, and analysed 
(b) Give reasons for non-participation at each stage 
(c) Consider use of a flow diagram 
Descriptive data 14* (a) Give characteristics of study participants (e.g. demographic, clinical, 
social) and information on exposures and potential confounders 
(b) Indicate number of participants with missing data for each variable of 
interest 
(c) Cohort study—Summarise follow-up time (e.g., average and total 
amount) 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures 
over time 
Case-control study—Report numbers in each exposure category, or sum-
mary measures of exposure 
Cross-sectional study—Report numbers of outcome events or summary 
measures 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted es-
timates and their precision (e.g., 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
(b) Report category boundaries when continuous variables were catego-
rised 
(c) If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period 
Other analyses 17 Report other analyses done—e.g. analyses of subgroups and interactions, 
and sensitivity analyses 
Discussion 
Key results 18 Summarise key results with reference to study objectives 
Limitations 19 Discuss limitations of the study, taking into account sources of potential 
bias or imprecision. Discuss both direction and magnitude of any potential 
bias 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study 
and, if applicable, for the original study on which the present article is 
based 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and 
unexposed groups in cohort and cross-sectional studies. 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological back-
ground and published examples of transparent reporting. The STROBE checklist is best used in conjunction with 
this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of In-
ternal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the 
STROBE Initiative is available at www.strobe-statement.org. 
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Table 8-A2. Systematic review results: sleep-impairing factors in women with breast cancer 
 N N  
Medline – EMBASEa 1,567b   
CINAHLa 794   
Total all databases 2,361   
Papers rejected on title/abstract  2,146  
Papers retained  191  
Papers extracted through snowballing  24  
Papers obtained in full-text  215  
Papers excluded after review  157 Reasons: 
 No sleep specific measure: 30 
 Mixed sample: 20 
 Review articles: 5 
 No associations tested: 35 
 No sleep measurement: 12 
 No breast cancer group: 2 
 Single item sleep scale only: 4 
 Tool development article: 2 
 Conference proceedings: 31 
 Dissertations: 4 
 Other: 12 
Papers retained and included in review  58  
Papers related to the chemotherapy period  26  
aLimits: 1990-March 2012; English language; abstract available 
bAfter duplicates were removed 
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Table 9-A2. Summaries of the characteristics of the 16 studies (26 articles) included in the systematic review reporting on sleep-impairing factors in women 
receiving neo-/adjuvant chemotherapy for breast cancer. 
Authors/ 
Study ref Country Research design 
Timing of 
assessment N 
Patient demo-
graphic character-
istics 
Patient clinical data Sleep measures Predictors/correlates/factors 
examined 
Ancoli-Israel et al. 
[120]; Liu et al. 
[8]; Liu et al. 
[145]; Liu et al. 
[146]; Rissling et 
al. [125] 
USA Descriptive, explorato-
ry, prospective 
Repeated measures 
Correlational 
Prior to CThC1, 
during the 3 
weeks of CThC1, 
before the start of 
CThC4, and 
during the 3 
weeks of CThC4 
97 Mean age 50.7±9.8 years 
(34-79); 73.2% Cauca-
sian; 68% married; educa-
tion: 77% college and 
above 
Response rate: 80.1% 
BC stage: I (30.2%), II (50%), IIIA 
(19.8%); Neo-adjuvant CT (n=13), adjuvant 
CT (n=83); Adjuvant CT patients: 40 
lumpectomy, 39 mastectomy, 4 double 
mastectomy 
CT regimen: AC (31%), AC+taxanes 
(50.6%); BMI 28.8±6.8 (17.4-51.8) kg/m2; 
Menopausal status: Baseline – pre-menop 
(38%) post-menop (24%); End of study: 
Peri-menop (15%) post-menop (62%). 
Sleeping medications: Baseline – Yes 
(49%); End of study – Yes (45.9%) 
Analgesics: Baseline – Yes (59.6%); End of 
study – Yes (25%) 
 
Self-report measures and objective 
recordings 
Continuous 72-hour objective measure-
ment starting at the beginning of each 
assessment point 
First data collection point: 1 week before 
the start of treatment 
Self-report sleep questionnaires and a 
sleep log 
Wrist actigraphy 
PSQI 
FOSQ 
Fatigue 
Functional status 
Depression 
Inflammatory markers (IL-6, IL-1RA, 
CRP) 
Climacteric status/symptomatology 
Beck et al. [7] USA Descriptive 
Prospective 
Secondary analysis of 
two separate RCT data 
sets (only Study 1 is 
considered here); 
analysis was conducted 
on the baseline data 
 
Prior to treatment 
and 3 consecutive 
nights post initial 
chemotherapy 
108 Mean age 50.5±9.3 years 
(28-75); 91.1% Cauca-
sian; 79.2% mar-
ried/partnered. 
Response rate: Unknown 
Stage I-IIIA BC: I (21%), II (55%), IIIA 
(24%); ≥1 month after initial surgery; 
anthracycline- and/or cyclophosphamide-
based CT; intervention and control group 
included. 
Objective (3 consecutive days and nights 
after initial chemotherapy) and subjective 
(prior to the treatment initiation) sleep 
measures 
PSQI 
Continuous 72-hour wrist actigraphy 
 
Physical health status and mental health 
status. 
Demographic and clinical information 
(age; ethinc/racial background; marital 
status; education; disease stage). 
Berger [126] 
Berger & Farr 
[127] 
USA Descriptive 
Prospective 
Repeated measures 
CThC1 through 
CThC3 
72 Mean age 49.5±8.6 years 
(33-69); 65% married; 
73% employed; 63% high 
school, 32% college. 
Response rate: 94% 
Attrition rate: 16.7% (60 
participants completed the 
study) 
Stage I or II BC: I (44%), II (56%); 53% 
mastectomy; 46% pre-menopausal, 40% 
post-menopausal; 64% anthracycline- (AC, 
CAF) and/or 36% cyclophosphamide-based 
(CMF) CT. 
Objective sleep measures used: continu-
ous 96-hour wrist actigraphy at the time 
of chemotherapy treatments (CThC1-3); 
continuous 72-hour wrist actigraphy at 
CThC1, CThC2, and CThC3 midpoints 
(days 11-17) 
Wrist actigraphy; sleep variables: mesor, 
amplitude, peak activity, nighttime 
awakenings 
 
Cancer-related fatigue 
Clinical data (time since surgery; CT 
regimen; timing of CT administration) 
Berger & Hig-
ginbotham [104] 
USA Descriptive, pilot study 
Prospective 
CThC3 and 
CThC4 
14 Mean age 52.4 (32-69); 
71% married; 64% work-
Stage I or II BC: I (50%), II (50%); 78% 
lumpectomy; 57% post-menopausal; AC 
Objective and self-reported sleep data 
Sleep data were collected at 48 hours 
Cancer-related fatigue 
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Authors/ 
Study ref Country Research design 
Timing of 
assessment N 
Patient demo-
graphic character-
istics 
Patient clinical data Sleep measures Predictors/correlates/factors 
examined 
Repeated measures ing outside the home 
(full- or part-time) 
Response rate: Unknown 
Attrition rate: 14.3% (12 
participants completed the 
study) 
 
treatment; 71% concurrent use of tamoxifen 
citrate. 
prior to CThC3; continuously during the 
21 days of CThC3; 72 hours three weeks 
after CThC4; 72 hours two months after 
CThC4 
Continuous wrist actigraphy 
Morin Sleep Diary 
 
Beck et al. [7]; 
Berger et al. 
[121]; Berger et 
al. [123]; Berger 
et al. [131]; Ber-
ger et al. [143]; 
Moore et al. [136] 
USA RCT 
Prospective, longitudi-
nal[104, 126, 127] 
Throughout CT 
treatment and 1-
year follow up 
219 Mean age 52.0±9.84 years 
(29-79); 95.3% Cauca-
sian; 72.6% married; 78% 
employed; 75% post-
secondary education 
Response rate: 82% 
BC stage: I (34%), II (53%), IIIA (13%); 
55% mastectomy; 54% post-menopausal, 
32% pre-menopausal. 
Objective and self-reported sleep data 
Continuous 48-hour wrist actigraphy (2 
days before initial chemotherapy); PSQI 
(day -2 prior to chemotherapy); CThC1-
CThC8 continuous 7-day wrist actigra-
phy and sleep diaries; CThC4 and 
CThC8 PSQI; 30, 60, 90 days after last 
chemotherapy continuous 7-day wrist 
actigraphy and sleep diaries, and PSQI 
(day 1); 1 year after CThC1 continuous 
7-day wrist actigraphy and sleep diaries, 
and PSQI (day 1) 
Wrist actigraphy 
Morin Sleep Diary 
PSQI 
 
Fatigue 
Demographic (age, education) and clini-
cal (stage of disease, menopausal status, 
surgical procedure, body mass index, 
performance status) variables 
Anxiety/depression 
Physical functioning 
Symptom distress 
Physical and mental health status 
Past sleep quality 
CT prescribed (with or without taxanes) 
Bower et al. [166] USA Descriptive, explorato-
ry 
Cross-sectional 
Correlational 
Part of a larger study of 
cognitive functioning 
after cancer treatment 
 
Within 3 months 
post-completion 
of CT 
103 Mean age: 51.2 years (32-
66); 86% white; 79% 
married/partnered; 81% 
post-secondary education 
Response rate: not report-
ed 
Type of treatment: 52% no CT (surgery ± 
RT); 48% CT (surgery ± RT + CT); time 
since diagnosis: mean 6.7 months (1.7-
12.5); time since last treatment: mean 31.8 
days (1-112) 
Self-reported sleep data only 
One measurement 
PSQI 
Fatigue 
Depressive symptoms 
Having received chemotherapy or not 
Three inflammatory markers: IL-1ra, 
sTNF-RII, CRP 
 
Colagiuri et al. 
[144] 
Denmark Descriptive, explorato-
ry 
Cross-sectional 
Correlational 
Part of a nationwide 
cohort of women treat-
ed for primary breast 
cancer 
Three to four 
months post-BC 
surgery 
3002 Mean age: 54.4 years (26-
70); 77% married/ part-
nered; 30% post-tertiary 
education 
Response rate: not report-
ed 
Type of treatment: 54% mastectomy; 44% 
receiving CT; 60% post-menopausal; 61% 
tumours < 20 mm; 12-16 months post-
surgery 
Self-reported sleep data only 
One measurement 
PSQI 
Demographics and socioeconomic status 
(personal income, net wealth, education, 
marital status, ethnicity, urbanicity, and 
children) 
Psychiatric and physical co-morbidity 
pre-cancer 
Clinical data (type of surgery, current 
chemotherapy, hormone therapy, radia-
tion therapy; tumour size, grade, axillary 
lymph node status, oestrogen receptor 
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Authors/ 
Study ref Country Research design 
Timing of 
assessment N 
Patient demo-
graphic character-
istics 
Patient clinical data Sleep measures Predictors/correlates/factors 
examined 
status) 
Health-related variables (BMI, menopau-
sal status, smoking status, weekly alco-
hol intake) 
Physical functioning 
Physical activity 
Psychological morbidity (depression, 
trait anxiety) 
 
Costantini et al. 
[137] 
USA Retrospective chart 
review 
Cross-sectional 
NA 124 Mean age: 51 years (26-
80); 50% >50 years; 62% 
married/partnered 
Response rate: NA 
BC stage: 19% I, 47% II, 32% III; 73% 
Oestrogen receptor positive; 19% HER2+; 
89% adjuvant CT; 43% post-menopausal; 
65% AC dose dense; 23% some psychiatric 
diagnosis; 26% some psychiatric medica-
tion; 14% prior sleep aid use; 52% dis-
cussed sleep aid use during CT; 32% were 
prescribed sleep aid during CT; Sleep aids: 
31% lorazepam, 29% zolpidem 
 
Retrospective recordings on prescriptions 
of sleep aid use 
Past history of sleep aid use 
Psychiatric medication use 
Psychiatric diagnosis 
Menopausal status 
Garrett et al. 
[153]; Merriman 
et al. [171] 
USA Descriptive, explorato-
ry 
Cross-sectional 
Comparative case-
control study 
Part of a larger longitu-
dinal study evaluating 
multiple symptoms in 
patients undergoing 
primary or adjuvant RT 
 
Approximately 
one week before 
the initiation of 
RT 
 
78 Mean age: 54.7±11.4 
years; 68% Caucasian; 
39% married/partnered; 
Mean years of education: 
16.2±2.7 years; 43% 
employed; 26% children 
at home; 7% parents at 
home; 40% lives alone. 
Response rate: not report-
ed 
 
Mean KPS: 88.9±11.3; Time since diagno-
sis: 5.2±2.7 months; Number of comorbidi-
ties: 5.2±2.6; stage of disease: 9% 0, 45% I, 
36% II, 10% III; 100% surgery before RT; 
56% CT before RT; 44% HT before RT 
Objective and self-reported sleep data 
Continuous sleep recording for 48 hours, 
two consecutive weekdays 
One measurement; between-groups 
comparisons 
PSQI 
GSDS 
Two-day sleep diary 
Wrist actigraphy 
BC or PC status 
Attentional fatigue (diminished ability to 
concentrate, difficulty engaging in pur-
poseful activity, and strained interper-
sonal relationships) 
Hanprasitkam et 
al. [165] 
Thailand Descriptive, explorato-
ry 
Cross-sectional 
Correlational 
During adjuvant 
CT (at least one 
CThC received) 
159 Mean age: 49.8±9.4 (27-
74) years; 65% married/ 
partnered; 65% employed 
Response rate: not report-
ed 
Time since diagnosis: not reported; BC 
stage: 12% I, 65% II, 23% III; 87% radical 
mastectomy; 54% CAF or AC, 46% CMF; 
14% one CThC received; 100% premedica-
tion with dexamethasone 
Self-reported sleep data only 
One measurement 
Modified GSDS 
Fatigue 
Haemoglobin 
Chemotherapy protocol 
Symptom distress (nausea and vomiting) 
Family and friend support 
Religious practices 
Anxiety 
Depression 
 
Kuo et al. [129] Korea Descriptive, explorato-
ry 
CThC3 and 
CThC4 
16 Mean age: 45 (29-59) 
years; 75% mar-
62.5% regular menstruation; 56% CMF (7 
patients, 28-day cycle) 
Objective and self-reported sleep data 
Two measurements: (1) 8th-9th day of 
Active versus recovery phase of chemo-
therapy 
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Authors/ 
Study ref Country Research design 
Timing of 
assessment N 
Patient demo-
graphic character-
istics 
Patient clinical data Sleep measures Predictors/correlates/factors 
examined 
Repeated measures 
Correlational 
ried/partnered; 50% 
college graduates; 56% 
employed 
Response rate: Not re-
ported 
CThC3 (active phase), (2) 2 days before 
CThC4 (recovery phase) 
Wrist actigraphy (continuous 48 hour 
recordings) 
Sleep logs 
ESS 
 
Physical distress 
Payne et al. [128] USA Descriptive, explorato-
ry 
Repeated measures, 
pilot 
Comparative 
Control group matched 
by age, ethnicity and 
menopausal status 
CThC1 and 
CThC4 
11 Mean age: 47.4±10.4 
years; 82% single/ di-
vorced; 64% > high 
school 
Response rate: not report-
ed 
5 pre-menopausal, 4 peri-menopausal; 27% 
use of sleep aids 
Objective sleep data (+ subjective sleep 
data through the fatigue questionnaire) 
Data were collected at four measurement 
points (i.e., during CThC1 and CThC4 
on days 1–3 and at the two-week nadir 
points) for two consecutive nights each 
in a sleep laboratory 
Continuous 48-hour wrist actigraphy 
Two outcome variables: sleep disturb-
ances, sleep duration 
 
Having breast cancer or not 
Roscoe et al. [147] USA Descriptive, explorato-
ry 
Repeated measures 
Secondary analysis of 
RCT data examining 
the efficacy of Paroxe-
tine 20mg in attenuat-
ing or preventing the 
development of fatigue. 
49% of final sample on 
daily paroxetine 20 mg. 
CThC2 and 
CThC4 
78 Mean age: 51.7 (34-79) 
years. 
Response rate: 63% 
CT regimens: 37% CMF, 45% CDoc±F, 
14% other; Mean KPS 89 (70-100) 
Objective sleep data 
6 days after administration of CThC2 and 
CThC4. 
Continuous 72-hour wrist actigraphy 
(days 6, 7 and 8). 
Three outcome variables: circadian 
consistency (or autocorrelation)-
similarity or dissimilarity of rest and 
activity patterns across measurement; 
daytime mean activity-average activity 
level during the day; daytime per cent 
sleep-proportion of time spent resting or 
sleeping during the day. 
 
Fatigue 
Depressive mood 
Performance status 
Overall mood 
Age 
Randomisation to paroxetine or placebo 
Savard et al. [172] Canada Descriptive, explorato-
ry 
Longitudinal, second-
ary analysis from a 
larger CBT intervention 
study for women re-
ceiving treatment for 
BC 
 
Throughout CT or 
RT 
Three assessment 
points (before 
treatment initia-
tion, post-
treatment, follow-
up 3 months) 
58 Mean age: 54.6±7.0 (36-
70) years; 65.5% mar-
ried/partnered; 51.7% at 
least a college degree; 
60.3% employed. 
Response rate: not report-
ed 
 
Time since diagnosis: not reported; BC 
stage: 67.2% I, 24.1% II, and 8.6% III. 
Surgery type: 94.8% lumpectomy, 8.6% 
mastectomy. Treatment: 26 CT+RT; 29 RT; 
3 CT only. 76% on HT; 77.6% post-
menopausal. 22%-29% psychotropic medi-
cation (mainly benzodiazepines) during the 
study. 
 
Self-report sleep data 
ISI 
Hot flashes (occurrence; prevalence; 
severity) 
Hot flashes-related quality of life 
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Authors/ 
Study ref Country Research design 
Timing of 
assessment N 
Patient demo-
graphic character-
istics 
Patient clinical data Sleep measures Predictors/correlates/factors 
examined 
Stein et al. [148] USA Descriptive, explorato-
ry 
Cross-sectional 
Secondary analyses of a 
larger longitudinal 
study 
 
4-6 weeks after 
treatment initia-
tion 
70 CT Patients: Mean age: 
57.1±8.9 (41-78) years; 
93% White; 68% Mar-
ried; 78% attended at least 
some college; 46% em-
ployed. 
CT treatment: BC stage: 14% I, 68% II, 
18% III; 54% mastectomy, 43% lumpecto-
my; Regimen: 25% A, 39% AC, 32% CAF, 
4% mitoxantrone; None HT. 
Self-report sleep data 
PSQI 
Hot flashes 
Vargas et al. [133] USA Descriptive, explorato-
ry 
Cross-sectional 
Part of a clinical trial of 
a cognitive behavioural 
stress management 
intervention. 
After surgery but 
before adjuvant 
treatment for early 
stage BC 
240 Mean age: 50.34±9.03 
years; 62.5% Mar-
ried/partnered; 67.5% 
Caucasian; 15.58±2.38 
years of education; 74.5% 
employed. 
Time since surgery: 40.13±22.70 days; 44.6 
pre-menopausal, 42.9% menopausal; BC 
stage: 16% 0, 37.8% I, 38.2% II, 8.0% III; 
Type of surgery: 50.8% lumpectomy, 
49.2% mastectomy; 29.6% breast recon-
struction at surgery; 17.9% prescribed sleep 
medication; 25% prescribed pain medica-
tion; 10.8% prescribed antidepressants; 
17.5% prescribed anti-anxiety medication. 
 
Self-report sleep data 
One assessment point 
PSQI 
Fatigue 
Functional well-being 
Abbreviations: IL-1ra – IL-1 receptor antagonist; sTNF-RII – soluble TNF receptor type II; CRP – C-reactive protein; CThC – chemotherapy cycle; CT – chemotherapy; BMI – body mass index; AC – Adriamycin + Cyclophosphamide; A – Adriamycin; PSQI – 
Pittsburgh Sleep Quality Index; FOSQ – Functional Outcome of Sleep Questionnaire; RCT – Randomised controlled trial; CAF – Cyclophosphamide + Adriamycin + 5-Fluorouracil; CMF – Cyclophosphamide + Methotrexate + 5-Fluorouracil; F – 5-Fluorouracil; 
RT – Radiation therapy; HT – Hormonal therapy; NA – Non applicable; HER2 – Human epidermal growth factor receptor 2; KPS – Karnofsky performance status; GSDS – General Sleep Disturbance Scale; ESS – Epworth Sleepiness Scale; CDocF – Cyclophos-
phamide + Docetaxel + 5-Fluorouracil; ISI – Insomnia Severity Index; CBT – Cognitive behavioural therapy 
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Table 10-A2. Methodological quality of the 16 studies included in the systematic review. 
Study LE 
Study Quality Criteria 
#1 #2 #3 #4 #5 #6 #7 #8 #9 #10 
Ancoli-Israel et al. [120]; 
Liu et al. [8]; Liu et al. 
[145]; Liu et al. [146]; 
Rissling et al. [125] 
B3 2 3 2 3 1 2 1 3 2 2 
Beck et al. [7] C1 3 3 2 2 1 1 2 3 1 2 
Berger [126]; Berger & Farr 
[127] 
B3 2 2 2 3 1 2 1 2 3 1 
Berger & Higginbotham 
[104] 
B3 1 2 2 3 1 1 1 3 3 1 
Beck et al. [7]; Berger et al. 
[121]; Berger et al. [123]; 
Berger et al. [131]; Berger 
et al. [143]; Moore et al. 
[136] 
B1 4 3 2 3 1 2 1 3 3 2 
Bower et al. [166] C1 3 2 2 1 1 1 2 1 2 2 
Colagiuri et al. [144] B3 4 2 3 1 1 1 2 1 2 2 
Costantini et al. [137] C1 3 2 1 1 1 1 1 1 1 2 
Garrett et al. [153]; Merri-
man et al. [171] 
B3 2 3 1 2 2 1 2 3 1 2 
Hanprasitkam et al. [165] C1 3 2 1 1 1 1 1 1 3 1 
Kuo et al. [129] B3 1 2 1 2 1 1 1 3 2 2 
Payne et al. [128] B3 1 2 2 3 2 2 1 2 1 2 
Roscoe et al. [147] B3 2 2 1 3 1 2 1 2 2 2 
Savard et al. [172] B3 2 3 1 3 1 1 1 1 2 2 
Stein et al. [148] C1 2 3 1 1 1 2 1 1 2 1 
Vargas et al [133] C1 4 2 1 1 1 1 2 1 3 2 
Abbreviations: LE – Levels of evidence according to the DOHNSF [116]. 
Notes: #1 Target group size [<50 participants = 1; 50-99 = 2; 100-200 = 3; >200 = 4]; #2 Sample homogeneity [No = 1; Partial = 2 (unclear inclu-
sion or exclusion criteria OR some criteria were stated but not in full); Yes = 3]; #3 Sample representativeness [None = 1; Random recruitment 
or recruitment at multiple sites OR ethnic/racial consideration = 2; Random recruitment or recruitment at multiple sites AND ethnic/racial con-
sideration = 3]; #4 Study design [Cross-sectional = 1; Prospective (repeated measures within one specific time point) = 2; Longitudinal (repeat-
ed measures over different time-points) = 3]; #5 Comparison group [No = 1; Yes = 2]; #6 Response rates and test for bias [No = 1; Partial = 2 
(only one of the two parameters was reported); Yes = 3 (both parameters were reported)]; #7 Time since diagnosis/treatment [No = 1; Yes = 2]; 
#8 Sleep measurement comprehensiveness [Subjective/self-report measures only = 1; Objective measures only = 2; A combination of the two 
methods = 3]; #9 Psychometric adequacy of measures of correlates [Not applicable = 1 (Demographic/clinical data were used only); No = 1 (in-
struments never validated in this population and no psychometric properties were reported); Partial = 2 (only part of the instruments were valid 
for this population OR validated instruments but no psychometric properties reported in this study OR non-validated instruments, but reliabil-
ity/validity was tested/reported for the specific study only); Yes = 3 (instruments were validated in this population AND reliability/validity was 
tested/reported for the specific study; OR biological measures were used)]; #10 Sleep as outcome variable [Secondary = 1; Primary = 2] 
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Table 11-A2. Effect sizes of associations between objectively recorded sleep/wake parameters and sleep-impairing covariates in women receiving neo-/adjuvant 
chemotherapy for breast cancer. 
 
Effect sizes r (95% CI) 
Sleep parameter 
Predictor/ corre-
late TST SL 
% Sleep 
(night) 
WASO 
(minutes) 
NOCAW 
(no.) 
NOCAW 
(minutes) 
TTIB 
(minutes) % WASO 
% Sleep 
(day) 
% Wake 
(day) EARLAW SE 
Mins. wake 
(day) 
Mins. sleep 
(day) 
Age -.35 (-.51, -.17) 
[7] 
-.22 (-.42, -.00) 
[7, 121, 123, 
131, 143] 
.0 [146] 
 -.28 (-.45, -.10) 
[7] 
-.17 (-.37, -.05) 
[7, 121, 123, 
131, 143] 
.18 (-.01, .36) 
[7] 
.15 (-.06, .36) 
[7, 121, 123, 
131, 143] 
.0 [146] 
.04 (-.15, .24) 
[7] 
.11 (-.11, .32) 
[7, 121, 123, 
131, 143] 
 -.14 (-.34, .08) 
[7] 
.17 (-.05, .37) 
[7] 
.0 [147]    .0 [146] .0 [146] 
Educational levela .0 [7] 
.0 [7, 121, 123, 
131, 143] 
.0 [146] 
 .0 [7] 
.0 [7, 121, 123, 
131, 143] 
.0 [7] 
.0 [7, 121, 123, 
131, 143] 
.0 [146] 
.0 [7] 
.0 [7, 121, 123, 
131, 143] 
 .0 [7] .0 [7]     .0 [146] .0 [146] 
Raceb -.17 (-.36, .03) 
[146] 
  -.22 (-.40, -.02) 
[146] 
        .0 [146] .0 [146] 
Marital status .0 [146]   .0 [146]         .0 [146] .0 [146] 
Personal income .0 [146]   .0 [146]         .0 [146] .0 [146] 
PS         -.17 (-.38, 
.05)* [147] 
     
BMI .26 (.06, .44) 
[146] 
  .24 (.04, .42) 
[146] 
        .0 [146] .0 [146] 
BC stage .0 [7] 
.0 [7, 121, 123, 
131, 143] 
.0 [146] 
 .0 [7] 
.0 [7, 121, 123, 
131, 143] 
.0 [7] 
.0 [7, 121, 123, 
131, 143] 
.0 [146] 
.0 [7] 
.0 [7, 121, 123, 
131, 143] 
 .0 [7] .0 [7]     .0 [146] .0 [146] 
Breast cancer 
statusc 
.22 (.06, .36) 
[153] 
.04 (-.11, .20) 
[153] 
  -.11 (-.26, .05) 
[153] 
-.13 (-.28, .03) 
[153] 
.15 (-.01, .29) 
[153] 
-.17 (-.32, -.02) 
[153] 
-.01 (-.16, .15) 
[153] 
.01 (-.15, .16) 
[153] 
.17 (.01, .31) 
[153] 
-.18 (-.32, -.02) 
[153] 
.01 (-.15, .16) 
[153] 
-.01 (-.15, .16) 
[153] 
Breast cancer 
statusd 
.41 (-.26, .81) 
[128] 
             
CT regimene     -.10 (-.38, .19) 
[126, 127] 
         
Active CThC 
periodf 
.0 [129] .0 [129]  .0 [129]        .0 [129]   
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Effect sizes r (95% CI) 
Sleep parameter 
Predictor/ corre-
late TST SL 
% Sleep 
(night) 
WASO 
(minutes) 
NOCAW 
(no.) 
NOCAW 
(minutes) 
TTIB 
(minutes) % WASO 
% Sleep 
(day) 
% Wake 
(day) EARLAW SE 
Mins. wake 
(day) 
Mins. sleep 
(day) 
Type of breast 
surgery 
.0 [146]   .0 [146]         .0 [146] .0 [146] 
Time from sur-
gery (days) 
    .0 [126, 127]          
Menopausal sta-
tusg 
-.16 (-.29, -.03) 
[7, 121, 123, 
131, 143] 
-.18 (-.40, .06) 
[125, 145, 146] 
 -.12 (-.34, .12) 
[125] 
.15 (.02, .28) 
[7, 121, 123, 
131, 143] 
.15 (-.09, .37) 
[125, 145, 146] 
.11 (-.03, .24) 
[7, 121, 123, 
131, 143] 
-.23 (-.44, .01) 
[125] 
.33 (.11, .53) 
[125] 
     -.14 (-.27, -.01) 
[7, 121, 123, 
131, 143] 
.0 [145, 146] .0 [145, 146] 
Cancer-related 
fatigue 
.0 [120, 146] 
.0 [7, 121, 123, 
131, 143] 
.0 [7, 121, 123, 
131, 143] 
.0 [120] .03 (-.17, .23) 
[120, 146] 
.0 [7, 121, 123, 
131, 143] 
.0 [120] 
.03 (-.17, .23) 
[126, 127] 
.44 (-.12, .78) 
[104] 
.0 [7, 121, 123, 
131, 143] 
 .11 (-.13, .33) 
[104] 
 .0 [7, 121, 123, 
131, 143] 
.29 (.07, .48) 
[147] 
.0 [7, 121, 123, 
131, 143] 
 .0 [7, 121, 123, 
131, 143] 
-.03 (-.22, .17) 
[120, 146] 
-.15 (-.31, .02) 
[7, 121, 123, 
131, 143] 
.0 [120, 146] 
.0 [7, 121, 123, 
131, 143] 
Overall mood         .36 (.15, .54) 
[147] 
     
Depression         .36 (.14, .54) 
[147] 
     
IL-1 .11 (-.16, .37) 
[145] 
  .17 (-.11, .42) 
[145] 
         -.13 (-.39, .15) 
[145] 
IL-6 -.06 (-.33, .21) 
[145] 
  -.12 (-.38, .16) 
[145] 
         .19 (-.09, .44) 
[145] 
CRP -.04 (-.31, .23) 
[145] 
  -.40 (-.61, -.15) 
[145] 
         .12 (-.16, .38) 
[145] 
Abbreviations: TST – Total sleep time; SL – Sleep latency; WASO – Wakefulness after sleep onset; TTIB – Total time in bed; NOCAW – Nocturnal awakenings; EARLAW – Early morning awakenings; SE – Sleep efficiency; PS – Performance status; BMI – Body 
mass index; BC – Breast cancer; CT – Chemotherapy; CThC – Chemotherapy cycle; IL-1 – Interleukin 1; IL-6 – Interleukin 6; CRP – C-Reactive protein; CI – Confidence interval 
*Karnofsky Performance Status scale 
Notes: aWith and without education beyond high school; bNon-Caucasian v. Caucasian; cVersus other type of cancer; dVersus no cancer diagnosis/healthy controls; eNon-doxorubicin v. doxorubicin; fActive CThC period (weeks 1-2) v. recovery CThC period (week 
3); gPre-/peri-menopausal v. post-menopausal 
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Table 12-A2. Effect sizes of associations between self-reported sleep/wake parameters and sleep-impairing covariates in women receiving neo-/adjuvant chemo-
therapy for breast cancer. 
 
Effect sizes r (95% CI) 
Sleep parameter 
Predictor/correlate TST SL Perceived SQ SDSTRB NOCAW DDYSF WASO HSE SAU Total scale scores 
Age         -.05 (-.18, .08) 
[136] 
.07 (.04, .11)* [144] 
.0* [146] 
.0* [148] 
Marital status          .01 (-.02, .05)* [144] 
.0* [148] 
Ethnicity/Racea          -.01 (-.05, .02)* [144] 
-.21 (-.39, -.01)* [146] 
.0* [148] 
Education         .0 [136] .04 (.01, .08)* [144] 
.22 (-.02, .43)* [148] 
.0* [146] 
Personal income          .08 (.05, .12)* [144] 
.0* [146] 
.0* [148] 
Employment statusb          .0* [148] 
Children living at home          .01 (-.03, .04)* [144] 
BMI          .06 (.02, .09)* [144] 
.0* [146] 
Number of co-morbidities          .05 (.02, .09)* [144] 
Alcohol consumption          .02 (-.02, .05)* [144] 
Household net 
wealth/person 
         .04 (-.00, .07)* [144] 
Urbanicity          .00 (-.03, .04)* [144] 
Cigarettes/day          .08 (.05, .12)* [144] 
Breast cancer statusd .01 (-.15, .16)† 
[153] 
.19 (.03, .33)† 
[153] 
.05 (-.11, .20)† 
[153] 
.26 (.10, .39)† 
[153] 
.04 (-.12, .19)† 
[153] 
.26 (.11, .40)† 
[153] 
 .0† [153] .04 (-.11, .20)† 
[153] 
.21 (.06, .35)† [153] 
Tumour size          .01 (-.03, .04)* [144] 
Tumour grade          .01 (-.03, .05)* [144] 
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Effect sizes r (95% CI) 
Sleep parameter 
Predictor/correlate TST SL Perceived SQ SDSTRB NOCAW DDYSF WASO HSE SAU Total scale scores 
Disease stage          .0* [146] 
Lymph node statuse          .01 (-.04, .06)* [144] 
Oestrogen receptor statusf          -.01 (-.05, .03)* [144] 
Type of surgeryg          -.03 (-.06, .01)* [144] 
.0* [146] 
Active CThC periodh .0$ [129] .0$ [129] .45 (-.06, .78)$,ǂ 
[129] 
 .0$ [129] .46 (-.04, .78)$ 
[129] 
 .0$ [129]   
Past sleep quality         .14 (.01, .27) 
[136] 
 
Past sleep aid use         .35 (.18, .50) 
[137] 
 
Psychiatric history         .16 (-.01, .33) 
[137] 
.08 (.04, .12)* [144] 
Psychiatric medication use         .18 (.01, .35) 
[137] 
 
Physical activity          .12 (.08, .15)* [144] 
Cancer-related fatigue .0 [120] 
.0 [7, 121, 123, 
131, 143] 
.0 [120] 
.30 (-.28, .72) 
[104] 
.25 (.08, .41)* [7, 
121, 123, 131, 
143] 
.21 (.00, .41)* 
[120] 
.31 (.15, .46)* [7, 
121, 123, 131, 
143] 
.22 (.10, .34)* 
[133] 
.21 (.00, .41)* 
[120] 
.28 (.11, .43)* [7, 
121, 123, 131, 
143] 
 .21 (.00, .41)* 
[120] 
.42 (.27, .55)* [7, 
121, 123, 131, 
143] 
-.14 (-.62, .42) 
[104] 
.0 [120] 
-.01 (-.53, .53) 
[104] 
.0 [7, 121, 123, 
131, 143] 
.0* [133] 
.21 (.00, .41) 
[120] 
.25 (.08, .41)* [7, 
121, 123, 131, 
143] 
.50 (.33, .63)* [8, 120, 
146] 
.36 (.20, .50)* [7, 121, 
123, 131, 143] 
.34 (.16, .50)* [166] 
.47 (.34, .58)§ [165] 
-.56 (-.87, -.40)§ [171] 
.12 (-.01, .24)* [133] 
Nausea & vomiting          .34 (.20, .47)§ [165] 
Overall symptom distress      .79 (.48, .92)$ 
[129] 
    
Hot flashes          .19 (-.07, .43)** [172] 
.17 (-.06, .39)* [148] 
Depression          .52 (.33, .67)* [8, 120] 
.52 (.36, .65)* [166] 
.36 (.33, .39)* [144] 
.38 (.24, .51)§ [165] 
Anxiety (trait)          .28 (.24, .31)* [144] 
.44 (.31, .56)§ [165] 
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Effect sizes r (95% CI) 
Sleep parameter 
Predictor/correlate TST SL Perceived SQ SDSTRB NOCAW DDYSF WASO HSE SAU Total scale scores 
Family support          -.44 (-.56, -.31)§ [165] 
Friend support          -.38 (-.51, -.24)§ [165] 
Religious practices (cop-
ing) 
         -.16 (-.31, -.01)§ [165] 
Menopausal status .16 (-.08, .39) 
[125] 
-.04 (-.27, .19) 
[125] 
-.19 (-.40, .05) 
[125] 
.13 (-.11, .36) 
[125] 
 -.22 (-.44, .02) 
[125] 
 -.12 (-.35, .12) 
[125] 
.0* [137] 
-.11 (-.33, .13) 
[125] 
.0* [7, 121, 123, 131, 
143] 
.08 (.04, .12)* [144] 
-.21 (-.42, .03) [125, 145, 
146] 
Treated with CTi          .23 (.04, .40)* [166] 
-.03 (-.06, .01)* [144] 
IL-1ra          .03 (-.17, .22)* [166] 
.32 (.05, .54) [145] 
IL-6          .35 (.09, .57) [145] 
sTNF-RII          .03 (-.17, .22)* [166] 
CRP          .03 (-.17, .22)* [166] 
.17 (-.11, .42) [145] 
Haemoglobin          -.14 (-.29, .02)§ [165] 
Abbreviations: TST – Total sleep time; SL – Sleep latency; SQ – Sleep quality; WASO – Wakefulness after sleep onset; SDSTRB – Nocturnal sleep disturbance; NOCAW – Nocturnal awakenings; DDYSF – Daytime sleepiness/dysfunction; HSE – Habitual sleep 
efficiency; BMI – Body mass index; BC – Breast cancer; CT – Chemotherapy; CThC – Chemotherapy cycle; IL-1ra – IL-1 receptor antagonist; sTNF-RII – soluble TNF receptor type II; IL-6 – Interleukin 6; CRP – C-Reactive protein; CI – Confidence interval 
*PSQI; †PSQI, GSDS; §GSDS; $ESS; ǂSleep log; **ISI 
Notes: aNon-Caucasian v. Caucasian; bEmployed v. not employed; cVersus general medical patients; dVersus other type of cancer; e1-3 v. >3 lymph nodes involved; fPositive v. negative; gMastectomy v. lumpectomy; hActive CThC period (weeks 1-2) v. recovery 
CThC period (week 3); iVersus other type of treatment 
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Table 13-A2. Effect sizes of associations between circadian activity parameters and sleep-impairing covariates in women receiving neo-/adjuvant chemotherapy for 
breast cancer. 
 
Effect sizes r (95% CI) 
Sleep parameter 
Predictor/correlate Sleep bouts (night, N) 
Sleep bouts 
(night, 
mins.) 
Activity 
bouts (day) 
Peak  
activity 
Mean  
activity 
(daytime) 
Mesor Acrophase 24h Auto-
correlation Amplitude 
Circadian 
quotient 
Mesor plus 
amplitude 
Up/down 
mesor 
Goodness 
of fit 
Age     .0 [147]   .0 [147]      
Performance status    -.07 (-.20, .06)* 
[7, 121, 123, 
131, 143] 
.29 (.07, .48) 
[147] 
-.07 (-.20, .06)* 
[7, 121, 123, 
131, 143] 
-.07 (-.20, .06)* 
[7, 121, 123, 
131, 143] 
.29 (.07, .48) 
[147] 
-.07 (-.20, .06) 
[7, 121, 123, 
131, 143] 
-.07 (-.20, .06) 
[7, 121, 123, 
131, 143] 
-.07 (-.20, .06) 
[7, 121, 123, 
131, 143] 
   
Body Mass Index    -.22 (-.34, -.09) 
[7, 121, 123, 
131, 143] 
 -.22 (-.34, -.09) 
[7, 121, 123, 
131, 143] 
-.22 (-.34, -.09) 
[7, 121, 123, 
131, 143] 
-.22 (-.34, -.09) 
[7, 121, 123, 
131, 143] 
-.22 (-.34, -.09) 
[7, 121, 123, 
131, 143] 
-.22 (-.34, -.09) 
[7, 121, 123, 
131, 143] 
   
Disease stage    -.04 (-.17, .10) 
[7, 121, 123, 
131, 143] 
 -.04 (-.17, .10) 
[7, 121, 123, 
131, 143] 
-.04 (-.17, .10) 
[7, 121, 123, 
131, 143] 
-.04 (-.17, .10) 
[7, 121, 123, 
131, 143] 
-.04 (-.17, .10) 
[7, 121, 123, 
131, 143] 
-.04 (-.17, .10) 
[7, 121, 123, 
131, 143] 
   
Breast cancer statusa      -.11 (-.26, .05) 
[153] 
.01 (-.14, .17) 
[153] 
-.02 (-.17, .14) 
[153] 
.0 [153] .12 (-.04, .27) 
[153] 
   
CT regimenb      -.44 (-.63, -.14) 
[126, 127] 
  -.30 (-.54, -.01) 
[126, 127] 
 -.45 (-.64, -.13) 
[126, 127] 
  
Timing of CT ad-
ministrationc 
     .12 (-.11, .35) 
[126, 127] 
  .15 (-.09, .37) 
[126, 127] 
 .27 (.04, .47) 
[126, 127] 
  
Time from surgery 
(days) 
     .0 [126, 127]   .0 [126, 127]  .0 [126, 127]   
Menopausal statusd -.25 (-.46, -.02) 
[125] 
-.06 (-.29, .18) 
[125] 
           
Cancer-related fa-
tigue 
.0 [120] 
 
 .0 [7, 121, 123, 
131, 143] 
-.19 (-.31, -.05) 
[7, 121, 123, 
131, 143] 
-.22 (-.42, .00) 
[147] 
-.35 (-.54, -.13) 
[126, 127] 
-.53 (-.83, -.00) 
[104] 
-.21 (-.33, -.08) 
[7, 121, 123, 
131, 143] 
.0 [120] 
.09 (-.04, .22) 
[7, 121, 123, 
131, 143] 
-.27 (-.46, -.05) 
[147] 
-.14 (-.26, -.00) 
[7, 121, 123, 
131, 143] 
-.14 (-.27, -.01) 
[7, 121, 123, 
131, 143] 
-.78 (-.86, -.67) 
[104] 
-.40 (-.58, -.18) 
[126, 127] 
.05 (-.08, .18) 
[7, 121, 123, 
131, 143] 
-.35 (-.54, .13) 
[126, 127] 
.0 [120] .0 [120] 
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Effect sizes r (95% CI) 
Sleep parameter 
Predictor/correlate Sleep bouts (night, N) 
Sleep bouts 
(night, 
mins.) 
Activity 
bouts (day) 
Peak  
activity 
Mean  
activity 
(daytime) 
Mesor Acrophase 24h Auto-
correlation Amplitude 
Circadian 
quotient 
Mesor plus 
amplitude 
Up/down 
mesor 
Goodness 
of fit 
Overall mood     -.26 (-.46, -.04) 
[147] 
  -.37 (-.55, -.16) 
[147] 
     
Depression    -.17 (-.30, -.04) 
[7, 121, 123, 
131, 143] 
-.28 (-.47, -.06) 
[147] 
-.19 (-.31, -.06) 
[7, 121, 123, 
131, 143] 
.0 [120] 
.10 (-.04, .23) 
[7, 121, 123, 
131, 143] 
-.29 (-.48, -.07) 
[147] 
-.16 (-.29, -.03) 
[7, 121, 123, 
131, 143] 
-.13 (-.26, .00) 
[7, 121, 123, 
131, 143] 
.03 (-.10, .16) 
[7, 121, 123, 
131, 143] 
 .0 [120] .0 [120] 
Anxiety    .03 (-.11, .16) 
[7, 121, 123, 
131, 143] 
 .06 (-.07, .19) 
[7, 121, 123, 
131, 143] 
.08 (-.05, .21) 
[7, 121, 123, 
131, 143] 
-.01 (-.14, .13) 
[7, 121, 123, 
131, 143] 
.03 (-.10, .16) 
[7, 121, 123, 
131, 143] 
.05 (-.09, .18) 
[7, 121, 123, 
131, 143] 
   
Abbreviations: CT – chemotherapy 
*Karnofsky Performance Status scale 
Notes: aVersus other type of cancer; bNon-doxorubicin v. doxorubicin; c28-day cycle v. 21-day cycle; dPre-/peri-menopausal v. post-menopausal 
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Table 14-A2. Systematic search results: sleep/wake patterns in informal caregivers 
 N N 
Medline – EMBASE 3,745  
CINAHL 7,942  
Total all databases 11,687  
Duplicates 1,915  
Total papers extracted 9,772  
Papers rejected based on title  9,697 
Papers rejected based on abstract  30 
Papers obtained in full  45 
Papers excluded after review  6 
Papers retained  39 
Papers extracted through snowballing  5 
Papers pooled for objective 1  44 
Papers extracted from pool for objective 2  17 
 
 
Table 15-A2. Systematic search results: sleep/wake patterns in couples or patient-caregiver 
dyads 
 N N 
Medline – EMBASE 215  
CINAHL 973  
Total all databases 1,188  
Duplicates 74  
Total papers extracted 1,114  
Papers rejected based on title  1,058 
Papers rejected based on abstract  22 
Papers obtained in full  34 
Papers excluded after review  14 
Papers retained  20 
Papers extracted through snowballing  7 
Papers pooled for objective 1  27 
Papers extracted from pool for objective 2  10 
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Table 16-A2. Methodological characteristics of generic self-report sleep measures identified in the literature 
Characteristic AIS [645] GSDS [646] ISI [409] JSPS [647] LSEQ [648] MOS-SS [408] PSQI [407] SAQ [649] VSH [650] 
WHIIRS 
[651, 652] 
No. of items 8 21 7 4 10 12 19 17 10 5 
Domains/components 1 7 1 1 4 6 7 6 1 1 
Global score × × × ×  × × × × × 
Test time, min – – ≤ 5 – 2-3 ≤ 5 5-10 – – – 
Recall 30 d 7 d 14 d 30 d Varies 1-30 d 28 d 30 d 30 d 1 d 28 d 
Dimensions measured 
Sleep duration × ×    × ×  ×  
Sleep latency × × × × × × ×  × × 
Bed/wake-times 
      × ×   
Sleep efficiency 
      ×    
Sleep disturbance 
    × × × × ×  
Daytime dysfunction × × ×    ×    
Daytime sleepiness × ×    × × ×   
Sleep medications 
 ×     ×    
Sleep quality × ×   ×  ×   × 
Daytime napping 
     ×   ×  
Sleep depth 
        ×  
Feelings upon arising/ 
satisfaction   × ×  ×  × ×  
Wakefulness after 
sleep onset     × ×  ×  × 
Leg restlessness 
       ×   
Early unplanned 
awakenings ×  ×       × 
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Characteristic AIS [645] GSDS [646] ISI [409] JSPS [647] LSEQ [648] MOS-SS [408] PSQI [407] SAQ [649] VSH [650] 
WHIIRS 
[651, 652] 
Nocturnal awakenings × × × × ×   × × × 
Snoring 
     ×     
Respiratory problems 
     ×  ×   
Concern due to in-
somnia   ×        
Psychometric characteristics 
Reliability 
(Cronbach’s α) .79-.90 .79-.89 .74-.78 .63-.79 .46-.79 .75-.86 .83 – .82 – 
Stability (test-retest 
reliability) 
× 
1 week   × ×  × ×   
Reproducibility × × ×   × × ×  × 
Validity 
× 
Criterion; Con-
vergent; Factor 
structure analy-
sis; Known-
groups 
– 
× 
Content; Crite-
rion; Conver-
gent 
× 
Convergent; 
Known-groups 
× 
Content; 
Known-groups 
× 
Content; Con-
vergent; Diver-
gent; Known-
groups; Factor 
structure analy-
sis 
× 
Content; Factor 
structure analy-
sis; Conver-
gent; Diver-
gent; Known-
groups; Criteri-
on 
× 
Content; Factor 
structure analy-
sis; Criterion; 
Convergent; 
Known-groups 
× 
Convergent; 
Known-groups 
× 
Factor structure 
analysis; 
Known-groups 
Acceptability Good Good Good Good Fair Good Good Good Fair Good 
Use in people affected by (breast) cancer 
Patients 
 × ×   × ×  × × 
Informal caregivers 
 ×     ×    
Abbreviations: ASI – Athens Insomnia Scale; GSDS – General Sleep Disturbance Scale; ISI – Insomnia Severity Index; JSPS – Jenkins Sleep Problem Scale; LSEQ – Leeds Sleep Evaluation Questionnaire; MOS-SS – 
Medical Outcomes Study Sleep Scale; PSQI – Pittsburgh Sleep Quality Index; SAQ – Sleep Assessment Questionnaire; VSH – Verran and Snyder-Halpern Sleep Scale; WHIIRS – Women’s Health Initiative Insomnia 
Rating Scale 
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Table 17-A2. Methodological characteristics of the four sleep hygiene measures identified in the literature 
Measure Population Items/ Domains Scoring & Ease of use Reliability Validity 
Sleep Hygiene 
Awareness and 
Practice Scale 
[413] 
Insomniacs and 
healthy individu-
als 
USA 
32 items 
2 domains: awareness 
(13); practices (19) 
Awareness: 7-point scale (beneficial to sleep 
1-3, no effect 4, disruptive to sleep 5-7) 
Practices: 0-7 (days per week engaging in 
activity) 
Two subscale scores 
Recall time frame: no 
Ease of use: Poor 
 
Internal: awareness α=.78; practices 
α=.47 
Test-retest: unknown 
Content: Poor (no clear rationale for item selection) 
Construct: Poor (overlapping instrument items) 
Sleep Hygiene 
Index [415] 
Healthy individu-
als 
USA 
13 items 
1 domain 
5-point scale (Frequency of engagement in 
behaviours: 1= never – 5 = always) 
Global score 
Recall time frame: no 
Ease of use: Good 
Internal: α=.66 
Test-retest (5-week interval): r=.71; 
p<.01 
Content: Acceptable (items were derived from the diagnostic 
criteria for inadequate sleep hygiene in the International Clas-
sification of Sleep Disorders) 
Construct: Moderate (convergent validity established through 
positive correlations with established criteria for inadequate 
sleep hygiene (r=.37-.46; p<.01), and self-reports of sleep 
quality (r=.48; p<.01) and daytime sleepiness (r=.24; p<.01) 
 
Sleep Hygiene 
Practice Scale 
[414] 
Insomniacs and 
healthy individu-
als 
Taiwan 
30 items 
4 domains: arousal-
related behaviours; 
sleep scheduling and 
timing; eating/drinking 
behaviours; sleep 
environment 
 
6-point scale 
(Frequency of engagement in behaviours: 1 
= never – 6 = always) 
Four subscale scores 
Recall time frame: no 
Ease of use: Moderate 
 
Internal: domain 1 – α=.70, .58; 
domain 2 – α=.82, .74; domain 3 – 
α=.72, .70; domain 4 – α=.67, .65 
(good sleepers and insomniacs, 
respectively) 
Test-retest: unknown 
Content: Moderate (items were modified from published in-
struments and general sleep hygiene guidelines of various 
sources) 
Construct: Good (exploratory and confirmatory factor analyses 
to verify factorial structure) 
Sleep Hygiene 
Self-Test [412] 
War veterans with 
post-traumatic 
sleep disorder 
USA 
30 items 
1 domain 
Binary data scale (Engagement in behav-
iours: yes/no) 
Global score 
Recall time frame: 1 month 
Ease of use: Moderate 
Internal: α=.54 
Test-retest: unknown 
Content: Poor (no clear rationale for item selection) 
Construct: Poor 
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Table 18-A2. Methodological characteristics of the thirteen measures of coping identified in the literature 
Instrument Items Dimensions 
Theoretical 
concept of 
coping 
Reliability Validity Notes 
Brief Approach/ 
Avoidance Cop-
ing Question-
naire [451] 
12  General approach/avoidance 
 Diversion 
Dispositional 
or trait-like 
Internal consistency: Cronbach’s 
α – .65-.68 (12 items), .59 (factor 
1), .55 (factor 2); Item-to-total 
correlations – .19-.45 
Stability: Unknown 
Principal component analysis and confirmatory 
factor analysis supported in part questionnaire’s 
structure. 
Weak-to-moderate correlations between the factors 
and measures of coping, anxiety, depression, in-
trusive thoughts and beliefs of locus control. 
 
Overlapping factor structure with 
factor 1 consisting of both ap-
proach and avoidance items. 
Limited availability of data on 
cancer populations. 
Brief COPE scale 
[457] 
28  Active coping; Planning; Positive 
reframing; Acceptance; Humour; 
Religion; Using emotional sup-
port; Using instrumental support; 
Self-distraction; Denial; Venting; 
Substance use; Behavioural dis-
engagement; Self-blame 
Dispositional 
or trait-like 
Internal consistency: Cronbach’s 
α – ranging from .50 to .90 for 
the 14 subscales 
Stability: 2-3 weeks after primary 
surgery for breast cancer, ICC 
ranged from <.0 to 1.0 for the 14 
subscales 
Item reduction technique from the original COPE 
inventory – structure approximates the original 
scale. 
Unstable factor structure – requires performing 
factor analytic procedures in every study. 
Active coping, planning and acceptance discrimi-
nated well between women undergone mastecto-
my versus lumpectomy for breast cancer. 
 
Feasibility of the scale’s use with 
patients with breast cancer con-
firmed. 
Researchers free to use all or a 
sub-set of the items/dimensions. 
Situational or state-like version 
also available. 
Cancer Coping 
Questionnaire 
[456] 
21  Total individual scale (4 sub-
scales: coping, positive focus, di-
version, planning) 
 Interpersonal scale 
Situational or 
state-like 
Internal consistency: Cronbach’s 
α – .87 (total individual scale), 
.82 (interpersonal scale) 
Stability: r=.90 (total individual 
scale), .84 (interpersonal scale) 
for a 4-week interval 
Principal component analysis confirmed a four-
factor structure for the total individual scale; no 
data available for the interpersonal scale. 
Able to discriminate between patients with breast 
cancer and patients attending a psycho-oncology 
service. 
The total individual scale was negatively but weak-
ly correlated with measures of depression, but no 
correlation with measures of anxiety. 
Positive moderate-to-strong correlations of both 
dimensions with measures of coping and adjust-
ment to cancer. 
 
Patient-oriented questionnaire – 
requires vast adaptation to be 
administered to informal caregiv-
ers. 
Replication of psychometric prop-
erties is needed in future studies 
of people with cancer. 
COPE Inventory 
[449] 
60  Emotion-focused (seeking social 
support; emotional vending emo-
tions) 
 Problem-solving (active coping, 
Dispositional 
or trait-like 
Internal consistency: Cronbach’s 
α – .45-.92 for the 15 subscales; 
Item-to-total correlations – -.19 
to .45 
Confirmatory factor analysis supported the full 15-
factor model structure. 
Adequate subscale correlations with measures of 
optimism, control, self-esteem, hardiness, and 
Researchers free to use all or a 
sub-set of the items/dimensions. 
Situational or state-like version 
also available. 
  
  287
 
Instrument Items Dimensions 
Theoretical 
concept of 
coping 
Reliability Validity Notes 
planning, suppression, restraint, 
seeking social support – instru-
mental) 
 Dysfunctional coping (behav-
ioural disengagement, mental 
disengagement, substance use) 
 Other strategies (positive re-
interpretation/growth, denial, ac-
ceptance, turning to religion) 
 
Stability: r ranged from .42 to .89 anxiety. The questionnaire’s length may 
increase participant burden. 
Coping Inventory 
for Stressful 
Situations [453] 
48  Task-oriented 
 Emotion-oriented 
 Avoidance-oriented (addressing 
both distraction and social diver-
sion) 
 
Dispositional 
or trait-like 
Internal consistency: Cronbach’s 
α – >.80 for the 3 dimensions. 
Stability: Good test-retest reliabil-
ities over a 6-week and 12-week 
interval. 
Factor analysis supported the three-coping dimen-
sions structure. 
Adequate correlations with measures of coping, 
depression, anxiety, neuroticism, and extraversion. 
Limited availability of data on 
cancer populations. 
Coping Respons-
es Indices [455] 
32  Cognitive coping strategies 
 Behavioural coping strategies 
 Avoidance coping strategies 
Situational or 
trait-like 
Internal consistency: Acceptable 
internal consistency reliabilities 
have been reported. 
Stability: unknown 
Factor structure has not been established through 
rigorous testing. 
Two scoring procedures may 
increase participant burden. 
Limited availability of data on 
cancer populations. 
Requires payment for use. 
 
Coping Strategies 
Inventory [447] 
72 Primary dimensions 
 Problem-solving; Cognitive re-
structuring; Suppressing emo-
tions; Social support; Problem-
avoidance; Wishful thinking; So-
cial withdrawal; Self-criticism 
Four secondary and two tertiary 
dimensions 
 
Dispositional 
or trait-like 
Internal consistency: Cronbach’s 
α – .72-.94 for the 15 dimensions 
Stability: rho ranged from .67 to 
.83. 
Factor analytic procedures have supported the 
inventory’s structure. 
No available data on cancer popu-
lations. 
The questionnaire’s length may 
increase participant burden. 
Coping Strategy 
Indicator [452] 
33  Problem-solving 
 Seeking support 
 Avoidance 
Dispositional 
or trait-like 
Internal consistency: Cronbach’s 
α – .84-.93 for the 3 dimensions 
Stability: rho ranged from .77 to 
.86. 
Factor analytic procedures have supported the 
three-scale solution. 
Fit indices from a confirmatory factor analysis 
supported the three-factor structure. 
Theoretical flaws in the instru-
ments development. 
Limited availability of data on 
populations of adults with cancer. 
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Instrument Items Dimensions 
Theoretical 
concept of 
coping 
Reliability Validity Notes 
Adequate convergent validity correlations with 
measures of coping. One unexpected significant 
correlation between the problem-solving scale and 
a measure of seeking social support. 
Appropriate correlations with measures of locus of 
control and depression. 
 
Jalowiec Coping 
Scale – Revised 
[450] 
60  Confrontive; Evasive; Optimis-
tic; Fatalistic; Emotive; Pallia-
tive; Supportive; Self-reliant 
Dispositional 
or trait-like 
Internal consistency: Cronbach’s 
α – ranged from .48 to .81 (use) 
and from .48 to .80 (helpfulness) 
for the 8 dimensions. 
Stability: unknown 
Rigid content analysis based on literature and a 
panel of experts. 
Strong correlations between the two different scor-
ing methods (.85-.95), which suggests that they 
may measure same aspects of coping. 
Factor analytic studies failed to replicate the pro-
posed eight-factor structure. 
 
Limited availability of data on 
populations of adults with cancer. 
The questionnaire’s length may 
increase participant burden. 
Life Situations 
Inventory [454] 
28  Problem-solving 
 Avoidance 
 Resignation 
Situational or 
state-like 
Internal consistency: Cronbach’s 
α – .75-.82 for the 3 dimensions; 
inter-scale correlations ranged 
from .01 to .51. 
Stability: unknown 
 
No supportive validation data have been provided. Coping strategies regarding a 
hypothetical rather than real situ-
ation are assessed. 
No available data on cancer popu-
lations. 
Measure of Daily 
Coping [448] 
55  Distraction; Situation redefini-
tion; Direct action; Catharsis; 
Acceptance; Social support; Re-
laxation; Religion 
Situational or 
state-like 
Internal consistency: Cronbach’s 
α – .36-.78; inter-scale correla-
tions ranged from -.28 to .18. 
Stability: unknown 
The Catharsis and Acceptance dimensions correlat-
ed with measures of perceived control 
No other supportive validation data have been 
provided. 
No available data on cancer popu-
lations. 
Coping strategies regarding a real 
situation are assessed. 
The questionnaire’s length may 
increase participant burden. 
 
Ways of Coping 
Checklist [445] 
68  Problem-focused coping 
 Emotion-focused coping 
Situational or 
state-like 
Internal consistency: Cronbach’s 
α – .80 (problem-focused), .81 
(emotion-focused). 
Stability: unknown 
 
Most factor-analytic studies failed to support the 
checklist’s hypothesised two-factor structure. 
Limited validation data are available. 
No available data on cancer popu-
lations. 
The questionnaire’s length may 
increase participant burden. 
Ways of Coping 
Questionnaire 
66  Confrontation coping; Distanc-
ing; Self-controlling; Seeking so-
Situational or 
state-like 
Internal consistency: Cronbach’s 
α – ranged from .56 to .85 for the 
Several factor-analytic studies failed to replicate 
the proposed eight-factor structure. 
Limited availability of data on 
populations of adults with cancer. 
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Instrument Items Dimensions 
Theoretical 
concept of 
coping 
Reliability Validity Notes 
[446] cial support; Accepting responsi-
bility; Escape-avoidance; Planful 
problem-solving; Positive reap-
praisal 
8 dimensions; inter-scale correla-
tions ranged from -.04 to .39. 
Stability: unknown 
The questionnaire’s length may 
increase participant burden. 
Abbreviations: ICC – Intraclass correlation coefficient 
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Table 19-A2. Univariate within-patient and within caregiver associations between outcome and demographic/clinical covariates (n=48 dyads) 
 Outcome variables 
Covariate 
Patients 
Covariate 
Caregivers 
PSQf DDISTf NAPTIME TST SL HSE WASO GSQI PSQf DDISTf 
NAPT
IME TST SL HSE WASO GSQI 
AGEPTa –.29** –.18† –.17†     –.28** AGECGa –.24*  .24*  –.21*   –.22* 
RELTYPEb  .39** .40** –.25†    .29* RELTYPEb  .30**       
RELATDURa –.24*  –.18†  –.18† .17†  –.25* RELATDURa –.28** –.22*   –.18†   –.28** 
CMRBDPTb .43** .40** . –
.46** 
.40** –.52*** .39** .52*** CMRBDCGb  .53***       
PSPTa .23† .38**  –.25*  –.28* .25* .29* PSCGa  .29*       
SLPASTPTb .42** .38**  –.30* .32* –.49*** .42** .54*** SLPASTCGb .59*** .57***  –.25† .45** –.52** .42** .65** 
SLCAPTb .32**   –.26†    .30* SLCACGb .26† .31*   .29* –.35* .31* .37** 
SLSROOMb  –.32* –.30*      SLSROOMb         
SLSHOUSb   –.36*      SLSHOUSb     –.25†    
         SEXCGb   –.31*      
BMIPTa  .22* .26*               
BCSTAGEa –.24*    –.29*    BCSTAGEa         
ALCHLPTa    –.25*     ALCHLCGa     –.20† .20†   
EDUCPTb         EDUCCGb      .26† –.29* –.25† 
Abbreviations: AGEPT/CG – Age; RELTYPE – Dyad’s type of relationship; RELATDUR – Dyad’s duration of relationship; CMRBDPT/CG – Presence of comorbidities; PSPT/CG – Performance status; 
SLPASTPT/CG – Past Sleep History; SLCAPT/CG – Sleep Affected by Cancer Diagnosis; SLSROOM – Dyad sleeps in the same bedroom; SLSHOUS – Dyad sleeps in the same house; SEXCG – Caregiver gen-
der; BMIPT – Patient’s Body Mass Index; BCSTAGE – Breast cancer stage; ALCHLPT/CG – Alcohol consumption status; EDUCPT/CG – Educational level; PSQf – Perceived Sleep Quality factor from 
PSQI; DDISTf – Daily Disturbances factor from PSQI; NAPTIME – Daytime napping duration; TST – Total Sleep Time; SL – self-reported Sleep Latency; HSE – self-reported Habitual 
Sleep Efficiency; WASO – Wakefulness after sleep onset; GSQI – Global Sleep Quality Index score. 
Notes: †p < .10; *p < .05; **p < .01; ***p < .001; Repeatedly measured outcome variables and covariates were averaged over 4 points of assessment. Sample size for BMIPT was N = 45. Blank cells denote non-
significant results. Additional covariates tested (no significant results emerged) included: physical activity; patient’s menopausal status; employment status; time since diagnosis; time since initial breast surgery; type 
of breast surgery; type of chemotherapy regimen received; and smoking status. 
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Table 20-A2. Explanatory MHLMs predicting patient and caregiver perceived sleep quality 
(PSQf) with own and cross-partner predictor effects 
 Own effects Cross-partner effects 
 Patient Caregiver Patient Caregiver 
 PE (SE) rES PE (SE) rES PE (SE) rES PE (SE) rES 
Fixed Effects         
Intercept 1.95 (.71)**  1.57 (.26)***  2.20 (.70)**  1.72 (.29)***  
Linear 2.03 (1.09)†  .22 (.27)ns  1.55 (1.08)ns  .37 (.31)ns  
Quadratic –.66 (.34)†  –.06 (.08)ns  –.60 (.33)†  –.11 (.09)ns  
PHYSPT_M .05 (.83)ns .01   –.13 (.78)ns –.03 1.57 (.55)** .45 
CRACB_M   .05 (.04)ns .24 –.03 (.04)ns –.12 .03 (.03)ns .14 
PSYCHPT_M –.06 (.38)ns –.03   .00 (.36)ns .00 .75 (.30)* .40 
PSYCHCG_M   –.26 (.32)ns –.13 –.18 (.34)ns –.10 –.38 (.29)ns –.22 
SHPT_M –.04 (.06)ns –.11   –.03 (.05)ns –.09 .00 (.04)ns .02 
SHCG_M   .00 (.03)ns .01 –.01 (.03)ns –.07 .02 (.03)ns .08 
COPNEGPT_M .12 (.08)ns .24   .16 (.08)* .37 .14 (.06)* .37 
COPNEGCG_M   .02 (.05)ns .05 –.10 (.05)† –.34 .02 (.04)ns .08 
SDSTRBPT_M .15 (.07)* .36   .27 (.07)*** .60 .14 (.05)* .41 
SDSTRBCG_M   .09 (.04)* .37 .02 (.04)ns .10 .12 (.04)** .48 
SDSTRBPT_TVC .18 (.04)*** .46   .21 (.04)*** .50 .02 (.03)ns .07 
SDSTRBCG_TVC   .12 (.05)* .27 –.08 (.05)† –.19 .12 (.04)** .30 
SHPT_TVC .04 (.03)ns .11   .00 (.04)ns .02 –.02 (.03)ns –.07 
SHCG_TVC   .04 (.02)ns .15 .02 (.03)ns .10 .05 (.02)† .21 
PHYSPT_TVC .53 (.37)ns .15   .46 (.37)ns .14 –.11 (.34)ns –.04 
CRACB_TVC   .08 (.03)** .30 .09 (.03)** .33 .06 (.03)* .23 
PSYCHPT_TVC .45 (.21)* .23   –.30 (.21)ns –.17 .42 (.18)* .26 
PSYCHCG_TVC   –.04 (.23)ns –.02 .07 (.23)ns .03 –.06 (.22)ns –.03 
COPNEGP_TVC .07 (.04)ns .17 .  .13 (.05)** .29 –.03 (.04)ns –.07 
COPNEGC_TVC   –.13 (.05)** –.28 .10 (.05)† .22 –.14 (.05)** –.32 
Random Effects         
Residual .91    .78    
Intercept .91***  .61**  .88***  .45**  
Linear 1.96***  .51ns  1.94***  .24ns  
Quadratic .19**  .07ns  .16***  .04ns  
Estim. parameters 73    93    
Deviance statistic 1138.6    1050.7    
χ2(df) 89.96 (34)***    87.93 (20)***    
Abbreviations: PE – Parameter estimate (coefficient); SE – Standard error; rES – Effect size r; TVC – time-varying covariate; M – time-invariant 
covariate (average); df – Degrees of freedom; PHYSPT – Physical burden (patient); CRACB – Caregiving burden (caregiver); PSYCHPT/CG – 
Psychological burden (patient/caregiver); SHPT/CG – Sleep hygiene (patient/caregiver); COPNEGPT/CG – Negative coping (pa-
tient/caregiver); SDTSRBPT/CG – Nocturnal sleep disturbances (patient/caregiver); PSQf – PSQI Factor 1 indicating Perceived Sleep Quality. 
Notes: The “own effects” model was compared with the deviance statistic from the quadratic model. The “cross-partner effects” model was com-
pared with the deviance statistic from the “own effects” model. All models were controlled for demographic/clinical covariates, including 
SLPAST, SLCA, AGE, RELATDUR, CMRBDT, PS, and BCSTAGE for patients; and SLPAST, SLCA, AGE, and RELATDUR for caregivers; 
only significant results (or trends towards significance) are shown. Time-varying (TVC) and time-invariant (mean) components of the predictors 
tested have been coded so that higher numbers reflect poorer/worse outcomes. nsp > .10; †p < .10; *p < .05; **p < .01; ***p < .001. 
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Table 21-A2. Explanatory MHLMs predicting patient and caregiver daily disturbance 
(DDISTf) with own and cross-partner predictor effects 
 Own effects Cross-partner effects 
 Patient Caregiver Patient Caregiver 
 PE (SE) rES PE (SE) rES PE (SE) rES PE (SE) rES 
Fixed Effects         
Intercept 2.18 (.31)***  1.39 (.28)***  1.96 (.32)***  1.43 (.29)***  
Linear .09 (.16)ns  .17 (.15)ns  .20 (.17)ns  .17 (.16)ns  
PHYSPT_M .96 (.28)** .49   1.01 (.28)** .53 –.02 (.23)ns –.02 
CRACB_M   .04 (.02)* .34 .01 (.02)ns .06 .03 (.02)† .32 
PSYCHPT_M .18 (.16)ns .19   .33 (.17)† .33 .08 (.16)ns .09 
PSYCHCG_M   .37 (.15)* .39 –.04 (.15)ns –.05 .39 (.15)* .42 
SHPT_M .04 (.02)ns .27   .02 (.02)ns .13 –.02 (.02)ns –.18 
SHCG_M   .01 (.02)ns .11 .04 (.02)* .35 .02 (.02)ns .18 
COPNEGPT_M –.02 (.04)ns –.10   –.04 (.04)ns –.18 .01 (.03)ns .06 
COPNEGCG_M   –.01 (.02)ns –.08 –.01 (.03)ns –.08 –.02 (.02)ns –.14 
SHPT_TVC .05 (.02)* .39   .04 (.02)* .16 .03 (.02)ns .11 
SHCG_TVC   .04 (.02)** .40 –.00 (.01)ns –.02 .04 (.01)** .20 
PHYSPT_TVC .74 (.19)*** .54   .70 (.18)*** .28 .03 (.18)ns .01 
CRACB_TVC   .05 (.02)** .42 .03 (.02)ns .11 .05 (.02)** .21 
PSYCHPT_TVC .07 (.12)ns .11   .08 (.11)ns .05 .06 (.11)ns .04 
PSYCHCG_TVC   .04 (.14)ns .04 .26 (.14)† .14 .03 (.14)ns .02 
COPNEGP_TVC .06 (.03)* .33 .  .07 (.03)** .20 –.02 (.03)ns –.05 
COPNEGC_TVC   .01 (.03)ns .14 –.02 (.03)ns –.06 .00 (.03)ns .01 
Random Effects         
Residual .39    .32    
Intercept .22***  .12**  .24***  .16***  
Linear .04**  .05***  .05***  .06***  
Estim. parameters 59    75    
Deviance statistic 748.7    686.6    
χ2(df) 87.26 (16)***    62.14 (16)***    
Abbreviations: PE – Parameter estimate (coefficient); SE – Standard error; rES – Effect size r; TVC – time-varying covariate; M – time-invariant 
covariate (average); df – Degrees of freedom; PHYSPT – Physical burden (patient); CRACB – Caregiving burden (caregiver); PSYCHPT/CG 
– Psychological burden (patient/caregiver); SHPT/CG – Sleep hygiene (patient/caregiver); COPNEGPT/CG – Negative coping (pa-
tient/caregiver); DDISTf – PSQI Factor 3 indicating Daily Disturbances. 
Notes: The “own effects” model was compared with the deviance statistic from the linear model. The “cross-partner effects” model was com-
pared with the deviance statistic from the “own effects” model. All models were controlled for demographic/clinical covariates, including 
SLPAST, SLCA, AGE, RELATDUR, CMRBDT, PS, and BCSTAGE for patients; and SLPAST, SLCA, AGE, and RELATUR for caregiv-
ers; only significant results (or trends towards significance) are shown. Time-varying (TVC) and time-invariant (mean) components of the 
predictors tested have been coded so that higher numbers reflect poorer/worse outcomes. nsp > .10; †p < .10; *p < .05; **p < .01; ***p < .001. 
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Table 22-A2. Explanatory MHLMs predicting patient and caregiver daytime napping duration 
(NAPTIME) with own and cross-partner predictor effects 
 Own effects Cross-partner effects 
 Patient Caregiver Patient Caregiver 
 PE (SE) rES PE (SE) rES PE (SE) rES PE (SE) rES 
Fixed Effects         
Intercept 23.22 (12.22)†  17.68 (12.61)ns  21.82 (11.98)†  27.64 (12.76)†  
Linear 85.91 (24.79)**  10.49 (4.75)*  103.82 (26.98)†  7.90 (5.46)ns  
Quadratic –26.53 (7.86)**  –2.43 (1.46)ns  –32.83 (9.04)***  –1.76 (1.56)ns  
PHYSPT_M 31.63 (14.63)* .35   27.56 (15.04)† .32 2.95 (11.17)ns .05 
CRACB_M   .07 (.74)ns .02 .26 (.88)ns .05 .19 (.70)ns .05 
PSYCHPT_M 2.59 (6.87)ns .06   3.63 (7.36)ns .09 –13.63 (5.94)* –.39 
PSYCHCG_M   15.94 (6.08)* .41 6.75 (7.23)ns .17 15.88 (5.87)* .44 
SHPT_M 2.75 (1.03)* .42   2.69 (1.11)* .41 –.38 (.92)ns –.08 
SHCG_M   .05 (.64)ns .01 –.55 (.78)ns –.13 –.77 (.66)ns –.21 
COPNEGPT_M –1.32 (1.56)ns –.14   –1.55 (1.69)ns –.17 3.27 (1.41)* .39 
COPNEGCG_M   –1.26 (1.07)ns –.20 –.58 (1.26)ns –.09 –1.12 (1.07)ns –.19 
SDSTRBPT_M –2.68 (1.33)† –.33   –2.61 (1.41)† –.33 1.23 (1.06)ns .21 
SDSTRBCG_M   –.58 (.78)ns –.12 –1.04 (.86)ns –.22 –.73 (.77)ns –.17 
SDSTRBPT_TVC .40 (.76)ns .06   .82 (.84)ns .11 –.01 (.51)ns –.00 
SDSTRBCG_TVC   1.47 (.67)* .23 1.25 (.99)ns .14 1.25 (.64)† .22 
SHPT_TVC .40 (.70)ns .06   1.11 (.71)ns .18 .67 (.49)ns .15 
SHCG_TVC   .38 (.39)ns .10 .02 (.55)ns .00 .36 (.38)ns .11 
PHYSPT_TVC –3.68 (7.40)ns –.05   –1.19 (7.38)ns –.02 4.79 (5.08)ns .11 
CRACB_TVC   –.21 (.41)ns –.06 1.91 (.60)** .34 –.27 (.40)ns –.23 
PSYCHPT_TVC 11.74 (4.05)** .30   10.49 (4.30)* .27 –4.52 (2.71)† –.19 
PSYCHCG_TVC   3.68 (3.29)ns .12 –8.73 (4.81)† –.20 3.92 (3.16)ns .14 
COPNEGP_TVC 1.36 (.93)ns .16 .  1.40 (.96)ns .16 .18 (.60)ns .03 
COPNEGC_TVC   –.76 (.69)ns –.12 .42 (1.02)ns .08 –.72 (.67)ns –.12 
Random Effects         
Residual 208.83    181.90    
Intercept 380.84***  159.28***  309.95***  130.50***  
Linear 2506.37***  371.03ns  2649.11***  388.34ns  
Quadratic 256.70***  32.83ns  300.65***  32.67ns  
Estim. parameters 79    99    
Deviance statistic 3200.5    3057.1    
χ2(df) 46.72 (20)***    143.43 (20)***    
Abbreviations: PE – Parameter estimate (coefficient); SE – Standard error; rES – Effect size r; TVC – time-varying covariate; M – time-invariant 
covariate (average); df – Degrees of freedom; PHYSPT – Physical burden (patient); CRACB – Caregiving burden (caregiver); PSYCHPT/CG – 
Psychological burden (patient/caregiver); SHPT/CG – Sleep hygiene (patient/caregiver); COPNEGPT/CG – Negative coping (pa-
tient/caregiver); SDTSRBPT/CG – Nocturnal sleep disturbances (patient/caregiver); NAPTIME – Average daytime napping duration. 
Notes: The “own effects” model was compared with the deviance statistic from the quadratic model. The “cross-partner effects” model was com-
pared with the deviance statistic from the “own effects” model. All models were controlled for demographic/clinical covariates, including 
SLSROOM, SLSHOUS, AGE, RELDYAD, RELATDUR, PS, and BMI for patients; and SLSROOM, SLSHOUS, RELDYAD, RELATUR, 
and SEXCG for caregivers; only significant results (or trends towards significance) are shown. Time-varying (TVC) and time-invariant (mean) 
components of the predictors tested have been coded so that higher numbers reflect poorer/worse outcomes. nsp > .10; †p < .10; *p < .05; **p < 
.01; ***p < .001. 
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Table 23-A2. Explanatory MHLMs predicting patient and caregiver total sleep time (TST) 
with own and cross-partner predictor effects 
 Own effects Cross-partner effects 
 Patient Caregiver Patient Caregiver 
 PE (SE) rES PE (SE) rES PE (SE) rES PE (SE) rES 
Fixed Effects         
Intercept 439.70 (22.12)***  413.35 (20.16)***  433.30 (21.74)***  413.59 (19.48)***  
PHYSPT_M –45.15 (39.86)ns –.19   –56.47 (35.97)ns –.27 35.62 (33.99)ns .17 
CRACB_M   –4.02 (2.53)ns –.24 –3.80 (2.10)† –.31 –4.73 (2.61)† –.29 
PSYCHPT_M 8.90 (15.63)ns .09   11.20 (20.83)ns .10 30.11 (23.10)ns .22 
PSYCHCG_M   35.87 (23.74)ns .23 29.03 (20.23)ns .25 40.27 (22.98)† .28 
SHPT_M 2.16 (2.34)ns .15   1.00 (2.43)ns .07 –4.81 (2.90)ns –.27 
SHCG_M   2.39 (1.67)ns .22 .11 (1.58)ns .01 2.93 (1.41)* .33 
COPNEGPT_M 2.69 (5.21)ns .09   2.90 (5.96)ns .09 3.75 (5.47)ns .12 
COPNEGCG_M   –5.04 (5.37)ns –.15 2.27 (2.76)ns .15 –6.29 (5.89)ns –.18 
SDSTRBPT_M –2.98 (2.72)ns –.18   –2.55 (3.02)ns –.15 –.03 (2.90)ns –.00 
SDSTRBCG_M   –5.33 (2.86)† –.28 –3.67 (2.38)ns –.27 –6.53 (2.61)* –.39 
Random Effects         
Residual 3089.24    3078.59    
Intercept 2360.40***  3522.29***  1969.57***  2835.80***  
Estim. parameters 24    34    
Deviance statistic 3946.4    3931.45    
χ2(df) 15.95 (10)ns    30.94 (20)†    
Abbreviations: PE – Parameter estimate (coefficient); SE – Standard error; rES – Effect size r; M – time-invariant covariate (average); df – 
Degrees of freedom; PHYSPT – Physical burden (patient); CRACB – Caregiving burden (caregiver); PSYCHPT/CG – Psychological burden 
(patient/caregiver); SHPT/CG – Sleep hygiene (patient/caregiver); COPNEGPT/CG – Negative coping (patient/caregiver); SDTSRBPT/CG – 
Nocturnal sleep disturbances (patient/caregiver); TST – Total Sleep Time. 
Notes: The “own effects” model was compared with the deviance statistic from the means-only model. The “cross-partner effects” model was 
compared with the deviance statistic from the “own effects” model. All models were controlled for demographic/clinical covariates, including 
SLPAST, SLCA, RELDYAD, CMRBDT, PS, and ALCHL for patients; and SLPAST and RELDYAD for caregivers; only significant results 
(or trends towards significance) are shown. Time-invariant (mean) components of the predictors tested have been coded so that higher num-
bers reflect poorer/worse outcomes. nsp > .10; †p < .10; *p < .05; **p < .01; ***p < .001. 
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Table 24-A2. Explanatory MHLMs predicting patient and caregiver sleep latency (SL) with 
own and cross-partner predictor effects 
 Own effects Cross-partner effects 
 Patient Caregiver Patient Caregiver 
 PE (SE) rES PE (SE) rES PE (SE) rES PE (SE) rES 
Fixed Effects         
Intercept 27.68 (3.38)***  17.47 (3.13)***  25.93 (3.22)***  18.94 (3.94)***  
Linear 13.05 (7.88)ns .24 6.47 (6.07)ns .15 18.30 (7.84)* .34 5.21 (6.88)ns .11 
Quadratic –4.75 (2.64)† –.26 –1.39 (1.55)ns –.13 –6.64 (2.63)* –.36 –1.25 (1.77)ns –.10 
SDSTRBPT_TVC .45 (.41)ns .12   .62 (.45)ns .16 .20 (.38)ns .06 
SDSTRBCG_TVC   .34 (.44)ns .08 1.09 (.69)ns .18 .33 (.50)ns .08 
SHPT_TVC .71 (.40)† .19   .82 (.41)† .22 –.63 (.55)ns –.13 
SHCG_TVC   –.18 (.31)ns –.06 .03 (.41)ns .00 –.07 (.30)ns –.03 
PHYSPT_TVC 2.54 (5.38)ns .05   2.30 (4.76)ns .06 3.35 (3.29)ns .12 
CRACB_TVC   .43 (.24)† .19 .44 (.24)† .21 .90 (.53)† .19 
PSYCHPT_TVC –1.15 (3.10)ns –.04   –.50 (2.94)ns –.02 5.74 (4.06)ns .16 
PSYCHCG_TVC   5.76 (6.51)ns .09 –.45 (3.41)ns –.02 5.30 (5.36)ns .11 
COPNEGP_TVC –.59 (.55)ns –.11 .  –.36 (.56)ns –.07 –.42 (.54)ns –.13 
COPNEGC_TVC   –1.91(1.37)ns –.15 .44 (.24)ns .09 –1.88 (1.32)ns –.16 
Random Effects         
Residual 191.23    172.85    
Intercept 170.57*  32.72ns  186.88**  53.61ns  
Linear 93.91*  371.34ns  127.68**  321.26ns  
Quadratic 10.74*  25.66ns  13.52**  20.96ns  
Estim. parameters 46    56    
Deviance statistic 2990.7    2871.8    
χ2(df) 46.12 (10)*    118.83 (10)***    
Abbreviations: PE – Parameter estimate (coefficient); SE – Standard error; rES – Effect size r; TVC – time-varying covariate; df – Degrees of 
freedom; PHYSPT – Physical burden (patient); CRACB – Caregiving burden (caregiver); PSYCHPT/CG – Psychological burden (pa-
tient/caregiver); SHPT/CG – Sleep hygiene (patient/caregiver); COPNEGPT/CG – Negative coping (patient/caregiver); SDTSRBPT/CG – Noc-
turnal sleep disturbances (patient/caregiver); SL – Sleep Latency. 
Notes: The “own effects” model was compared with the deviance statistic from the quadratic model. The “cross-partner effects” model was com-
pared with the deviance statistic from the “own effects” model. All models were controlled for demographic/clinical covariates, including 
SLPAST, RELATDUR, CMRBDT, and BCSTAGE for patients; no covariates were entered for caregivers due to lack of significant variability; 
only significant results (or trends towards significance) are shown. Time-varying (TVC) components of the predictors tested have been coded so 
that higher numbers reflect poorer/worse outcomes. nsp > .10; †p < .10; *p < .05; **p < .01; ***p < .001. 
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Table 25-A2. Explanatory MHLMs predicting patient and caregiver habitual sleep efficiency 
(HSE) with own and cross-partner predictor effects 
 Own effects Cross-partner effects 
 Patient Caregiver Patient Caregiver 
 PE (SE) rES PE (SE) rES PE (SE) rES PE (SE) rES 
Fixed Effects 
        
Intercept 85.05 (2.28)***  84.65 (2.18)***  86.49 (2.45)***  84.56 (2.42)***  
Linear –7.81 (2.91)*  –1.88 (1.74)ns  –8.40 (3.91)*  –.20 (2.30)ns  
Quadratic 2.34 (.98)*  .37 (.55)ns  2.48 (1.24)†  –.05 (.66)ns  
PHYSPT_M –2.70 (5.16)ns –.08   –2.04 (4.60)ns –.08 2.62 (4.18)ns .11 
CRACB_M   –.97 (.30)** –.54 –.51 (.26)† –.33 –.94 (.27)** –.52 
PSYCHPT_M 2.57 (1.84)ns .22   2.28 (2.16)ns .18 2.69 (2.30)ns .20 
PSYCHCG_M   4.51 (2.44)† .29 –5.09 (2.08)* –.39 3.75 (2.43)ns .26 
SHPT_M –.14 (.31)ns –.07   –.13 (.33)ns –.07 .32 (.35)ns .16 
SHCG_M   –.63 (.24)* –.39 .21 (.21)ns .17 .51 (.24)* .36 
COPNEGPT_M 1.20 (.53)* .43   .64 (.50)ns .22 –.09 (.49)ns –.03 
COPNEGCG_M   –.00 (.40)ns –.00 –.59 (.34)† –.29 .02 (.38)ns .01 
SDSTRBPT_M –.69 (.36)† –.30   –.91 (.39)* –.38 .01 (.41)ns .00 
SDSTRBCG_M   –.88 (.31)** –.42 –.19 (.27)ns –.12 –.88 (.28)** –.48 
SDSTRBPT_TVC –.86 (.25)*** –.35   –.81 (.26)** –.33 –.32 (.23)ns –.16 
SDSTRBCG_TVC   –.28 (.37)ns –.08 –.56 (.32)† –.20 –.22 (.29)ns –.09 
SHPT_TVC –.96 (.23)*** –.41   –.94 (.24)*** –.41 –.09 (.22)ns –.05 
SHCG_TVC   –.27 (.18)ns –.16 –.39 (.18)* –.24 –.29 (.17)† –.20 
PHYSPT_TVC –4.61 (2.31)* –.21   –4.92 (2.46)* –.22 –1.86 (2.28)ns –.09 
CRACB_TVC   –.20 (.19)ns –.12 –.37 (.20)† –.21 –.24 (.18)ns –.15 
PSYCHPT_TVC 1.23 (1.18)ns .11   1.70 (1.34)ns .14 1.47 (1.22)ns .14 
PSYCHCG_TVC   –1.38 (1.55)ns –.10 –.36 (1.58)ns –.03 –.62 (1.43)ns –.05 
COPNEGP_TVC .22 (.32)ns .08   .16 (.30)ns .06 –.24 (.27)ns –.10 
COPNEGC_TVC   .69 (.43)ns .17 –.17 (.33)ns –.06 .79 (.30)* .29 
Random Effects         
Residual 42.72    36.53    
Intercept 22.98**  33.27***  13.02**  33.46***  
Linear 49.84*  20.41ns  74.23**  47.11†  
Quadratic 6.44**  1.96ns  8.63***  4.19†  
Estim. parameters 65    85    
Deviance statistic 2485.4    2356.5    
χ2(df) 91.06 (20)***    128.94 (20)***    
Abbreviations: PE – Parameter estimate (coefficient); SE – Standard error; rES – Effect size r; TVC – time-varying covariate; M – time-invariant 
covariate (average); df – Degrees of freedom; PHYSPT – Physical burden (patient); CRACB – Caregiving burden (caregiver); PSYCHPT/CG – 
Psychological burden (patient/caregiver); SHPT/CG – Sleep hygiene (patient/caregiver); COPNEGPT/CG – Negative coping (pa-
tient/caregiver); SDTSRBPT/CG – Nocturnal sleep disturbances (patient/caregiver); HSE – Habitual Sleep Efficiency. 
Notes: The “own effects” model was compared with the deviance statistic from the quadratic model. The “cross-partner effects” model was com-
pared with the deviance statistic from the “own effects” model. All models were controlled for demographic/clinical covariates, including 
SLPAST, RELATDUR, CMRBDT, and PS for patients; and SLPAST, SLCA, RELATUR, EDUCCG, and ALCHLCG for caregivers; only sig-
nificant results (or trends towards significance) are shown. Time-varying (TVC) and time-invariant (mean) components of the predictors tested 
have been coded so that higher numbers reflect poorer/worse outcomes. nsp > .10; †p < .10; *p < .05; **p < .01; ***p < .001. 
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Table 26-A2. Explanatory MHLMs predicting patient and caregiver wakefulness after sleep 
onset (WASO) with own and cross-partner predictor effects 
 Own effects Cross-partner effects 
 Patient Caregiver Patient Caregiver 
 PE (SE) rES PE (SE) rES PE (SE) rES PE (SE) rES 
Fixed Effects 
        
Intercept 65.54 (16.18)***  51.42 (10.33)***  52.02 (18.92)*  55.63 (11.62)***  
Linear 25.66 (26.80)ns  3.75 (8.04)ns  31.09 (29.09)ns  –1.66 (10.53)ns  
Quadratic –10.66 (8.65)ns  –.41 (2.64)ns  –11.99 (9.50)ns  .97 (3.05)ns  
PHYSPT_M –22.86 (25.64)ns –.14   –34.08 (27.47)ns –.21 3.78 (20.43)ns .03 
CRACB_M   3.12 (1.46)* .33 .29 (1.61)ns .03 3.48 (1.28)* .43 
PSYCHPT_M –17.95 (12.41)ns –.23   –14.99 (12.76)ns –.20 –6.51 (11.24)ns –.10 
PSYCHCG_M   –9.61 (13.27)ns –.12 –30.76 (13.48)* –.37 –3.68 (11.65)ns –.05 
SHPT_M 3.10 (1.71)† .28   4.26 (1.88)* .37 .13 (1.48)ns .02 
SHCG_M   2.94 (1.25)* .36 –.91 (1.33)ns –.12 –2.52 (1.11)* –.37 
COPNEGPT_M 6.05 (2.75)* .34   –3.85 (3.03)ns –.22 .09 (2.47)ns .01 
COPNEGCG_M   –1.55 (1.36)ns –.18 1.31 (2.43)ns .09 –2.33 (1.86)ns –.21 
SDSTRBPT_M 4.63 (2.08)* .34   5.69 (2.36)* .39 –2.43 (1.99)ns –.21 
SDSTRBCG_M   2.70 (1.18)* .35 –.98 (1.75)ns –.10 3.27 (1.32)* .40 
SDSTRBPT_TVC 6.36 (1.70)*** .38   5.68 (1.46)*** .41 1.21 (1.03)ns .13 
SDSTRBCG_TVC   –.84 (1.45)ns –.06 4.98 (1.83)** .30 –.84 (1.34)ns –.07 
SHPT_TVC 3.47 (1.48)* .24   3.17 (1.30)* .27 .98 (1.01)ns .11 
SHCG_TVC   1.94 (.63)** .31 3.39 (1.00)** .36 1.82 (.78)* .26 
PHYSPT_TVC 4.07 (14.50)ns .03   9.99 (13.31)ns .09 5.68 (10.48)ns .06 
CRACB_TVC   .23 (.83)ns .03 –1.13 (1.07)ns –.12 .19 (.83)ns .03 
PSYCHPT_TVC –11.79 (8.23)ns –.15   –13.27 (7.56)† –.20 –6.95 (5.60)ns –.14 
PSYCHCG_TVC   6.93 (6.35)ns .12 3.84 (8.74)ns .05 3.89 (6.54)ns .06 
COPNEGP_TVC 2.19 (1.86)ns .13 .  1.81 (1.67)ns .12 .65 (1.22)ns .06 
COPNEGC_TVC   .32 (1.14)ns .03 3.05 (1.87)ns .18 .21 (1.40)ns .02 
Random Effects         
Residual 980.3    795.52    
Intercept 2191.07***  501.33**  1649.41***  502.82***  
Linear 3653.22***  681.43ns  5371.62***  892.91*  
Quadratic 366.21***  70.63†  547.12***  86.91**  
Estim. parameters 64    84    
Deviance statistic 3648.1    3475.7    
χ2(df) 79.02 (20)***    172.38 (20)***    
Abbreviations: PE – Parameter estimate (coefficient); SE – Standard error; rES – Effect size r; TVC – time-varying covariate; M – time-invariant 
covariate (average); df – Degrees of freedom; PHYSPT – Physical burden (patient); CRACB – Caregiving burden (caregiver); PSYCHPT/CG – 
Psychological burden (patient/caregiver); SHPT/CG – Sleep hygiene (patient/caregiver); COPNEGPT/CG – Negative coping (pa-
tient/caregiver); SDTSRBPT/CG – Nocturnal sleep disturbances (patient/caregiver); WASO – Wakefulness after Sleep Onset. 
Notes: The “own effects” model was compared with the deviance statistic from the quadratic model. The “cross-partner effects” model was com-
pared with the deviance statistic from the “own effects” model. All models were controlled for demographic/clinical covariates, including 
SLPAST, CMRBDT, and PS for patients; and SLPAST, SLCA, and EDUC for caregivers; only significant results (or trends towards signifi-
cance) are shown. Time-varying (TVC) and time-invariant (mean) components of the predictors tested have been coded so that higher numbers 
reflect poorer/worse outcomes. nsp > .10; †p < .10; *p < .05; **p < .01; ***p < .001. 
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Table 27-A2. Explanatory MHLMs predicting patient and caregiver overall sleep/wake im-
pairment (GSQI) with own and cross-partner predictor effects 
 Own effects Cross-partner effects 
 Patient Caregiver Patient Caregiver 
 PE (SE) rES PE (SE) rES PE (SE) rES PE (SE) rES 
Fixed Effects         
Intercept 3.83 (.76)***  4.22 (.57)***  3.56 (.89)**  4.19 (.63)***  
Linear 2.87 (.99)** .41 .58 (.47)ns .18 3.21 (1.31)* .36 .79 (.60)ns .19 
Quadratic –.96 (.32)** –.43 –.15 (.13)ns –.17 –1.02 (.40)* –.37 –.22 (.17)ns –.18 
PHYSPT_M 3.17 (1.42)* .34   3.08 (1.40)* .36 –1.21 (.97)ns –.21 
CRACB_M   .18 (.08)* .30 .12 (.09)ns .24 .21 (.07)** .44 
PSYCHPT_M –.13 (.58)ns –.04   –.04 (.73)ns –.01 –.12 (.66)ns –.03 
PSYCHCG_M   –.14 (.62)ns –.04 –.75 (.68)ns –.19 –.47(.64)ns –.12 
SHPT_M –.01 (.10)ns –.03   –.03 (.11)ns –.06 –.02 (.09)ns –.04 
SHCG_M   –.06 (.06)ns –.15 .02 (.07)ns .05 –.01 (.07)ns –.03 
COPNEGPT_M .16 (.19)ns .14   .20 (.16)ns .21 .01 (.14)ns .01 
COPNEGCG_M   .10 (.11)ns .14 –.13 (.11)ns –.20 .05 (.09)ns .10 
SHPT_TVC .32 (.08)*** .39   .27 (.07)*** .41 –.01 (.06)ns –.01 
SHCG_TVC   .09 (.03)** .32 –.02 (.05)ns –.06 .11 (.04)** .28 
PHYSPT_TVC 2.80 (.68)*** .40   2.57 (.63)*** .42 –.19 (.58)ns –.04 
CRACB_TVC   .12 (.05)* .23 –.07 (.05)ns –.15 .14 (.05)** .30 
PSYCHPT_TVC –.12 (.43)ns –.03   –.08 (.37)ns –.02 .54 (.33)ns .18 
PSYCHCG_TVC   .51 (.51)ns .11 .83 (.43)† .21 .43 (.39)ns .12 
COPNEGP_TVC .10 (.11)ns .10 .  .06 (.09)ns .08 .04 (.08)ns .06 
COPNEGC_TVC   .13 (.09)ns .14 .18 (.09)* .22 .13 (.08)ns .17 
Random Effects         
Residual 2.96    2.82    
Intercept 3.50***  4.02***  3.66***  4.19***  
Linear 7.17***  1.45ns  6.40***  1.55ns  
Quadratic .71***  .08ns  .57***  .09ns  
Estim. parameters 67    83    
Deviance statistic 1581.6    1497.8    
χ2(df) 80.36 (16)***    83.80 (16)***    
Abbreviations: PE – Parameter estimate (coefficient); SE – Standard error; rES – Effect size r; TVC – time-varying covariate; M – time-invariant 
covariate (average); df – Degrees of freedom; PHYSPT – Physical burden (patient); CRACB – Caregiving burden (caregiver); PSYCHPT/CG – 
Psychological burden (patient/caregiver); SHPT/CG – Sleep hygiene (patient/caregiver); COPNEGPT/CG – Negative coping (pa-
tient/caregiver); GSQI – Global Sleep Quality Index. 
Notes: The “own effects” model was compared with the deviance statistic from the quadratic model. The “cross-partner effects” model was com-
pared with the deviance statistic from the “own effects” model. All models were controlled for demographic/clinical covariates, including 
SLPAST, SLCA, AGE, RELATDUR, CMRBDT, and PS for patients; and SLPAST, SLCA, AGE, RELATDUR, and EDUC for caregivers; on-
ly significant results (or trends towards significance) are shown. Time-varying (TVC) and time-invariant (mean) components of the predictors 
tested have been coded so that higher numbers reflect poorer/worse outcomes. nsp > .10; †p < .10; *p < .05; **p < .01; ***p < .001. 
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Appendix 3. Literature Review Methods #1 
 
 
A3.1. Title of Review 
A Critical Review of Women’s Sleep-Wake Patterns in the Context of Neo-/Adjuvant Chemotherapy 
for Early-stage Breast Cancer 
 
A3.2. Search Strategy 
A defined search strategy used a wide range of key terms and synonyms including the following (ex-
ample as conducted in Medline): 
1. exp Sleep Disorders, Circadian Rhythm/ or exp Sleep/ or exp Sleep Deprivation/ or exp 
Sleep Disorders/ or exp "Sleep Initiation and Maintenance Disorders"/ or exp Sleep Disor-
ders, Intrinsic/ or sleep.mp. 
2. sleep.mp. or insomnia.mp. or sleep disturbance$.mp. or sleep disorder$.mp. or sleepless-
ness.mp. or sleepiness.mp. or circadian rhythm$.mp. or circadian activity.mp. or sleep effi-
ciency.mp. or quality of sleep.mp. or sleep quality.mp. or daytime disturbance.mp. or 
nap$.mp. or awakening.mp. or sleep latency.mp. or sleep regulation.mp. or sleep architec-
ture.mp. or sleep physiology.mp. or drowsiness.mp. or homeostatic.mp. or sleep propensi-
ty.mp. or WASO.mp. 
3. 1 or 2 
4. breast cancer.mp. or exp Breast Neoplasms/ 
5. 3 and 4 
 
A3.3. Search Results and Study Characteristics 
Table 6-A2 outlines the flow of papers through the review. Three thousand three hundred and forty 
five articles were identified through the searches, twenty-one of which reported on twelve studies 
examining sleep/wake patterns of women with early-stage breast cancer receiving chemotherapy 
treatment. Summaries of the methodological characteristics of the studies included can be 
found in Kotronoulas et al. [119] (Appendix 7). In cases of more than one article in the context 
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of one study, relevant information from all articles was included. In cases of secondary analyses of 
larger research data, the original study is indicated. 
Study design and context: Nine of the 21 papers selected reported on secondary analyses [7, 49, 121, 
122, 134, 136] from, or were part [8, 9, 125] of, two of the twelve studies identified. The twelve stud-
ies included two cross-sectional [120, 133] and nine longitudinal designs [7, 8, 104, 122, 124, 126-
131], while an additional one was a retrospective chart review [137]. Of the longitudinal studies, four 
aimed at testing an intervention to improve sleep using a control group [7, 122, 124, 130, 131]; the 
remainder were descriptive, exploratory in nature [8, 104, 126-129], with only one study including a 
comparison group of age-, ethnicity- and menopausal status-matched healthy women [128]. No cross-
sectional study included a comparison group. Sample sizes ranged from as low as 11 to as high as 240 
participants. 
Three studies included mixed samples of women receiving either adjuvant or neo-adjuvant chemo-
therapy for early-stage breast cancer [8, 9, 120, 125, 137], whereas the remainder specifically focused 
on adjuvant chemotherapy only. The two cross-sectional studies described sleep within a month prior 
to the initiation of chemotherapy [120, 121, 133], whereas five studies reported sleep data only during 
chemotherapy [104, 126-129, 137]. Finally, five studies explored sleep patterns at variable points be-
fore, during and even up to one year after chemotherapy for early-stage breast cancer [7-9, 49, 122, 
124, 125, 130, 131, 134, 136]. 
Sample demographic characteristics: In their vast majority, study samples were derived from the 
American population, whereas only two studies were conducted in a non-American context (Taiwan 
[129] and Turkey [130]). No European study was retrieved. Study populations in the American stud-
ies were predominantly Caucasian (72%-100%). The age of participants across studies ranged from 
26 to 83 years, with a grand weighted mean age slightly overreaching 50 years (50.9±1.2 years; range 
of means 45.0-54.3 years). The majority of women were married or partnered (62%-76%) and em-
ployed (60%-78%) at the time of their participation. 
Sample clinical characteristics: In accordance to the selection criteria, women had been diagnosed 
with stage I (28%-50%), stage II (41%-100%), or stage IIIA (8%-32%) breast cancer. Participants had 
undergone either lumpectomy (44%-79%) or mastectomy (21%-56%). Where women’s menopausal 
status was reported, 24%-63% were pre-menopausal, 9%-76% were post-menopausal, whereas 7%-
36% were peri-menopausal. In the majority of studies, women were scheduled to receive three- or 
four-weekly cycles of anthracycline-based (mainly doxorubicin, but also epirubicin) and/or cyclo-
phosphamide-based regimens, whereas in two studies [8, 122, 131] a sub-group of women received 
additional cycles of taxane-based regimens. 
Sleep measures: Assessment of sleep through self-reports only was conducted in two studies [130, 
133], whereas two studies used only objective sleep measures [126-128]. In seven studies (fourteen 
papers) a combination of subjective and objective sleep measures were used [7-9, 49, 104, 121, 122, 
124, 125, 129, 131, 132, 134, 136]. Although polysomnography is considered the gold standard for 
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assessing sleep architecture [49], no studies were found that used polysomnography for data collec-
tion. Instead, wrist actigraphy was used in nine studies to measure sleep and wake time [7-9, 49, 104, 
121, 122, 124-129, 131, 132, 134, 136]. Wrist actigraphs were worn for 48-168 hours across studies, 
although in most of them women wore the devices for 24-48 hours only. On the other hand, the Pitts-
burgh Sleep Quality Index (PSQI) [407] was the most frequently used self-report measure in the stud-
ies reviewed [7, 8, 49, 120-122, 124, 125, 130, 131, 133, 134], assessing quality of sleep over the pre-
vious month. The Morin Sleep Diary [409] was used in two studies [104, 124], whereas generic sleep 
diaries [7, 49, 122, 131, 134, 136] and sleep logs [129] were used in other studies as well. To assess 
sleepiness, one study [129] used the Epworth Sleepiness Scale (ESS) [404], whereas the Brief Sleep 
History [653] was used in one study [124] to determine sleep patterns of women before the diagnosis 
of cancer. 
Level of evidence: Based on the DOHNSF evidence categories, two papers [122, 131] reporting on an 
individual randomised clinical trial were identified (level of evidence B1), whereas two papers [124, 
130] reported on two individual experimental/intervention studies (level of evidence B2). Fourteen 
papers [7-9, 49, 104, 121, 125-129, 134, 136] reporting on seven studies were classified as level of 
evidence B3 (Table 5-A2). Finally, three papers [120, 133, 137] reporting on three studies were clas-
sified as level of evidence C1. 
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Appendix 4. Literature Review Methods #2 
 
 
A4.1. Title of Review 
A Systematic Review of Factors Affecting Sleep/Wake Patterns of Women Living with a Diagnosis 
of Breast Cancer 
 
A4.2. Background 
The aetiology of sleep/wake impairment in women with breast cancer is multidimensional since mul-
tiple factors are likely to alter the normal regulatory processes of sleep [4, 59]. Although several uni-
versal sleep-impairing factors exist that apply to the general population and patients with any type of 
cancer and their caregivers [3, 4, 49], a more focused examination is necessary. 
Knowledge of the underlying reasons may guide in-depth assessment and targeted treatment of sleep 
disorders [60], given that care is specifically rather than vaguely focused on the source of the prob-
lem, potentially leading to quicker relief and dramatic improvement in sleep quality and sleep-related 
outcomes. 
 
A4.3. Objectives 
The objectives of the present review will be to synthesise and critically analyse evidence regarding 
contributing factors, or correlates, affecting sleep patterns of women throughout the trajectory of the 
experience of living with breast cancer, as well as to identify methodological and research gaps in this 
body of evidence. 
 
A4.4. Review Questions 
 What is the evidence for factors affecting sleep patterns of female patients receiving multi-modal 
treatment for early stage breast cancer? 
 What is the evidence for factors affecting sleep patterns of female patients during survivorship 
(>3 months after the end of treatment) from breast cancer? 
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 What is the evidence for factors affecting sleep patterns of female patients with locally advanced 
or metastatic breast cancer? 
 
A4.5. Search Strategy 
Deliberately inclusive search terms will be used so that relevant articles are not missed. The search 
strategy will include the following terms: 
1. exp Sleep Disorders, Circadian Rhythm/ or exp Sleep/ or exp Sleep Deprivation/ or exp Sleep 
Disorders/ or exp "Sleep Initiation and Maintenance Disorders"/ or exp Sleep Disorders, In-
trinsic/ or sleep.mp. 
2. sleep.mp. or insomnia.mp. or sleep disturbance$.mp. or sleep disorder$.mp. or sleepless-
ness.mp. or sleepiness.mp. or circadian rhythm$.mp. or circadian activity.mp. or sleep effi-
ciency.mp. or quality of sleep.mp. or sleep quality.mp. or daytime disturbance.mp. or nap$.mp. 
or awakening.mp. or sleep latency.mp. or sleep regulation.mp. or sleep architecture.mp. or 
sleep physiology.mp. or drowsiness.mp. or homeostatic.mp. or sleep propensity.mp. or 
WASO.mp. 
3. 1 or 2 
4. breast cancer.mp. or exp Breast Neoplasms/ 
5. 3 and 4 
6. Limit 5 to (period January 1990 – March 2012) and (English language) and (Adults) and (Fe-
male) 
7. Remove duplicates from 6 
 
A4.6. Electronic Bibliographic Databases 
Studies will be identified by systematically searching three research and evidence electronic data-
bases, namely Ovid (Medline 1988 – 2012), EMBASE (1980 – 2012), and CINAHL (Inception – 
2012). 
 
A4.7. Hand Search 
The reference lists of included studies will be searched by hand for any studies that may have been 
overlooked. 
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A4.8. Study Selection Criteria 
Inclusion Criteria 
To be eligible studies should be published in English; employ any research design (cross-
sectional/longitudinal surveys, case-control studies, intervention controlled/non-controlled trials etc.), 
although less weight will be given to intervention studies because their results may have been influ-
enced by the nature of the intervention and their recruited participants may be unrepresentative of the 
target population; study adult (≥ 18 years of age) female patients with histologically confirmed diag-
nosis of breast cancer, irrespective of tumour stage or type of treatment; examine sleep as a primary or 
secondary variable via use of sleep-specific measures, namely polysomnography or actigraphy (objec-
tive) and/or validated sleep scales/instruments (subjective); study patients with no other medical co-
morbidities; provide measures of statistical associations between sleep patterns and sleep-impairing 
factors in the target population; be published in the period between January 1990 and March 2012. 
 
Exclusion Criteria 
Studies will be excluded from this review if they utilise generic quality of life measures or symptom 
scales, or single item sleep scales to elicit information about sleep patterns; report on mixed cancer 
samples, except if separate analyses and associations are reported for groups of patients with breast 
cancer; are unpublished studies, conference papers, or dissertation abstracts. 
 
A4.9. Outcome measures 
Definition of sleep patterns will be based on the previously proposed key parameters for the assess-
ment of sleep in cancer populations [3]. These parameters are total sleep time, sleep latency, nocturnal 
awakenings, wake time after sleep onset, napping during the day, daytime sleepiness/dysfunction, 
quality of perceived sleep, stability of circadian rhythms (e.g. mesor, amplitude, peak activity), and 
sleep efficiency. Data on predictors of sleep aid use and overall scale scores (as indicators of dis-
turbed sleep) will also be recorded. 
 
A4.10. Search Procedure 
The lead reviewer will select studies for inclusion in the review. A second reviewer will independent-
ly screen a random third of articles for suitability (using a study suitability for the review form). 
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A4.11. Study Quality Assessment 
Methodological quality of each study will be evaluated through use of an adapted version of the 14-
item standardised checklist of pre-defined criteria introduced by Mols and colleagues [138]. Adapta-
tion was based on information from previous similar reviews [139, 140]. Areas of concern include a 
study’s research design, sampling and bias, and data collection and measurement. Studies will be de-
fined as “good quality” if they exceed the third quartile of the obtained scores, and as “moderate qual-
ity” if they exceed the second quartile. Clarification of the different methodological components will 
be aided through use of the STROBE statement checklist for reports of observational studies (Table 
7-A2) [141]. 
To promote an evidence-type approach, a validated grading hierarchy will also be used to assess the 
level of evidence presented according to the type of research using the evidence categories employed 
by the Department of Health in the National Service Frameworks (DOHNSF, 2001) [116] (Table 6-
A2). 
Studies will be appraised for methodological quality by the lead reviewer. A second reviewer will 
independently appraise a random third of selected studies. Agreement between reviewers will be as-
sessed by calculating percentage agreement and Cohen’s kappa statistic for the two appraisal sets. 
Any discrepancies will be discussed and resolved by consensus. 
 
A4.12. Data Extraction Strategy 
General details 
Details (study design, method of data collection, outcome measures, correlate measures, participant 
summary, sample size, response rate, method of analysis) of the studies eligible for the review will be 
extracted and compiled into tables by the lead researcher and double-checked. 
 
Tables of Outcomes 
The lead reviewer will create skeleton tables containing each predictor variable examined in the in-
cluded studies according to the sleep parameters these predictors were associated with. Skeleton ta-
bles will refer to each of the three review questions. The direction and strength of these associations 
also will be extracted. All data will be extracted and entered into the table by the lead researcher and 
double-checked. 
 
Notes on Levels of Evidence for Predictors 
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Findings will be considered consistent if ≥75% of the studies that investigated a predictor showed the 
same direction of the association. Four levels of evidence for the identified predictors will be used 
[138], for which definitions are provided below. 
 
Notes on Data Synthesis 
Point 1. If variation between the included studies exists, while sufficient detail for the relevant effect 
sizes to be calculated is absent, the evidence will be synthesised in a narrative review. 
Point 2. Effect sizes will be computed as point-biserial correlation coefficients, or rs [654, 655]. As a 
rule of thumb, effect sizes less than 0.10 will be considered small, 0.25 will be considered medium, 
and effect sizes greater than 0.40 will be considered to be large [507, 654]. 
Point 3. Separate tables containing the effect sizes for each predictor variable will be drawn up by the 
lead reviewer. Where three or more studies measure predictors in a similar way (same sleep measure 
and same/similar sleep-correlate measure), a pooled effect size will be calculated for meta-analysis 
purposes. When both univariate and adjusted associations between the predictors and outcomes are 
given in a study, the univariate result will be preferred for consistency. Where only adjusted associa-
tions are given, these will be included. Where results can be pooled statistically, an inverse variance 
random-effects model will be used to allow for heterogeneity between studies [654]. Sensitivity anal-
yses will be performed excluding the adjusted associations from the pooled results. Forest plots of 
effects sizes and confidence intervals will be created in Microsoft Office® Excel [656]. 
Point 4. Multiple articles published from the same dataset will be combined into a single study to 
avoid violating the independence of observations assumption [657]. Multiple articles will be com-
bined into a single study be aggregating all effect sizes for a given predictor into a single effect size 
estimate. Thus, predictors will have only one effect size for a given sleep parameter rather than multi-
ple ones. 
Point 5. In studies where multiple follow-ups are examined, a pooled result will be calculated and 
reported. 
Statistical considerations: Effect size with 95% CI: rs (…, …), if 0 is included then association is 
non-significant. If a significant relationship along with the direction of the effect were reported, but p 
is given as <.05, <.01, or <.001, then assume p value as .05, .01 and .001, respectively. If a significant 
relationship along with direction of the effect were reported, but no inferential statistics were given, 
then assume p value as .05. If no direction was reported, then exclude effect size. If a non-significant 
relationship is reported but no statistical information is provided, then assume effect size as 0. If a 
study provides data on two or more measures of the same predictor, then a combine effect size is to be 
computed by transforming r into a Fisher Zr coefficient, average across the Fisher Zrs, and convert the 
resulting Zr back into an r [657]. Similarly, if a study provides data on multiple measurements of the 
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same relationship (i.e. longitudinal studies), then a combine effect size is to be computed by trans-
forming r into a Fisher Zr coefficient, average across the Fisher Zrs, and convert the resulting Zr back 
into an r; cells are to be left blank where the predictor was not examined. 
 
A4.14. Search Results and Study Characteristics 
Table 8-A2 outlines the flow of papers through the review. Two thousand five hundred and sixty one 
articles were identified through initial search. After application of selection criteria, 215 articles were 
retained and retrieved in full-text. Fifty eight articles were finally included in the current review, 26 of 
which reported on 16 studies examining sleep-impairing factors/covariates in women with early-stage 
breast cancer receiving chemotherapy treatment. Summaries of the methodological characteristics of 
the studies included are provided in Table 9-A2. In cases of more than one article in the context of 
one study, relevant information from all articles was extracted. In cases of secondary analyses of larg-
er research data, the original study is indicated. 
Study design and context: Ten of the 26 papers selected reported on secondary analyses from, or 
were part of, three of the 16 studies identified. Eight studies were parts or secondary analyses of larg-
er projects [7, 133, 144, 147, 148, 153, 166, 171, 172]. Fifteen studies employed a prospective design, 
nine of which involving repeated sleep measurements [7, 8, 104, 120, 121, 123, 125-129, 131, 143, 
145-147, 172] and six relying on cross-sectional data [133, 144, 148, 153, 165, 166, 171]. An addi-
tional study was a retrospective chart review [137]. Of the longitudinal studies, four aimed at testing 
an intervention to improve sleep using a control group [7, 121, 123, 131, 143, 147, 172]; the remain-
der were descriptive, exploratory in nature, with only one study including a comparison group of age-, 
ethnicity- and menopausal status-matched healthy women [128]. Similarly, only one cross-sectional, 
case-control study included a comparison group of men with prostate cancer [153, 171]. Sample sizes 
ranged from as small as 11 to as large as 3002 participants for a total sample of 4,449 participants 
(median 88 participants). 
Five studies included mixed samples of women about to receive, receiving or having received differ-
ent types of adjuvant treatment [133, 144, 153, 166, 171, 172], where chemotherapy was administered 
in 45% (range 44%-56%) of the cases. All other studies exclusively focussed on patients receiving 
neo-/adjuvant chemotherapy for breast cancer. In terms of the timing of sleep assessments, cross-
sectional studies focussed on the period after initial surgery but before adjuvant treatment (N=1) 
[133], during chemotherapy (N=3) [144, 148, 165], or within 3 months post-chemotherapy comple-
tion [153, 166, 171]. Of the longitudinal studies (N=9), sleep assessments spanned different periods, 
yet only four studies collected pre-chemotherapy sleep data [7, 8, 120, 121, 123, 125, 131, 143, 145, 
146, 172]. Sleep assessment frequency varied with studies collecting data on two [7, 104, 128, 129, 
147], three [126, 127, 172], four [8, 120, 125, 145, 146], or more than four occasions throughout 
chemotherapy [7, 121, 123, 131, 136, 143]. Only two studies explicitly stated attrition rates of 14.3% 
and 16.7% [104, 126, 127]. 
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Sample demographic characteristics: In their vast majority, study samples were derived from the 
American population; only four studies were conducted in a non-American context, namely Denmark 
[144], Thailand [165], Korea [129], and Canada [172]. Except for two studies where random sampling 
techniques were involved [7, 121, 123, 131, 143, 144], the studies relied on convenience samples of 
women with recruitment taking place at medical centres, community clinics and practices, or through 
published advertisements. Only four studies explicitly stated response rates, reaching 81% (range 63% 
to 94%) [7, 8, 120, 121, 123, 125-127, 131, 136, 143, 145-147]. Where reported, study populations in 
the American studies were predominantly Caucasian (82%; range 67.5%-95.3%). Across studies, par-
ticipant age ranged from 28 to 80 years, with a grand weighted mean age of 53.4 years (weighted SD 
1.9 years; range of means 49.5-57.1 years). The majority of women were married/partnered (74%; 
range 18%-79.2%) and employed at the time of their participation (68%; range 43%-78%). 
Sample clinical characteristics: In accordance to the selection criteria, women had been diagnosed 
with stage I (31%; range 12%-67.2%), stage II (50%; range 24.1%-68%) or stage IIIA (16%; range 
8%-32%). Women had undergone either lumpectomy (46%; range 13%-94.8%) or mastectomy (54%; 
8.6%-87%). Where women’s menopausal status was reported, 38% (range 32%-57%) were pre-
menopausal, whereas 57% (range 22%-60%) were post-menopausal. In the majority of studies, wom-
en were scheduled to receive, were receiving or received three- or four-weekly cycles of anthracy-
cline-based (mainly doxorubicin, but also epirubicin) and/or cyclophosphamide-based chemotherapy 
regimens, in some cases complemented by additional cycles of taxanes [120, 136]. 
Sleep measures: Assessment of sleep through self-reports only was conducted in six studies [133, 
144, 148, 165, 166, 172], whereas three studies utilised only objective sleep measures [126-128, 147]. 
In six studies, a combination of subjective and objective sleep measures were employed [7, 8, 104, 
120, 121, 123, 125, 129, 131, 136, 143, 145, 146, 153, 171]. Although polysomnography is consid-
ered the gold standard for assessing sleep architecture [49], no studies were found that used poly-
somnographic recordings for data collection. Instead, wrist actigraphs were used in nine studies to 
measure sleep and wake time [7, 8, 104, 120, 121, 123, 125-129, 131, 136, 143, 145-147, 153, 171]. 
Wrist actigraphs were worn continuously for 48 to 96 hours per time-point across studies, although in 
most of them (N=5) women wore the devices for only 48 hours/assessment point. On the other hand, 
the Pittsburgh Sleep Quality Index (PSQI) was the most frequently used self-report measure in the 
studies reviewed (67%, N=8). Five studies relied upon self-report data collected through use of sleep 
diaries/logs with or without concurrent use of objective recordings and/or other self-report measures 
[7, 8, 104, 120, 121, 123, 125, 129, 131, 136, 143, 145, 146, 153, 171]. Only one study included a 
specific questionnaire to evaluate sleepiness in women during chemotherapy [129]. 
Predictors/correlates/covariates examined: Six categories were formulated of sleep-impairing co-
variates examined in the studies identified. Chemotherapy-related (e.g. symptom distress) (75%; 
N=12) and clinical/medical covariates (62.5%; N=10) were the factors most frequently evaluated for 
their sleep-disrupting effects in the studies reviewed. Considerably less frequent investigation of psy-
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chological/emotional (31%; N=5), demographic (25%; N=4) and biological factors (19%; N=3) took 
place in the included studies.  
Methodological quality and Level of evidence: Table 10-A2 outlines marks awarded according to the 
quality criteria the studies were evaluated against. In general, the reviewed studies were of fair to 
good methodological standard (median total score 18; range 14-24; possible range 10-27); however, 
studies differed widely with respect to individual criteria. Based on the DOHNSF evidence categories, 
one individual randomised controlled trial was identified (level of evidence B1) [7, 121, 123, 131, 
136, 143]. Nine studies were classified as level of evidence B3 (Table 5-A2), whereas the remainder 
were classified as level of evidence C1. 
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Appendix 5. Literature Review Methods #3 
 
 
A5.1. Title of Review 
Sleep/Wake Patterns and Sleep-Impairing Factors of Persons Providing Informal Care for People with 
Cancer 
 
A5.2. Search strategy 
A defined search strategy used a wide range of key terms and synonyms including the following (ex-
ample as conducted for Medline): 
1. exp Sleep Disorders, Circadian Rhythm/ or exp Sleep/ or exp Sleep Deprivation/ or exp Sleep 
Disorders/ or exp "Sleep Initiation and Maintenance Disorders"/ or exp Sleep Disorders, In-
trinsic/ or sleep.mp. 
2. sleep.mp. or insomnia.mp. or sleep disturbance$.mp. or sleep disorder$.mp. or sleepless-
ness.mp. or sleepiness.mp. or circadian rhythm$.mp. or circadian activity.mp. or sleep effi-
ciency.mp. or quality of sleep.mp. or sleep quality.mp. or daytime disturbance.mp. or nap$.mp. 
or awakening.mp. or sleep latency.mp. or sleep regulation.mp. or sleep architecture.mp. or 
sleep physiology.mp. or drowsiness.mp. or homeostatic.mp. or sleep propensity.mp. or 
WASO.mp. 
3. 1 or 2 
4. caregiver$.mp. or carer$.mp. or caregiving.mp. or partner$.mp. or family member$.mp. or sig-
nificant other$.mp. or friend$.mp. or exp Caregivers/ 
5. 3 and 4 
 
A5.2. Search Results and Study Characteristics 
Table 13-A2 outlines the flow of papers through the review. Forty-four papers were pooled to meet 
the overall purpose of the review, seventeen of which reported on eleven studies that specifically ex-
amined sleep/wake patterns of informal caregivers of patients with cancer. Summaries of the method-
ological characteristics of the included studies can be found in Kotronoulas et al. [182] (Appendix 8). 
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In cases of multiple articles in the context of one study, relevant information from all articles was 
included. In cases of secondary analyses of larger research data, the original study is indicated. 
Study design: The ten studies included seven cross-sectional [23, 25, 27, 30, 232, 234, 237-240, 242, 
277, 521, 522] and three longitudinal [28, 29, 244] designs. Of the longitudinal studies, one aimed at 
testing a brief sleep intervention for caregivers of patients with advanced cancer [29], whereas the 
other two were descriptive exploratory in nature [28, 244]. Gibbins et al.[244] included a group of 
patients with advanced cancer to compare sleep patterns with their family members. Only one cross-
sectional study included comparison groups of caregivers of elders with Alzheimer’s and Parkinson’s 
disease, as well as an additional group of persons in non-caregiving roles [234]. In a sub-report, Wil-
lette-Murphy et al.[240] used a case-control design to compare sleep patterns of female caregivers of 
patients with cancer prior to radiotherapy based on their perceived physical activity. Sample sizes 
ranged widely from as small as 10 to as large as 103 participants. 
Sample characteristics and context: In their majority, study samples were derived from the Ameri-
can and Canadian populations; however, four studies were conducted in a non-American context, i.e. 
Korea [23], Taiwan [30], Turkey [521], and United Kingdom [244]. Study populations in the Ameri-
can, Canadian and European studies were predominantly Caucasian (79%-100%). The age of caregiv-
ers across studies ranged from 15 to 86 years, with a grand weighted mean age of 55.4±9.4 years 
(range of means 41.2-74.0 years). In the majority of studies caregivers were predominantly female 
(51.5%-100%), married or partnered (83.6%-100%), and employed (35%-61.5%) at the time of their 
participation. Four papers reporting on two studies specifically focused on female caregivers [25, 232, 
239, 240], whereas in the study of Chang et al.[30] caregivers of women with breast cancer were 
mainly male (82%). All studies aimed at recruiting family members in caregiving roles, except for 
one study [232], where however, family members accounted for as much as 92% of the total sample. 
Most frequently caregivers were patients’ spouses (44%-100%) or adult children (5%-34%). 
Only two studies focused on sleep patterns of caregivers of patients with a specific diagnosis, namely 
breast [30] and gastric [23] cancer. Two study sub-reports provided evidence in the context of prostate 
cancer [25, 239]. In all other studies, care recipients had various diagnoses, mainly breast, lung, or 
prostate cancer, or leukaemia. Six studies included caregivers of patients with advanced cancer [27-
29, 232, 237, 238, 244, 277], two studies included caregivers of patients with non-metastatic disease 
[25, 30, 239, 240, 242, 522], whereas in three studies stage of disease was not stated [23, 234, 521]. In 
four studies, participants provided care for a person receiving or scheduled to receive anti-cancer 
treatment, i.e. chemotherapy [23, 30, 521] or radiotherapy [25, 239, 240, 242, 522]. 
Data with regard to time since patient diagnosis, duration of caregiving since diagnosis, and hours of 
daily caregiving were rather inconsistently and only partially reported in the studies. In general, care-
givers of patients with non-metastatic cancer were mainly approached within the first year after diag-
nosis, five to nine months on average [25, 30, 239, 240, 242, 522]. On the other hand, Carter et al.[28] 
reported that time since diagnosis of advanced cancer ranged from 1 month to 6 years, whereas Teel 
et al.[234] reported a mean time of 3 years. Where reported, duration of caregiving exceeded even 
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two years in caregivers with advanced cancer [27, 28, 232, 237, 238, 277], whereas hours of caregiv-
ing exceeded 14 per day on average [27, 29, 232, 237, 238]. In caregivers of patients receiving chem-
otherapy, Aslan et al.[521] reported a mean caregiving duration of 5 months. 
Sleep measures: Assessment of sleep through self-reports only was conducted in seven [23, 27, 30, 
232, 234, 237, 238, 277, 521] studies , whereas the remainder implemented a combination of subjec-
tive and objective sleep measures [25, 28, 29, 239, 240, 242, 244, 522]. Of note, two studies utilised 
semi-structured interviews to complement subjective sleep data [237, 277]. 
Although polysomnography is considered the gold standard for assessing sleep architecture [49], no 
studies were found that used polysomnography for data collection. Instead, wrist actigraphy was used 
in all four studies to measure sleep and wake time of caregivers, where wrist devices were worn for 
48 [25, 239, 240, 242, 522], 72 [28, 29], and 168 [244] hours. On the other hand, the Pittsburgh Sleep 
Quality Index (PSQI) [407] was the most frequently used self-report measure in the studies reviewed 
[23, 27-30, 232, 238, 240, 242, 521, 522], assessing quality of sleep over the previous month. The 
General Sleep Disturbance Scale (GSDS) [646] was used in one study [25, 239, 240, 242, 522], 
whereas the Verran and Snyder-Halpern Sleep Scale (VSH) [650] was used in another [234]. A gener-
ic daily sleep diary [244], sleep logs [29], and sleep-related open-ended questions [237, 521] were 
used in other studies as well. To assess sleepiness and past history of sleep disturbance, one study 
[244] used the Epworth Sleepiness Scale (ESS) [404] and author-constructed sleep history questions, 
respectively. 
Level of evidence: Based on the DOHNSF evidence categories, one paper [29] reporting on an indi-
vidual experimental/intervention study was identified (level of evidence B2). Eight papers [25, 28, 
234, 239, 240, 242, 244, 522] reporting on four studies were classified as level of evidence B3 (Table 
5-A2). Finally, eight papers [23, 27, 30, 232, 237, 238, 277, 521] reporting on six studies were classi-
fied as level of evidence C1. 
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Appendix 6. Literature Review Methods #4 
 
 
A6.1. Title of Review 
Sleep/Wake Patterns and Sleep-Impairing Factors in Care Recipient-Informal Caregiver Dyads in the 
Context of Major Chronic Illnesses 
 
A6.2. Search Strategy 
A defined search strategy used a wide range of key terms and synonyms including the following (ex-
ample as conducted for OVID): 
1. exp Sleep Disorders, Circadian Rhythm/ or exp Sleep/ or exp Sleep Deprivation/ or exp Sleep 
Disorders/ or exp "Sleep Initiation and Maintenance Disorders"/ or exp Sleep Disorders, In-
trinsic/ or sleep.mp. 
2. sleep.mp. or insomnia.mp. or sleep disturbance$.mp. or sleep disorder$.mp. or sleepless-
ness.mp. or sleepiness.mp. or circadian rhythm$.mp. or circadian activity.mp. or sleep effi-
ciency.mp. or quality of sleep.mp. or sleep quality.mp. or daytime disturbance.mp. or nap$.mp. 
or awakening.mp. or sleep latency.mp. or sleep regulation.mp. or sleep architecture.mp. or 
sleep physiology.mp. or drowsiness.mp. or homeostatic.mp. or sleep propensity.mp. or 
WASO.mp. 
3. 1 or 2 
4. caregiver$.mp. or carer$.mp. or caregiving.mp. or partner$.mp. or family member$.mp. or sig-
nificant other$.mp. or friend$.mp. or exp Caregivers/ 
5. dyad$.mp. or dyadic approach.mp. or dyadic context.mp. or couples.mp. or interdepend$.mp. 
or interpersonal.mp. or patient-caregiver interaction$.mp. or patient-caregiver dyad$.mp. 
6. 3 and 4 and 5 
 
A6.3. Search Results and Study Characteristics 
Table 13-A2 outlines the flow of papers through the review. Twenty-seven papers were pooled to 
meet the overall purpose of the review, ten of which reported on ten studies meeting additional eligi-
bility criteria specific to concurrent examination of sleep patterns in patient-caregiver dyads. Summar-
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ies of the methodological characteristics of the studies included can be found in Kotronoulas et al. 
[366] (Appendix 9). 
Study design: The ten studies included five cross-sectional [233, 242, 247, 251, 285] and five pro-
spective designs [244, 278, 363, 367, 368]. Of the prospective studies, one was a prospective case 
series to evaluate sleep in patient-caregiver dyads before, during, and after periods of institutional 
dementia respite care [367]. The remainder were descriptive exploratory in nature. Pollak et al.[278] 
included a control group of 18 dyads of non-demented elders and their caregivers. Only one cross-
sectional study included a comparison group of healthy adults [251]. Sample sizes ranged widely 
from as low as 6 to as high as 153 dyads. 
Sample characteristics and context: Seven studies were conducted with patients with a neurodegen-
erative disease (i.e., dementia [247, 278, 363, 367] or Parkinson’s disease [233, 251, 285]) and their 
informal caregivers, whereas one study included a group of community elders (>65 years) with mixed 
related co-morbidities [368]. Only two studies included people diagnosed with cancer and their in-
formal caregivers [242, 244]. 
In their majority, study samples were derived from the American population; however, five studies 
were conducted in a non-American context, i.e. United Kingdom [244, 367], Germany [233, 251], and 
Canada [285]. Where stated, patient and caregiver populations were predominantly Caucasian (81%-
100% and 67%-100%, respectively). In the studies reviewed, patients had a grand weighted mean age 
of 69.2±5.9 years (range of means 64.4-80.7 years), whereas caregivers were slightly younger (X¯ = 
63.8±1.9 years; range of means 61.7-67.4 years). However, in the studies where patients with demen-
tia were assessed mean age exceeded 78 years, whereas it fluctuated around 65 years for patients with 
cancer or Parkinson’s disease. In the majority of studies, patients were predominantly male (65%-
78%) and caregivers were predominantly female (63%-100%). 
All studies aimed at recruiting family members in caregiving roles, except for one study [242], where 
however, family members accounted for as much as 93% of the total sample. Caregivers were either 
patients’ spouses/partners (39%-100%) or children (2%-53%). Most frequently patients and caregiv-
ers were living together in the same household (54%-100%). However, only four studies explicitly 
stated percentages (54%-86%) of patients and caregivers sharing the same bedroom [242, 247, 363, 
367]. Finally, data pertinent to time since patient diagnosis and to caregiving responsibilities were 
reported in only a part of the studies, whereas in the studies conducted in the context of cancer no 
relevant data were provided [242, 244]. In general, people with dementia [247, 363, 367] and Parkin-
son’s disease [233, 285] had been diagnosed at least 4 and 7 years ago on average, respectively. 
Sleep measures: Assessment of sleep through self-reports only was conducted in three studies [233, 
251, 285], one study was based only objective recordings [363], whereas the remainder implemented 
a combination of subjective and objective sleep measures [242, 244, 247, 278, 367, 368]. Although 
polysomnography is considered the gold standard for assessing sleep architecture [49], only one study 
was found that used polysomnography for collection of 3-day data on caregivers’ sleep [247]. Instead, 
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wrist actigraphy was used in all seven studies to measure sleep and wake time of patients and caregiv-
ers, where wrist devices were worn for 48 [242], 72 [247], 168 [244, 363], 144-192 [368], 214 [278], 
and 1008 [367] consecutive days. On the other hand, the Pittsburgh Sleep Quality Index (PSQI) [407] 
was the most frequently used self-report measure in the studies reviewed [242, 247, 285, 367], as-
sessing quality of sleep over the previous month. The General Sleep Disturbance Scale (GSDS) [646] 
was used in one study [242]. One study used an author-constructed General Sleep Questionnaire 
[285], whereas two studies used questions derived from non-sleep-specific questionnaires [233, 251]. 
Daily sleep diaries [242, 244, 247] and sleep logs [278, 368] facilitated data collection in other studies 
as well. To assess sleepiness, three studies [244, 247, 367] used the Epworth Sleepiness Scale (ESS) 
[404]. Finally, past history of sleep disturbance was examined in one study [244] via author-
constructed sleep history questions. 
Methodological Quality and Level of evidence: Overall, studies varied in methodological quality: 
quality scores ranged from 25 to 33 (highest possible 40), with a mean score of 28.4±2.7. On average, 
reporting of the studies was of a fair to good standard. Research bias, ethical issues, and introduction 
and aims were the areas receiving the lowest marks. Based on the DOHNSF evidence categories, one 
paper [367] reporting on an individual intervention study was identified (level of evidence B2). The 
remainder nine studies [233, 242, 244, 247, 251, 278, 285, 363, 368] were classified as level of evi-
dence B3 (Table 5-A2). 
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